

US 20060034853A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2006/0034853 A1**

**Yuen et al.** (43) **Pub. Date: Feb. 16, 2006**

(54) **NOVEL HUMAN VIRUS CAUSING  
RESPIRATORY TRACT INFECTION AND  
USES THEREOF**

(76) Inventors: **Kwok Yung Yuen**, Hong Kong (CN);  
**Chiu Yat Patrick Woo**, Hong Kong  
(CN); **Kar Pui Susanna Lau**, Hong  
Kong (CN); **Kwok Hung Chan**, Hong  
Kong (CN)

Correspondence Address:  
**DICKSTEIN SHAPIRO MORIN & OSHINSKY  
LLP  
1177 AVENUE OF THE AMERICAS (6TH  
AVENUE)  
41 ST FL.  
NEW YORK, NY 10036-2714 (US)**

(21) Appl. No.: **11/129,741**

(22) Filed: **May 16, 2005**

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 10/895,064,  
filed on Jul. 21, 2004.

**Publication Classification**

(51) **Int. Cl.**  
*A61K 39/42* (2006.01)  
*C07H 21/04* (2006.01)  
*C12P 21/06* (2006.01)  
*C07K 14/005* (2006.01)  
(52) **U.S. Cl.** ..... **424/159.1**; 530/388.3; 435/69.1;  
435/456; 435/325; 530/350;  
536/23.72

(57) **ABSTRACT**

The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 ("HCoV-HKU1"), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by HCoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the HCoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the HCoV-HKU1.

SEQ:1	1	TCGTGCTATGCCAAATATTTGCGTATTGTTAGTAGTTAGTTTGGCCCGCAAACAT	58
SEQ:2	1	R A M P N I L R I V S S L V L A R K H	19
	59	GAATTTGTGTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTT	118
	20	E F C C S H G D R F Y R L A N E C A Q V	39
	119	TTGAGTGAATAGTTATGTGTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGT	178
	40	L S E I V M C G G C Y Y V K P G G T S S	59
	179	GGTGATGCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATGTCAGGCTGTACTGCT	238
	60	G D A T T A F A N S V F N I C Q A V T A	79
	239	AATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAAT	298
	80	N V C S L M A C N G H K I E D L S I R N	99
	299	TTACAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTT	358
	100	L Q K R L Y S N V Y R T D Y V D Y T F V	119
	359	AATGAGTATTATGAATTTTATGTAAGCATTTTAG	393
	120	N E Y Y E F L C K H F	130

FIG. 1

SEQ:3 1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGAGATCTCAT 60  
E \* E R I A S V P S I S L R S L V R S H  
N K S E L R P Y R L S A Y D L L S D L I  
I R A N C V R T V Y Q L T I S C Q I S L

61 TAAATCTAAACTTTTTAAACAAGATTCCCTGTTATCCATGCTTGTGAGTGTGGTTAATC 120  
\* I \* T F \* T R F P V I H A C E C G L I  
K S K L F K Q D S L L S M L V S V V \* S  
N L N F L N K I P C Y P C L \* V W F N H

121 ATAATCTGTATTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTGGTTGTC 180  
I I L Y F T F H T F H L S A S D V L V V  
\* S C I L L S T L F I S L P V T C W L S  
N L V F Y F P H F S S L C Q \* R V G C P

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAACCAGCAAATACGGTCTCGGCTTCAA 240  
L S V P P I G R N D \* N Q Q I R S R L Q  
S A S L P \* V A M I K T S K Y G L G F K  
Q R P S H R S Q \* L K P A N T V S A S S

241 GTGGCGCCAGAATTCGTTGGCTGCTCCGGATGCAGCGGAGGAGTTGGCTAGTCTCTAT 300  
V G A R I S L A A S G C S G G V G \* S Y  
W A P E F R W L L P D A A E E L A S P M  
G R Q N F V G C F R M Q R R S W L V L \*

301 GAAGTCAGATGAGGGTGGTTATGCCCTCTACTGGTCAAGCGATGGAAAGTGTGGATT 360  
E V R \* G W V M P L Y W S S D G K C W I  
K S D E G G L C P S T G Q A M E S V G F  
S Q M R V G Y A P L L V K R W K V L D S

361 CGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420  
R L \* \* S C E D R L S L H S W T R M A C  
V Y D N H V K I D C R C I L G Q E W H V  
F M I I M \* R \* I V A A F L D K N G M C

421 GCAGTCAAATCTTATCCGTGATATTTTGTTCATGAAGATCTACATGTTGTAGAAGTTCT 480  
A V K S Y P \* Y F C S \* R S T C C R S S  
Q S N L I R D I F V H E D L H V V E V L  
S Q I L S V I F L F M K I Y M L \* K F \*

481 AACTAAAACAGCCGTAAAGTCCGGTACGGCAATTTTAATTAATCACCTTGCATAGCTT 540  
N \* N S R K V R Y G N F N \* I T F A \* L  
T K T A V K S G T A I L I K S P L H S L  
L K Q P \* S P V R Q F \* L N H L C I A W

FIG. 2

541 GGGTGGTTTTCTAAAGGGTATGTTATGGGCTTGTCCGTTTCATACAAGACTAAACGTTA 600  
 G W F S \* R V C Y G L V P F I Q D \* T L  
 G G F P K G Y V M G L F R S Y K T K R Y  
 V V F L K G M L W A C S V H T R L N V M

601 TGTTGTACATCATCTTTCTATGACTACATCTACTACTAATTTGGTGAAGATTTTTGGG 660  
 C C T S S F Y D Y I Y Y \* F W \* R F F G  
 V V H H L S M T T S T T N F G E D F L G  
 L Y I I F L \* L H L L L I L V K I F W V

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTCCACAAATGGTTTCAATTCTGTAG 720  
 L D C T F W F Y A I L C S Q M V S I L \*  
 W I V P F G F M P S Y V H K W F Q F C R  
 G L Y L L V L C H L M F T N G F N S V G

721 GTTGTATATTGAAGAGAGTGATTTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780  
 V V Y \* R E \* F N N F K F \* I \* \* L \* F  
 L Y I E E S D L I I S N F K F D D Y D F  
 C I L K R V I \* \* F Q I L N L M I M I L

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGTAAATATTCACAAA 840  
 \* C R R C L C \* G S C \* A \* R \* I F T K  
 S V E D A Y A E V H A E P K G K Y S Q K  
 V \* K M L M L R F M L S L K V N I H K K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAAACCCGACTTTTTGTAGACCAGTA 900  
 S L C F T \* T I S W Y \* T R T F C R P V  
 A Y A L L R Q Y R G I K P V L F V D Q Y  
 L M L Y L D N I V V L N P Y F L \* T S M

901 TGGTTGTGACTATTCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATTCTTT 960  
 W L \* L F W \* I S R L S S S L W S L F F  
 G C D Y S G K L A D C L Q A Y G H Y S L  
 V V T I L V N \* Q I V F K L M V I I L C

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGTGACTTTGATATTGTAGT 1020  
 A R Y E T K A V C M A C Q L \* L \* Y C S  
 Q D M R Q K Q S V W L A N C D F D I V V  
 K I \* D K S S L Y G L P I V T L I L \* W

1021 GGCTTGGCATGTAGTTCGTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080  
 G L A C S S \* F T I C Y A P A D Y S Y Y  
 A W H V V R D S R F V M R L Q T I A T I  
 L G M \* F V I H D L L C A C R L \* L L F

FIG. 2 CONT.

1081 TTGTGGTATTAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGATGTAGTTAT 1140  
L W Y \* I C C T T Y R R C S R W R C S Y  
C G I K Y V A Q P T E D V V D G D V V I  
V V L N M L H N L Q K M \* \* M E M \* L Y

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTAAAGCTTCCTAGTTTGAT 1200  
T \* T C T F I I C \* C N S P K A S \* F D  
R E P V H L L S A D A I V L K L P S L M  
V N L Y I Y Y L L M Q \* F \* S F L V \* \*

1201 GAAAGTTATGACTCATATGGATGATTTTTCTATTAATCTATATATAATGTTGATTTGTG 1260  
E S Y D S Y G \* F F Y \* I Y I \* C \* F V  
K V M T H M D D F S I K S I Y N V D L C  
K L \* L I W M I F L L N L Y I M L I C V

1261 TGATTGTGGTTTGTATGTCAGTATGGTTATGTAGATTGTTTTAATGATAAATGTGATTT 1320  
\* L W F C Y A V W L C R L F \* \* \* L \* F  
D C G F V M Q Y G Y V D C F N D N C D F  
I V V L L C S M V M \* I V L M I I V I F

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTCTGTCCATTGTGTTGACAGT 1380  
L W L G F R \* Y D G W F F L S I V L Y S  
Y G W V S G N M M D G F S C P L C C T V  
M V G F Q V I \* W M V F L V H C V V Q F

1381 TTATGACTCTAGCGAAGTTAAAGCCCAATCATCTGGTGTATTCTCGAAAATCCTGTGTT 1440  
L \* L \* R S \* S P I I W C Y S \* K S C V  
Y D S S E V K A Q S S G V I P E N P V L  
M T L A K L K P N H L V L P L K I L C Y

1441 ATTTACTAATAGTACTGATACTGTTAACCATGATTCTTTAATTTGTATGGTTATTCTGT 1500  
I Y \* \* Y \* Y C \* P \* F F \* F V W L F C  
F T N S T D T V N H D S F N L Y G Y S V  
L L I V L I L L T M I L L I C M V I L S

1501 CACACCATTGGTTCTTGTATATATTGGTCGCCGCTCCTGGATTGTGGATTCTATAAT 1560  
H T I W F L Y I L V A A S W I V D S Y N  
T P F G S C I Y W S P R P G L W I P I I  
H H L V L V Y I G R R V L D C G F L \* L

1561 TAAATCTCAGTCAAGTCTTATGATGATTTGGTTTATTTCAGGTGTAGTAGTTGTAATC 1620  
\* I F S Q V L \* \* F G L F R C S R L \* I  
K S S V K S Y D D L V Y S G V V G C K S  
N L Q S S L M M I W F I Q V \* \* V V N L

FIG. 2 CONT.

1621 TATTGTAAAGAACTGCTCTTATTACTCATGCACCTTACTTAGATTATGTTCAATGTAA 1680  
Y C \* R N C S Y Y S C T L L R L C S M \*  
I V K E T A L I T H A L Y L D Y V Q C K  
L L K K L L L L L M H F T \* I M F N V S

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGCGTTAATAATTCTTGGTGTAGGCAACT 1740  
V W \* S \* T K S Y S W R \* \* F L V \* A T  
C G N L E Q N H I L G V N N S W C R Q L  
V V I L N K I I F L A L I I L G V G N C

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTCTAAAAAATATTGACTTGTTTGTTAAGCG 1800  
V A \* \* R \* L \* Y A S K K Y \* L V C \* A  
L L N R G D Y N M L L K N I D L F V K R  
C L I E V I I I C F \* K I L T C L L S V

1801 TCGTGCTGATTTTGCTTGCAGTTTGCAGTTTGTGGAGATGGTTTTGTACCTTTTTTACT 1860  
S C \* F C L Q V C S L W R W F C T F F T  
R A D F A C K F A V C G D G F V P F L L  
V L I L L A S L Q F V E M V L Y L F Y \*

1861 AGATGGTTAATCCCGTAGTTATTATCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920  
R W F N S P \* L L S N S E W Y F L Y I F  
D G L I P R S Y Y L I Q S G I F F T S L  
M V \* F P V V I I \* F R V V F S L H L \*

1921 GATGTCTCAATTTTCACAAGAAGTTTCTGATATGTGTTAAAAATGTGTATTTTGTTTAT 1980  
D V S I P T R S F \* Y V F K N V Y F V Y  
M S Q F S Q E V S D M C L K M C I L F M  
C L N F H K K F L I C V \* K C V F C L W

1981 GGACAGAGTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGTTGGTTACTCA 2040  
G Q S F S C Y I L Y R A L C \* \* V G Y S  
D R V S V A T F Y I E H Y V N R L V T Q  
T E F Q L L H F I \* S I M L I G W L L N

2041 ATTTAAGTTATTGGGTACTACACTTGTAAATAAAATGGTTAATGGTTAATACCATGTT 2100  
I \* V I G Y Y T C \* \* N G \* L V \* Y H V  
F K L L G T T L V N K M V N W P N T M L  
L S Y W V L H L L I K W L I G L I P C \*

2101 AGATGCTAGTGCACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTTGT 2160  
R C \* C T C Y R L A S L P I I E W S F C  
D A S A P A T G W L L Y Q L L N G L F V  
M L V H L L Q A G F F T N Y \* M V F L \*

FIG. 2 CONT.

2161 AGTATCTCAAGCCAACTTTAATTTTGTGCTTTAATACCTGATTATGCTAAAATTTTAGT 2220  
S I S S Q L \* F C C F N T \* L C \* N F S  
V S Q A N F N F V A L I P D Y A K I L V  
Y L K P T L I L L L \* Y L I M L K F \* L

2221 TAATAAATTTTACACTTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTAAA 2280  
\* \* I L H F F \* V I I R V C Y S \* C F K  
N K F Y T F F K L L L E C V T V D V L K  
I N P T L F L S Y Y \* S V L Q L M F \* K

2281 AGATATGCCTGTTCTTAAACTATTAATGGTTTAGTTTGTATTGTAGGCAATAAGTTTTA 2340  
R Y A C S \* N Y \* W F S L Y C R Q \* V L  
D M P V L K T I N G L V C I V G N K F Y  
I C L F L K L L M V \* F V L \* A I S F I

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTTGTTTTACCATGTAATGCACAGGAACAACA 2400  
\* R \* Y R V N S W F C F T M \* C T G T T  
N V S T G L I P G F V L P C N A Q E Q Q  
T L V Q G \* F L V L F Y H V M H R N N K

2401 AATTTATTTTTTTGAAGGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAGAA 2460  
N L F F \* R R C R I C Y S R R \* C Y \* E  
I Y F F E G V A E S V I V E D D V I E N  
F I F L K A L Q N L L \* \* K M M L L R M

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAAT 2520  
C Q I F F I I L \* V L S T T \* I C R K N  
V K S S L S S Y E Y C Q P P K S V E K I  
S N L L Y H L M S I V N H L N L \* K K F

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTTCCCTATTGTCAT 2580  
L Y Y R \* Y V H G \* V W \* \* I F P Y C H  
C I I D N M Y M G K C G D K F F P I V M  
V L \* I I C T W V S V V I N F S L L S \*

2581 GAATGATAAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTTCCATGTGCAGGTAGAAA 2640  
E \* \* K Y L S F R S G L A F S M C R \* K  
N D K N I C L L D Q A W R F P C A G R K  
M I K I F V F \* I R L G V F H V Q V E K

2641 AGTTAATTTTAAACGAGAAACCTGTTGTTATGGAGATTCGGTCTTTGATGACAGTTAAGGT 2700  
S \* F \* R E T C C Y G D S V F D D S \* G  
V N F N E K P V V M E I P S L M T V K V  
L I L T R N L L L W R F R L \* \* Q L R L

FIG. 2 CONT.

2701 TATGTTTGATTAGATTCTACTTTTGATGATATTTTAGGTTAAAGTTGTCAGAATTGA 2760  
Y V \* F R F Y F \* \* Y F R \* S L F R I \*  
M F D L D S T F D D I L G K V C S E F E  
C L I \* I L L L M I F \* V K F V Q N L K

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTGCTGTTGTTTGTGATGCTATAGAGAA 2820  
S R K G C Y C R \* F C C C C L \* C Y R E  
V E K G V T V D D F V A V V C D A I E N  
\* K R V L L \* M I L L L L F V M L \* R M

2821 TGCTTTAAACTCTTGTAAGAGCATCCAGTGGTGGTTATCAAGTTCGTGCATTTTAA 2880  
C F K L L \* R A S S G W L S S S C I F K  
A L N S C K E H P V V G Y Q V R A F L N  
L \* T L V K S I Q W L V I K F V H F \* I

2881 TAAACTTAATGAGAATGTGTTTATTATTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940  
\* T \* \* E C C L F I \* \* G W \* \* S N G L  
K L N E N V V Y L F D E A G D E A M A S  
N L M R M L F I Y L M R L V M K Q W P L

2941 TCGTATGATTGTACTTTTGCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000  
S Y V L Y F C Y \* G C \* R R Y Q \* \* S C  
R M Y C T F A I E D V E D V I S S E A V  
V C I V L L L L R M L K T L S V V K L S

3001 CGAAGATACTATTGATGGTGTGTTGAAGACACTATTAATGACGATGAAGATGTTGTTAC 3060  
R R Y Y \* W C R \* R H Y \* \* R \* R C C Y  
E D T I D G V V E D T I N D D E D V V T  
K I L L M V S L K T L L M T M K M L L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3181 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

FIG. 2 CONT.



3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3361 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3420  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3421 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATAACGATGAAGAGATTGTTAC 3480  
W \* Q \* R \* R C C Y W \* Q \* R \* R D C Y  
G D N D D E D V V T G D N N D E E I V T  
V T M T M K M L L L V T I T M K R L L L

3481 TGGTGACAATGATGACCAAATGTTGTTACTGGTGATGATGTAGATGATATTGAAAGTAT 3540  
W \* Q \* \* P N C C Y W \* \* C R \* Y \* K Y  
G D N D D Q I V V T G D D V D D I E S I  
V T M M T K L L L L V M M \* M I L K V F

3541 TTATGACTTGGATACTTATAAAGCTCTTTTAGTTTTAATGATGCTATAATGATGCTTT 3600  
L \* L \* Y L \* S S F S F \* \* C L \* \* C F  
Y D F D T Y K A L L V F N D V Y N D A L  
M T L I L I K L F \* F L M M S I M M L C

3601 GTTTGTAGTTATGGTTCTAGTGTGAAACAGAAACATATTTTAAAGTTAATGGTTTATG 3660  
V C \* L W F \* C \* N R N I F \* S \* W F M  
F V S Y G S S V E T E T Y F K V N G L W  
L L V M V L V L K Q K H I L K L M V Y G

3661 GTCACCTACTATTACACATACTAATGTTGGTTGCGTCTGTGTTACTTGTAAATGCAGAA 3720  
V T Y Y Y T Y \* L L V A F C V T C N A E  
S P T I T H T N C W L R S V L L V M Q K  
H L L L H I L I V G C V L C Y L \* C R N

3721 ATTACCTTTAAGTTAAGGATTTAGCTATTGAAAATATGTGGTTATCTTATAAGGTGGG 3780  
I T F \* V \* G F S Y \* K Y V V I L \* G G  
L P F K F K D L A I E N M W L S Y K V G  
Y L L S L R I \* L L K I C G Y L I R W V

FIG. 2 CONT.

3781 TTATAATCAAAGTTTGTGGATTATTTACTGACCACTATTTCCTAAAGCTATTGTTTTGCC 3840  
L \* S K F C \* L F T D H Y S \* S Y C F A  
Y N Q S F V D Y L L T T I P K A I V L P  
I I K V L L I I Y \* P L F L K L L F C L

3841 TCAAGTGGTTTTGTAGCTGATTTTGCTTATTGGTTTTTAAACCAGTTGATATTAATGC 3900  
S R W F C S \* F C L L V F K P V \* Y \* C  
Q G G F V A D F A Y W F L N Q F D I N A  
K V V L \* L I L L I G F \* T S L I L M R

3901 GTATGCTAATTGGTGTGTTAAAATGGTTTTTCTTTTGATTTAAATGGTTGGATGC 3960  
V C \* L V L F K M W F F F \* F K W F G C  
Y A N W C C L K C G F S F D L N G L D A  
M L I G V V \* N V V F L L I \* M V W M L

3961 TTGTGTTTTTATGGAGATATTGTGTCTCATGTTTGTAAAGTGGACATAATGACTCT 4020  
F V F L W R Y C V S C L \* V W T \* Y D S  
L F F Y G D I V S H V C K C G H N M T L  
C F F M E I L C L M F V S V D I I \* L \*

4021 AATAGCAGCGGACTTACCTGTACATTACATTTTCATTATTTGATGACAATTTTGTGC 4080  
N S S G L T L Y I T F F I I \* \* Q F L C  
I A A D L P C T L H F S L F D D N F C A  
\* Q R T Y L V H Y I F H Y L M T I F V L

4081 TTTTTCACCCCTAAAAAATTTTATTGCTGCATGTGCTGGATGTAAACGTTTGTCA 4140  
F L H P \* K N F Y C C M C C G C K R L S  
F C T P K K I F I A A C A V D V N V C H  
F A P L K K F L L L H V L W M \* T F V I

4141 TTCTGTAGCTGTTATAGGTGATGAACAAATAGATGGTAAGTTTGTACTAAATTTAGTGG 4200  
F C S C Y R \* \* T N R W \* V C Y \* I \* W  
S V A V I G D E Q I D G K F V T K F S G  
L \* L L \* V M N K \* M V S L L L N L V V

4201 TGATAAATTTGATTTTATAGTAGGTTATGGAATGTCATTTAGTATGTCTCTTTTGAGTT 4260  
\* \* I \* F Y S R L W N V I \* Y V F F \* V  
D K F D F I V G Y G M S F S M S S F E L  
I N L I L \* \* V M E C H L V C L L L S Y

4261 ACCTCAATTGTATGGTTTGTGTATAACACCTAATGTATGTTTGTAAAGGTGATATTAT 4320  
T S I V W F V Y N T \* C M F C \* R \* Y Y  
P Q L Y G L C I T P N V C F V K G D I I  
L N C M V C V \* H L M Y V L L K V I L \*

FIG. 2 CONT.

4321 AAATGTTGCTAGACTTGTTAAAGCTGATGTTATTGTTAATCCTGCTAATGGGCATATGCT 4380  
 K C C \* T C \* S \* C Y C \* S C \* W A Y A  
 N V A R L V K A D V I V N P A N G H M L  
 M L L D L L K L M L L L I L L M G I C S

4381 CCATGGTGGTGGAGTTGCAAAAGCTATAGCTGTAGCTGCAGGTAAAAAATTTTCTAAAGA 4440  
 P W W W S C K S Y S C S C R \* K I F \* R  
 H G G G V A K A I A V A A G K K F S K E  
 M V V E L Q K L \* L \* L Q V K N F L K K

4441 AACTGCTGCTATGTTAAATCTAAAGGTGTTTCCCAAGTAGGAGATTGTTATGTTTCTAC 4500  
 N C C Y G \* I \* R C L P S R R L L C F Y  
 T A A M V K S K G V C Q V G D C Y V S T  
 L L L W L N L K V F A K \* E I V M P L P

4501 CGGTGTAATTATGTAAAACAATTCTTAATATTGTAGGCCCTGATGCTAGACAAGATGG 4560  
 R W \* I M \* N N S \* Y C R P \* C \* T R W  
 G G K L C K T I L N I V G P D A R Q D G  
 V V N Y V K Q F L I L \* A L M L D K M E

4561 AAGACAATCTTATGTTTTGTTAGCACGCTGCTTATAAGCATCTTAATAATTATGATTGTTG 4620  
 K T I L C F V S T C L \* A S \* \* L \* L L  
 R Q S Y V L L A R A Y K H L N N Y D C C  
 D N L M F C \* H V L I S I L I I M I V V

4621 TTTGCTACTCTCATATCGGCTGGTATATTTAGTGTTCTGCTGATGTGTCATTAECTTA 4680  
 F V Y S H I G W Y I \* C S C \* C V I N L  
 L S T L I S A G I F S V P A D V S L T Y  
 C L L S Y R L V Y L V F L L M C H \* L T

4681 CCTTCTAGGTGTTGTTGATAAACAAGTTATCCTTGTAGTAATAATAAAGAAGATTTGA 4740  
 P S R C C \* \* T S Y P C \* \* \* \* R R F \*  
 L L G V V D K Q V I L V S N N K E D F D  
 F \* V L L I N K L S L L V I I K K I L I

4741 TATTATTCAAAAATGTCAAATTACTTCAGTTGTTGGTACTAAAGCATTGGCTGTTAGATT 4800  
 Y Y S K M S N Y F S C W Y \* S I G C \* I  
 I I Q K C Q I T S V V G T K A L A V R L  
 L F K N V K L L Q L L V L K H W L L D \*

4801 AACTGCTAATGTAGGCCGTGTTATTAATTTGAGACAGATGCATACAAACTTTTTTTGAG 4860  
 N C \* C R P C Y \* I \* D R C I Q T P F E  
 T A N V G R V I K F E T D A Y K L F L S  
 L L M \* A V L L N L R Q M H T N F F \* V

FIG. 2 CONT.

4861 TGGTGATGATTGTTTTGTTTCAAATTCTTCTGTTATACAAGAAGTTTTATTGCTTCGTCA 4920  
W \* \* L F C F K F F C Y T R S F I A S S  
G D D C F V S N S S V I Q E V L L L R H  
V M I V L F Q I L L L Y K K F Y C F V M

4921 TGATATACAATTGAATAATGACGTTTCGTGATTATTTGTTGTCTAAGATGACTAGTCTTCC 4980  
\* Y T I E \* \* R S \* L F V V \* D D \* S S  
D I Q L N N D V R D Y L L S K M T S L P  
I Y N \* I M T F V I I C C L R \* L V F L

4981 TAAAGATTGGCGTCTTATCAATAAATTGATGTTATTAACGGTGTAAAACTGTTAAGTA 5040  
\* R L A S Y Q \* I \* C Y \* R C \* N C \* V  
K D W R L I N K F D V I N G V K T V K Y  
K I G V L S I N L M L L T V L K L L S I

5041 TTTTGAGTGTCTAATTCTATTTATATATGTAGTCAGGGTAAAGACTTTGGTTATGTATG 5100  
F \* V S \* P Y L Y M \* S G \* R L W L C M  
F E C P N S I Y I C S Q G K D F G Y V C  
L S V L I L F I Y V V R V K T L V M Y V

5101 TGATGGTTCTTTTTATAAAGCAACTGTTAATCAAGTTTGTGTTTTATTAGCTAAGAAGAT 5160  
\* W F F L \* S N C \* S S L C F I S \* E D  
D G S F Y K A T V N Q V C V L L A K K I  
M V L F I K Q L L I K F V F Y \* L R R \*

5161 AGATGTTTTGCTTACTGTAGATGGTGTAAATTTAAATCTATTTCTTACTGTAGGTGA 5220  
R C F A Y C R W C \* F \* I Y F S Y C R \*  
D V L L T V D G V N F K S I S L T V G E  
M F C L L \* M V L I L N L F L L L \* V K

5221 AGTTTTTGGTAAAATACTTGGTAATGTTTTCTGTGATGGCATTGATGTTACTAAGTTAAA 5280  
S F W \* N T W \* C F L \* W H \* C Y \* V K  
V F G K I L G N V F C D G I D V T K L K  
F L V K Y L V M F S V M A L M L L S \* S

5281 GTGTAGTGATTTTTATGCCGATAAAAATTTATATCAGTATGAAAATTTGTCTTTAGCTGA 5340  
V \* \* F L C R \* N F I S V \* K F V F S \*  
C S D F Y A D K I L Y Q Y E N L S L A D  
V V I F M P I K F Y I S M K I C L \* L I

5341 TATTTCTGCTGTACAAAGTTCATTTGGGTTTGATCAGCAACAATTGCTTGCTTATTATAA 5400  
Y F C C T K F I W V \* S A T I A C L L \*  
I S A V Q S S F G F D Q Q Q L L A Y Y N  
F L L Y K V H L G L I S N N C L L I I I

FIG. 2 CONT.

5401 TTTTTAACAGTATGTAATGGTCTGTAGTTGTTAACGGTCCATTTTTTCTTTTGAACA 5460  
 F F N S M \* M V C S C \* R S I F F F \* T  
 F L T V C K W S V V V N G P F F S F E Q  
 F \* Q Y V N G L \* L L T V H F F L L N S

5461 GTCTCATAATAATGTTATGTGAATGTAGCTTGTCTTATGTTGCAGCATATTAATCTTAA 5520  
 V S \* \* L L C E C S L S Y V A A Y \* S \*  
 S H N N C Y V N V A C L M L Q H I N L K  
 L I I I V M \* M \* L V L C C S I L I L N

5521 ATTTAATAAATGGCAGTGGCAGGAAGCATGGTATGAATTCGTGCTGGCAGACCACATAG 5580  
 I \* \* M A V A G S M V \* I S C W Q T T \*  
 F N K W Q W Q E A W Y E F R A G R P H R  
 L I N G S G R K H G M N F V L A D H I G

5581 GTTAGTTGCTCTTGTGTTTAAAGGTCATTTTAAATTTGATGAACCATCAGATGCTAC 5640  
 V S C S C F S \* R S F \* I \* \* T I R C Y  
 L V A L V L A K G H F K F D E P S D A T  
 \* L L L F \* L K V I L N L M N H Q M L L

5641 TGATTTTATTCGTGTTGTTTGAACAAGCTGATTATCAGGTGCAATTTGTGAATTAGA 5700  
 \* F Y S C C F E T S \* F I R C N L \* I R  
 D F I R V V L K Q A D L S G A I C E L E  
 I L F V L F \* N K L I Y Q V Q F V N \* N

5701 ACTTATTTGTGATTGTGGTATTAAACAAGAAAGTCGTGTTGGTGTGATGCTGTTATGCA 5760  
 T Y L \* L W Y \* T R K S C W C \* C C Y A  
 L I C D C G I K Q E S R V G V D A V M H  
 L F V I V V L N K K V V L V L M L L C I

5761 TTTTGGTACATTAGCAAAGACTGATCTTTTAAATGGTTATAAGATTGGCTGTAATTGTGC 5820  
 F W Y I S K D \* S F \* W L \* D W L \* L C  
 F G T L A K T D L F N G Y K I G C N C A  
 L V H \* Q R L I F L M V I R L A V I V Q

5821 AGGTAGAATTGTCCATTGTACTAAATGAATGTACCATTTTTGATTTGTTCTAATACTCC 5880  
 R \* N C P L Y \* I E C T I F D L F \* Y S  
 G R I V H C T K L N V P F L I C S N T P  
 V E L S I V L N \* M Y H F \* F V L I L L

5881 TCTGAGTAAGGATTACCTGATGATGTTGTTGCAGCTAACATGTTTATGGGTGTAGGTGT 5940  
 S E \* G F T \* \* C C C S \* H V Y G C R C  
 L S K D L P D D V V A A N M F M G V G V  
 \* V R I Y L M M L L Q L T C L W V \* V \*

FIG. 2 CONT.

5941 AGGCCATTATACACATTTGAAATGTGGTTCACCTTACCAACATTATGATGCTTGTAGTGT 6000  
R P L Y T F E M W F T L P T L \* C L \* C  
G H Y T H L K C G S P Y Q H Y D A C S V  
A I I H I \* N V V H L T N I M M L V V L

6001 TAAAAATATACAGGTGTAGTGGTTGTTAACTGACTGCTTGTATCTTAAAAATTTAAC 6060  
\* K I Y R C \* W L F N \* L L V S \* K F N  
K K Y T G V S G C L T D C L Y L K N L T  
K N I Q V L V V V \* L T A C I L K I \* P

6061 CCGACTTTTACATCTATGTTGACTAATTATTTTTGGATGATGTTGAAATGGTTGCTTA 6120  
P D F Y I Y V D \* L F F G \* C \* N G C L  
Q T F T S M L T N Y F L D D V E M V A Y  
R L L H L C \* L I I F W M M L K W L L I

6121 TAACCCTGATCTTTCACAATATTATTGTGATAATGGTAAGTATTATACAAAACCTATTAT 6180  
\* P \* S F T I L L \* \* W \* V L Y K T Y Y  
N P D L S Q Y Y C D N G K Y Y T K P I I  
T L I F H N I I V I M V S I I Q N L L \*

6181 AAAGGCTCAGTTTAAACCATTGCTAAAGTTGACGGTGTATACTAACTTTAAGTTAGT 6240  
K G S V \* T I C \* S \* R C L Y \* L \* V S  
K A Q F K P F A K V D G V Y T N F K L V  
R L S L N H L L K L T V F I L T L S \* L

6241 TGGACATGATATTTGTGCTCAATTGAATGATAAGTTAGGTTTAAATGTAGATTGCCGTT 6300  
W T \* Y L C S I E \* \* V R F \* C R F A V  
G H D I C A Q L N D K L G F N V D L P F  
D M I F V L N \* M I S \* V L M \* I C R L

6301 TGTTGAGTACAAAGTAACAGTCTGGCCTGTAGCTACTGGTGATGTTGTTTTGGCATCTGA 6360  
C \* V Q S N S L A C S Y W \* C C F G I \*  
V E Y K V T V W P V A T G D V V L A S D  
L S T K \* Q S G L \* L L V M L F W H L M

6361 TGATTTATATGTGAAACGTTATTTTAAAGGATGTGAAACTTTTGGTAAGCCTGTTATTTG 6420  
\* F I C E T L F \* R M \* N F W \* A C Y L  
D L Y V K R Y F K G C E T F G K P V I W  
I Y M \* N V I L K D V K L L V S L L F G

6421 GTTTTGTGATGATGAAGCATCATTTGAATCTCTACTTATTTTAAATAAACCTAGTTTAA 6480  
V L S \* \* S I I E F S Y L F \* \* T \* F \*  
F C H D E A S L N S L T Y F N K P S F K  
F V M M K H H \* I L L L I L I N L V L N

FIG. 2 CONT.

6481 ATCTGAAAATAGATATAGTGTTTTGTCTGTTGATTCTGTATCTGAGGAGTCACAAGGTAA 6540  
 I \* K \* I \* C F V C \* F C I \* G V T R \*  
 S E N R Y S V L S V D S V S E E S Q G N  
 L K I D I V F C L L I L Y L R S H K V M

6541 TGTGGTTACTTCTGTATGGAATCGCAGATTAGTACTAAAGAGGTTAAGTTAAAGGGTGT 6600  
 C G Y F C Y G I A D \* Y \* R G \* V K G C  
 V V T S V M E S Q I S T K E V K L K G V  
 W L L L L W N R R L V L K R L S \* R V L

6601 TAGAAAGACTGTAAAATAGAAGATGCTATTATTGTTAATGATGAAAATAGTCTATTAA 6660  
 \* K D C \* N R R C Y Y C \* \* \* K \* F Y \*  
 R K T V K I E D A I I V N D E N S S I K  
 E R L L K \* K M L L L L M M K I V L L R

6661 GGTGTGTTAAAAGTTTATCTTTAGTTGATGTTGGGATATGTATTGACAGGTGTGATTA 6720  
 G C \* K F I F S \* C L G Y V F D R L \* L  
 V V K S L S L V D V W D M Y L T G C D Y  
 L L K V Y L \* L M F G I C I \* Q V V I M

6721 TGTGTTTTGGGTTGCTAATGAATTGTCACGCCTAGTTAAATCACCAACAGTTAGGGAATA 6780  
 C C L G C \* \* I V T P S \* I T N S \* G I  
 V V W V A N E L S R L V K S P T V R E Y  
 L F G L L M N C H A \* L N H Q Q L G N I

6781 TATACGATATGGTATTAACCTATTACTATACCTATAGATTTGTTATGTTTAAAGAGATGA 6840  
 Y T I W Y \* T Y Y Y T Y R F V M F K R \*  
 I R Y G I K P I T I P I D L L C L R D D  
 Y D M V L N L L L Y L \* I C Y V \* E M I

6841 TAATCAAACCTCTTTAGTTCCTAAAATTTTTAAAGCAAGAGCTATAGAATTTTATGGTTT 6900  
 \* S N S F S S \* N F \* S K S Y R I L W F  
 N Q T L L V P K I F K A R A I E F Y G F  
 I K L F \* F L K F L K Q E L \* N F M V F

6901 TTTGAAGTGGTTGTTTATTATGTTTTAGTTTATTACATTTTACAAATGATAAAACCAT 6960  
 F E V V V Y L C F \* F I T F Y K \* \* N H  
 L K W L F I Y V F S L L H P T N D K T I  
 \* S G C L F M F L V Y Y I L Q M I K P F

6961 TTTTATACTACAGAAATAGCTTCTAAGTTTACTTTAAATTTGTTTTGTTGGCTCTTAA 7020  
 F L Y Y R N S F \* V Y F \* F V L F G S \*  
 F Y T T E I A S K F T F N L F C L A L K  
 F I L Q K \* L L S L L L I C F V W L L K

FIG. 2 CONT.

7021 AAATGCTTTTCAGACATTTAGATGGAGTATATTTATAAAAAGGTTTTCTTGTGTAGCCAC 7080  
 K C F S D I \* M E Y I Y K R F S C C S H  
 N A F Q T F R W S I F I K G F L V V A T  
 M L F R H L D G V Y L \* K V F L L \* P L

7081 TGTGTTTTGTTTTGGTTAAATTTTTGTATATAAATGTTATTTTTAGTGACTTTTATCT 7140  
 C V F V L V \* F F V Y K C Y F \* \* L L S  
 V F L F W F N F L Y I N V I F S D F Y L  
 C F C F G L I F C I \* M L F L V T F I F

7141 TCCTAATATTAGTGTTTTCCCTATTTTTGTGGGAAGAATTGTTATGTGGATAAAGGCTAC 7200  
 S \* Y \* C F S Y F C G K N C Y V D K G Y  
 P N I S V F P I F V G R I V M W I K A T  
 L I L V F F L F L W E E L L C G \* R L L

7201 TTTTGGTTTGGTTACAATTTGTGATTTTTATTCTAAGTTAGGTGTAGGTTTACAAGTCA 7260  
 F W F G Y N L \* F L F \* V R C R F Y K S  
 F G L V T I C D F Y S K L G V G F T S H  
 L V W L Q P V I F I L S \* V \* V L Q V I

7261 TTTTGTAAATGGTAGTTTTATATGTGAATTGTGTCATTCTGGTTTTGATATGTTGGATAC 7320  
 F L \* W \* P Y M \* I V S F W F \* Y V G Y  
 F C N G S F I C E L C H S G F D M L D T  
 F V M V V L Y V N C V I L V L I C W I H

7321 ATATGCAGCTATAGATTTTTGTTCAGTATGAAGTAGATAGACGTGTTTTATTGATTATGT 7380  
 I C S Y R F C S V \* S R \* T C F I \* L C  
 Y A A I D F V Q Y E V D R R V L F D Y V  
 M Q L \* I L F S M K \* I D V F Y L I M L

7381 TAGTTTAGTCAAATTAATTGTTGAACTCGTTATTGGTTATTCATTATACACAGTATGGTT 7440  
 \* F S Q I N C \* T R Y W L F I I H S M V  
 S L V K L I V E L V I G Y S L Y T V W F  
 V \* S N \* L L N S L L V I H Y T Q Y G F

7441 TTATCCATTATTTGICTTATTGGTTTACAATTTACTACATGGTTGCCTGATTGTGTT 7500  
 L S I I L S Y W F T I I Y Y M V A \* F V  
 Y P L F C L I G L Q L F T T W L P D L F  
 I H Y F V L L V Y N Y L L H G C L I C L

7501 TATGTTAGAAACTATGCATTGGTTGATTAGATTTATTGTATTTGTAGCTAATATGTTACC 7560  
 Y V R N Y A L V D \* I Y C I C S \* Y V T  
 M L E T M H W L I R F I V F V A N M L P  
 C \* K L C I G \* L D L L Y L \* L I C Y L

FIG. 2 CONT.



7561	TGCTTTTGTCTTGTTCGGTTTTATATAGTTGTTACTGCTATGTATAAAGTAGTTGGTT C F C L V A V L Y S C Y C Y V * S S W F A F V L L R F Y I V V T A M Y K V V G F L L S C C G F I * L L L L C I K * L V L	7620
7621	TATTAGGCATATTGTCTATGGTTGTAATAAAGCTGGTTGTTTATTTTGTATAAACGAAA Y * A Y C L W L * * S W L F I L L * T K I R H I V Y G C N K A G C L F C Y K R N L G I L S M V V I K L V V Y F V I N E I	7680
7681	TTGTAGTGTTCGTGTTAAGTGTAGTACTATTGTTGGTGGTGAATTCGTTATTATGATAT L * C S C * V * Y Y C W W C N S L L * Y C S V R V K C S T I V G G V I R Y Y D I V V F V L S V V L L L V V * F V I M I L	7740
7741	TACTGCTAATGGTGGTACTGGTTTTTGTGTTAAACATCAATGGAATTGTTTTAATGCCA Y C * W W Y W F L C * T S M E L F * L P T A N G G T G F C V K H Q W N C F N C H L L M V V L V F V L N I N G I V L I A I	7800
7801	TTCTTTTAAACCAGGTAACACTTTTATAACTGTAGAAGCTGCTATAGAACTTTCTAAGA F F * T R * H F Y N C R S C Y R T F * R S F K P G N T F I T V E A A I E L S K E L L N Q V T L L * L * K L L * N F L K S	7860
7861	GCTTAAACGACCTGTAAATCCAACCTGATGCTTACATTATGTAGTACTGATATTAAGCA A * T T C K S N * C F T L C S Y * Y * A L K R P V N P T D A S H Y V V T D I K Q L N D L * I Q L M L H I M * L L I L S K	7920
7921	AGTTGGTGTATGATGCGTTTGTCTATGATAGAGATGGACAGCGTGTACGATGATGT S W L Y D A F V L * * R W T A C L R * C V G C M M R L F Y D R D G Q R V Y D D V L V V * C V C S M I E M D S V F T M M L	7980
7981	TGATGCTAGTTTATTTGTAGATATTAATAATCTGTTACATTCTAAAGTTAAAGTTGTTCC * C * F I C R Y * * S V T F * S * S C S D A S L F V D I N N L L H S K V K V V P M L V Y L * I L I I C Y I L K L K L F L	8040
8041	TAATTTGTATGTAGTTGTAGTAGAGATGATGCTGATAGAGCTAATTTTCTGAATGCTGT * F V C S C S R E * C * * S * F S E C C N L Y V V V V E S D A D R A N F L N A V I C M * L * * R V M L I E L I F * M L L	8100

FIG. 2 CONT.

8101	TGTGTTTTATGCACAATCATTGTATAGGCCTATATTACTTGTAGACAAAAAGTTAATTAC C V L C T I I V * A Y I T C R Q K V N Y V F Y A Q S L Y R P I L L V D K K L I T C F M H N H C I G L Y Y L * T K S * L L	8160
8161	TACAGCTTGAATGGTATCTCTGTAACCCAGACTATGTTTGTATGTTTATGTTGATACTTT Y S L * W Y L C N P D Y V * C L C * Y F T A C N G I S V T Q T M F D V Y V D T F Q L V M V S L * P R L C L M F M L I L L	8220
8221	TATGTCTCATTTTGTATGTTGATAGAAAGAGTTTTAATAATTTGTTAACATTGCTCATGC Y V S F * C * * K E F * * F C * H C S C M S H F D V D R K S F N N F V N I A H A C L I L M L I E R V L I I L L T L L M L	8280
8281	TTCTCTTAGAGAGGGTGTGCAATTAGAAAAGTTTTAGATACTTTTGTGGGATGTGTACG F S * R G C A I R K G F R Y F C G M C T S L R E G V Q L E K V L D T F V G C V R L L E R V C N * K R F * I L L W D V Y V	8340
8341	TAAATGTTGTCCATTGATTGAGATGTTGAAACAAGATTTACTAAATCTATGATATC * M L F H * F R C * N K I Y Y * I Y D I K C C S I D S D V E T R F I T K S M I S N V V P L I Q M L K Q D L L L N L * Y L	8400
8401	TGCAGTAGCTGCTGGTTTGAATTTACTGATGAAAATTATAACAATTTGGTACCTACATA C S S C W F G I Y * * K L * Q F G T Y I A V A A G L E F T D E N Y N N L V P T Y Q * L L V W N L L M K I I T I W Y L H I	8460
8461	TTTAAAGAGTGATAATATTGTAGCTGCTGATTTAGGTGTTCTTATACAGAATGGTGCTAA F K E * * Y C S C * F R C S Y T E W C * L K S D N I V A A D L G V L I Q N G A K * R V I I L * L L I * V F L Y R M V L S	8520
8521	GCATGTACAGGGTAATGTTGCTAAGGCAGCTAATATTTCTTGTATATGGTTTATTGATGC A C T G * C C * G S * Y F L Y M V Y * C H V Q G N V A K A A N I S C I W F I D A M Y R V M L L R Q L I F L V Y G L L M L	8580
8581	TTTTAATCAACTTACTGCTGATTTACAGCATAAATAAAAAAGCATGTGTTAAACTGG F * S T Y C * F T A * I K K S M C * N W F N Q L T A D L Q H K L K K A C V K T G L I N L L L I Y S I N * K K H V L K L A	8640

FIG. 2 CONT.

8641	CTTGAAGTTAAAATTGACTTTTAATAAGCAAGAGGCAAGTGTCCCTATTCTTACAACACC L E V K I D F * * A R G K C P Y S Y N T L K L K L T F N K Q E A S V P I L T T P * S * N * L L I S K R Q V S L F L Q H P	8700
8701	CTTTTCACTTAAAGGAGGTGTGTATTGAGTAATTTGTTATATATATTATTTTTTGTAG L F T * R R C C I E * F V I Y I I F C * F S L K G G V V L S N L L Y I L F F V S F H L K E V L Y * V I C Y I Y Y F L L V	8760
8761	TTTAATCTGTTTTATATATTGTGGGCTTTATTCCTACATATAGTGTTTATAAGTCTGA F N L F Y I I V G F I A Y I * C L * V * L I C F I L L W A L L P T Y S V Y K S D * S V L Y Y C G L Y C L H I V F I S L I	8820
8821	TATTCATTTGCCTGCTTATGCTAGTTTTAAAGTTATTGATAATGGTGTGTAGAGATAT Y S F A C L C * F * S Y * * W C C * R Y I H L P A Y A S F K V I D N G V V R D I F I C L L M L V L K L L I M V L L E I F	8880
8881	TTCAGTTAATGATTTATGTTTTGCTAATAAATTTTTCCAATTTGATCAATGGTATGAGTC F S * * F M F C * * I F P I * S M V * V S V N D L C F A N K F F Q F D Q W Y E S Q L M I Y V L L I N F S N L I N G M S P	8940
8941	CACTTTGGGTCGTTTACTATCATAATTCATGGATTGCCCTATTGTAGTGGCAGTTAT H F W V C L L S * F Y G L P Y C S G S Y T F G S V Y Y H N S M D C P I V V A V M L L G L F T I I I L W I A L L * W Q L W	9000
9001	GGATGAAGATATCGGTTCTACTATGTTTAAATGTTCCCTACTAAAGTTTGAGACATGGCTT G * R Y R F Y Y V * C S Y * S F E T W L D E D I G S T M F N V P T K V L R H G F M K I S V L L C L M F L L K F * D M A F	9060
9061	TCATGTTTTACATTTTTAACTTATGCATTGCTAGTGATAGTGTTCAGTGCTATACACC S C F T F F N L C I C * * * C S V L Y T H V L H F L T Y A F A S D S V Q C Y T P M F Y I F * L M H L L V I V F S A I H H	9120
9121	ACATATTCAGATTTCTTATAATGATTTTTATGCTAGTGGTTGTGTTTTATCATCTTTGTG T Y S D F L * * F L C * W L C F I I F V H I Q I S Y N D F Y A S G C V L S S L C I F R F L I M I F M L V V V F Y H L C V	9180

FIG. 2 CONT.

9181 TACTATGTTTTAAAAGAGGTGATGGTACACCACATCCTTATTGTTATTCAGATGGTGTAT 9240  
 Y Y V \* K R \* W Y T T S L L L F R W C Y  
 T M F K R G D G T P H P Y C Y S D G V M  
 L C L K E V M V H H I L I V I Q M V L \*

9241 GAAGAATGCTTCTTTGTATACATCTTTGGTTCCACATACACGTTATAGCCTTGCTAATTC 9300  
 E E C F F V Y I F G S T Y T L \* P C \* F  
 K N A S L Y T S L V P H T R Y S L A N S  
 R M L L C I H L W F H I H V I A L L I L

9301 TAATGGTTTTATAAGATTTCTGATGTTATTAGTGAAGGTATTGTACGTATTGTAAGAAC 9360  
 \* W F Y K I S \* C Y \* \* R Y C T Y C K N  
 N G F I R F P D V I S E G I V R I V R T  
 M V L \* D F L M L L V K V L Y V L \* E R

9361 GCGCTCTATGACTTATTGTAGAGTGGGTGCATGTGAATACGCCGAAGAGGGTATATGTTT 9420  
 A L Y D L L \* S G C M \* I R R R G Y M F  
 R S M T Y C R V G A C E Y A E E G I C F  
 A L \* L I V E W V H V N T P K R V Y V L

9421 TAATTTAATAGTTCCTGGGTTTTGAATAATGATTATTATAGAAGTATGCCTGGAACTTT 9480  
 \* F \* \* F L G F E \* \* L L \* K Y A W N F  
 N F N S S W V L N N D Y Y R S M P G T F  
 I L I V P G F \* I M I I I E V C L E L F

9481 TTGTGGTAGAGATCTTTTTGATTGTTTATCAATTTTTAGTAGTTAATTCGTCCTAT 9540  
 L W \* R S F \* F V L S I F \* \* F N S S Y  
 C G R D L F D L F Y Q F F S S L I R P I  
 V V E I F L I C F I N F L V V \* F V L \*

9541 AGATTTCTTTTCTTACTGCTAGTTCATTTTTGGAGCTATATTGGCTATAGTTGTTGT 9600  
 R F L F S Y C \* F Y F W S Y I G Y S C C  
 D F F S L T A S S I F G A I L A I V V V  
 I S F L L L L V L F L E L Y W L \* L L S

9601 CTTGGTTTTTTATTATTAAATAAACTTAAGCGTGCTTTTGGAGATTATACTAGTGTGT 9660  
 L G F L L F N K T \* A C F W R L Y \* C C  
 L V F Y Y L I K L K R A F G D Y T S V V  
 W F F I I \* \* N L S V L L E I I L V L \*

9661 AGTTATAAATGTTGTTGTTGGTGTATTAATTTCTTATGCTTTTTGTTTTTCAAGTTTA 9720  
 S Y K C C C L V Y \* F S Y A F C F S S L  
 V I N V V V W C I N P L M L F V F Q V Y  
 L \* M L L F G V L I F L C F L F F K F I

FIG. 2 CONT.

9721 TCCTATTTGTCATGTGTTTATGCTTGTTTTATTTTATGTAACATTGATTTTCCTTC 9780  
S Y L C M C L C L F L F L C N I V F S F  
P I C A C V Y A C F Y F Y V T L Y F P S  
L F V H V F M L V F I F M \* H C I F L L

9781 TGAAATTAGTGAATTATGCATTGCAATGGATTGTTATGTATGGTGCTATAATGCCTTT 9840  
\* N \* C N Y A F A M D C Y V W C Y N A F  
E I S V I M H L Q W I V M Y G A I M P F  
K L V \* L C I C N G L L C M V L \* C L F

9841 TTGGTTTTGTGTCACATATGTAGCTATGGTTATTGCAAACCATGTTTTATGGTTATTTTC 9900  
L V L C H I C S Y G Y C K P C F M V I F  
W F C V T Y V A M V I A N H V L W L F S  
G F V S H M \* L W L L Q T M F Y G Y F H

9901 ATATTGTAGGAAAATTGGTGTAAATGTATGTAGTAGTACATTGAAGAAACATCTCT 9960  
I L \* E N W C \* C M \* \* \* Y I \* R N I S  
Y C R K I G V N V C S D S T F E E T S L  
I V G K L V L M Y V V I V H L K K H L L

9961 TACTACTTTTATGATTACTAAAGATTCTTATTGTAGATTAAGAATTCTGTTTCTGATGT 10020  
Y Y F Y D Y \* R F L L \* I K E F C F \* C  
T T F M I T K D S Y C R L K N S V S D V  
L L L \* L L K I L I V D \* R I L F L M L

10021 TGCCTACAATAGATATTTGAGTTTGTATAATAAGTATCGTTACTATAGTGGTAAAATGGA 10080  
C L Q \* I F E F V \* \* V S L L \* W \* N G  
A Y N R Y L S L Y N K Y R Y Y S G K M D  
P T I D I \* V C I I S I V T I V V K W I

10081 TACTGCTGCCTATAGAGAAGCGCGTGTCTCAGTTAGCTAAAGCTATGGAAACATTTAA 10140  
Y C C L \* R S G V F S V S \* S Y G N I \*  
T A A Y R E A A C S Q L A K A M E T F N  
L L P I E K R R V L S \* L K L W K H L I

10141 TCACAATAATGGTAATGATGTCTTATACCAACCTCCTACAGCATCTGTTTCTACATCTTT 10200  
S Q \* W \* \* C L I P T S Y S I C F Y I F  
H N N G N D V L Y Q P P T A S V S T S F  
T I M V M M S Y T N L L Q H L F L H L F

10201 TTTGCAATCAGGTATTGTAAGATGGTATCTCCTACGTCAAAAATTGAACCTTGATTGT 10260  
F A I R Y C K D G I S Y V K N \* T L Y C  
L Q S G I V K M V S P T S K I E P C I V  
C N Q V L \* R W Y L L R Q K L N L V L L

FIG. 2 CONT.

10261	TAGTGTTACTTATGGTAGTATGACTTTGAATGGTTTATGGTTAGATGACAAAGTTTATTG * C Y L W * Y D F E W F M V R * Q S L L S V T Y G S M T L N G L W L D D K V Y C V L L M V V * L * M V Y G * M T K F I V	10320
10321	TCCTCGTCATGTTATATGTTTCATCCTCTAATATGAACGAACCTGATTATTCTGCCTTATT S S S C Y M F I L * Y E R T * L F C L I P R H V I C S S S N M N E P D Y S A L L L V M L Y V H P L I * T N L I I L P Y C	10380
10381	GTGTAGAGTTACTCTAGGTGATTTTACTATAATGTCTGGTCGGATGAGTTTAAACAGTTGT V * S Y S R * F Y Y N V W S D E F N S C C R V T L G D F T I M S G R M S L T V V V E L L * V I L L * C L V G * V * Q L C	10440
10441	GTCTTACCAGATGCAGGGCTGTCAACTTGTTTTGACAGTCTCTTTACAAAATCCTTACAC V L P D A G L S T C F D S L F T K S L H S Y Q M Q G C Q L V L T V S L Q N P Y T L T R C R A V N L F * Q S L Y K I L T L	10500
10501	TCCAAAATATACTTTTGGTAATGTTAAACCTGGTGAAACTTTTACTGTTTTAGCTGCGTA S K I Y F W * C * T W * N F Y C F S C V P K Y T F G N V K P G E T F T V L A A Y Q N I L L V M L N L V K L L L F * L R I	10560
10561	TAATGGCCGACCACAAGGGGCATTTTCATGTTACTATGCGTAGTAGTTATACTATTAAGG * W P T T R G I S C Y Y A * * L Y Y * R N G R P Q G A F H V T M R S S Y T I K G M A D H K G H F M L L C V V V I L L K V	10620
10621	TTCTTTTTTGTGTGGGTCATGTGGATCTGTTGGTTATGTATTAACAGGTGATAGTGTAA F F F V W V M W I C W L C I N R * * C * S F L C G S C G S V G Y V L T G D S V K L F C V G H V D L L V M Y * Q V I V L S	10680
10681	GTTTGFATATATGCATCAATTAGAGCTCAGTACTGGTTGTCACACTGGCACTGATTTTAC V C I Y A S I R A Q Y W L S H W H * F Y F V Y M H Q L E L S T G C H T G T D F T L Y I C I N * S S V L V V T L A L I L L	10740
10741	TGTAATTTTTATGGTCCATATAGAGATGCTCAAGTTGTACAGTTGCCAGTTAAGGACTA W * F L W S I * R C S S C T V A S * G L G N F Y G P Y R D A Q V V Q L P V K D Y V I F M V H I E M L K L Y S C Q L R T T	10800

FIG. 2 CONT.

10801 CGTCCAGACTGTTAATGTTATTGCTTGGCTCTATGCAGCTATACTTAATAATTGTGCTTG 10860  
R P D C \* C Y C L A L C S Y T \* \* L C L  
V Q T V N V I A W L Y A A I L N N C A W  
S R L L M L L L G S M Q L Y L I I V L G

10861 GTTTGTACAAAATGATGTTTGTCTACTGAAGATTTTAAATGTTGGGCTATGGCAAATGG 10920  
V C T K \* C L F Y \* R F \* C L G Y G K W  
F V Q N D V C S T E D F N V W A M A N G  
L Y K M M F V L L K I L M F G L W Q M V

10921 TTTTAGCCAAGTAAAAGCAGATCTTGTCTTAGATGCTTGGCTTCAATGACAGGTGTTTC 10980  
F \* P S K S R S C L R C F G F N D R C F  
F S Q V K A D L V L D A L A S M T G V S  
L A K \* K Q I L S \* M L W L Q \* Q V F L

10981 TATTGAACTTTATTGGCTGCTATTAAGCGTCTATATATGGGATTTCAAGTCGTCAAAT 11040  
Y \* N F I G C Y \* A S I Y G I S R S S N  
I E T L L A A I K R L Y M G F Q G R Q I  
L K L Y W L L L S V Y I W D F K V V K Y

11041 ACTAGGAAGTTGTA CTTTGAAGATGAATTGGCACCTTCTGACGTTTATCAACAATTGGC 11100  
T R K L Y F \* R \* I G T F \* R L S T I G  
L G S C T F E D E L A P S D V Y Q Q L A  
\* E V V L L K M N W H L L T F I N N W L

11101 TGGTGTAAATGCAATCTAAAACAAAAGATTTATTAAAGAAACAATTTATTGGATTTT 11160  
W C \* I A I \* N K K I Y \* R N N L L D F  
G V K L Q S K T K R F I K E T I Y W I L  
V L N C N L K Q K D L L K K Q F I G F \*

11161 GATATCTACATTTTGTGTTAGTTGTATAATTTCTGCATTGTTAAATGGACTATATTTAT 11220  
D I Y I F V \* L Y N F C I C \* M D Y I Y  
I S T F L F S C I I S A F V K W T I F M  
Y L H F C L V V \* F L H L L N G L Y L C

11221 GTATATTAATACACATATGATTGGTGTACATTATGTGTA CTTTGTGTTAGTTTAT 11280  
V Y \* Y T Y D W C Y I M C T L F C \* F Y  
Y I N T H M I G V T L C V L C F V S F M  
I L I H I \* L V L H Y V Y F V L L V L \*

11281 GATGTTACTAGTTAAACATAAGCATTTTTATTGACTATGTATATAATTCCTGTACTCTG 11340  
D V T S \* T \* A F L F D Y V Y N S C T L  
M L L V K H K H F Y L T M Y I I P V L C  
C Y \* L N I S I F I \* L C I \* F L Y S V

FIG. 2 CONT.

11341 TACCTTGTTTTATGTA AATTATTTAGTTGTTTATAAGGAAGGTTTTAGAGGTTTTACTTA 11400  
 Y L V L C K L F S C L \* G R F \* R P Y L  
 T L F Y V N Y L V V Y K E G F R G F T Y  
 P C F M \* I I \* L F I R K V L E V L L M

11401 TGCTGGCTCTCATATTTTGTTCGCTGTGAATTTTACTTATGTTTATGAAGTATTTTA 11460  
 C L A L I F C S C C E F Y L C L \* S I L  
 V W L S Y F V P A V N F T Y V Y E V F Y  
 S G S H I L F L L \* I L L M F M K Y F M

11461 TGGTTGATTTTATGTGTTTTGCTATTTTATAACTATGCATAGTATTAATCATGACAT 11520  
 W L Y F M C F C Y F Y N Y A \* Y \* S \* H  
 G C I L C V F A I F I T M H S I N H D I  
 V V F Y V F L L F L \* L C I V L I M T F

11521 TTTTCTTTGATGTTTTGGTTGGTAGAATAGTTACTTTAATTTCTATGTGGTATTTTGG 11580  
 F F F D V F G W \* N S Y F N F Y V V F W  
 F S L M F L V G R I V T L I S M W Y F G  
 F L \* C F W L V E \* L L \* F L C G I L G

11581 GTCGAATTTAGAAGAGGATGTTTTGTTATTTATTACAGCCTTTTTAGGTA CTTATACATG 11640  
 V E F R R G C F V I Y Y S L F R Y L Y M  
 S N L E E D V L L F I T A F L G T Y T W  
 R I \* K R M F C Y L L Q P F \* V L I H G

11641 GACCACTATTTTGT CATTAGCTATAGCAAAAATGTTGCTAATTGGTTGCTGTTAATAT 11700  
 D H Y F V I S Y S K N C C \* L V V C \* Y  
 T T I L S L A I A K I V A N W L S V N I  
 P L F C H \* L \* Q K L L L I G C L L I Y

11701 ATTTTATTTTACAGATGTACCTTATATTA AATTGATTCCTTGAGTTACTTATTTATAGG 11760  
 I L F Y R C T L Y \* I D S L E L L I Y R  
 F Y F T D V P Y I K L I L L S Y L F I G  
 F I L Q M Y L I L N \* F S \* V T Y L \* G

11761 GTATATTTTATCTTGTTATTGGGGATTTTCTCTCTTTTAAACAGTGT TTTTATAGAATGCC 11820  
 V Y F I L L L G I F L S F K Q C F \* N A  
 Y I L S C Y W G F F S L L N S V F R M P  
 I F Y L V I G D F S L F \* T V F L E C L

11821 TATGGGTGTTTATAA TTATAAAAATTTCTGTTCAAGAATTGCGTTATATGAATGCTAATGG 11880  
 Y G C L \* L \* N F C S R I A L Y E C \* W  
 M G V Y N Y K I S V Q E L R Y M N A N G  
 W V F I I I K F L F K N C V I \* M L M A

FIG. 2 CONT.



11881	CTTACGTCCACCTCGTAATAGTTTTGAGGCTATTTTGTAAATTTAAAACCTGCTTGAAT L T S T S * * F * G Y F V K F K T A W N L R P P R N S F E A I L L N L K L L G I Y V H L V I V L R L F C * I * N C L E *	11940
11941	AGGTGGCGTGCCAGTTATTGAAGTCTCCCAAATTC AATCAA AATGACTGATGTGAAATG R W R A S Y * S L P N S I K I D * C E M G G V P V I E V S Q I Q S K L T D V K C V A C Q L L K S P K F N Q N * L M * N V	12000
12001	TGCTAATGTTGTTTTGTTAAATGTTTACAGCATTGTCATGTTGCTTCTAATTCTAAGTT C * C C F V K L F T A F A C C F * F * V A N V V L L N C L Q H L H V A S N S K L L M L F C * I V Y S I C M L L L I L S C	12060
12061	GTGGCAGTATTGTAGTGTTTTACATAATGAAATACTATCTACTTCAGATTTGAGTGTAGC V A V L * C F T * * N T I Y F R F E C S W Q Y C S V L H N E I L S T S D L S V A G S I V V F Y I M K Y Y L L Q I * V * L	12120
12121	TTTTGATAAGCTTGCTCAATTATTGATTGTTTTATTGCGCAATCCTGCTGCAGTTGATAC F * * A C S I I D C F I R Q S C C S * Y F D K L A Q L L I V L F A N P A A V D T L I S L L N Y * L F Y S P I L L Q L I L	12180
12181	TAAGTGTCTTGCAAGTATAGATGAAGTTAGCGATGATTATGTTCAAGATAGTACCGTTTT * V S C K Y R * S * R * L C S R * Y R F K C L A S I D E V S D D Y V Q D S T V L S V L Q V * M K L A M I M F K I V P F C	12240
12241	GCAGGCTTTGCAAAGTGAGTTTGTAATATGGCTAGTTTTGTTGAATATGAAGTCGCAAA A G F A K * V C K Y G * F C * I * S R K Q A L Q S E F V N M A S F V E Y E V A K R L C K V S L * I W L V L L N M K S Q R	12300
12301	GAAAAATTTGGCTGATGCTAAAAATAGTGGTTCTGTTAATCAACAACAGATAAAACAGTT E K F G * C * K * W F C * S T T D K T V K N L A D A K N S G S V N Q Q Q I K Q L K I W L M L K I V V L L I N N R * N S *	12360
12361	AGAAAAAGCATGTAATATAGCTAAGTCTGTGTATGAACGTGATAAAGCTGTAGCTCGCAA R K S M * Y S * V C V * T * * S C S S Q E K A C N I A K S V Y E R D K A V A R K K K H V I * L S L C M N V I K L * L A N	12420

FIG. 2 CONT.

12421 ACTTGAACGTATGGCAGACCTAGCACTTACTAACATGTATAAAGAGGCTCGGATTAATGA 12480  
T \* T Y G R P S T Y \* H V \* R G S D \* \*  
L E R M A D L A L T N M Y K E A R I N D  
L N V W Q T \* H L L T C I K R L G L M I

12481 TAAGAAGAGTAAAGTTGTTTCCGCTTTGCAGACAATGCTTTTTAGCATGGTTCGTAAT 12540  
\* E E \* S C F R F A D N A F \* H G S \* I  
K K S K V V S A L Q T M L F S M V R K L  
R R V K L F P L C R Q C F L A W F V N W

12541 GGATAATCAGGCTTTAAATTCTATCTGGATAATGCTGTTAAAGGTTGTGTACCTTTGAG 12600  
G \* S G F K F Y S G \* C C \* R L C T F E  
D N Q A L N S I L D N A V K G C V P L S  
I I R L \* I L F W I M L L K V V Y L \* V

12601 TGCTATCCAGCATTGGCTGCTAATACTTTAACTATAGTAATACCAGATAAACAAGTTTT 12660  
C Y S S I G C \* Y F N Y S N T R \* T S F  
A I P A L A A N T L T I V I P D K Q V F  
L F Q H W L L I L \* L \* \* Y Q I N K F L

12661 TGATAAAGTTGTTGATAATGTTTATGTTACATATGCTGGTAGTGTATGGCATATACAGAC 12720  
\* \* S C \* \* C L C Y I C W \* C M A Y T D  
D K V V D N V Y V T Y A G S V W H I Q T  
I K L L I M F M L H M L V V Y G I Y R L

12721 TGTTCAAGATGCTGATGGTATTAATAAACAGTTAACTGATATTAGTGTGATTCTAATTG 12780  
C S R C \* W Y \* \* T V N \* Y \* C \* F \* L  
V Q D A D G I N K Q L T D I S V D S N W  
F K M L M V L I N S \* L I L V L I L I G

12781 GCCTCTGTTATCATTGCCAACAGGTATAATGAAGTTGCTAATGCTGTTATGCAGAATAA 12840  
A S C Y H C E Q V \* \* S C \* C C Y A E \*  
P L V I I A N R Y N E V A N A V M Q N N  
L L L S L R T G I M K L L M L L C R I M

12841 TGAGTTGATGCCTCATAAATTAATAAACAAGTTGTTAATAGTGGTTCTGATATGAATTG 12900  
\* V D A S \* I K N T S C \* \* W F \* Y E L  
E L M P H K L K I Q V V N S G S D M N C  
S \* C L I N \* K Y K L L I V V L I \* I V

12901 TAATATCCTACTCAATGTTATTATAATAATGGTAGTAGTGGTAGAATAGTTTATGCTGT 12960  
\* Y S Y S M L L \* \* W \* \* W \* N S L C C  
N I P T Q C Y Y N N G S S G R I V Y A V  
I F L L N V I I I M V V V V E \* F M L F

FIG. 2 CONT.

12961 TCTTAGTGATGTTGATGGTCTTAAGTATACTAAGATAATGAAAGATGATGGAAATTGTGT 13020  
S \* \* C \* W S \* V Y \* D N E R \* W K L C  
L S D V D G L K Y T K I M K D D G N C V  
L V M L M V L S I L R \* \* K M M E I V L

13021 TGTTTTAGAGCTTGATCCTCCTTGTAATTTTCTATACAAGATGTTAAGGGACTTAAAAT 13080  
C F R A \* S S L \* I F Y T R C \* G T \* N  
V L E L D P P C K F S I Q D V K G L K I  
F \* S L I L L V N F L Y K M L R D L K L

13081 TAAGTATCTTTATTTTATTAAAGGATGTAACACTTTAGCTAGAGGGTGGGTTGTTGGTAC 13140  
\* V S L F Y \* R M \* H F S \* R V G C W Y  
K Y L Y F I K G C N T L A R G W V V G T  
S I F I L L K D V T L \* L E G G L L V L

13141 TTTATCTTCAACAATTAGATTGCAGGCTGGTGTGCTACTGAGTATGCAGCTAATTCTTC 13200  
F I F N N \* I A G W C C Y \* V C S \* F F  
L S S T I R L Q A G V A T E Y A A N S S  
Y L Q Q L D C R L V L L L S M Q L I L L

13201 TATACTTTCATTATGTGCATTTTCTGTAGATCCTAAGAAACTTATTAGATTATATACA 13260  
Y T F I M C I F C R S \* E N L F R L Y T  
I L S L C A F S V D P K K T Y L D Y I Q  
Y F H Y V H F L \* I L R K L I \* I I Y N

13261 ACAAGTGGTGACCTATAATTAATTGTGTAAATGCTCTGTGATCATGCTGGTACTGG 13320  
T R W C T Y N \* L C \* N A L \* S C W Y W  
Q G G V P I I N C V K M L C D H A G T G  
K V V Y L \* L I V L K C S V I M L V L V

13321 TATGGCCACTACTATTAACCTGAGGCTACTATTAACCAAGATTCTTATGGTGGTGCCTC 13380  
Y G H Y Y \* T \* G Y Y \* P R F L W W C L  
M A I T I K P E A T I N Q D S Y G G A S  
W P L L L N L R L L L T K I L M V V P Q

13381 AGTTTGTATTTATTGCCGTGCAGTGTAGAGCATCCAGATGTAGATGGTATATGTAAATT 13440  
S L Y L L P C T C R A S R C R W Y M \* I  
V C I Y C R A R V E H P D V D G I C K L  
F V F I A V H V \* S I Q M \* M V Y V N Y

13441 ACGTGGTAAATTTGTACAAGTCCCTTTGGGTATAAAAGATCCTATTCTTTATGTGTTAAC 13500  
T W \* I C T S P F G Y K R S Y S L C V N  
R G K F V Q V P L G I K D P I L Y V L T  
V V N L Y K S L W V \* K I L F F M C \* H

FIG. 2 CONT.

13501	ACATGATGTTTGTCAAGTCTGTGGTTTTTGGAGAGATGGCAGTTGTTCCCTGTGTAGGTTCT T * C L S S L W F L E R W Q L F L C R F H D V C Q V C G F W R D G S C S C V G S M M F V K S V V F G E M A V V P V * V Q	13560
13561	AAGTGTGCTGTCAATCTAAAGATTTAAATTTTTTAAACGGGTTCCGGGTTACTAGTGTG K C R C S I * R F K F F K R V R G T S V S V A V Q S K D L N F L N G F G V L V * V S L F N L K I * I F * T G S G Y * C E	13620
13621	AATGCCCGCTAGTACCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATT N A R L V P C A S G L S T D V Q L R A F M P G * Y P V L V V Y L L M F N * G H L C P A S T L C * W F I Y * C S I K G I *	13680
13681	GACATTTGTAATACCAATAGAGCTGGTATAGTTTTATATTATAAAGTGAATTGTTGCCGT D I C N T N R A G I G L Y Y K V N C C R T F V I P I E L V * V Y I I K * I V A V H L * Y Q * S W Y R F I L * S E L L P F	13740
13741	TTTGAGCGTATAGATGACGACGGTAATAAATGGATAAGTTCTTTGTTGTCAAAGAACT F Q R I D D D G N K L D K F F V V K R T F S V * M T T V I N W I S S L L S K E L S A Y R * R R * * I G * V L C C Q K N *	13800
13801	AATTTAGAAGTTTATAATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGGTGGTT N L E V Y N K E K T Y Y E L T K S C G V I * K F I I K R K L I M S * L K V V V L F R S L * * R E N L L * V D * K L W C C	13860
13861	GTGGCTGAACATGATTCTTTACATTTGATATTGATGGTAGTCGCGTCCACATATAGTT V A E H D F F T F D I D G S R V P H I V W L N M I S L H L I L M V V A C H I * F G * T * F L Y I * Y * W * S R A T Y S S	13920
13921	CGTAGGAATCTTTCAAAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGAT R R N L S K Y T M L D L C Y A L R H F D V G I F Q S I L C * I F A M H C V I L I * E S F K V Y Y V R S L L C I A S F * S	13980
13981	CGTAATGATTGTTCAATATTGTGTGAAATCTTTGTGAGTATGCTGATTGTAAAGAATCC R N D C S I L C E I L C E Y A D C K E S V M I V Q Y C V K F F V S M L I V K N P * * L F N I V * N S L * V C * L * R I L	14040

FIG. 2 CONT.

14041 TACTTTTCTAAGAAAGATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATAT 14100  
Y F S K K D W Y D F V E N P D I I N I Y  
T F L R K I G M I L L K I L I L L I Y I  
L F \* E R L V \* F C \* K S \* Y Y \* Y I \*

14101 AAAAAATTAGGCCCTATTTTTAATAGAGCTTACTTAATACTGTCATTTTGCAGACACC 14160  
K K L G P I F N R A L L N T V I F A D T  
K N \* A L F L I E L Y L I L S F L Q T P  
K I R P Y F \* \* S F T \* Y C H F C R H L

14161 TTAGTTGAAGTAGGTTTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAA 14220  
L V E V G L V G V L T L D N Q D L Y G Q  
\* L K \* V \* L V F \* L \* I T K I C M V N  
S \* S R F S W C F N F R \* P R F V W S M

14221 TGGTATGATTTTGGTATTTTATACAAACAGCCCCAGGGTTTGGTGTGGCAGTTGCAGAT 14280  
W Y D F G D F I Q T A P G F G V A V A D  
G M I L V I L Y K Q P Q G L V W Q L Q I  
V \* F W \* F Y T N S P R V W C G S C R F

14281 TCCTACTATTCTTATATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTA 14340  
S Y Y S Y M M P M L T M C H V L D C E L  
L T I L I \* C L C \* L C V M Y \* I V N Y  
L L F L Y D A Y V D Y V S C I R L \* I I

14341 TTTGTTAATGATAGTTATAGACAATTCGATCTGTACAGTATGATTTTACTGATTACAAG 14400  
F V N D S Y R Q F D L V Q Y D F T D Y K  
L L M I V I D N S I L Y S M I L L I T S  
C \* \* \* L \* T I R S C T V \* F Y \* L Q V

14401 TTAGAGTTGTTTAATAAGTATTTTAAGTATGGGGTATGAAGTATCATCCTAATACTGTG 14460  
L E L F N K Y F K Y W G M K Y H P N T V  
\* S C L I S I L S I G V \* S I I L I L W  
R V V \* \* V F \* V L G Y E V S S \* Y C G

14461 GATTGTGATAATGATAGGTGATTTATTTCATTGTGCTAATTTAATACTATTTAGTATG 14520  
D C D N D R C I I H C A N F N I L F S M  
I V I M I G V L F I V L I L I Y Y L V W  
L \* \* \* \* V Y Y S L C \* F \* Y T I \* Y G

14521 GTTTTACCTAATACTTGTGTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCG 14580  
V L P N T C F G P L V R Q I F V D G V P  
F Y L I L V L V P L L D K F L \* M V Y R  
F T \* Y L F W S P C \* T N F C R W C T V

FIG. 2 CONT.

14581	TTTGTTGTTTCTATTGGTTACCAATACAAAGAGTTAGGTGTAGTTATGAACTTAGATGTT F V V S I G Y H Y K E L G V V M N L D V L L F L L V T I T K S * V * L * T * M L C C F Y W L P L Q R V R C S Y E L R C *	14640
14641	GACACACACCGTTATCGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCT D T H R Y R L S L K D L L L Y A A D P A T H T V I V C L L K I Y F F M Q Q I L L H T P L S F V S * R F T S L C S R S C Y	14700
14701	ATGCACGTTGCATCTGCTAGTGTCTGCTTGATTACGAACTTGTTGTTTTAGTGTAGCT M H V A S A S A L L D L R T C C F S V A C T L H L L V L C L I Y E L V V L V * L A R C I C * C S A * F T N L L F * C S C	14760
14761	GCCATTACAAGTGGTATAAAAATTTCAAAGTGTAAAACCAGGTAACCTTAACCAAGACTTT A I T S G I K F Q T V K P G N F N Q D F P L Q V V * N F K L * N Q V T L T K T F H Y K W Y K I S N C K T R * L * P R L L	14820
14821	TACGAGTTTGTTAAAAGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTGAAACAT Y E F V K S K G L F K E G S T V D L K H T S L L K V K A C L K R V V Q L I * N I R V C * K * R L V * R G * Y S * F E T F	14880
14881	TTTTCTTTACTCAAGATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAAT F F F T Q D G N A A I T D Y N Y Y K Y N F S L L K M V M L Q L L I I I I I S I I F L Y S R W * C C N Y * L * L L * V * F	14940
14941	TTACCTACTATGGTTGATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTATAAATAT L P T M V D I K Q L L F V L E V V Y K Y Y L L W L I L S S Y C L Y * K L F I N I T Y Y G * Y * A V I V C I R S C L * I F	15000
15001	TTTGAAATTTATGATGGTGGTTGTATACCAGCATCACAGTTATTGTTAATAATTATGAT F E I Y D G G C I P A S Q V I V N N Y D L K F M M V V V Y Q H H K L L L I I M I * N L * W W L Y T S I T S Y C * * L * *	15060
15061	AAAAGTCTGGTTATCCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTA K S A G Y P F N K F G K A R L Y Y E A L K V L V I H L I N L V K P D F I M R H Y K C W L S I * * I W * S Q T L L * G I I	15120

FIG. 2 CONT.

15121 TCATTGAGGAACAGAATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTA 15180  
S F E E Q N E I Y A Y T K R N V L P T L  
H L R N R M K F M H I L N V M F C P P \*  
I \* G T E \* N L C I Y \* T \* C S A H L N

15181 ACTCAAATGAATTTAAAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGT 15240  
T Q M N L K Y A I S A K N R A R T V A G  
L K \* I \* N M L S V L R I E L A L \* Q V  
S N E F K I C Y Q C \* E \* S S H C S R C

15241 GTTTCTATTCTTAGTACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATA 15300  
V S I L S T M T G R M F H Q K C L K S I  
F L F L V L \* Q A E C S I K N V \* R V \*  
F Y S \* Y Y D R P N V P S K M F E E Y S

15301 GCAGCTACCCGAGGTGTTCTGTTTATAGGAACCACTAAATTTTATGGTGGTGGGAC 15360  
A A T R G V P V V I G T T K F Y G G W D  
Q L P E V F L L L \* E P L N F M V V G T  
S Y P R C S C C Y R N H \* I L W W L G R

15361 GATATGTTACGTCATCTTATAAAGGATGTTGACAACCCTGTTCTTATGGGTGGGATTAT 15420  
D M L R H L I K D V D N P V L M G W D Y  
I C Y V I L \* R M L T T L F L W V G I I  
Y V T S S Y K G C \* Q P C S Y G L G L S

15421 CCTAAATGTGATCGTCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTGGCC 15480  
P K C D R A M P N I L R I V S S L V L A  
L N V I V L C Q I F C V L L V V \* F W P  
\* M \* S C Y A K Y F A Y C \* \* F S F G P

15481 CGCAAACATGAATTTTGTGTTTCACATGGTGATAGATTTTATCGCCTTCCGAATGATGT 15540  
R K H E F C C S H G D R F Y R L A N E C  
A N M N F V V H M V I D F I A L R M N V  
Q T \* I L L F T W \* \* I L S P C E \* M C

15541 GCTCAAGTTTGTGAGTGAATAGTTATGTGTGGCGGTGCTATTATGTTAAGCCTGGTGGT 15600  
A Q V L S E I V M C G G C Y Y V K P G G  
L K F \* V K \* L C V A V A I M L S L V V  
S S F E \* N S Y V W R L L L C \* A W W Y

15601 ACTAGCAGTGGTGTGCAACTACTGCTTTTGCTAATTCTGTTTTAATATATGTCAGGCT 15660  
T S S G D A T T A F A N S V F N I C Q A  
L A V V M Q L L L L L I L F L I Y V R L  
\* Q W \* C N Y C F C \* F C F \* Y M S G C

FIG. 2 CONT.

15661 GTTACTGCTAATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGT 15720  
V T A N V C S L M A C N G H K I E D L S  
L L L M F V L L W P V M A I R L K I \* V  
Y C \* C L F S Y G L \* W P \* D \* R F K Y

15721 ATACGCAATTTACAAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTAT 15780  
I R N L Q K R L Y S N V Y R T D Y V D Y  
Y A I Y K N A Y T L M F I V Q I M L I I  
T Q F T K T L I L \* C L S Y R L C \* L Y

15781 ACATTTGTTAATGAGTATTATGAATTTTATGTAAGCATTITAGTATGATGATTTTGAGT 15840  
T F V N E Y Y E F L C K H F S M M I L S  
H L L M S I M N F Y V S I L V \* \* F \* V  
I C \* \* V L \* I F M \* A P \* Y D D F E \*

15841 GATGATGGTGTGTCTGTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATA 15900  
D D G V V C Y N S D Y A S K G Y I A N I  
M M V L S V I T L I M L V R V I \* L I \*  
\* W C C L L \* L \* L C \* \* G L Y S \* Y K

15901 AGTGTTTTTCACAAGTTTGTACTATCAGAATAATGCTTTTATGCTGAATCTAAATGT 15960  
S V F Q Q V L Y Y Q N N V F M S E S K C  
V F F N K F C T I R I M S L C L N L N V  
C F S T S F V L S E \* C L Y V \* I \* M L

15961 TGGGTTGAAAATGATATTACTAATGGTCTCATGAATTTTGTCCCAACATACTATGTTA 16020  
W V E N D I T N G P H E F C S Q H T M L  
G L K M I L L M V L M N F V P N I L C \*  
G \* K \* Y Y \* W S S \* I L F P T Y Y V S

16021 GTTAAGATAGATGGTGATTATGTTTATTACCATATCCAGATCCTTCTAGAATTTTAGGA 16080  
V K I D G D Y V Y L P Y P D P S R I L G  
L R \* M V I M F I Y H I Q I L L E F \* E  
\* D R W \* L C L F T I S R S F \* N F R S

16081 GCTGGTTGTTTTGTTGATGATTTATTGAAGACTGACAGTGTTCITTTGATAGAGCGCTTT 16140  
A G C F V D D L L K T D S V L L I E R F  
L V V L L M I Y \* R L T V F F \* \* S A L  
W L F C \* \* F I E D \* Q C S F D R A L C

16141 GTAAGTCTAGCTATAGATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAAA 16200  
V S L A I D A Y P L V H H E N E E Y Q K  
\* V \* L \* M L T L \* Y I M K M K N T K K  
K S S Y R C L P F S T S \* K \* R I P K S

FIG. 2 CONT.



16201	GTCTTTCGTGTATATTTAGAATATATAAAAAAACTGTATAATGATCTTGGTACTCAGATC V F R V Y L E Y I K K L Y N D L G T Q I S F V Y I * N I * K N C I M I L V L R S L S C I F R I Y K K T V * * S W Y S D L	16260
16261	TTAGATAGTTATAGTGTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCA L D S Y S V I L S T C D G L K F T E E S * I V I V L P * V L V M V * S L L K N H R * L * C Y F K Y L * W F K V Y * R I I	16320
16321	TTTTACAAGAATATGTATTTAAAAAGTGCCGTGATGCAGAGTGTAGGTGCATGCGTTGTT F Y K N M Y L K S A V M Q S V G A C V V F T R I C I * K V P * C R V * V H A L F L Q E Y V F K K C R D A E C R C M R C L	16380
16381	TGTTTCATCACAACCTTCTTTGCGTTGTGGCAGTTGTATACGTAAGCCTTTGTTATGTTGT C S S Q T S L R C G S C I R K P L L C C V H H K L L C V V A V V Y V S L C Y V V F I T N F F A L W Q L Y T * A F V M L *	16440
16441	AAATGTTGTTATGACCATGTTATGGCAACTAATCATAAATATGTTTTGAGTGTCTCACCT K C C Y D H V M A T N H K Y V L S V S P N V V M T M L W Q L I I N M F * V S H L M L L * P C Y G N * S * I C F E C L T L	16500
16501	TACGTTTGAATGCACCTAAGTGTGATGTGAGTGTGATGCACCAAATTATATTTGGGCGGT Y V C N A P N C D V S D V T K L Y L G G T F V M H L T V M * V M S P N Y I W A V R L * C T * L * C E * C H Q I I F G R Y	16560
16561	ATGTCTTACTATTGTGAAAACCATAAACCCATTATTCATTTAAGTTAGTTATGAATGGT M S Y Y C E N H K P H Y S F K L V M N G C L T I V K T I N P I I H L S * L * M V V L L L * K P * T P L F I * V S Y E W Y	16620
16621	ATGGTCTTTGGTTTGTATAACAATCTTGACGGGTTACCTTATATAGATGATTTTAAAT M V F G L Y K Q S C T G S P Y I D D F N W S L V C I N N L A R V H L I * M I L I G L W F V * T I L H G F T L Y R * F * *	16680
16681	AAGTAGCTAGTTGTAATGGACAGAAGTTGATGATTATGTTCTGGCAAATGAGTGTATT K I A S C K W T E V D D Y V L A N E C I R * L V V N G Q K L M I M F W Q M S V L D S * L * M D R S * * L C S G K * V Y *	16740

FIG. 2 CONT.

16741 GAACGTTTAAAGTTATTGCTGCAGAACTCAAAGGCAACTGAAGAGGCTTTTAAACAA 16800  
 E R L K L F A A E T Q K A T E E A F K Q  
 N V \* S Y L L Q K L K R Q L K R L L N K  
 T F K V I C C R N S K G N \* R G F \* T K

16801 AGCTATGCTTCTGCTACCATTCAAGAGATTGTTAGTGATAGAGAAGTTATTTTGTGTTGG 16860  
 S Y A S A T I Q E I V S D R E V I L C W  
 A M L L L P F K R L L V I E K L F C V G  
 L C F C Y H S R D C \* \* \* R S Y F V L G

16861 GAGACAGGTAAGTTAAACCACCCTTAATAAAAATTATGTTTTCACAGGCTACCATTTT 16920  
 E T G K V K P P L N K N Y V F T G Y H F  
 R Q V K L N H H L I K I M F S Q A T I L  
 D R \* S \* T T T \* \* K L C F H R L P F Y

16921 ACTAGTACTGGTAAGACAGTTTTAGGTGAGTATGTTTTTGATAAAGTGAATTAACAACTAAC 16980  
 T S T G K T V L G E Y V F D K S E L T N  
 L V L V R Q F \* V S M F L I K V N \* L T  
 \* Y W \* D S F R \* V C F \* \* K \* I N \* R

16981 GGTGTGTATTACCGCGCTACAACACTTATAAACTTTCTATAGGTGATGTTTTTGTTTTA 17040  
 G V Y Y R A T T T Y K L S I G D V F V L  
 V C I T A L Q L L I N F L \* V M F L F \*  
 C V L P R Y N Y L \* T F Y R \* C F C F N

17041 ACATCACATTCTGTAGCTAGTTTAAGTGCACCTACACTTGTCCCAAGAGAAGTATGCT 17100  
 T S H S V A S L S A P T L V P Q E N Y A  
 H H I L \* L V \* V H L H L S H K R T M L  
 I T F C S \* F K C T Y T C P T R E L C \*

17101 AGTATAAGATTTTCTAGTGTATAGTGTCCATTGGTGTTCAAAATAATGTTGCTAAT 17160  
 S I R F S S V Y S V P L V F Q N N V A N  
 V \* D F L V F I V F H W C F K I M L L I  
 Y K I F \* C L \* C S I G V S K \* C C \* L

17161 TATCAGCACATTGGAATGAAACGTTATTGCACTGTTCAAGGTCCCCTGGTACGGGAAG 17220  
 Y Q H I G M K R Y C T V Q G P P G T G K  
 I S T L E \* N V I A L F K V P L V R E S  
 S A H W N E T L L H C S R S P W Y G K V

17221 TCTCATCTTGCTATAGGTCTAGCTGTTTATTACTACACAGCACGTGTAGTTTACTGCT 17280  
 S H L A I G L A V Y Y Y T A R V V Y T A  
 L I L L \* V \* L F I T T Q H V \* F I L L  
 S S C Y R S S C L L L H S T C S L Y C C

FIG. 2 CONT.

17281 GCTAGTCATGCTGCTGTAGATGCATTGTGTGAAAAAGCTTATAAGTTTTTAAATATTAAC 17340  
A S H A A V D A L C E K A Y K F L N I N  
L V M L L \* M H C V K K L I S F \* I L T  
\* S C C C R C I V \* K S L \* V F K Y \* R

17341 GATTGTACACGTATTATTCCTGCTAAAGTTCGTGTAGATTGTTATGATAAGTTAAAATT 17400  
D C T R I I P A K V R V D C Y D K F K I  
I V H V L F L L K F V \* I V M I S L K L  
L Y T Y Y S C \* S S C R L L \* \* V \* N \*

17401 AATGATACCACTTGTAAGTATGTTTTACCACAATAAATGCATTACCAGAGTTGGTTACA 17460  
N D T T C K Y V F T T I N A L P E L V T  
M I P L V S M F L P Q \* M H Y Q S W L Q  
\* Y H L \* V C F Y H N K C I T R V G Y R

17461 GATATTGTTGTTGTTGATGAAGTTAGTATGCTTACTAATTATGAATTGTCTGTTATAAAT 17520  
D I V V V D E V S M L T N Y E L S V I N  
I L L L L M K L V C L L I M N C L L \* M  
Y C C C \* \* S \* Y A Y \* L \* I V C Y K C

17521 GCTCGTATTAAGCTAAACATTATGTATATATTGGAGATCCTGCTCAATTACCTGCACCA 17580  
A R I K A K H Y V Y I G D P A Q L P A P  
L V L K L N I M Y I L E I L L N Y L H H  
S Y \* S \* T L C I Y W R S C S I T C T T

17581 CGTGTGCTGTTGAGCAAGGTTCTTTAGAACCTAGGCACTTCAATTCTATTACTAAAATA 17640  
R V L L S K G S L E P R H F N S I T K I  
V C C \* A R V L \* N L G T S I L L L K \*  
C A V E Q G F F R T \* A L Q F Y Y \* N N

17641 ATGTGTTGTTTAGGTCCTGATATCTTTTTGGGAAATTGTTATAGGTGTCCTAAAGAAATT 17700  
M C C L G P D I F L G N C Y R C P K E I  
C V V \* V L I S F W E I V I G V L K K L  
V L F R S \* Y L F G K L L \* V S \* R N C

17701 GTAGAACTGTTTCAGCATTGGTTTATGATAATAAACTCAAGGCTAAAAATGATAATAGT 17760  
V E T V S A L V Y D N K L K A K N D N S  
\* K L F Q H W F M I I N S R L K M I I V  
R N C F S I G L \* \* \* T Q G \* K \* \* \* F

17761 TCATTATGTTTTAAAGTATATTTTAAGGGACAGACAACACATGAGAGTTCAAGTGCTGTA 17820  
S L C F K V Y F K G Q T T H E S S S A V  
H Y V L K Y I L R D R Q H M R V Q V L \*  
I M F \* S I F \* G T D N T \* E F K C C K

FIG. 2 CONT.

17821 AATATTC AACAGATATATCTAATTAGTAAATTTTAAAAGCTAATCCAGTTTGGAAATAGT 17880  
N I Q Q I Y L I S K F L K A N P V W N S  
I F N R Y I \* L V N F \* K L I Q F G I V  
Y S T D I S N \* \* I F K S \* S S L E \* C

17881 GCTGTTTTTATTAGTCCTTATAATAGTCAGAATTATGTTGCTAAGCGTGTTTTAGGTGTT 17940  
A V F I S P Y N S Q N Y V A K R V L G V  
L F L L V L I I V R I M L L S V F \* V F  
C F Y \* S L \* \* S E L C C \* A C F R C S

17941 CAAACACAAACTGTAGATTCTGCTCAAGGTTCCGGAATATGATTATGTTATATATTCACAA 18000  
Q T Q T V D S A Q G S E Y D Y V I Y S Q  
K H K L \* I L L K V R N M I M L Y I H K  
N T N C R F C S R F G I \* L C Y I F T N

18001 ACAGCAGAAACAGCCCATTCTGTTAATGTTAATCGATTTAATGTTGCCATAACTAGAGCC 18060  
T A E T A H S V N V N R F N V A I T R A  
Q Q K Q P I L L M L I D L M L P \* L E P  
S R N S P F C \* C \* S I \* C C H N \* S Q

18061 AAGAAGGGCATTTTTTGTGTATGAGTAATATGCAATTATTGAATCTCTTAATTTTATT 18120  
K K G I F C V M S N M Q L F E S L N F I  
R R A F F V L \* V I C N Y L N L L I L L  
E G H F L C Y E \* Y A I I \* I S \* F Y Y

18121 ACTCTACCTTTAGATAAAAATCAAATCAAACCTTTACCTCGTTTGCATTGCACAATAA 18180  
T L P L D K I Q N Q T L P R L H C T T N  
L Y L \* I K F K I K L Y L V C I A Q L I  
S T F R \* N S K S N F T S F A L H N \* S

18181 CTTTTAAAGATTGTAGTAAAAGTTGCTTAGGTTATCATCCAGCGCATGCCCCCTCATT 18240  
L F K D C S K S C L G Y H P A H A P S F  
F L K I V V K V A \* V I I Q R M P P H F  
F \* R L \* \* K L L R L S S S A C P L I F

18241 TTAGCAGTTGATGATAAATAAGGTTAATGAAAATTGGCTGTAAATTTAAATATTGTT 18300  
L A V D D K Y K V N E N L A V N L N I C  
\* Q L M I N I R L M K I W L \* I \* I F V  
S S \* \* \* I \* G \* \* K F G C K F K Y L \*

18301 GAACCTGTTTTAACATATTCTCGTTAATATCTCTTATGGGTTTTAAATTAGATTGACT 18360  
E P V L T Y S R L I S L M G F K L D L T  
N L F \* H I L V \* Y L L W V L N \* I \* L  
T C F N I F S F N I S Y G F \* I R F D S

FIG. 2 CONT.

18361	CTTGATGGTTATTCTAAATTGTTTATTACTAAAGATGAAGCCATTAAACGTGTTAGAGGT L D G Y S K L F I T K D E A I K R V R G L M V I L N C L L L K M K P L N V L E V * W L F * I V Y Y * R * S H * T C * R L	18420
18421	TGGGTTGGTTTTGATGTTGAGGGCGCTCATGCTACTCGCGAAAACATTGGAACAACTTT W V G F D V E G A H A T R E N I G T N F G L V L M L R A L M L L A K T L E Q T F G W F * C * G R S C Y S R K H W N K L S	18480
18481	CCACGTCAAATAGGTTTTCAACTGGTGGATTTTGTAGTTGAAGCTACTGGCTTATTT P L Q I G F S T G V D F V V E A T G L F H C K * V F Q L V W I L * L K L L A Y L T A N R F F N W C G F C S * S Y W L I C	18540
18541	GCTGAGAGAGATTGTTATACTTTTAAAAAACTGTAGCTAAAGCTCCTCCTGGTGA AAAA A E R D C Y T F K K T V A K A P P G E K L R E I V I L L K K L * L K L L L V K N * E R L L Y F * K N C S * S S S W * K I	18600
18601	TTTAAACATTTAATACCCCTTATGTCAAAGGTCAAAGTGGGATATTGTTAGAATTAGA F K H L I P L M S K G Q K W D I V R I R L N I * Y P L C Q K V K S G I L L E L E * T F N T P Y V K R S K V G Y C * N * N	18660
18661	ATTGTTCAAATGTTATCTGATTATCTTTTAGACCTTTCTGATAGTGTAGTATTATTACT I V Q M L S D Y L L D L S D S V V F I T L F K C Y L I I F * T F L I V * Y L L L C S N V I * L S F R P F * * C S I Y Y L	18720
18721	TGGTCTGCCAGTTTTGAACTTACTTGTTTAAGGTATTTTGCTAAATTAGGCAGAGAGCTT W S A S F E L T C L R Y F A K L G R E L G L P V L N L L V * G I L L N * A E S L V C Q F * T Y L F K V F C * I R Q R A *	18780
18781	AATTGTAATGTGTGTTCTAATCGTGCTACATGCTACAATTCTAGAACTGGTTATTATGGT N C N V C S N R A T C Y N S R T G Y Y G I V M C V L I V L H A T I L E L V I M V L * C V F * S C Y M L Q F * N W L L W L	18840
18841	TGTGGCGCCATAGTTATACTTGTGATTATGTGTATAATCCACTTATTGTAGATATACAA C W R H S Y T C D Y V Y N P L I V D I Q V G A I V I L V I M C I I H L L * I Y N L A P * L Y L * L C V * S T Y C R Y T T	18900

FIG. 2 CONT.

18901	CAGTGGGGTTATACAGGTTCTTTAACTAGTAATCAGATATAATTTGTAATGTACATAAA Q W G Y T G S L T S N H D I I C N V H K S G V I Q V L * L V I T I * F V M Y I K V G L Y R F F N * * S R Y N L * C T * R	18960
18961	GGTGCACATGTTGCGTCAGCTGATGCAATTATGACTCGTTGTTTAGCAATCTATGATTGT G A H V A S A D A I M T R C L A I Y D C V H M L R Q L M Q L * L V V * Q S M I V C T C C V S * C N Y D S L F S N L * L F	19020
19021	TTTTGTAATCTGTTAATTGGAATTTAGAGTATCCAATAATTTCTAATGAGGTCAGTATA F C K S V N W N L E Y P I I S N E V S I F V N L L I G I * S I Q * F L M R S V * L * I C * L E F R V S N N F * * G Q Y K	19080
19081	AATACATCTTGTAGGTTATGTCAGCGTGTATGCTTAAAGCTGCCATGCTATGTAATAGA N T S C R L L Q R V M L K A A M L C N R I H L V G Y C S V S C L K L P C Y V I D Y I L * V I A A C H A * S C H A M * * I	19140
19141	TACAACCTTATGTTATGACATAGGCAATCCTAAAGGTTTGTAGCTGTGCAAGATTATGAA Y N L C Y D I G N P K G L A C V K D Y E T T Y V M T * A I L K V * L V S K I M N Q L M L * H R Q S * R F S L C Q R L * I	19200
19201	TTTAAATTTTATGATGCTTTTCCTGTAGCCAAGTCTGTAAACAGTTATTTTATGTCTAT F K F Y D A F P V A K S V K Q L F Y V Y L N F M M L F L * P S L L N S Y F M S M * I L * C F S C S Q V C * T V I L C L *	19260
19261	GATGTGCATAAAGATAATTTTAAAGATGGTTTATGTATGTTTGGAAATTGTAATGTTGAT D V H K D N F K D G L C M F W N C N V D M C I K I I L K M V Y V C F G I V M L I C A * R * F * R W F M Y V L E L * C * *	19320
19321	AAATATCCATCTAATTCATTTGTTTGTAGATTTGACACTCGAGTGTAAATAAATTAAC K Y P S N S I V C R F D T R V L N K L N N I H L I Q L F V D L T L E C * I N * T I S I * F N C L * I * H S S V K * I K P	19380
19381	CTCCTGGATGTAATGGTGGTAGTTTGTATGTTAATAAACATGCATTCCATACTAATCCT L P G C N G G S L Y V N K H A F H T N P F L D V M V V V C M L I N M H S I L I L S W M * W W * F V C * * T C I P Y * S F	19440

FIG. 2 CONT.

19441	TTTACTAGAACTGTTTTGAAAATCTTAAGCCTATGCCTTTTTCTATTATTTCAGATACG F T R T V F E N L K P M P F F Y Y S D T L L E L F L K I L S L C L F S I I Q I R Y * N C F * K S * A Y A F F L L F R Y A	19500
19501	CCTTGTGTGTACGTAGATGGTTTGAATCTAAACAAGTTGATTACGTTCCCTTAAGAAGC P C V Y V D G L E S K Q V D Y V P L R S L V C T * M V * N L N K L I T F L * E A L C V R R W F R I * T S * L R S F K K R	19560
19561	GCCACTGTATCACACGGTGAATCTAGGTGGAGCTGTTTGTCAAAGCATGCTGAAGAA A T C I T R C N L G G A V C S K H A E E P L V S H G V I * V E L F V Q S M L K N H L Y H T V * S R W S C L F K A C * R I	19620
19621	TATTGTAACCTGAGTCTTATAATATAGTTACTACAGCAGGCTTTACTTTTTGGGTT Y C N Y L E S Y N I V T T A G F T F W V I V T T L S L I I * L L Q Q A L L F G F L * L P * V L * Y S Y Y S R L Y F L G L	19680
19681	TATAAGAATTTTGATTTTTATAATTTTGAACACTTTTACTACGTTACAGAGTTAGAA Y K N F D F Y N L W N T F T T L Q S L E I R I L I F I I Y G T L L L R Y R V * K * E F * F L * F M E H F Y Y V T E F R K	19740
19741	AACGTAATATATAACTTGGTTAATGTTGGTCATTATGATGGACGTACAGGTGAATTACCT N V I Y N L V N V G H Y D G R T G E L P T * Y I T W L M L V I M M D V Q V N Y L R N I * L G * C W S L * W T Y R * I T L	19800
19801	TGTGCTATTATGAATGACAAAGTTGTTGTTAAGATTAATAATGTAGATACTGTTATTTTT C A I M N D K V V V K I N N V D T V I F V L L * M T K L L L R L I M * I L L F L C Y Y E * Q S C C * D * * C R Y C Y F *	19860
19861	AAAAATAATACATCATTTCCTACTAATATAGCTGTTGAATTGTTTACAAAACGTAGTATC K N N T S F P T N I A V E L F T K R S I K I I H H F L L I * L L N C L Q N V V S K * Y I I S Y * Y S C * I V Y K T * Y P	19920
19921	CGGCACCACCTGAACCTAAGATTCTTAGAAAATTGAACATTGATATTTGTTGGAAGCAT R H H P E L K I L R N L N I D I C W K H G T T L N L R F L E I * T L I F V G S M A P P * T * D S * K F E H * Y L L E A C	19980

FIG. 2 CONT.

19981	GTCCTGTGGGATTATGTTAAAGATAGTTTGTGTTTGTAGTTCCACTTATGGTGTGTTGTA V L W D Y V K D S L F C S S T Y G V C K S C G I M L K I V C F V V P L M V F V N P V G L C * R * F V L * F H L W C L * I	20040
20041	TACACAGATTGAAAGTTCATCGAAAATTTGAATATACTTTTGTGATGGTCGTGACACTGGC Y T D L K F I E N L N I L F D G R D T G T Q I * S S S K I * I Y F L M V V T L A H R F E V H R K F E Y T F * W S * H W R	20100
20101	GCTTTAGAAGCTTTTAGAAAAGCAAGAAATGGTGTGTTTATTAGTACTGAAAATTAAGT A L E A F R K A R N G V F I S T E K L S L * K L L E K Q E M V F L L V L K N * V F R S F * K S K K W C F Y * Y * K I K *	20160
20161	AGGTTATCAATGATTAAAGGTCGCCAACCAGCTGATTAAATGGTGTGATTGTGGATAAA R L S M I K G P Q R A D L N G V I V D K G Y Q * L K V R N E L I * M V * L W I K V I N D * R S A T S * F K W C D C G * S	20220
20221	GTTGGAGAACTCAAAGTTGAGTTTGGTTCGCTATGAGAAAAGATGGTGACGATGTTATC V G E L K V E F W F A M R K D G D D V I L E N S K L S F G S L * E K M V T M L S W R T Q S * V L V R Y E K R W * R C Y L	20280
20281	TTCAGCCGAACAGACAGCCCTATGCTCAAGCCATTACTGGAGCCACAGGTAATCTAGGT F S R T D S L C S S H Y W S P Q G N L G S A E Q T A Y A Q A I T G A H K V I * V Q P N R Q P M L K P L L E P T R * S R W	20340
20341	GGTAATTCGCGGGTAATGTCATTGGTAATGATGCTCTAACACGTTTTACTATCTTTACT G N C A G N V I G N D A L T R F T I F T V I A R V M S L V M M L * H V L L S L L * L R G * C H W * * C S N T F Y Y L Y S	20400
20401	CAGAGTCGTGTTATGTCAGTTTGAACCTCGCTCAGATTAGAACGGGATTTTATTGAT Q S R V L S S F E P R S D L E R D F I D R V V Y C Q V L N L A Q I * N G I L L I E S C I V K F * T S L R F R T G F Y * Y	20460
20461	ATGGATGATAATCTGTTATTGCTAAATATGGTTTAGAAGACTATGCATTTGATCATATA M D D N L F I A K Y G L E D Y A F D H I W M I I C L L L N M V * K T M H L I I * G * * S V Y C * I W F R R L C I * S Y S	20520

FIG. 2 CONT.



20521	GTTTATGGTAGTTTTAACCATAAAGTTATAGGAGGTTGCATTTGCTTATAGGCTTATTT V Y G S F N H K V I G G L H L L I G L F F M V V L T I K L * E V C I C L * A Y F L W * F * P * S Y R R F A F A Y R L I S	20580
20581	CGTAGGAAAAAAAAATCTAATTTGTTAATTCAGAGTTTTTACAGTATGATTCTAGTATT R R K K K S N L L I Q E F L Q Y D S S I V G K K N L I C * F K S F Y S M I L V F * E K K I * F V N S R V F T V * F * Y S	20640
20641	CATTCAATTTTATTACTGATCAGGAGTGTGGTAGTAGTAAGAGTGTGTGACAGTTATT H S Y F I T D Q E C G S S K S V C T V I I H I L L L I R S V V V V R V F V Q L L F I F Y Y * S G V W * * * E C L Y S Y *	20700
20701	GATTTATTATTAGATGATTTTGTCTATTGTTAAGTCATTAATTTGAGTTGTGTTAGT D L L L D D F V S I V K S L N L S C V S I Y Y * M I L F L L L S H * I * V V L V F I I R * F C F Y C * V I K F E L C * *	20760
20761	AAAGTTGTTAATTAATGTTGATTTAAGGATTTTCAATTTATGTTGGTGTAAATGAT K V V N I N V D F K D F Q F M L W C N D K L L I L M L I L R I F N L C C G V M I S C * Y * C * F * G F S I Y V V V * * *	20820
20821	AATAAAATATGACTTTTTATCCTAAAATGCAAGCCACTAATGATTGGAACCTGGCTAT N K I M T F Y P K M Q A T N D W K P G Y I K L * L F I L K C K P L M I G N L A I * N Y D F L S * N A S H * * L E T W L F	20880
20881	TCTATGCCTGTTTTGTATAAGTATTTGAATGTTCCATTAGAGAGAGTCTCTTTATGGAAT S M P V L Y K Y L N V P L E R V S L W N L C L F C I S I * M F H * R E S L Y G I Y A C F V * V F E C S I R E S L F M E L	20940
20941	TATGGTAAACCTATTAATTTGCCTACAGGCTGTATGATGAATGTTGCTAAGTACACTCAA Y G K P I N L P T G C M M N V A K Y T Q M V N L L I C L Q A V * * M L L S T L N W * T Y * F A Y R L Y D E C C * V H S I	21000
21001	TTATGTCAGTATTTGAATACTACAACATTAGCTGTTCCGTGTTAATATGCGTGTGTTTACAT L C Q Y L N T T T L A V P V N M R V L H Y V S I * I L Q H * L F L L I C V F Y I M S V F E Y Y N I S C S C * Y A C F T F	21060

FIG. 2 CONT.

21061	TTAGGTGCAGGGTCTGATAAAGAAGTAGCTCCAGGTTCTGCTGTTTTAAGACAGTGGTTA L G A G S D K E V A P G S A V L R Q W L * V Q G L I K K * L Q V L L F * D S G Y R C R V * * R S S S R F C C F K T V V T	21120
21121	CCATCTGGTAGTATTCTTGTAGATAATGATTTAAACCCATTGTTAGCGATAGTTTAGTT P S G S I L V D N D L N P F V S D S L V H L V V F L * I M I * T H L L A I V * L I W * Y S C R * * F K P I C * R * F S Y	21180
21181	ACTTATTTGGAGATTGTATGACTTTACCAATTGATGTGCATTGGGATTGATAATATCT T Y F G D C M T L P F D C H W D L I I S L I L E I V * L Y H L I V I G I * * Y L L F W R L Y D F T I * L S L G F D N I *	21240
21241	GATATGTATGATCCTCTTACTAAAAATATTGGTGATTATAATGTGAGTAAGGATGGGTTT D M Y D P L T K N I G D Y N V S K D G F I C M I L L L K I L V I I M * V R M G F Y V * S S Y * K Y W * L * C E * G W V F	21300
21301	TTTACTTACATTGTCATTTAATTCGTGATAAATTATCTTTGGGTGGTAGTGTAGCTATA F T Y I C H L I R D K L S L G G S V A I L L T F V I * F V I N Y L W V V V * L * Y L H L S F N S * * I I F G W * C S Y K	21360
21361	AAAATTACAGAGTTTCTTGAATGCTGATTTATATAAATTAATGAGTTGTTTTGCATTT K I T E F S W N A D L Y K L M S C F A F K L Q S F L G M L I Y I N * * V V L H F N Y R V F L E C * F I * I N E L F C I L	21420
21421	TGGACAGTTTTTTGTTACTAATGTAATGCTTCTTCTAGTGAAGGGTTTTTAATAGGTATA W T V F C T N V N A S S S E G F L I G I G Q F F V L M * M L L L V K G F * * V * D S F L Y * C K C F F * * R V F N R Y K	21480
21481	AATTACCTGGGTAAATCTTCTTTGAAATAGATGGCAATGTTATGCATGCTAACTATTTG N Y L G K S S F E I D G N V M H A N Y L I T W V N L L L K * M A M L C M L T I C L P G * I F F * N R W Q C Y A C * L F V	21540
21541	TTTTGGAGAAATAGTACAACATGGAATGGCGGTCTTATAGTTTATTTGATATGACTAAA F W R N S T T W N G G A Y S L F D M T K F G E I V Q H G M A V L I V Y L I * L N L E K * Y N M E W R C L * F I * Y D * I	21600

FIG. 2 CONT.

21601	TTTTCTTTGAAATGGCTGGCACTGCTGTTGTTAATTTAAGACCAGATCAATTAATGAT F S L K L A G T A V V N L R P D Q L N D F L * N W L A L L L L I * D Q I N * M I F F E I G W H C C C * F K T R S I K * F	21660
21661	TTAGTTTATTCTCTTATTGAAAGAGGTAATTATTAGTTCGCGATACGCGTAAAGAGATT L V Y S L I E R G K L L V R D T R K E I * F I L L L K E V N Y * F A I R V K R F S L F S Y * K R * I I S S R Y A * R D F	21720
21721	TTTGTTGGTGATAGTCTTGAAATACTGTTAGATCTCATTAAATCTAAACTATGTTAAT F V G D S L V N T C * I S L N L N Y V N L L V I V L * I L V R S H * I * T M L I C W * * S C K Y L L D L I K S K L C * L	21780
21781	TATTTTTTTATTTTTTTTATTCTGTTATGGTTTTAATGAACCTCTTAATGTTGTCTCA Y F F I F L F L L W F * * T S * C C V S I F L F F Y F C Y G F N E P L N V V S H F F Y F F I S V M V L M N L L M L C L I	21840
21841	TTAAACCATGACTGGTTTTTTATTTGGTGATAGTCGTCTGATTGTAACCATATTAATAA F K P * L V F I W * * S F * L * P Y * * L N H D W F L F G D S R S D C N H I N N * T M T G F Y L V I V V L I V T I L I I	21900
21901	TTTAAAAATAAAAATTTGATTATTGGATATTCACCCTAGTTTGTGCAACAATGGTAA F K N * K F * L F G Y S P * F V Q Q W * L K I K N F D Y L D I H P S L C N N G K * K L K I L I I W I F T L V C A T M V R	21960
21961	GATTTCACTAGTGCCGGTGATTCTATTTTTAAGAGTTTTCATTTCACTCGATTTTATAA D F I * C R * F Y F * E F S F H S I L * I S S S A G D S I F K S F H F T R F Y N F H L V P V I L F L R V F I S L D F I I	22020
22021	TTACTGCGGAAGGTGATCAAAATTTTTTTATGAGGGTGTAAATTTAATCCTTATCA L H W R R * S N Y F L * G C * F * S L S Y T G E G D Q I I F Y E G V N F N P Y H T L A K V I K L F F M R V L I L I L I I	22080
22081	TAGATTTAAGTGTTCCTAATGGTAGTAATGATGTATGGCTTCTTAACAAGGTAAGATT * I * V F S * W * * * C M A S * Q G K I R F K C F P N G S N D V W L L N K V R F D L S V F L M V V M M Y G F L T R * D F	22140

FIG. 2 CONT.

22141	TTATCGTGCCTTATATTCTAATATGGCCTTTTTTCGTTATCTTACTTTTGTGATATTC L S C L I F * Y G L F S L S Y F C * Y S Y R A L Y S N M A F F R Y L T F V D I P I V P Y I L I W P F F V I L L L L I F L	22200
22201	TTATAATGTTTCTCTTTCTAAGTTTAATCTTGTAAGGATATTTTATCACTTAACAA L * C F S F * V * F L * K * Y F I T * Q Y N V S L S K F N S C K S D I L S L N N I M P L F L S L I L V K V I F Y H L T I	22260
22261	TCCTATTTTATTAATTATTCTAAGGAAGTTTATTTTACTTTATTAGGTTGTTCTCTTA S Y F Y * L F * G S L F Y F I R L F S L P I F I N Y S K E V Y F T L L G C S L Y L F L L I I L R K F I L L Y * V V L F I	22320
22321	TTTAGTACCGCTTTGCCTTTTTAAATCTAACTTTAGTCAGTACTATTATAACATAGATAC F S T A L P F * I * L * S V L L * H R Y L V P L C L F K S N F S Q Y Y Y N I D T * Y R F A F L N L T L V S T I I T * I L	22380
22381	TGGCTCTGTTTATGGTTTTCTAATGTTGTTTATCCTGATTAGACTGTATTTATATTTTC W L C L W F F * C C L S * F R L Y L Y F G S V Y G F S N V V Y P D L D C I Y I S A L F M V F L M L F I L I * T V F I F L	22440
22441	TCTTAAACCAGGTTCTTATAAAGTTCCACCACTGCACCTTTTTTATCCTTACCTACTAA S * T R F L * S F H H C T F F I L T Y * L K P G S Y K V S T T A P F L S L P T K L N Q V L I K F P P L H L F Y P Y L L K	22500
22501	AGCTCTCTGTTTGGATAAATCTAAACAATTTGTACCTGTACAGGTTGTTGATTCTAGATG S S L F * * I * T I C T C T G C * F * M A L C F D K S K Q F V P V Q V V D S R W L S V L I N L N N L Y L Y R L L I L D G	22560
22561	GAACAACGAGCGTGCCTCAGATATTCTTTATCTGTTGCATGTCAATTGCCATATTGTTA E Q R A C L R Y F F I C C M S I A I L L N N E R A S D I S L S V A C Q L P Y C Y T T S V P Q I F L Y L L H V N C H I V I	22620
22621	TTTTCGCAATTCTTCTGCTAATTATGTTGGCAAGTATGATATTAACCACGGTGATAGTGG F S Q F F C * L C W Q V * Y * P R * * W F R N S S A N Y V G K Y D I N H G D S G F A I L L L I M L A S M I L T T V I V V	22680

FIG. 2 CONT.

22681	TTTTATTTCTATTTTATCTGGTCTTTTATATAATGTTTCTTGATTTTCATATTATGGTGT F Y F Y F I W S F I * C F L Y F I L W C F I S I L S G L L Y N V S C I S Y Y G V L F L F Y L V F Y I M F L V F H I M V Y	22740
22741	ATTTTATATGATAATTTTACATCCATTTGGCCCTATTATTCTTTTGGTAGGTGCCTAC I F I * * F Y I H L A L L F F W * V S Y F L Y D N F T S I W P Y Y S F G R C P T F Y M I I L H P F G P I I L L V G V L H	22800
22801	ATCTTCTATTATTAAACATCCAATTTGTGTTTATGATTTTTTGCCTATTATTTTACAAGG I F Y Y * T S N L C L * F F A Y Y F T R S S I I K H P I C V Y D F L P I I L Q G L L L L N I Q F V F M I F C L L F Y K V	22860
22861	TATTTTATTATGTTTAGCTTTACTTTTTGTGTTTTTCTATTATTTTTGTATATAACGA Y F I M F S F T F C C F S I I F V I * R I L L C L A L L F V V F L L F L L Y N D F Y Y V * L Y F L L F F Y Y F C Y I T I	22920
22921	TAAATCTCATTAATCTAAACATGTTATTAATTTTTTATTTTGCCTACAACATTAGCT * I S L N L N M L L I I F I L P T T L A K S H * I * T C Y * L F L F C L Q H * L N L I K S K H V I N Y F Y F A Y N I S C	22980
22981	GTTATAGGTGATTTAATTGTTACTAATTTTGTCTATTAATGATTTAAACACCACAGTTCTCT V I G D F N C T N F A I N D L N T T V P L * V I L I V L I L L L M I * T P Q F L Y R * F * L Y * F C Y * * F K H H S S S	23040
23041	CGCATAAGTGAGTATGTTGGGATGTTTCTTATGGTTTGGGTACATATTATATACTTGAT R I S E Y V V D V S Y G L G T Y Y I L D A * V S M L W M F L M V W V H I I Y L I H K * V C C G C F L W F G Y I L Y T * S	23100
23101	CGTGTTTATTTAAATACTACTATATTATTACTGGTTATTTCCCTAAATCTGGTGCCAAT R V Y L N T T I L F T G Y F P K S G A N V F I * I L L Y Y L L V I S L N L V P I C L F K Y Y Y I I Y W L F P * I W C Q F	23160
23161	TTTAGGGATCTATCTTTAAAAGGTACTACATATTTGAGTACTCTTTGGTATCAGAAACCC F R D L S L K G T T Y L S T L W Y Q K P L G I Y L * K V L H I * V L F G I R N P * G S I F K R Y Y I F E Y S L V S E T L	23220

FIG. 2 CONT.

23221	TTTTATCTGATTTTAATAATGGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTT F L S D F N N G I F S R V K N T K L Y V F Y L I L I M V F F L E L R I L S C M L F I * F * * W Y F F * S * E Y * V V C *	23280
23281	AATAAACTTTGTATAGTGAGTTTAGTACTATAGTTATAGGTAGTGTTTTTATTAACAAC N K T L Y S E F S T I V I G S V F I N N I K L C I V S L V L * L * V V F L L T T * N F V * * V * Y Y S Y R * C F Y * Q L	23340
23341	TCTTATACTATTGTGTTCACCTCATAATGGTGTGGAGATTACAGCTTGTCAATAC S Y T I V V Q P H N G V L E I T A C Q Y L I L L L F N L I M V F W R L Q L V N T L Y Y C C S T S * W C F G D Y S L S I H	23400
23401	ACTATGTGTGAGTATCCTCATACTATTTGTAAATCTAAAGGTAGTTCTCGTAATGAATCT T M C E Y P H T I C K S K G S S R N E S L C V S I L I L F V N L K V V L V M N L Y V * V S S Y Y L * I * R * F S * * I L	23460
23461	TGGCATTGATAAATCTGAACCTTTGTGTCTGTTCAGAAAAATTTACTTATAATGTT W H F D K S E P L C L F K K N F T Y N V G I L I N L N L C V C S R K I L L I M F A F * * I * T F V S V Q E K F Y L * C F	23520
23521	TCTACAGATTGGTTGTATTTTCATTTTATCAAGAACGTGGCACTTTTATGCTTATTAT S T D W L Y F H F Y Q E R G T F Y A Y Y L Q I G C I F I F I K N V A L F M L I M Y R L V V F S F L S R T W H F L C L L C	23580
23581	GCTGATTCTGGCATGCCTACTACTTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCT A D S G M P T T F L F S L Y L G T L L S L I L A C L L L F Y L V C I L V L F Y L * F W H A Y Y F F I * F V S W Y S F I S	23640
23641	CATTATTATGTTTTGCCTTTGACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACT H Y Y V L P L T C N A I S S N T D N E T I I M F C L * L V M L Y L L I L I M R L L L C F A F D L * C Y I F * Y * * * D F	23700
23701	TTACAATATTGGGTCACACCTTTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGT L Q Y W V T P L S K R Q Y L L K F D N R Y N I G S H L C L N A N I F L N L T T V T I L G H T F V * T P I S S * I * Q P W	23760

FIG. 2 CONT.

23761	GGTGTATTACTAATGCTGTTGATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAA G V I T N A V D C S S S F F S E I Q C K V L L L M L L I V L V V S L A R F N V K C Y Y * C C * L F * * F L * R D S M * N	23820
23821	ACTAAATCTTTATTACCTAATACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCT T K S L L P N T G V Y D L S G F T V K P L N L Y Y L I L V F M T Y L V L L L S L * I F I T * Y W C L * L I W F Y C * A C	23880
23881	GTTGCAACTGTACATCGTCGTATTCTGATTTACCTGATTGTGACATTGATAAATGGCTT V A T V H R R I P D L P D C D I D K W L L Q L Y I V V F L I Y L I V T L I N G L C N C T S S Y S * F T * L * H * * M A *	23940
23941	AACAAATTTAATGTACCCTCACCTCTTAATGGGAACGTAAAATTTTTCTAATGCAAC N N F N V P S P L N W E R K I F S N C N T I L M Y P H L L I G N V K F F L I A T Q F * C T L T S * L G T * N F F * L Q L	24000
24001	TTTAAATTTGAGTACTTTGCTTCGTTTAGTTCATACTGATTCTTTTTCTTGAATAATTTT F N L S T L L R L V H T D S F S C N N F L I * V L C F V * F I L I L F L V I I L * F E Y F A S F S S Y * F F F L * * F *	24060
24061	GATGAATCTAAGATATATGGTAGTTGTTTAAAGAGTATTGTTTTAGATAAATTTGCCATA D E S K I Y G S C F K S I V L D K F A I M N L R Y M V V V L R V L F * I N L P Y * I * D I W * L F * E Y C F R * I C H T	24120
24121	CCCAACTCCAGACGATCTGATTGCGAGTTGGGAGTTCTGGTTTTCTGCAATCTTCTAAT P N S R R S D L Q L G S S G F L Q S S N P T P D D L I C S W A V L V F C N L L I Q L Q T I * F A V G Q F W F S A I F * L	24180
24181	TATAAAATGACACTACTTCTAGTTCTTGCAATTGTATTATAGTTTGCCTGCAATTAAT Y K I D T T S S S C Q L Y Y S L P A I N I K L T L L L V L V N C I I V C L Q L M * N * H Y F * F L S I V L * F A C N * C	24240
24241	GTTACTATTAATAATTATAATCCTTCTTCTTGGGAATAGAAGGTATGGTTTTAATAATTTT V T I N N Y N P S S W N R R Y G F N N F L L L I I I I L L L G I E G M V L I I L Y Y * * L * S F F L E * K V W F * * F *	24300

FIG. 2 CONT.

24301	AATTTGAGCTCTCATAGTGTGTTTACTCACGTTATTGTTTTTCTGTTAATAATACTTTT N L S S H S V V Y S R Y C F S V N N T F I * A L I V L F T H V I V F L L I I L F F E L S * C C L L T L L F F C * * Y F L	24360
24361	TGTCCTTGTGCTAAACCTTCTTTTGTCTCAAGTTGCAAGAGTCATAAACCCACCTTCTGCT C P C A K P S F A S S C K S H K P P S A V L V L N L L L L Q V A R V I N H L L L S L C * T F F C F K L Q E S * T T F C F	24420
24421	TCCTGTCTATTGGTACTAATTATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACT S C P I G T N Y R S C E S T T V L D H T P V L L V L I I V L V R V L L Y S T T L L S Y W Y * L S F L * E Y Y C T R P H *	24480
24481	GACTGGTGTAGGTGTTCTTGTTTACCTGATCCTATAACTGCTTATGACCCTAGGTCTTGT D W C R C S C L P D P I T A Y D P R S C T G V G V L V Y L I L * L L M T L G L V L V * V F L F T * S Y N C L * P * V L F	24540
24541	TCTCAAAAAAGTCTCTGGTTGGTGTGGTGAACATTGTGCAGGGTTCGGTGTGATGAA S Q K K S L V G V G E H C A G F G V D E L K K S L W L V L V N I V Q G S V L M K S K K V S G W C W * T L C R V R C * * R	24600
24601	GAAAAGTGTGGTGTATTGGATGGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCC E K C G V L D G S Y N V S C L C S T D A K S V V Y W M D H I M F L V F V V L M P K V W C I G W I I * C F L S L * Y * C L	24660
24661	TTTCTAGGTTGGTCTTATGACACTTGCCTCAGTAACAACCGTTGTAATATTTTTTCTAAT F L G W S Y D T C V S N N R C N I F S N F * V G L M T L A S V T T V V I F F L I S R L V L * H L R Q * Q P L * Y F F * F	24720
24721	TTTATTTTAAATGGTATCAATAGTGGTACCCTTGTCTAATGATTATTATGCAGCCTAAT F I L N G I N S G T T C S N D L L Q P N L F * M V S I V V P L V L M I Y C S L I Y F K W Y Q * W Y H L F * * F I A A * Y	24780
24781	ACTGAAGTTTTTACTGATGTTTGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGT T E V F T D V C V D Y D L Y G I T G Q G L K F L L M F V L I T T F M V L Q D K V * S F Y * C L C * L R P L W Y Y R T R Y	24840

FIG. 2 CONT.



24841	ATTTTAAAGAAGTTTCTGCTGTTTATTATAAGTTGGCAAATCTTTGTATGATCT I F K E V S A V Y Y N S W Q N L L Y D S F L K K F L L F I I I V G K I F C M I L F * R S F C C L L * * L A K S F V * F *	24900
24901	AATGGCAACATTATTGGTTTTAAAGATTTTGTACTAATAAAACATATAATATTTCCCT N G N I I G F K D F V T N K T Y N I F P M A T L L V L K I L L L I K H I I F S L W Q H Y W F * R F C Y * * N I * Y F P L	24960
24961	TGTTATGCAGGAAGAGTTTCTGCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTT C Y A G R V S A A F H Q N A S S L A L L V M Q E E F L L L F I K M L P L W L Y F L C R K S F C C F S S K C F L F G F T L	25020
25021	TATCGTAATTTAAATGTAGCTATGTTTTGAATAATATTTCTTAACTACTCAGCCATAT Y R N L K C S Y V L N N I S L T T Q P Y I V I * N V A M F * I I F L * L L S H I S * F K M * L C F E * Y F F N Y S A I F	25080
25081	TTTGATAGTTATCTTGGTTGCGTTTTTAATGCTGATAATTTAACTGATTATTCTGTTTCT F D S Y L G C V F N A D N L T D Y S V S L I V I L V A F L M L I I * L I I L F L * * L S W L R F * C * * F N * L F C F F	25140
25141	TCTTGTCTCTTCGCATGGGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCTTCTCC S C A L R M G S G F C V D Y N S P S S S L V L F A W V V V F V L I I T H L L L P L C S S H G * W F L C * L * L T F F F L	25200
25201	TCTTCGCGTCGTAAACGTAGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCC S S R R K R R S I S A S Y R F V T F E P L R V V N V E V F L L L I V L L L L N P F A S * T * K Y F C F L S F C Y F * T L	25260
25261	TTTAATGTCAGTTTGTAAATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAA F N V S F V N D S I E S V G G L Y E I K L M S V L L M T V L S L W V V F M R S K * C Q F C * * Q Y * V C G W S L * D Q N	25320
25321	ATCCCACTAACTTTACTATAGTTGGTCAAGAGGAATTTATTCAAATAATTCTCCTAAA I P T N F T I V G Q E E F I Q T N S P K F P L T L L * L V K R N L F K L I L L K S H * L Y Y S W S R G I Y S N * F S * S	25380

FIG. 2 CONT.

25381 GTTACTATTGATTGTTCTTTATTGTCTGTTCTAATTATGCAGCTTGCCATGACTTATTG 25440  
V T I D C S L F V C S N Y A A C H D L L  
L L L I V L Y L S V L I M Q L A M T Y C  
Y Y \* L F F I C L F \* L C S L P \* L I V

25441 TCAGAGTATGGCACTTTTTGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTA 25500  
S E Y G T F C D N I N S I L D E V N G L  
Q S M A L F V I I L I V F \* M K L M V Y  
R V W H F L \* \* Y \* \* Y F R \* S \* W F T

25501 CTTGATACTACTCAATTGCATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCC 25560  
L D T T Q L H V A D T L M Q G V T L S S  
L I L L N C M \* L I L L C K V S H L A P  
\* Y Y S I A C S \* Y S Y A R C H T \* L Q

25561 AATCTTAATACTAATTGCAATTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGA 25620  
N L N T N L H F D V D N I N F K S L V G  
I L I L I C I L M L I I L I L N P \* L D  
S \* Y \* F A F \* C \* \* Y \* F \* I P S W M

25621 TGTTTAGGTCACACTGCGGTTCTTCTCTCGTTCTTTTTTTGAAGATTTATGTTTGAC 25680  
C L G P H C G S S S R S F F E D L L F D  
V \* V H T A V L L L V L F L K I Y C L T  
F R S T L R F F F S F F F \* R F I V \* Q

25681 AAAGTTAACTTTCAGATGTGGTTTTGTTGAAGCTTATAACAATTGACTGGTGGTAGT 25740  
K V K L S D V G F V E A Y N N C T G G S  
K L N F Q M L V L L K L I T I V L V V V  
S \* T F R C W F C \* S L \* Q L Y W W \* \*

25741 GAAATTAGAGATCTTCTTTGTGTACAATCCTTTAATGGTATTAAAGTTTTGCCTCCTATT 25800  
E I R D L L C V Q S F N G I K V L P P I  
K L E I F F V Y N P L M V L K F C L L F  
N \* R S S L C T I L \* W Y \* S F A S Y F

25801 TTGTCTGAATCTCAAATTTCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCA 25860  
L S E S Q I S G Y T T A A T V A A M F P  
C L N L K F L V T P Q P L L L L L C F H  
V \* I S N F W L H H S R Y C C C Y V S T

25861 CCATGGTCAGCAGCAGCTGGCATAACCATTTTCTCTTAATGTACAATATAGAATTAATGGT 25920  
P W S A A A G I P P S L N V Q Y R I N G  
H G Q Q Q L A Y H F L L M Y N I E L M V  
M V S S S W H T I F S \* C T I \* N \* W F

FIG. 2 CONT.

25921	TTGGGTGTTACTATGGATGTTCTTAATAAAAAATCAAAGTTGATAGCTACTGCTTTTAAAT L G V T M D V L N K N Q K L I A T A F N W V L L W M F L I K I K S * * L L L L I G C Y Y G C S * * K S K V D S Y C F * *	25980
25981	AATGCTCTTCTTCTATTTCAGAATGGTTTTAGTGCTACCAACTCTGCACTTGCTAAAATA N A L L S I Q N G F S A T N S A L A K I M L F F L F R M V L V L P T L H L L K Y C S S F Y S E W F * C Y Q L C T C * N T	26040
26041	CAAAGTGTGTTAATTCTAATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAAT Q S V V N S N A Q A L N S L L Q Q L F N K V L L I L M L K H L I V C Y S N Y L I K C C * F * C S S T * * F V T A I I * *	26100
26101	AAATTTGGTGCAATTAGTTCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAG K F G A I S S S L Q E I L S R L D A L E N L V Q L V L L Y K K F Y L V S M L * R I W C N * F F F T R N F I S S R C F R G	26160
26161	GCTCAGGTTGAGATTGATAGGCTTATTAATGGTTCGTTAACTGCTTTAAATGCTTATGTC A Q V Q I D R L I N G R L T A L N A Y V L R F R L I G L L M V V * L L * M L M S S G S D * * A Y * W S F N C F K C L C L	26220
26221	TCTCAACAGCTTAGTGATATTTCTCTTGTAATAATTTGGTGCTGCTTTAGCTATGGAGAAG S Q Q L S D I S L V K F G A A L A M E K L N S L V I F L L * N L V L L * L W R R S T A * * Y F S C K I W C C F S Y G E G	26280
26281	GTTAATGAGTGTGTTAAAAGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCAT V N E C V K S Q S P R I N F C G N G N H L M S V L K V N L L V L I F V V M V I I * * V C * K S I S S Y * F L W * W * S Y	26340
26341	ATTTTGCATTAGTTCAAAATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAA I L S L V Q N A P Y G L L F M H F S Y K F C H * F K M L L M V C C L C I L V I N F V I S S K C S L W F V V Y A F * L * T	26400
26401	CCTATTTCTTTTAAAAGTGTGTTTAGTAAGTCTGTTTGTGTATATCAGGTGATGTAGGT P I S F K T V L V S P G L C I S G D V G L P L L K L F * * V L V C V Y Q V M * V Y F F * N C F S K S W F V Y I R * C R Y	26460

FIG. 2 CONT.

26461	ATTGCACCTAAACAAGGGTATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGT I A P K Q G Y F I K H N D H W M F T G S L H L N K G I L L N I M I I G C S L V V C T * T R V F Y * T * * S L D V H W * F	26520
26521	TCTTACTATTATCCTGAACCAATTCAGATAAAAATGTTGTTTTATGAATACTTGTCTCT S Y Y Y P E P I S D K N V V F M N T C S L T I I L N Q F Q I K M L F L * I L V L L L L S * T N F R * K C C F Y E Y L F C	26580
26581	GTTAATTTTACTAAAGCGCCTCTTGTATTGTAATCATTCTGTACCAAATGCTCTGAT V N F T K A P L V Y L N H S V P K L S D L I L L K R L L F I * I I L Y Q N C L I * F Y * S A S C L F E S F C T K I V * F	26640
26641	TTTGAATCTGAGTTATCTCATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACT F E S E L S H W F K N Q T S I A P N L T L N L S Y L I G L K I K H P L R L I * L * I * V I S L V * K S N I H C A * F D F	26700
26701	TTAATCTTCATACTATTAATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATT L N L H T I N A T F L D L Y Y E M N L I * I F I L L M L L F * I C I M R * I L F K S S Y Y * C Y F F R F V L * D E S Y S	26760
26761	CAAGAGTCTATTAAGTCTTTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATAT Q E S I K S L N N S Y I N L K D I G T Y K S L L S L * I I V I S I L K I * V H M R V Y * V F E * * L Y Q S * R Y R Y I *	26820
26821	GAAATGTATGTAATAATGGCCTTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATA E M Y V K W P W Y V W L L I S F S F I I K C M * N G L G M F G Y * F L F H L * Y N V C K M A L V C L A T N F F F I Y N I	26880
26881	TTCCTGTATTGCTCTTTTTATATGTTGTTGTTACTGGTTGTGGTTCTGCATGTTTTAGT F L V L L F F I C C C T G C G S A C F S S L Y C S F L Y V V V L V V V L H V L V P C I A L F Y M L L Y W L W F C M F * *	26940
26941	AAATGTCATAATTGTTGTGATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCT K C H N C C D E Y G G H H D F V I K T S N V I I V V M S M V V I M I L L S K H L M S * L L * * V W W S S * F C Y Q N I S	27000

FIG. 2 CONT.

27001	CATGATGATTAGAATCTCTTGTGCAGATCTCATTAAATCTAAACTTTATTTATGGACGTTT H D D * N L L S D L I K S K L Y L W T F M M I R I S C Q I S L N L N F I Y G R L * * L E S L V R S H * I * T L F M D V W	27060
27061	GGAGACCTAGCTACACACATTCTCTTGTATTAGAGAATTTGGTGTACAAACCTTGAAG G D L A T H I L L L L E N L V L Q T L K E T * L H T F S C Y * R I W C Y K P * R R P S Y T H S L V I R E F G V T N L E D	27120
27121	ATTTGTGTCTAAAGTATAATTACTGTCAACCTATTGTTGGTTACTGTATTGTACCTTTAA I C V * S I I T V N L L L V T V L Y L * F V S K V * L L S T Y C W L L Y C T F K L C L K Y N Y C Q P I V G Y C I V P L N	27180
27181	ATGTTTGGTGTGCGCAAGTTTGGCAAATTTGCTTCTCACTTTACATTACGTAGTCACGATA M F G V A S L A N L L L T L H Y V V T I C L V S Q V W Q I C F S L Y I T * S R Y V W C R K F G K F A S H F T L R S H D I	27240
27241	TTTCCCATAGTAATAATTTTGGTGTGTAACTAGTTTTACTACTTATGGTAATACTGTTT F P I V I I L V L * L V L L L M V I L F F P * * * F W C C N * F Y Y L W * Y C F S H S N N F G V V T S F T T Y G N T V S	27300
27301	CTGAGGCTGTGTCTAGATTAGTTGAATCAGCTTCTGAATTTATGTTTGGCGTGCAGAGG L R L C L D * L N Q L L N L L F G V Q R * G C V * I S * I S F * I Y C L A C R G E A V S R L V E S A S E F I V W R A E A	27360
27361	CACTTAATAAGTATGGTTGATTTATTTTCAATGATACTGCTTGGTACATAGGACAGATT H L I S M V D L F F N D T A W Y I G Q I T * * V W L I Y F S M I L L G T * D R F L N K Y G * F I F Q * Y C L V H R T D F	27420
27421	TTAGTTTTAGTTTTATTTTGTCTTATTTCTTTAATCTTTGTTGTTGCTTTTTTAGCAACT L V L V L F C L I S L I F V V A F L A T * F * F Y F V L F L * S L L L L F * Q L S F S F I L S Y F F N L C C C F F S N Y	27480
27481	ATTAAGCTTTGTATGCAACTTTGTGGTTTTGTAAATTTCTTTATTTTACCTTCGGCT I K L C M Q L C G F C N F F I I S P S A L S F V C N F V V F V I S L L F H L R L * A L Y A T L W F L * F L Y Y F T F G L	27540

FIG. 2 CONT.

27541 TACGTTTATAAAAAGAGGTATGCAGTTGTATAAGTCTTATAGTGAACAAGTTATACCACCC 27600  
Y V Y K R G M Q L Y K S Y S E Q V I P P  
T F I K E V C S C I S L I V N K L Y H P  
R L \* K R Y A V V \* V L \* \* T S Y T T H

27601 ACTTCAGATTATTTAATCTAAATCTAAACATTATGAATAAATCTTTCTTCCTCAATTTA 27660  
T S D Y L I \* I \* T L \* I N L F F L N L  
L Q I I \* S K S K H Y E \* I F S S S I Y  
F R L F N L N L N I M N K S F L P Q F T

27661 CTTCTGATCAAGCTGTTACATTCTTAAAGAATGGAATTTCTCTTTGGGTGAATACTAC 27720  
L L I K L L H S \* K N G I S L W V \* Y Y  
F \* S S C Y I L K R M E F L F G C N T T  
S D Q A V T F L K E W N F S L G V I L L

27721 TTTTATTACTATCATATTGCAGTTCGGTTATACGAGCCGTAGTATGTTTGTATTACTTA 27780  
F L L L S Y C S S V I R A V V C L F I L  
F Y Y Y H I A V R L Y E P \* Y V C L S Y  
F I T I I L Q F G Y T S R S M F V Y L I

27781 TCAAGATGATTATTCTTTGGCTTATGTGGCCATTGACTATCACCTTGACTATATTTAATT 27840  
S R \* L F F G L C G H \* L S P \* L Y L I  
Q D D Y S L A Y V A I D Y H L D Y I \* L  
K M I I L W L M W P L T I T L T I F N C

27841 GTTTTATGCTTTGAATAATGCTTTTCTTGCAATTTCTATAGTGTACTATTATTCTA 27900  
V F M L \* I M L F L H F L \* C L L L F L  
F L C F E \* C F S C I F Y S V Y Y Y F Y  
F Y A L N N A F L A F S I V F T I I S I

27901 TTGTTATATGGATTCTTTATTTGTTAATAGTATTCGGCTTTTATTAGAACTGGCAGTT 27960  
L L Y G F F I L L I V F G F L L E L A V  
C Y M D S L F C \* \* Y S A F Y \* N W Q L  
V I W I L Y F V N S I R L F I R T G S W

27961 GGTGGAGTTTAAATCCAGAGACCAATAATCTTATGTGTATTGATATGAAAGGCAAGATGT 28020  
G G V L I Q R P I I L C V L I \* K A R C  
V E F \* S R D Q \* S Y V Y \* Y E R Q D V  
W S F N P E T N N L M C I D M K G K M F

28021 TTGTTAGGCCAGTTATTGAGGACTATCACACTTAACTGCTACTGTTATTTCGTGGTCATC 28080  
L L G Q L L R T I T H \* L L L L F V V I  
C \* A S Y \* G L S H I N C Y C Y S W S S  
V R P V I E D Y H T L T A T V I R G H L

FIG. 2 CONT.

28081	TTTATATACAGGGTGTCAAACCTGGCACTGGTTATACTCTTTCAGATTGCCCCGTATATG F I Y R V S N L A L V I L F Q I C P Y M L Y T G C Q T W H W L Y S F R F A R I C Y I Q G V K L G T G Y T L S D L P V Y V	28140
28141	TTACTGTAGCTAAGGTGCAAGTACTTTGTACCTATAAACGTGCCTTTTGTAGATAAGTTAG L L * L R C K Y F V P I N V P F * I S * Y C S * G A S T L Y L * T C L F R * V R T V A K V Q V L C T Y K R A F L D K L D	28200
28201	ATGTTAATAGTGGTTTGTCTGTTTGTGTTAAGTCTAAAGTTGGTAACTATCGTTTACCGT M L I V V L L F L L S L K L V T I V Y R C * * W F C C F C * V * S W * L S F T V V N S G F A V F V K S K V G N Y R L P S	28260
28261	CTAGTAAACCTAGTGGTATGGATACTGCCTTGTAAAGAGCTTAAATCTAAACTATTAGGA L V N L V V W I L P C * E L K S K L L G * * T * W Y G Y C L V K S L N L N Y * D S K P S G M D T A L L R A * I * T I R M	28320
28321	TGCTTTATACTCCCGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGAA C L I L P V I M L E V E A P L E I V Q E V L Y S R S L C W K * K L L W K S F R N S Y T P G H Y A G S R S S S G N R S G I	28380
28381	TCCTCAAGAAAACTTCTGGGCTGACCAATCTGAGCGAAATTACCAACCTTTAATAGAG S S R K L L G L T N L S E I T K P L I E P Q E N F L G * P I * A K L P N L * * R L K K T S W A D Q S E R N Y Q T F N R G	28440
28441	GCAGAAAAACCAACCTAAATTCACTGTGTCTACTCAACCACAAGGAAATACTATCCCAC A E K P N L N S L C L L N H K E I L S H Q K N P T * I H C V Y S T T R K Y Y P T R K T Q P K F T V S T Q P Q G N T I P H	28500
28501	ATTATTCTGGTTCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCAG I I P G S P G S L N F K K V E T L N F Q L F L V L R D H S I S K R * R L * I F R Y S W F S G I T Q F Q K G R D F K F S D	28560
28561	ATGGTCAAGGAGTTCCCATGCTTTCCGAGTACCCCTTCTGAAGCAAAAGGATATTGGT M V K E F P L L S E Y P L L K Q K D I G W S R S S H C F R S T P F * S K R I L V G Q G V P I A F G V P P S E A K G Y W Y	28620

FIG. 2 CONT.

28621 ATAGACACAGCCGGCGTTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCGA 28680  
 I D T A G V L L K Q L M V N K S S C Y R  
 \* T Q P A F F \* N S \* W S T K A V V T E  
 R H S R R S F K T A D G Q Q K Q L L P R

28681 GATGGTATTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCCC 28740  
 D G I S T I S V P A H M P M H P M V N P  
 M V F L L S R Y R P I C Q C I L W \* I P  
 W Y F Y Y L G T G P Y A N A S Y G E S L

28741 TCGAAGGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTTT 28800  
 S K G S S G L L I T K L T L L L P P M F  
 R R G L L G C \* S P S \* H F Y S L R C F  
 E G V F W V A N H Q A D T S T P S D V S

28801 CGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATTT 28860  
 R Q G I L L L K K L S L L G F R L V R F  
 V K G S Y Y S R S Y P Y \* V S A W Y D F  
 S R D P T T Q E A I P T R F P P G T I L

28861 TGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGTT 28920  
 C L K A I M L K A Q E G L L L I V D Q V  
 A S R L L C \* R L R K V C F \* \* S T R F  
 P Q G Y Y V E G S G R S A S N S R P G S

28921 CACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATTCTAATTTTA 28980  
 H V L N H V D P I I V H \* V E V I L I L  
 T F S I T W T Q \* S F I K \* K \* F \* F \*  
 R S Q S R G P N N R S L S R S N S N F R

28981 GACATTGATTTCTATAGTAAACCTGATATGGCTGATGAGATCGCTAATCTTGTTTTAG 29040  
 D I Q I L \* \* N L I W L M R S L I L F \*  
 T F R F Y S K T \* Y G \* \* D R \* S C F S  
 H S D S I V K P D M A D E I A N L V L A

29041 CCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAATGCCAAGGAAATCA 29100  
 P S L V K I L N L S K S L S K M P R K S  
 Q A W \* R F \* T S A S H \* A K C Q G N Q  
 K L G K D S K P Q Q V T K Q N A K E I R

29101 GGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 29160  
 G I K F \* Q N L A K S E L L I N I V M F  
 A \* N F N K T S P K A N S \* \* T L \* C S  
 H K I L T K P R Q K R T P N K H C N V Q

FIG. 2 CONT.



29161	AACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAGC N S V L V K E D L L K I L V M L K C * S T V F W * K R T F S K F W * C * N V K A Q C F G K R G P S Q N F G N A E M L K L	29220
29221	TTGGTACTAATGATCCTCAGTTTCTTATTTCTGCAGAATTAGCTCCTACACCAGGTGCTT L V L M I L S F L F L Q N * L L H Q V L W Y * * S S V S Y S C R I S S Y T R C F G T N D P Q F P I L A E L A P T P G A F	29280
29281	TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTTA F S L V L N * T W L K E I P R L T H L L F L W F * I R L G * K R F R G * L T C * F F G S K L D L V K R D S E A D S P V K	29340
29341	AAGATGTTTTTGAACCTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGCT K M F L N F I I L V L L G L I V L Y Q A R C F * T S L F W F Y * V * * Y F T R L D V F E L H Y S G S I R F D S T L P G F	29400
29401	TTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATTCTAATCAGA L R Q L * K F L K R I * M L T L I L I R * D N Y E S S * R E F K C L R * F * S E E T I M K V L E E N L N A Y V N S N Q N	29460
29461	ACACTGATTCTGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTAC T L I L I R * V L N L S V K E V L N N Y H * F * F V E P * T S A * K R C * T I T T D S D S L S S K P Q R K R G V K Q L P	29520
29521	CAGAACAGTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTTA Q N S L T L L I * V L V L S T F Q M I L R T V * L S * F K C W Y S A H F K * F Y E Q F D S L N L S A G T Q H I S N D P T	29580
29581	CTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTTG L L R I I V Y L L L L M I L M * K T L L S * G S * F T C Y S * * S L C R R L C C P E D H S L L A T L D D P Y V E D S V A	29640
29641	CTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTCGCTATTATTCCGGAAT L N E N E S * F D T R W * P L A I I R N L M R M N P N S T L G G N P S L L F G I * * E * I L I R H * V V T P R Y Y S E *	29700

FIG. 2 CONT.

29701 AGGACACTCTCTATCAGAATGAATTCTTGCTGTAATAACAGATAGAGTAGGTTGTTACAG 29760  
R T L S I R M N S C C N N R \* S R L L Q  
G H S L S E \* I L A V I T D R V G C Y R  
D T L Y Q N E F L L \* \* Q I E \* V V T D

29761 ACTATATATTAATTAGTAGAAAATTTATATTTAGACATTTGATTGTTAGAGTAGTTATAA 29820  
T I Y \* L V E I L Y L D I \* L L E \* L \*  
L Y I N \* \* K F Y I \* T F D C \* S S Y K  
Y I L I S R N F I F R H L I V R V V I R

29821 GGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTATCAATTGTAGTGTTTAATATATA 29880  
G L A V V \* T P P G R A I N C S V \* Y I  
V \* L \* Y K R L R E E L S I V V F N I Y  
F S C S I N A S G K S Y Q L \* C L I Y I

29881 TATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTACAAAAAAAAAAAAAA 29940  
Y \* Y M I E I N Y S L L E E L Q K K K K  
I S I \* L K L I I A F W R N Y K K K K K  
L V Y D \* N \* L \* P F G G I T K K K K K

29941 AA 29942

FIG. 2 CONT.

1 CTTATTCTCGCTTAACGCAGGCATGGCAGATAGTCGAATGCTAGAGAACAGTCTAGAGTA 60  
     Y S R I A D T G D I L K R D R T L D \*  
     I L A F Q T R V T \* \* S V I E Q \* I E  
     F L L S N R G Y R R D A \* S R K D S R M

61 ATTTAGATTTGAAAAATTTGTTCTAAGGGACAATAGGTACGAACACTCACACCAAATTAG 120  
     \* I \* V K \* V L N G T I W A Q S H P K I  
     N F R F K K F L I G Q \* G H K H T H N L  
     L D L S K L C S E R N D M S T L T T \* D

121 TATTAGAACATAAAATGAAAGGTGTGAAAAGTAGAGAGACGGTCACTGCACAACCAACAG 180  
     M I K Y K V K W V K \* R E A L S T N T T  
     \* L R T N \* K G C K E D R Q W H R T P Q  
     Y D Q I K S E V S K M E R G T V H Q N D

181 GAGTCGCAGGGAGGGTATCCAGCGTTACTAATTTTGGTCGTTTATGCCAGAGCCGAAGTT 240  
     R L T G G M P R L S \* F W C I R D R S \*  
     G \* R G E W L D C H N F G A F V T E A E  
     E A D R G Y T A I I L V L L Y P R P K L

241 CACCCGCGGTCTTAAAGCAACCGACGAAGGCCTACGTCCCTCCTCAACCGATCAGGATA 300  
     T P A L I E N A A E P H L P P T P \* D \*  
     L P R W F K T P Q K R I C R L L Q S T R  
     H A G S N R Q S S G S A A S S N A L G I

301 CTTCACTACTCCCACCAATACGGGAGATGACCAGTTGCTACCTTTCACAACCTAA 360  
     S T L H P H T I G R \* Q D L S P F H Q I  
     H L \* I L T P \* A G R S T L R H F T N S  
     F D S S P P N H G E V P \* A I S L T P N

361 GCAAATACTATTAGTACACTTCTATCTAACAGCGACGTAAGAACCTGTTCTTACCCTACA 420  
     R K H Y D H S S L N D S C E Q V L I A H  
     E N I I I M H L Y I T A A N K S L F P M  
     T \* S L \* T F I S Q R Q M R P C S H C T

421 CGTCAGTTTAGAATAGGCACTATAAAAAACAAGTACTTCTAGATGTACAAACATCTTCAAGA 480  
     A T L D \* G H Y K Q E H L D V H Q L L E  
     H L \* I K D T I N K N M F I \* M N Y F N  
     C D F R I R S I K T \* S S R C T T S T R

481 TTGATTTTGTGCGCATTTTCAGGCCATGCCGTTAAAATTAATTTAGTGAAACGTATCGAA 540  
     L \* F L R L T R Y P L K L \* I V K A Y S  
     \* S F C G Y L G T R C N \* N F \* R Q M A  
     V L V A T F D P V A I K I L D G K C L K

FIG. 3

541 CCCACAAAAGGATTTCCCATACAATACCCGAACAAGGCAAGTATGTTCTGATTGCAAT 600  
 P H N E \* L T H \* P S T G N M C S \* V N  
 Q T T K R F P I N H A Q E T \* V L S F T  
 P P K G L P Y T I P K N R E Y L V L R \*

601 ACAACATGTAGTAGAAAGATACTGATGTAGATGATGATTAAAACCACTTCTAAAAACCC 660  
 H Q V D D K \* S \* M \* \* \* N Q H L N K P  
 I N Y M M K R H S C R S S I K T F I K Q  
 T T C \* R E I V V D V V L K P S S K K P

661 AACCTAACATGGAAAACCAAATACGGTAGAATAACAAGTGTTTACCAAAGTTAAGACATC 720  
 N S Q V K Q N \* A M K H E C I T E I R Y  
 T P N Y R K T K H W R I N V F P K L E T  
 Q I T G K P K I G D \* T \* L H N \* N Q L

721 CAACATATAACTTCTCTCACTAAATTATTAAAGTTTAAAATTTAAACTACTAATACTAAA 780  
 T T Y Q L S H N L L K L N \* I Q H N H N  
 P Q I N F L T I \* Y N \* I K F K I I I I  
 N Y I S S L S K I I E F K L N S S \* S K

781 ATCACATCTTCTACGAATACGACTCCAAGTACGACTCGGATTTCCATTATAAGTGTTTT 840  
 \* H L L H K H Q P E H Q A \* L Y I N V F  
 K T Y F I S I S L N M S L R F T F I \* L  
 L T S S A \* A S T \* A S G L P L Y E C F

841 TCGAATACGAAATGAATCTGTTATAGCACCATAATTTGGGCATGAAAAACATCTGGTCAT 900  
 L K H K V \* V I D H Y \* V R V K Q L G T  
 F S I S \* K S L I T T N F G Y K K Y V L  
 A \* A K S L C Y R P I L G T S K T S W Y

901 ACCAACACTGATAAGACCATTTAATCGTCTAACAGAAGTTTGAATACCAGTAATAAGAAA 960  
 H N H S N Q Y I L L N D E L K H D N N K  
 I T T V I R T F \* C I T K L S I T M I R  
 P Q S \* E P L N A S Q R \* A \* P \* \* E K

961 CGTTCTATACTCTGTTTTCGTCAGACATACCGAACGGTTAACACTGAAACTATAACATCA 1020  
 A L Y S V F A T Q I A Q W N H S Q Y Q L  
 Q L I H S L L L R Y P K G I T V K I N Y  
 C S I L C F C D T H S A L Q S K S I T T

1021 CCGAACCGTACATCAAGCACTAAGTGCTAAACAATACGCGGACGTCTGATATCGATGATA 1080  
 P K A H L E H N V I Q \* A G A S \* L \* \*  
 H S P M Y N T I \* S K N H A Q L S Y S S  
 A Q C T T R S E R N T I R R C V I A V I

FIG. 3 CONT'D

1081 AACACCATAATTTATACAACGTGTTGGATGTCTTCTACATCATCTACCTCTACATCAATA 1140  
 K H Y \* I H Q V V \* L L H L L H L H L \*  
 N T T N F I N C L R C F I Y Y I S I Y N  
 Q P I L Y T A C G V S S T T S P S T T I

1141 TGCACCTGGACATGTAAATAATAGACGACTACGTTATCAAAATTCGAAGGATCAAACATA 1200  
 V H V Q V N I I Q Q H L L K L A E \* N S  
 Y T F R Y M \* \* R S I C Y N \* L K R T Q  
 R S G T C K N D A S A I T K F S G L K I

1201 CTTTCAATACTGAGTATACTACTAAAAAGATAATTTAGATATATATTACAACTAAACAC 1260  
 S L \* S E Y P H N K \* \* I \* I Y H Q N T  
 H F N H S M H I I K R N F R Y I I N I Q  
 F T I V \* I S S K E I L D I Y L T S K H

1261 ACTAACACCAAAAACAATACGTCATACCAATACATCTAACAAAATTACTATTAACTAAAC 1320  
 H N H N Q \* A T H N H L N N \* H Y N H N  
 T I T T K N H L I T I Y I T K I I I T I  
 S Q P K T I C Y P \* T S Q K L S L Q S K

1321 AATACCAACCCAAAGTCCATTATACTACCTACCAAAAAGAACAGGTAACACAACATGTCA 1380  
 K H N P K L Y Y S P H N K K D M T N Y L  
 K I T P N \* T I H H I T K R T W Q T T C  
 \* P Q T E P L I I S P K E Q G N H Q V T

1381 AATACTGAGATCGCTTCAATTTCCGGTTAGTAGACCACAATAAGGACTTTTAGGACACAA 1440  
 K H S \* R L \* L G I M Q H \* E Q F D Q T  
 N I V R A F N F G L \* R T N N R F I R H  
 \* S E L S T L A W D D P T I G S F G T N

1441 TAAATGATTATCATGACTATGACAATTTGGTACTAAGAAAATTAACATACCAATAAGACA 1500  
 I \* \* Y Y Q Y Q \* G H N K \* N T H N N Q  
 \* K S I T S I S N V M I R K I Q I T I R  
 N V L L V S V T L W S E K L K Y P \* E T

1501 GTGTGGTAAACCAAGAACATATATAACCAGCGCGCAGGACCTAACACCTAAGGATATTA 1560  
 \* V M Q N K Y I N T A A D Q I T S E \* L  
 D C W K T R T Y I P R R T R S Q P N R Y  
 V G N P E Q I Y Q D G R G P N H I G I I

1561 ATTTAGAAGTCAGTTCAGAATACTACTAAACCAATAAGTCCACATCATCCAACATTTAG 1620  
 \* I K L \* T K H H N P K N L H L L N Y I  
 N F R \* D L R I I I Q N I \* T Y Y T T F  
 L D E T L D \* S S K T \* E P T T P Q L D

FIG. 3 CONT'D

1621 ATAACAATTTCTTTGACGAGAATAATGAGTACGTGAAATGAATCTAATACAAGTTACATT 1680  
 \* Q \* L F Q E \* \* E H V K S L N H E I Y  
 R N N F F S S K N S M C K V \* I I N L T  
 I T L S V A R I V \* A S \* K S \* T \* H L

1681 CACACCATTAGAACTTGTTTTAGTATAAGAACCGCAATTATTAAGAACCACATCCGTTGA 1740  
 T H Y D Q V F D Y E Q R \* Y N K T Y A V  
 L T T I K F L I M N K A N I I R P T P L  
 H P L R S C F \* I R P T L L E Q H L C S

1741 CAACGAATTATCTCCACTAATATTATACGAAGATTTTTTATAACTGAACAAACAATTCGC 1800  
 T A \* Y L H N Y Y A E L F Y Q S T Q \* A  
 Q Q K I S T I I I H K \* F I N V Q K N L  
 N S L L P S \* L I S R F F I S K N T L R

1801 AGCACCAGTAAAACGAACGTTCAAACGTCAAACACCTCTACCAAACATGGAAAAATGA 1860  
 D H Q N Q K C T Q L K H L H N Q V K K V  
 T T S I K S A L K C N T S I T K Y R K \*  
 R A S K A Q L N A T Q P S P K T G K K S

1861 TCTACCAAATTAAGGGGCATCAATAATAGATTAAGTCTCACCATAAAAGAAATGTAGAAA 1920  
 L H N L E G Y N N D L E S H Y K R \* M K  
 \* I T \* N G T T I I \* N L T T N E K C R  
 S P K I G R L \* \* R I \* L P I K K V D K

1921 CTACAGAGTAAAAGTGTCTTCAAAGACTATACACAAATTTTACACATAAAACAAATA 1980  
 S T E I K V L L K Q Y T N L F T Y K T \*  
 Q H R L K \* L F N R I H T \* F H T N Q K  
 I D \* N E C S T E S I H K F I H I K N I

1981 CCTGTCTCAAAGTCAACGATGTAAAATATATCTCGTAATACAATTATCCAACCAATGAGT 2040  
 P C L K L Q \* M K Y L A N H \* Y T P \* E  
 H V S N \* N S C K I Y L M I N I P Q N S  
 S L T E T A V N \* I S C \* T L L N T V \*

2041 TAAATTC AATAACCCATGATGTGAACAATTATTTTACCAATTAACCAAATTATGGTACAA 2100  
 I \* T I P Y \* V Q \* Y F P \* N T \* Y W T  
 L K L \* Q T S C K N I F H N I P K I G H  
 N L N N P V V S T L L I T L Q N L V M N

2101 TCTACGATCACGTGGACGATGTCCGACCGAAGAAATGGTTAATAACTTACCAGAAAAACA 2160  
 L H \* H V Q \* L S A E K G I I S H D K Q  
 \* I S T C R S C A P K K V L \* Q I T K K  
 S A L A G A V P Q S R \* W N N F P R K T

FIG. 3 CONT'D

2161 TCATAGAGTTCGGTTGAAATTAAAACAACGAAATTATGGACTAATACGATTTTAAAATCA 2220  
 L I E L W S \* N Q Q K L V Q N H \* F K L  
 Y Y R L G V K I K N S \* Y R I I S F N \*  
 T D \* A L K L K T A K I G S \* A L I K T

2221 ATTATTTAAAATGTGAAAAAATTCATAATAATCTCACACAATGTCAACTACAAAATTT 2280  
 \* Y I K C K K \* T I I L T H \* L Q H K L  
 N I F K V S K K L \* \* \* L T N C N I N \*  
 L L N \* V K K L N N N S H T V T S T K F

2281 TCTATACGGACAAGAATTTTGATAATTACCAAATCAAACATAACATCCGTTATTCAAAT 2340  
 L Y A Q E \* F \* \* H N L K Y Q L C Y T K  
 F I H R N K F S N I T \* N T N Y A I L K  
 S I G T R L V I L P K T Q I T P L L N \*

2341 ATTGCAATCAATGTCCCAATTAAGGACCAAAACAAAATGGTACATTACGTGCCTTGTGT 2400  
 Y R \* Y L T L E Q N Q K V M Y H V P V V  
 I V N T C P \* N R T K N \* W T I C L F L  
 L T L V P N I G P K T K G H L A C S C C

2401 TTAATAAAAAAACTTCGCAACGTCTTAGACAATATCATCTTCTACTACAATAACTCTT 2460  
 F K N K Q L R Q L I Q \* L L L H H \* Q S  
 L N I K K F A N C F R N Y Y F I I N N L  
 I \* K K S P T A S D T I T S S S T I S F

2461 ACAGTTAGAAGAAATAGTAGAATACTCATAACAGTTGGTGGATTTAGACATCTTTTTTA 2520  
 H \* I K K I M K H T N D V V \* I Q L F F  
 I D F R R \* \* R I L I T L W R F R Y F F  
 T L D E K D D \* S Y Q \* G G L D T S F I

2521 AACATAATATCTATTATACATGTACCCATTACACCACTATTTAAAAGGGATAACAGTA 2580  
 K Y \* L Y Y T C P Y T H H Y I K G \* Q \*  
 N T N Y I I H V H T L T T I F K E R N D  
 Q I I S L I Y M P L H P S L N K G I T M

2581 CTTACTATTTTTATAAACAGAAAATCTAGTCCGAACCGCAAAGGTACACGTCCATCTTT 2640  
 S H Y F Y K D K L D P K A N E M H L Y F  
 H I I F I N T K \* I L S P T K W T C T S  
 F S L F I Q R K S \* A Q R K G H A P L F

2641 TCAATTAATAATGCTCTTTGGACAACAATACCTCTAAGGCAGAACTACTGTCAATTCCA 2700  
 L \* N \* R S V Q Q \* P S E T K S S L \* P  
 F N I K V L F R N N H L N R R Q H C N L  
 T L K L S F G T T I S I G D K I V T L T

FIG. 3 CONT'D

2701 ATACAAACTAAATCTAAGATGAAAACACTACTATAAAATCCATTTCAAACAAGTCTTAAACT 2760  
 \* T Q N L N \* K Q H Y K L Y L K N L I Q  
 N H K I \* I R S K I I N \* T F N T \* F K  
 I N S K S E V K S S I K P L T Q E S N S

2761 TCATCTTTTCCCACAATGACATCTACTAAAACAACGACAACAACACTACGATATCTCTT 2820  
 L L F P H \* Q L H N Q Q Q Q K H H \* L S  
 F Y F L T N S Y I I K N S N N T I S Y L  
 T S F P T V T S S K T A T T Q S A I S F

2821 ACGAAATTTGAGAACATTTCTCGTAGGTACCAACCAATAGTTCAAGCACGTAAAAATTT 2880  
 H K L S K Y L A D L P Q N D L E H M K L  
 I S \* V R T F L M W H N T I L N T C K \*  
 A K F E Q L S C G T T P \* \* T R A N K F

2881 ATTTGAATTACTCTTACAACAAATAAAATAAACTACTCCGACCACTACTTCGTTACCGGAG 2940  
 Y V \* H S H Q K N I Q H P Q H H L L P R  
 I F K I L I N N I \* K I L S T I F C H G  
 L S L S F T T \* K N S S A P S S A I A E

2941 AGCATACATAACATGAAAACGATAACTCCTACAACCTCTGCAATAGTCATCACTTCGACA 3000  
 E Y T N Y K Q \* Q P H Q L R \* \* Y H L Q  
 R T H I T S K S N L I N F V N D T T F S  
 R I Y Q V K A I S S T S S T I L L S A T

3001 GCTTCTATGATAACTACCACAGCAACTTCTGTGATAAATTACTGCTACTTCTACAACAATG 3060  
 R L Y \* Q H H R Q L C \* \* H R H L H Q \*  
 D F I S N I T D N F V S N I V I F I N N  
 S S V I S P T T S S V I L S S S S T T V

3061 ACCACTGTACTGCTACTTCTACAACAATGACCACTGTACTGCTACTTCTACAACAATG 3120  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3121 ACCACTGTACTGCTACTTCTACAACAATGACCACTGTACTGCTACTTCTACAACAATG 3180  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3181 ACCACTGTACTGCTACTTCTACAACAATGACCACTGTACTGCTACTTCTACAACAATG 3240  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

FIG. 3 CONT'D



3241 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3300  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3301 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3360  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3361 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3420  
 Q H C H R H L H Q \* Q H C H R H L H Q \*  
 S T V I V I F I N N S T V I V I F I N N  
 P S L S S S S T T V P S L S S S S T T V

3421 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTATTGCTACTTCTACAACAATG 3480  
 Q H C H R H L H Q \* Q H C Y R H L S Q \*  
 S T V I V I F I N N S T V I V I F L N N  
 P S L S S S S T T V P S L L S S S I T V

3481 ACCACTGTTACTACTGGTTTAAACAACAATGACCACTACTACATCTACTATAACTTTTCATA 3540  
 Q H C H H G F Q Q \* Q H H H L H Y Q F Y  
 S T V I I V L N N N S T I I Y I I N F T  
 P S L S S W I T T V P S S T S S I S L I

3541 AATACTGAAACTATGAATATTTTCGAGAAAATCAAAAATTACTACAGATATTACTACGAAA 3600  
 K H S Q Y K Y L E K L K \* H H R Y H H K  
 N I V K I S I F S K \* N K I I D I I I S  
 \* S K S V \* L A R K T K L S T \* L S A K

3601 CAAACAATCAATACCAAGATCACAACCTTGTCTTTGTATAAAAATTTCAATTACCAAATAC 3660  
 T Q \* N H N \* H Q F L F M N \* L \* H N I  
 Q K N T I T R T N F C F C I K F N I T \*  
 N T L \* P E L T S V S V Y K L T L P K H

3661 CAGTGGATGATAATGTGTATGATTAACAACCAACGCAAGACACAATGAACATTACGTCIT 3720  
 T V \* \* \* V Y \* N N T A N Q T V Q L A S  
 P \* R S N C M S I T P Q T R H \* K Y H L  
 D G V I V C V L Q Q N R E T N S T I C F

3721 TAATGGAAAATTCAAATTCCTAAATCGATAACTTTTATACACCAATAGAATATTCCACCC 3780  
 I V K \* T \* P N L \* Q F Y T T I K Y P P  
 F \* R K L K L I \* S N F I H P \* R I L H  
 N G K L N L S K A I S F I H N D \* L T P

FIG. 3 CONT'D

3781 AATATTAGTTTCAAACAACATAAATGACTGGTGATAAGGATTCGATAACAAAACGG 3840  
 N Y D F N Q Q N N V S W \* E \* L \* Q K A  
 T I I L T K N I I \* Q G S N R F S N N Q  
 \* L \* L K T S \* K S V V I G L A I T K G

3841 AGTTCACCAAAACATCGACTAAAACGAATAACCAAAAATTGGTCAAACATAAATTACG 3900  
 E L H N Q L Q N Q K N T K L G T Q Y \* H  
 R L T T K Y S I K S I P K \* V L K I N I  
 \* P P K T A S K A \* Q N K F W N S I L A

3901 CATACGATTAACCACAACAAATTTACACCAAAAAGAAAATAAATTTACCAAACTACG 3960  
 T H \* N T N N L I H N K K Q N L H N P H  
 R I S I P T T \* F T T K R K I \* I T Q I  
 Y A L Q H Q K F H P K E K S K F P K S A

3961 AAACAAAAAATACCTCTATAACACAGAGTACAAACATTCACACCTGTATTATACTGAGA 4020  
 K T K K H L Y Q T E H K Y T H V Y Y S E  
 S Q K K I S I N H R M N T L T S M I H S  
 K N K \* P S I T D \* T Q L H P C L I V R

4021 TTATCGTCGCCTGAATGGAACATGTAATGTAAAAAGTAATAAACTACTGTAAAAACACG 4080  
 L L L P S V K Y M V N K M I Q H C N K H  
 \* Y C R V \* R T C \* M K \* \* K I V I K T  
 I A A S K G Q V N C K E N N S S L K Q A

4081 AAAAACTGGGGATTTTTTAAAAATAACGACGTACACGACCTACATTTGCAAAACAGT 4140  
 K K C G \* F F K \* Q Q M H Q P H L R K D  
 S K A G R F F N K N S C T S H I Y V N T  
 K Q V G L F I K I A A H A T S T F T Q \*

4141 AAGACATCGACAATATCCACTACTTGTATTATCTACCATTCAAACAATGATTTAAATCACC 4200  
 N Q L Q \* L H H V F L H Y T Q \* \* I \* H  
 M R Y S N Y T I F L Y I T L K N S F K T  
 E T A T I P S S C I S P L N T V L N L P

4201 ACTATTTAACTAAAATATCATCCAATACCTTACAGTAAATCATAAGAAGAAAACAA 4260  
 H Y I Q N \* L L N H F T M \* Y T K K Q T  
 T I F K I K Y Y T I S H \* K T H R R K L  
 S L N S K I T P \* P I D N L I D E K S N

4261 TGGAGTTAACATACCAACACATATTGTGGATTACATACAAAACAATTTCCACTATAATA 4320  
 V E I T H N T Y L V \* H I N Q \* L H Y \*  
 \* R L Q I T Q T Y C R I Y T K N F T I N  
 G \* N Y P K H I V G L T H K T L P S I I

FIG. 3 CONT'D

4321 TTTACAACGATCTGAACAATTTTCGACTACAATAACAATTAGGACGATTACCCGTATACGA 4380  
 L H Q \* V Q \* L Q H \* Q \* D Q \* H A Y A  
 Y I N S S K N F S I N N N I R S I P M H  
 F T A L S T L A S T I T L G A L P C I S

4381 GGTACCACCACCTCAACGTTTTTCGATATCGACATCGACGTCCATTTTTTAAAAGATTCT 4440  
 G H H H L Q L L \* L Q L Q L Y F I K \* L  
 E M T T S N C F S Y S Y S C T F F K R F  
 W P P P T A F A I A T A A P L F N E L S

4441 TTGACGACGATACCAATTTAGATTCCACAAACGGTTCATCCTCTAACAATACAAAGATG 4500  
 F Q Q \* P \* I \* L H K G L L L N N H K \*  
 F S S S H N F R F T N A L Y S I T I N R  
 V A A I T L D L P T Q W T P S Q \* T E V

4501 GCCACCATTTAATACATTTTGTGAAGAATTATAACATCCGGGACTACGATCTGTCTACC 4560  
 R H Y I I Y F L E \* Y Q L G Q H \* V L H  
 G T T F \* T F C N K I N Y A R I S S L I  
 P P L N H L V I R L I T P G S A L C S P

4561 TTCTGTTAGAATACAAAACAATCGTGCACGAATATTCGTAGAATTATTAATACTAACAAC 4620  
 F V I K H K T L V H K Y A D \* Y N H N N  
 S S L R I N Q \* C T S I L M K I I I I T  
 L C D \* T K N A R A \* L C R L L \* S Q Q

4621 AAACAGATGAGAGTATAGCCGACCATATAAATCACAAGGACGACTACACAGTAATTGAAT 4680  
 N T \* E \* I P Q Y I \* H E Q Q H T M L K  
 T Q R S E Y R S T Y K T N R S I H \* \* S  
 K D V R M D A P I N L T G A S T D N V \*

4681 GGAAGATCCACAACAACACTATTTGTTCAATAGGAACAATCATTATTATTCTTCTAAAAC 4740  
 G E L H Q Q Y V L \* G Q \* Y Y Y L L N Q  
 V K \* T N N I F L N D K N T I I F F I K  
 R R P T T S L C T I R T L L L L S S K S

4741 ATAATAAGTTTTTACAGTTAATGAAGTCAACAACCATGATTTTCGTAACCGACAATCTAA 4800  
 Y \* E F I D F \* K L Q Q Y \* L M P Q \* I  
 I N N L F T L N S \* N N T S F C Q S N S  
 I I \* F H \* I V E T T P V L A N A T L N

4801 TTGACGATTACATCCGGCACAATAATTTAAACTCTGTCTACGTATGTTGAAAAAACTC 4860  
 L Q \* H L G H \* \* I Q S L H M C V K K S  
 \* S S I Y A T N N F K L C I C V F K K Q  
 V A L T P R T I L N S V S A Y L S K K L

FIG. 3 CONT'D

4861 ACCACTACTAACAAAACAAAGTTTAAGAAGACAATATGTTCTTCAAATAACGAAGCAGT 4920  
H H H N N Q K L N K Q \* V L L K I A E D  
T T I I T K N \* I R R N Y L F N \* Q K T  
P S S Q K T E F E E T I C S T K N S R \*

4921 ACTATATGTTAACTTATTACTGCAAGCACTAATAAACACAGATTCTACTGATCAGAAGG 4980  
H Y V I S Y H R E H N N T T \* S S \* D E  
M I Y L Q I I V N T I I Q Q R L H S T K  
S I C N F L S T R S \* K N D L I V L R G

4981 ATTTCTAACCGCAGAATAGTTATTTAACTACAATAATTGCCACAATTTTGACAATTCAT 5040  
\* L N A D \* \* Y I Q H \* \* R H \* F Q \* T  
R F I P T K D I F K I N N V T N F S N L  
L S Q R R I L L N S T I L P T L V T L Y

5041 AAAACTCACAGGATTAAGATAAATATATACATCAGTCCCATTCTGAAACCAATACATAC 5100  
N Q T D \* N \* K Y I Y D P Y L S Q N H I  
I K L T R I R N I Y T T L T F V K T I Y  
K S H G L E I \* I H L \* P L S K P \* T H

5101 ACTACCAAGAAAAATATTTTCGTTGACAATTAGTTCAAACACAAAATAATCGATTCTTCTA 5160  
H H N K K Y L L Q \* D L K H K I L \* S S  
T I T R K I F C S N I L N T N \* \* S L L  
S P E K \* L A V T L \* T Q T K N A L F I

5161 TCTACAAAACGAATGACATCTACCACAATTAATAATTTAGATAAAGAGAATGACATCCACT 5220  
L H K A \* Q L H H \* N \* I \* K E \* Q L H  
Y I N Q K S Y I T N I K F R N R K S Y T  
S T K S V T S P T L K L D I E R V T P S

5221 TCAAAAACCATTTTATGAACCATTACAAAAGACACTACCGTAACTACAATGATTCAATTT 5280  
L K Q Y F V Q Y H K R H H C Q H \* \* T L  
F N K T F Y K T I N E T I A N I N S L \*  
T K P L I S P L T K Q S P M S T V L N F

5281 CACATCACTAAAAATACGGCTATTTTAAAATATAGTCATACTTTTAAACAGAAATCGACT 5340  
T Y H N K H R Y F K I D T H F N T K L Q  
L T T I K I G I F N \* I L I F I Q R \* S  
H L S K \* A S L I K Y \* Y S F K D K A S

5341 ATAAAGACGACATGTTTCAAGTAAACCCAACTAGTCGTTGTTAACGAACGAATAATATT 5400  
Y K Q Q V F N M Q T Q D A V I A Q K N Y  
I N R S Y L T \* K P K I L L L Q K S I I  
I E A T C L E N P N S \* C C N S A \* \* L

FIG. 3 CONT'D

5401 AAAAAATTGTCATACATTTACCAGACATCAACAATTGCCAGGTAAGAAAAAGAAAAGTTGT 5460  
 N K L L I Y I T Q L Q \* R D M K K K Q V  
 I K \* C Y T F P R Y N N V T W K K R K F  
 K K V T H L H D T T T L P G N K E K S C

5461 CAGAGTATTATTAACAATACACTTACATCGAACAGAATACAACGTCGTATAATTAGAATT 5520  
 T E Y Y N N H S H L K D \* T A A Y \* D \*  
 L R M I I T I H I Y S T K H Q L M N I K  
 D \* L L Q \* T F T A Q R I N C C I L R L

5521 TAAATTATTTACCGTCACCGTCCTTCGTACCATACTTAAAGCAGCACCCTCTGGTGTATC 5580  
 I \* Y I A T A P L M T H I E H Q C V V Y  
 F K I F P L P L F C P I F K T S A S W M  
 N L L H C H C S A H Y S N R A P L G C L

5581 CAATCAACGAGAACAATAATCGATTTCAGTAAATTTAAACTACTTGGTAGTCTACGATG 5640  
 T L Q E Q K L \* L D N \* I Q H V M L H \*  
 P \* N S K N \* S F T M K F K I F W \* I S  
 N T A R T K A L P \* K L N S S G D S A V

5641 ACTAAAATAAGCACAACAAAACCTTTGTTTCGACTAAATAGTCCACGTTAAACACTTAATCT 5700  
 Q N \* E H Q K S V L Q N I L H L K H I L  
 S I K N T N N Q F L S I \* \* T C N T F \*  
 S K I R T T K F C A S K D P A I Q S N S

5701 TGAATAAACACTAACACCATAATTTGTTCTTTTCAGCACAACCACAACACTACGACAATACGT 5760  
 V \* K H N H Y \* V L F D H Q H Q H Q \* A  
 F K N T I T T N F L F T T N T N I S N H  
 S I Q S Q P I L C S L R T P T S A T I C

5761 AAAACCATGTAATCGTTTCTGACTAGAAAAATTACCAATATTCTAACCGACATTAACACG 5820  
 N Q Y M L L S Q D K \* H N Y S Q S Y N H  
 M K T C \* C L S I K K I T I L N A T I T  
 K P V N A F V S R K L P \* L I P Q L Q A

5821 TCCATCTTAACAGGTAACATGATTTAACTTACATGGTAAAACTAAACAAGATTATGAGG 5880  
 L Y F Q G N Y \* I S H V M K S K N \* Y E  
 C T S N D M T S F Q I Y W K Q N T R I S  
 P L I T W Q V L N F T G N K I Q E L V G

5881 AGACTCATTCTAAATGGACTACTACAACAACGTCGATTGTACAAATACCCACATCCACA 5940  
 E S Y P N V Q H H Q Q L \* C T \* P H L H  
 R Q T L I \* R I I N N C S V H K H T Y T  
 R L L S K G S S T T A A L M N I P T P T

FIG. 3 CONT'D

5941 TCCGGTAATATGTGTAAACTTTACACCAAGTGGAAATGGTTGTAATACTACGAACATCACA 6000  
 L G N Y V N S I H N V K G V N H H K Y H  
 Y A M I C M Q F T T \* R V L M I I S T T  
 P W \* V C K F H P E G \* W C \* S A Q L T

6001 ATTTTTTATATGTCCACAATCACCAACAAATTGACTGACGAACATAGAATTTTTAAATTG 6060  
 \* F I Y L H \* H N N L Q S S T D \* F N L  
 N F F I C T N T T T \* S V A Q I K F I \*  
 L F Y V P T L P Q K V S Q K Y R L F K V

6061 GGTCTGAAAATGTAGATACAACCTGATTAAATAAAAAACCTACTACAACCTTTACCAACGAAT 6120  
 G S K \* M \* T S \* N N K P H H Q F P Q K  
 G L S K C R H Q S I I K Q I I N F H N S  
 W V K V D I N V L \* K K S S T S I T A \*

6121 ATTGGGACTAGAAAAGTGTATAATAACACTATTACCATTTCATAATATGTTTGGATAATA 6180  
 Y G Q D K V I N N H Y H Y T N Y L V \* \*  
 I V R I K \* L I I T I I T L I I C F R N  
 L G S R E C Y \* Q S L P L Y \* V F G I I

6181 TTTCCGAGTCAAATTTGGTAAACGATTTCAACTGCCACAAATATGATTGAAATTCAATCA 6240  
 L P E T \* V M Q \* L Q R H K Y \* S \* T L  
 Y L S L K F W K S F N V T N I S V K L \*  
 F A \* N L G N A L T S P T \* V L K L N T

6241 ACCTGTACTATAAACACGAGTTAACTTACTATTCAATCCAAAATTACATCTAAACGGCAA 6300  
 Q V H Y K H E I S H Y T L N \* H L N A T  
 N S M I N T S L Q I I L \* T K I Y I Q R  
 P C S I Q A \* N F S L N P K L T S K G N

6301 ACAACTCATGTTTCATTGTTCAGACCGACATCGATGACCACTACAACAAAACCGTAGACT 6360  
 Q Q T C L L L R A Q L \* Q H H Q K P M Q  
 K N L V F Y C D P R Y S S T I N N Q C R  
 T S Y L T V T Q G T A V P S T T K A D S

6361 ACTAAATATACACTTTGCAATAAAATTTCTTACTTTGAAAACCATTTCGGACAATAAAC 6420  
 H N I H S V N N \* L I H F K Q Y A Q \* K  
 I I \* I H F T I K F S T F S K T L R N N  
 S K Y T F R \* K L P H S V K P L G T I Q

6421 CAAAACGACTACTTTCGTAGTAACTTAAGAGAATGAATAAAATTTATTTGGATCAAAT 6480  
 T K D H H L M M S N E \* K N \* Y V \* N \*  
 P K T M I F C \* Q I R K S I K I F R T K  
 N Q \* S S A D N F E R V \* K L L G L K L

FIG. 3 CONT'D

6481 TAGACTTTTATCTATATCACAAAACAGACAACCTAAGACATAGACTCCTCAGTGTCCATT 6540  
 I Q F Y I Y H K T Q Q N Q I Q P T V L Y  
 F R F I S I T N Q R N I R Y R L L \* L T  
 D S F L Y L T K D T S E T D S S D C P L

6541 ACACCAATGAAGACAATACCTTAGCGTCTAATCATGATTTCTCCAATTC AATTCCACACA 6600  
 H P \* K Q \* P I A S \* Y \* L P \* T L P H  
 I H N S R N H F R L N T S F L N L \* L T  
 T T V E T I S D C I L V L S T L N F P T

6601 ATCTTTCTGACAATTTTATCTTCTACGATAATAACAATTACTACITTTTATCAAGATAATT 6660  
 \* F S Q \* F L L H \* \* Q \* H H F Y N \* \*  
 N S L S N P Y F I S N N N I I F I T R N  
 L F V T L I S S A I I T L S S F L E I L

6661 CCAACAATTTTCAAATAGAAATCAACTACAAACCCTATACATAAACTGTCCAACACTAAT 6720  
 P Q \* F N I K L Q H K P Y T N S L N H N  
 L N N F T \* R \* N I N P I H I Q C T T I  
 T T L L K D K T S T Q S I Y K V P Q S \*

6721 ACAACAAACCCAACGATTACTTAAACAGTCCGGATCAATTTAGTGGTTGTCAATCCCTTAT 6780  
 H Q K P Q \* H I T V G L \* I V L L \* P I  
 I N N P N S I F Q \* A \* N F \* W C N P F  
 T T Q T A L S N D R R T L D G V T L S Y

6781 ATATGCTATACCATAATTTGGATAATGATATGGATATCTAAACAATACAAATTTCTCTACT 6840  
 Y V I H Y \* V \* \* \* V \* L N T I N L L H  
 I Y S I T N F R N S Y R Y I Q \* T \* S I  
 I R Y P I L G I V I G I S K N H K L S S

6841 ATTAGTTTGAGAAAATCAAGGATTTTAAAAAATTCGTTCTCGATATCTTAAAATACCAAA 6900  
 Y D F E K L E \* F K \* L L L \* L I K H N  
 I I L S K \* N R F N K F C S S Y F K I T  
 L \* V R K T G L I K L A L A I S N \* P K

6901 AAACCTTACCAACAAATAAATACAAAAATCAAATAATGTAAAATGTTTACTATTTTGGTA 6960  
 K S T T T \* K H K \* N I V N \* L H Y F W  
 K Q L P Q K N I N K T \* \* M K C I I F G  
 K F H N N I \* T K L K N C K V F S L V M

6961 AAAAAATATGATGTCTTTTATCGAAGATTCAAATGAAAATTAACAAAAACAAACCGAGAATT 7020  
 K K Y \* L F L K \* T \* K \* N T K N P E \*  
 N K I S C F Y S R L K S K I Q K T Q S K  
 K \* V V S I A E L N V K L K N Q K A R L

FIG. 3 CONT'D

7021 TTTACGAAAAGTCTGTAAATCTACCTCATATAAATATTTTCCAAAAGAACAACATCGGTG 7080  
 F H K E S M \* I S Y I \* L L N E Q Q L W  
 F I S K L C K S P T Y K Y F T K K N Y G  
 F A K \* V N L H L I N I F P K R T T A V

7081 ACACAAAAACAAAACCAAAATTA AAAACATATATTTACAATAAAAATCACTGAAAATAGA 7140  
 Q T K T K T \* N K T Y L H \* K \* H S K D  
 S H K Q K P K I K Q I Y I N N K T V K I  
 T N K N Q N L K K Y I F T I K L S K \* R

7141 AGGATTATAATCACAAAAAGGATAAAAACACCCTTCTTAACAATACACCTATTTCCGATG 7200  
 E \* Y \* H K E \* K Q P F F Q \* T S L P \*  
 K R I N T N K R N K H S S N N H P Y L S  
 G L I L T K G I K T P L I T I H I F A V

7201 AAAACCAAACCAATGTTAAACTA AAAATAAGATTCAATCCACATCCAAAATGTTTCAGT 7260  
 K Q N P \* L K H N K N \* T L H L N \* L D  
 S K T Q N C N T I K I R L \* T Y T K C T  
 K P K T V I Q S K \* E L N P T P K V L \*

7261 AAAACATTACCATCAAAATATACACTTAACACAGTAAGACCAAAACTATACAACCTATG 7320  
 N K Y H Y N \* I H I T D N Q N Q Y T P Y  
 M K T I T T K Y T F Q T M R T K I H Q I  
 K Q L P L K I H S N H \* E P K S I N S V

7321 TATACGTCGATATCTAAAACAAGTCATACCTCATCTATCTGCACAAAATAAACTAATACA 7380  
 M H L \* L N Q E T H L L Y V H K I Q N H  
 C I C S Y I K N L I F Y I S T N \* K I I  
 Y A A I S K T \* Y S T S L R T K N S \* T

7381 ATCAAATCAGTTTAATTAACAACCTTGAGCAATAACCAATAAGTAATATGTGTCATACCAA 7440  
 \* N L \* I L Q Q V R \* Q N N M I C L I T  
 N T \* D F \* N N F E N N T I \* \* V C Y P  
 L K T L N I T S S T I P \* E N Y V T H N

7441 AATAGGTAATAAAACAGAATAACCAAATGTTAATAAATGATGTACCAACGGACTAAACAA 7500  
 K D M I K D \* Q N V I I \* \* M T A Q N T  
 K I W \* K T K N T \* L \* K S C P Q R I Q  
 \* G N N Q R I P K C N N V V H N G S K N

7501 ATACAATCTTTGATACGTAACCAACTAATCTAAATAACATAAACATCGATTATACAATGG 7560  
 \* T L F \* A N T S \* I \* Q I Q L \* Y T V  
 K H \* F S H M P Q N S K N Y K Y S I H \*  
 I N S V I C Q N I L N I T N T A L I N G

FIG. 3 CONT'D



7561 ACGAAAACAGAACAACGCCAAAATATATCAACAATGACGATACATATTTTCATCAACCCAAA 7620  
 Q K Q R T A T K Y L Q \* Q \* T Y L L Q N  
 R S K D Q Q P K I Y N N S S H I F Y N T  
 A K T K N R N \* I T T V A I Y L T T P K

7621 ATAATCCGTATAACAGATACCAACATTATTTGACCAACAAATAAAACAATATTTGCTTT 7680  
 \* \* A Y Q R H N Y Y L Q N N I K N Y V F  
 K N P M N D I T T I F S T T \* K T I F S  
 I L C I T \* P Q L L A P Q K N Q \* L R F

7681 AACATCACAAGCACAATTACATCATGATAACAACCACCACATTAAGCAATAATACTATA 7740  
 N Y H E H \* T Y Y \* Q Q H H L E N N H Y  
 I T T N T N L T T S N N T T Y N T I I I  
 Q L T R T L H L V I T P P T I R \* \* S I

7741 ATGACGATTACCACCATGACCAAAAACACAATTTGTAGTTACCTTAACAAAATTAACGGT 7800  
 \* Q \* H H Y Q N K H \* V D I S N N \* N G  
 N S S I T T S T K T N F M L P I T K I A  
 V A L P P V P K Q T L C \* H F Q K L Q W

7801 AAGAAAATTTGGTCCATTGTGAAAATATTGACATCTTCGACGATATCTTGAAAGATTCT 7860  
 N K \* V L Y C K \* L Q L L Q \* L V K \* L  
 M R K F W T V S K Y S Y F S S Y F K R F  
 E K L G P L V K I V T S A A I S S E L S

7861 CGAATTTGCTGGACATTTAGGTTGACTACGAAGTGAATACATCAATGACTATAATTCGT 7920  
 A \* V V Q L D L Q H K V N H L \* Q Y \* A  
 L K F S R Y I W S I S \* M I Y N S I N L  
 S L R G T F G V S A E C \* T T V S I L C

7921 TCAACCAACATACTACGCAAACAAGATACTATCTCTACCTGTCGCACAAATGCTACTACA 7980  
 L Q N Y S A N T R H Y L H V A H K R H H  
 L N T T H H T Q E I I S I S L T N V I I  
 T P Q I I R K N \* S L S P C R T \* S S T

7981 ACTACGATCAAATAAACATCTATAATTATTAGACAATGTAAGATTCAATTTCAACAAGG 8040  
 Q H \* N I Q L Y \* Y D T V N \* L \* L Q E  
 N I S T \* K Y I N I I Q \* M R F N F N N  
 S A L K N T S I L L R N C E L T L T T G

8041 ATTAACATACATCAACATCATCTCTCACTACGACTATCTCGATTAAAAGACTTACGACA 8100  
 \* N T H L Q L L S H H Q Y L \* N E S H Q  
 R I Q I Y N Y Y L T I S I S S I K Q I S  
 L K Y T T T T S L S A S L A L K R F A T

FIG. 3 CONT'D

8101 ACACAAAATACGTGTTAGTAACATATCCGGATATAATGAACATCTGTTTTTCAATTAATG 8160  
 Q T K H V I M T Y A \* I V Q L C F T L \*  
 N H K I C L \* Q I P R Y \* K Y V F L \* N  
 T N \* A C D N Y L G I N S T S L F N I V

8161 ATGTCGAACATTACCATAGACATTGGGTCTGATACAACTACAAATACAACATGAAA 8220  
 \* L K Y H Y R Q L G S \* T Q H K H Q Y K  
 S C S T I T D R Y G L S H K I N I N I S  
 V A Q L P I E T V W V I N S T \* T S V K

8221 ATACAGAGTAAACTACAACATCTTTCTCAAATATTAAACAATGTAACGAGTACG 8280  
 \* T E N Q H Q Y F S N \* Y N Q \* C Q E H  
 K H R M K I N I S L T K I I K N V N S M  
 I D \* K S T S L F L K L L K T L M A \* A

8281 AAGAGAATCTCTCCACACGTTAATCTTTTCCAAAATCTATGAAAACACCCTACACATGC 8340  
 K E \* L P H A I L F P K L Y K Q P I H V  
 S R K S L T H L \* F L N \* I S K H S T Y  
 E R L S P T C N S F T K S V K T P H T R

8341 ATTTACAACAAGGTAACACTAAGTCTACAACCTTTGTTCTAAATAATGATTTAGATACTATAG 8400  
 Y I N N W Q N L H Q F L I \* \* \* I \* S I  
 T F T T G N I \* I N F C S K N S F R H Y  
 L H Q E M S E S T S V L N I V L D I I D

8401 ACGTCATCGACGACCAAACTTAAATGACTACTTTTAAATATGTTAAACCATGGATGTAT 8460  
 Q L L Q Q N P I \* Q H F N Y C N P V \* M  
 R C Y S S T Q F K S I F I I V I Q Y R C  
 A T A A P K S N V S S F \* L L K T G V Y

8461 AAATTTCTCACTATTATAACATCGACGACTAAATCCACAAGAATATGTCTTACCAGATT 8520  
 N L S H Y Y Q L Q Q N L H E \* V S H H \*  
 I \* L T I I N Y S S I \* T N K Y L I T S  
 K F L S L I T A A S K P T R I C F P A L

8521 CGTACATGTCCCATTACAACGATTCCGTCGATTATAAAGAACATATACCAAATAACTACG 8580  
 A H V P Y H Q \* P L \* Y K K Y I T \* Q H  
 L M Y L T I N S L C S I N R T Y P K N I  
 C T C P L T A L A A L I E Q I H N I S A

8581 AAAATTAGTTGAATGACGACTAAATGTCGTATTTAATTTTTTTCGTACACAATTTTGACC 8640  
 K \* D V \* Q Q N V A Y I L F L M H \* F Q  
 S K I L K S S I \* L M F \* F F C T N F S  
 K L \* S V A S K C C L N F F A H T L V P

FIG. 3 CONT'D

8641 GAACTTCAATTTTAACTGAAAATTATTCGTTCTCCGTTACAGGGATAAGAATGTTGTGG 8700  
 S S T L I S K \* Y A L P L H G \* E \* L V  
 A Q L \* F Q S K I L L L C T D R N K C C  
 K F N F N V K L L C S A L T G I R V V G

8701 GAAAAGTGAATTTCTCCACAACATAACTCATTAAACAATATATATAATAAAAAACAATC 8760  
 R K V \* L L H Q I S Y N T I Y I I K Q \*  
 G K \* K F S T N Y Q T I Q \* I Y \* K K N  
 K E S L P P T T N L L K N Y I N N K T L

8761 AAATTAGACAAAATATAATAACACCCGAAATAACGGATGTATATCACAATATTAGACT 8820  
 N L R N \* I I T P K I A \* M Y H K Y T Q  
 T \* D T K Y \* Q P S \* Q R C I T N I L R  
 K I Q K I N N H A K N G V Y L T \* L D S

8821 ATAAGTAAACGGACGAATACGATCAAAAATTTCAATAACTATTACCACAACAATCTCTATA 8880  
 Y E N A Q K H \* N \* L \* Q Y H H Q \* L Y  
 I N M Q R S I S T K F N N I I T N N S I  
 I \* K G A \* A L K L T I S L P T T L S I

8881 AAGTCAATTACTAAATACAAAACGATTATTTAAAAAGGTTAAACTAGTTACCATACTCAG 8940  
 K L \* H N I N Q \* Y I K G I Q D I T H T  
 N \* N I I \* T K S I F K E L K I L P I L  
 E T L S K H K A L L N K W N S \* H Y S D

8941 GTGAAAACCCAGACAAATGATAGTATTAAGATACCTAACGGGATAACATCACCGTCAATA 9000  
 W K Q T Q K S D Y N \* P N G \* Q L P L \*  
 G S K P R N V I M I R H I A R N Y H C N  
 V K P D T \* \* \* L E I S Q G I T T A T I

9001 CCTACTTCTATAGCCAAGATGATACAAAATTACAAGGATGATTTCAAAACTCTGTACCGAA 9060  
 P H L Y R N \* \* T \* H E \* \* L K S V H S  
 H I F I D T R S H K I N R S F N Q S M A  
 S S S I P E V I N L T G V L T K L C P K

9061 AGTACAAAATGTAAAAAATGAATACGTAACGATCACTATCACAAGTCACGATATGTGG 9120  
 E H K V N K L K H M Q \* H Y H E T S Y V  
 K M N \* M K \* S I C K S T I T N L A I C  
 \* T K C K K V \* A N A L S L T \* H \* V G

9121 TGTATAAGTCTAAAGAATATTACTAAAAATACGATCACCAACACAAAATAGTAGAAACAC 9180  
 V Y E S K K Y H N K H \* H N H K I M K T  
 W M N L N R I I I K I S T T T N \* \* R Q  
 C I \* I E \* L S K \* A L P Q T K D D K H

FIG. 3 CONT'D

9181 ATGATACAAATTTTCTCCACTACCATGTGGTGTAGGAATAACAATAAGTCTACCACAATA 9240  
 Y \* T \* F L H H Y V V D K N N N L H H \*  
 T S H K F S T I T C W M R I T I \* I T N  
 V I N L L P S P V G C G \* Q \* E S P T I

9241 CTTCTTACGAAGAAACATATGTAGAAACCAAGGTGTATGTGCAATATCGGAACGATTAAG 9300  
 S S H K K T Y M K P E V Y V N Y G Q \* N  
 H L I S R Q I C R Q N W M C T I A K S I  
 F F A E K Y V D K T G C V R \* L R A L E

9301 ATTACCAAAATATTCTAAAGGACTACAATAATCACTTCCATAACATGCATAACATTCTTG 9360  
 \* H N \* L I E Q H \* \* H L Y Q V Y Q L F  
 R I T K Y S K R I N N T F T N Y T N Y S  
 L P K I L N G S T I L S P I T R I T L V

9361 CGCGAGATACTGAATAACATCTCACCCACGTACTTATGCGGCTTCTCCCATATACAAA 9420  
 A S \* S K N Y L P H M H I R R L P Y I N  
 R A R H S I T S H T C T F V G F L T Y T  
 R E I V \* Q L T P A H S Y A S S P I H K

9421 ATTAAAATTATCAAGGACCCAAAACCTTATTACTAATAATATCTTCATACGGACCTTGAAA 9480  
 \* N \* Y N R P K S Y H N N Y F Y A Q F K  
 K I K I T G P N Q I I I I I S T H R S S  
 L K L L E Q T K F L S \* \* L L I G P V K

9481 AACACCATCTCTAGAAAACTAAACAAAATAGTTAAAAAATCATCAAATTAAGCAGGATA 9540  
 K H Y L D K Q N T K D I K \* Y N L E D \*  
 K T T S I K K I Q K I L K K T T \* N T R  
 Q P L S R K S K N \* \* N K L L K I R G I

9541 TCTAAAGAAAAGAGAATGACGATCAAGATAAAAACCTCGATATAACCGATATCAACAACA 9600  
 L N R K E \* Q \* N \* K Q L \* I P \* L Q Q  
 Y I E K R K S S T R N K S S Y Q S Y N N  
 S K K E R V A L E I K P A I N A I T T T

9601 GAACCAAAAATAATAAATTTTGAATTCGCACGAAAACCTCTAATATGATCACAACA 9660  
 R P K K N N L L V \* A H K Q L N Y \* H Q  
 D Q N K I I \* Y F K L T S K S I I S T N  
 K T K \* \* K I F S L R A K P S \* V L T T

9661 TCAATATTTACAACAACAAACCACATAATTAAGAATACGAAAAACAAAAGTTCAAAT 9720  
 L \* L H Q Q K T Y \* N E \* A K Q K E L K  
 Y N Y I N N N P T N I K K H K K N K L N  
 T I F T T T Q H I L K R I S K T K \* T \*

FIG. 3 CONT'D

9721 AGGATAAACACGTACACAAATACGAACAAAAATAAAAATACATTGTAACATAAAAGGAAG 9780  
D \* K H M H K H K N K N K H L M T N E K  
I R N T C T N I S T K I K I Y C Q I K R  
G I Q A H T \* A Q K \* K \* T V N Y K G E

9781 ACTTTAATCACATTAATACGTAAACGTTACCTAACAATACATACCACGATATTACGGAAA 9840  
Q F \* H L \* A N A I S Q \* T H H \* L A K  
R F N T Y N H M Q L P N N H I T S Y H R  
S I L T I I C K C H I T I Y P A I I G K

9841 AACCAAAACACAGTGTATACATCGATACCAATAACGTTTGGTACAAAATACCAATAAAAAG 9900  
K T K H \* M H L \* P \* Q L G H K I T I K  
K P K T D C I Y S H N N C V M N \* P \* K  
Q N Q T V Y T A I T I A F W T K H N N E

9901 TATAACATCCTTTTAACCACAATTACATACATCACTATCATGTAAACTTCTTTGTAGAGA 9960  
M N Y S F Q H \* H I Y H Y Y M Q L F M E  
\* I T P F N T N I Y T T I T C K F F C R  
Y Q L F I P T L T H L S L V N S S V D R

9961 ATGATGAAAATACTAATGATTTCTAAGAATAACATCTAATTTCTTAAGACAAAGACTACA 10020  
\* \* K \* S \* \* L N K N Y I L S N Q K Q H  
K S S K H N S F I R I T S \* L I R N R I  
V V K I I V L S E \* Q L N F F E T E S T

10021 ACGGATGTTATCTATAAACTCAAACATATTATTCATAGCAATGATATCACCATTTTACCT 10080  
Q R C Y I N S N T Y Y T D N S Y H Y F P  
N G V I S I Q T Q I I L I T V I T T F H  
A \* L L Y K L K Y L L Y R \* \* L P L I S

10081 ATGACGACGATATCTCTTCGCGCACAAGAGTCAATCGATTTGATACCTTTGTA AATT 10140  
Y Q Q R Y L L P T N E T L \* L \* P F M \*  
I S S G I S F R R T R L \* S F S H F C K  
V A A \* L S A A H E \* N A L A I S V N L

10141 AGTGTTATTACCATTACTACAGAATATGGTTGGAGGATGTCGTAGACAAAGATGTAGAAA 10200  
D C Y H Y H H R I G V E \* L M Q K \* M K  
I V I I T I I D \* V L R R C C R N R C R  
\* L L P L S T K Y W G G V A D T E V D K

10201 AAACGTTAGTCCATAACATTTCTACCATAGAGGATGCAGTTTTTAACTTGGAACATAACA 10260  
K A I L Y Q L S P I E \* T L F Q V K Y Q  
K Q L \* T N Y L H Y R R R \* F N F R T N  
K C D P I T F I T D G V D F I S G Q I T

FIG. 3 CONT'D

10261 ATCACAATGAATACCATCATACTGAAACTTACCAAATACCAATCTACTGTTTCAAATAAC 10320  
 \* H \* K H Y Y S K S H N I T L H C L K N  
 N T N S I T T H S Q I T \* P \* I V F N I  
 L T V \* P L I V K F P K H N S S L T \* Q

10321 AGGAGCAGTACAATATACAAGTAGGAGATTATACTTGCTTGGACTAATAAGACGGAATAA 10380  
 D E D H \* I N M R \* Y S R V Q N N Q R I  
 T R T M N Y T \* G R I H V F R I I R G \*  
 G R \* T I H E D E L I F S G S \* E A K N

10381 CACATCTCAATGAGATCCACTAAAAATGATATTACAGACCAGCCTACTCAAATGTCAACA 10440  
 T Y L \* E L H N \* \* L T Q D S S N L L Q  
 Q T S N S \* T I K S Y H R T P H T \* C N  
 H L T V R P S K V I I D P R I L K V T T

10441 CAGAATGGTCTACGTCCCGACAGTTGAACAAAACGTGTCAGAGAAATGTTTTAGGAATGTG 10500  
 T K G S A P S D V Q K S L R K V F D K C  
 H R V L H L A T L K N Q C D R \* L I R V  
 D \* W I C P Q \* S T K V T E K C F G \* V

10501 AGGTTTTATATGAAAACCATTAACAATTTGGACCCTTTGAAAATGACAAAATCGACGCAT 10560  
 E L I Y K Q Y H \* V Q H F K \* Q K L Q T  
 S W F I S K T I N F R T F S K S N \* S R  
 G F Y V K P L T L G P S V K V T K A A Y

10561 ATTACCGGCTGGTGTCCCGTAAAGTACAATGATACGCATCATCAATATGATAATTTCC 10620  
 Y H G V V L P M E H \* \* A Y Y N Y \* \* L  
 I I A S W L P C K M N S H T T T I S N F  
 L P R G C P A N \* T V I R L L \* V I L P

10621 AAGAAAAAACACACCCAGTACACCTAGACAACCAATACATAATTGTCCACTATCACAATT 10680  
 N K K T H T M H I Q Q N H I L L H Y H \*  
 T R K Q T P \* T S R N T I Y \* C T I T N  
 E K K H P D H P D T P \* T N V P S L T L

10681 CAAACATATATACGTAGTTAATCTCGAGTCATGACCAACAGTGTGACCGTGACTAAAATG 10740  
 T Q I Y A D I L A \* Y Q N D C Q C Q N \*  
 L K Y I H M L \* L E T S T T V S A S I K  
 N T Y I C \* N S S L V P Q \* V P V S K V

10741 ACCATTA AAAATACCAGGTATATCTCTACGAGTCAACATGTCAACGGTCAATTCCTGAT 10800  
 Q Y N K H D M Y L H E L Q V T A L \* P S  
 S T I K I T W I S I S L N Y L Q W N L V  
 P L K \* P G Y L S A \* T T C N G T L S \*

FIG. 3 CONT'D

10801 GCAGGTCTGACAATTACAATAACGAACCGAGATACGTCGATATGAATTATTAACACGAAC 10860  
R G S Q \* H \* Q K A R H L \* V \* Y N H K  
V D L S N I N N S P E I C S Y K I I T S  
T W V T L T I A Q S \* A A I S L L Q A Q

10861 CAAACATGTTTTACTACAACAAGATGACTTCTAAAATTACAAACCGATACCGTTTACC 10920  
T Q V F H H K N \* Q L N \* H K P \* P L H  
P K Y L I I N T R S F I K I N P S H C I  
N T C F S T Q E V S S K L T Q A I A F P

10921 AAAATCGTTTCATTTTCGTCTAGAACAGAATCTACGAAACCGAAGTTACTGTCCACAAAG 10980  
N \* G L L L L D Q R L H K P K L S L H K  
T K A L Y F C I K D \* I S Q S \* H C T N  
K L W T F A S R T K S A K A E I V P T E

10981 ATAAC TTTGAAATAACCGACGATAATTCGCAGATATATACCCTAAAGTTCCAGCAGTTTA 11040  
\* Q F K I P Q \* \* A D I Y P I E L D D F  
R N F S \* Q S S N L T \* I H S K L T T L  
I S V K N A A I L R R Y I P N \* P R \* I

11041 TGATCCTTCAACATGAAAAC TTTCTACTTAACCGTGAAGACTGCAAATAGTTGTTAACCG 11100  
V L F N Y K Q L H I P V K Q R K D V I P  
Y \* S T T S K F I F Q C R R V N I L L Q  
S P L Q V K S S S N A G E S T \* \* C N A

11101 ACCACAATTTAACGTTAGATTTTGT TTTTCTAAATAATTTCTTTGTTAAATAACCTAAAA 11160  
Q H \* I A I \* F L F I \* \* L F L K N S K  
S T N F Q L R F C F S K N F F C N I P N  
P T L N C D L V F L N I L S V I \* Q I K

11161 CTATAGATGTA AAAACAATCAACATATTAAGACGTAACAATTTACCTGATATAAATA 11220  
S I \* M K T \* N Y L K Q M Q \* I S \* I \*  
Q Y R C K Q K T T Y N R C K N F P S Y K  
I D V N K N L Q I I E A N T L H V I N I

11221 CATATAATTATGTGTATACTAACCACAATGTAATACACATGAAACAAAACAATCAAATA 11280  
T Y \* Y V Y S Q H \* M I H V K N Q \* N \*  
H I N I C M H N T N C \* T Y K T K N T K  
Y I L V C I I P T V N H T S Q K T L K I

11281 CTACAATGATCAATTTGTATTTCGTAAAAATAAACTGATACATATATTAAGGACATGAGAC 11340  
S T V L \* V Y A N K N S \* T Y L E Q V R  
H H \* \* N F M L M K I Q S H I Y N R Y E  
I N S T L C L C K \* K V I Y I I G T S Q

FIG. 3 CONT'D

11341 ATGGAACAAATACATTTAATAAATCAACAAATATTCCTTCCAAAATCTCCAAAATGAAT 11400  
 Y R T K H L N N L Q K Y P L N \* L N \* K  
 T G Q K I Y I I \* N N I L F T K S T K S  
 V K N \* T F \* K T T \* L S P K L P K V \*

11401 ACAGACCGAGAGTATAAAAAAAGGACGACACTTAAAATGAATACAAATACTTCATAAAAT 11460  
 H R A R M N Q E Q Q S N \* K H K H L I K  
 I D P E \* I K N R S H I K S I N I F Y K  
 T Q S E Y K T G A T F K V \* T \* S T N \*

11461 ACCAACATAAAATACACAAAAACGATAAAAAATTTGATACGTATCATAATTAGTACTGTA 11520  
 H N Y K I H K Q \* K \* L \* A Y Y \* D H C  
 I T T N \* T N K S N K Y S H M T N I M V  
 P Q I K H T K A I K I V I C L I L \* S M

11521 AAAAAGAACTACAAAAACCAACCATCTTATCAATGAAATTAAGATACACCATAAAACC 11580  
 K K K S T K P Q Y F L \* K L K \* T T N Q  
 N K R Q H K Q N T S Y N S \* N R H P I K  
 K E K I N K T P L I T V K I E I H Y K P

11581 CAGCTTAAATCTTCTCTACAAAACAATAAATAATGTCGGAAAAATCCATGAATATGTAC 11640  
 T S N L L P H K T I \* \* L R K L Y K Y M  
 P R I \* F L I N Q \* K N C G K \* T S I C  
 D F K S S S T K N N I V A K K P V \* V H

11641 CTGGTGATAAAACAGTAATCGATATCGTTTTTAAACAACGATTAACCAACAGACAATTATA 11700  
 S W \* K T M L \* L L F Q Q \* N T T Q \* Y  
 P G S N Q \* \* S Y C F N N S I P Q R N I  
 V V I K D N A I A F I T A L Q N D T L I

11701 TAAAATAAAATGTCTACATGGAATATAATTTAACTAAGAGAACTCAATGAATAAATATCC 11760  
 I K N \* L H V K Y \* I S E R S N S I \* L  
 Y K I K C I Y R I N F Q N E Q T V \* K Y  
 N \* K V S T G \* I L N I R K L \* K N I P

11761 CATATAAAATAGAACAATAACCCCTAAAAGAGAGAAAATTTGTCACAAAATCTTACGG 11820  
 T Y K I K N N P I K R E K L C H K \* F A  
 P I N \* R T I P S K E R K \* V T N K S H  
 Y I K D Q \* Q P N K E R K F L T K L I G

11821 ATACCCACAAATATTAATATTTTAAAGACAAGTTCTTAACGCAATATACTTACGATTACC 11880  
 \* P H K Y N Y F K Q E L I A N Y S H \* H  
 R H T N I I I F N R N L F Q T I H I S I  
 I P T \* L \* L I E T \* S N R \* I F A L P

FIG. 3 CONT'D



11881 GAATGCAGGTGGAGCATTATCAAAACTCCGATAAAACAATTTAAATTTTGACGAACCTTA 11940  
S V D V E Y Y N Q P \* K T L N L V A Q F  
A \* T W R T I T K L S N Q \* I \* F Q K S  
K R G G R L L K S A I K N F K F S S P I

11941 TCCACCGCACGGTCAATAACTTCAGAGGGTTTAAGTTAGTTTTAACTGACTACACTTTAC 12000  
L H R A L \* Q L R G F E I L I S Q H S I  
Y T A H W N N F D G L N L \* F Q S I H F  
P P T G T I S T E W I \* D F N V S T F H

12001 ACGATTACAACAAAACAATTTAACAATGTCGTAAACGTACAACGAAGATTAAGATTCAA 12060  
H \* H Q K T L N N V A N A H Q K \* N \* T  
T S I N N Q \* I T \* L M Q M N S R I R L  
A L T T K N F Q K C C K C T A E L E L N

12061 CACCGTCATAACATCAAAAATGTATTACTTTATGATAGATGAAGTCTAAACTCACATCG 12120  
T A T N Y H K V Y H F V I \* K L N S H L  
Q P L I T T N \* M I F Y \* R S \* I Q T Y  
H C Y Q L T K C L S I S D V E S K L T A

12121 AAAACTATTGGAACGAGTTAATAACTAACAAAATAAGCGGTTAGGACGACGTCAACTATG 12180  
K Q Y A Q E I I S Q K I R W D Q Q L Q Y  
S K I L K S L \* Q N N \* E G I R S C N I  
K S L S A \* N N I T K N A L G A A T S V

12181 ATTCACAGAACGTTTCATATCTACTTCAATCGCTACTAATAACAAGTTCTATCATGGCAAAA 12240  
\* T D Q L Y L H L \* R H N H E L Y Y R K  
S L T K C T Y I F N A I I I N L I T G N  
L H R A L I S S T L S S \* T \* S L V T K

12241 CGTCCGAAACGTTTCACTCAAACATTTATACCGATCAAAACAACCTTATACTTCAGCGTTT 12300  
A P K A F H T Q L Y P \* N Q Q I H L R L  
Q L S Q L T L K Y I H S T K N F I F D C  
C A K C L S N T F I A L K T S Y S T A F

12301 CTTTTTAAACCGACTACGATTTTATCACCAAGACAATTAGTTGTTGTCTATTTTGTCAA 12360  
S F N P Q H \* F Y H N Q \* D V V S L V T  
L F I Q S I S F I T T R N I L L L Y F L  
F F K A S A L F L P E T L \* C C I F C N

12361 TCTTTTTCGTACATTATATCGATTTCAGACACATACTTGCACTATTTTCGACATCGAGCGTT 12420  
L F L M Y Y L \* T Q T H V H Y L Q L E C  
\* F F C T I Y S L R H I F T I F S Y S A  
S F A H L I A L D T Y S R S L A T A R L

FIG. 3 CONT'D

12421 TGAACCTGCATACCGTCTGGATCGTGAATGATTGTACATATTTCTCCGAGCCTAATTACT 12480  
V Q V Y P L G L V \* \* C T Y L P E S \* H  
F K F T H C V \* C K S V H I F L S P N I  
S S R I A S R A S V L M Y L S A R I L S

12481 ATTCTTCTCATTCAACAAAGGCGAAACGTCTGTTACGAAAAATCGTACCAAGCATTAA 12540  
Y S S Y L Q K R K A S L A K \* C P E Y I  
I L L T F N N G S Q L C H K K A H N T F  
L F L L T T E A K C V I S K L M T R L N

12541 CCTATTAGTCCGAAATTTAAGATAAGACCTATTACGACAATTTCCAACACATGGAAACTC 12600  
P Y D P K L N \* E P Y H Q \* L N H V K S  
Q I I L S \* I R N Q I I S N F T T Y R Q  
S L \* A K F E I R S L A T L P Q T G K L

12601 ACGATAAGGTCGTAACCGACGATTATGAAATGATATCATTATGGTCTATTTGTTCAAAA 12660  
H \* E L M P Q \* Y K L \* L L V L Y V L K  
T S N W C Q S S I S \* S Y Y Y W I F L N  
A I G A N A A L V K V I T I G S L C T K

12661 ACTATTCAACAACCTATTACAAATACAATGATACGACCATCACATACCGTATATGTCTG 12720  
Q Y L Q Q Y H K H \* M H Q Y H I A Y V S  
K I F N N I I N I N C I S T T Y P M Y L  
S L T T S L T \* T V Y A P L T H C I C V

12721 ACAAGTCTACGACTACCATAATTATTTGTCAATTGACTATAATCACAACTAAGATTAAC 12780  
Q E L H Q H Y \* Y V T L Q Y \* H Q N \* N  
S N L I S I T N I F L \* S I N T N I R I  
T \* S A S P I L L C N V S I L T S E L Q

12781 CGGAGAACAATAGTAACGCTTGCCATATTACTTCAACGATTACGACAATACGTCTTATT 12840  
A E Q \* \* Q S C T Y H L Q \* H Q \* A S Y  
P R K N D N R V P I I F N S I S N H L I  
G R T I M A F L Y L S T A L A T I C F L

12841 ACTCAACTACGGAGTATTTAATTTTATGTTCAACAATTATCACCAAGACTATACTTAAC 12900  
H T S A E Y I L F V L Q \* Y H N Q Y S N  
I L Q H R M F \* F Y L N N I T T R I H I  
S N I G \* L N F I C T T L L P E S I F Q

12901 ATTATAAGGATGAGTTACAATAATATTATTACCATCATCACCATCTTATCAAATACGACA 12960  
Y Y E \* E I N N Y Y H Y Y H Y F L K H Q  
T I N R S L T I I I I T T T T S Y N I S  
L I G V \* H \* \* L L P L L P L I T \* A T

FIG. 3 CONT'D

12961 AGAATCACTACAACCTACCAGAATTCATATGATTCTATTACTTTCTACTACCTTTAACACA 13020  
 E \* H H Q H D \* T Y \* S L S L H H F N H  
 N K T I N I T K L I S L Y H F I I S I T  
 R L S T S P R L Y V L I I F S S P F Q T

13021 ACAAATCTCGAACTAGGAGGAACATTTAAAAGATATGTTCTACAATTCCTGAAATTTTA 13080  
 Q K L A Q D E K Y I K \* V L H \* P V \* F  
 N N \* L K I R R T F K R Y L I N L S K F  
 T K S S S G G Q L N E I C S T L P S L I

13081 ATTCATAGAAATAAAATAATTTCTACATTGTGAAATCGATCTCCCAACCAACCATG 13140  
 \* T D K N \* \* L I Y C K L \* L T P Q Q Y  
 N L I K I K N F S T V S \* S S P P N N T  
 L Y R \* K I L P H L V K A L P H T T P V

13141 AAATAGAAGTTGTTAATCTAACGTCGACCACAACGATGACTCATACGTCGATTAAGAAG 13200  
 K I K L L \* I A P Q H Q \* Q T H L \* N K  
 S \* R \* C N S Q L S T N S S L I C S I R  
 K D E V I L N C A P T A V S Y A A L E E

13201 ATATGAAAGTAATACACGTAAAAGACATCTAGGATTCTTTTGAATAAATCTAATATATGT 13260  
 \* V K M I H M K Q L D \* S F K N L N Y V  
 R Y K \* \* T C K R Y I R L F S I \* I I Y  
 I S E N H A N E T S G L F V \* K S \* I C

13261 TGTTCCACCACATGGATATTAATTAACACAATTTTACGAGACACTAGTACGACCATGACC 13320  
 V L H H V \* L \* N H \* F A R H D H Q Y Q  
 L L T T Y R Y N I T N F H E T I M S T S  
 C P P T G I I L Q T L I S Q S \* A P V P

13321 ATACCGGTAATGATAATTTGGACTCCGATGATAATGGTTCTAAGAATACCACCACGGAG 13380  
 Y P W \* \* \* V Q P \* \* \* G L N K H H H R  
 T H G N S N F R L S S N V L I R I T T G  
 I A M V I L G S A V I L W S E \* P P A E

13381 TCAAACATAAATAACGGCACGTGCACATCTCGTAGGTCTACATCTACCATATACATTAA 13440  
 L K Y K N G H V H L A D L H L H Y I Y I  
 \* N T N I A T C T Y L M W I Y I T Y T F  
 T Q I \* Q R A R T S C G S T S P I H L N

13441 TGCACCATTTAAACATGTTTCAGGAAACCCATATTTTCTAGGATAAGAAATACACAATTG 13500  
 V H Y I Q V L G K P Y L L D \* E K H T L  
 \* T T F K Y L D R Q T Y F I R N K I H \*  
 R P L N T C T G K P I F S G I R \* T N V

FIG. 3 CONT'D

13501 TGTACTACAAACAGTTCAGACACCAAAAACCTCTCTACCGTCAACAAGGACACATCCAAG 13560  
V H H K D L R H N K S L H C N N R H L N  
C M I N T L D T T K P S I A T T G T Y T  
C S T Q \* T Q P K Q L S P L Q E Q T P E

13561 TTCACAGCGACAAGTTAGATTTCTAAATTTAAAAAATTTGCCCAAGCCCATGATCACAC 13620  
L H R Q E I \* L N L N K L R T R P V L T  
\* T D S N L R F I \* I K \* V P E P Y \* H  
L T A T \* D L S K F K K P P N P T S T H

13621 TTACGGGCCGATCATGGGACACGATCACCAAATAGATGACTACAAGTTAATTCCTCCGTAAA 13680  
F A R S T G Q A L P K D V S T \* N L A N  
S H G A L V R H \* H N I \* Q H E I L P M  
I G P \* Y G T S T T \* R S I N L \* P C K

13681 CTGTAAACATTATGGTTATCTCGACCATATCCAAATATAATATTTCACTTAACAACGGCA 13740  
S M Q L V L L A P I P K Y \* L T F Q Q R  
Q C K Y Y W Y L Q Y L N I N Y L S N N G  
V N T I G I S S T Y T \* I I F H I T A T

13741 AAAGTCGCATATCTACTGCTGCCATTATTTAACCTATTCAAGAAACAACAGTTTCTTGA 13800  
K \* R I S S S P L L N S L N K T T L L V  
N E A Y L H R R Y Y I P Y T R Q Q \* F F  
K L T Y I V V T I F Q I L E K N D F S S

13801 TTAATCTTCAAATATTATTTCTCTTTTGAATAATACTCAACTGATTTTCAACACCACAA 13860  
L K S T \* L L S F V \* \* S N V L L Q P T  
\* N L L K Y Y L S F K N H T S \* F N H H  
I \* F N I I F L F S I I L Q S F T T T N

13861 CACCGACTTGTAATAAGAAATGTAAACTATAACTACCATCAGCGCACGGTGTATATCAA 13920  
T A S C S K K V N S I S P L R T G C I T  
Q P Q V H N R \* M Q Y Q H Y D R A V Y L  
H S F M I E K C K I N I T T A H W M Y N

13921 GCATCCTTAGAAAGTTTCATATGATACAATCTAGAAACGATACGTAACGCAGTAAACTA 13980  
R L F R E F Y V I N S R Q \* A N R \* K S  
E Y S D K L T Y \* T L D K S H M A D N Q  
T P I K \* L I S H \* I K A I C Q T M K I

13981 GCATTAATAACAAGTTATAACACACTTTAAGAAACACTCATAACGACTAACATTTCTTAGG 14040  
R L S Q E I N H S I R Q S Y A S Q L S D  
D Y H N N L I T H F E K H T H Q N Y L I  
T I I T \* Y Q T F N K T L I S I T F F G

FIG. 3 CONT'D

14041 ATGAAAAGATTCTTTCTAACCATATAAAACAACCTTTTAGGACTATAATAATTATATATA 14100  
 \* K E L F S Q Y S K T S F G S I I L I Y  
 R S K \* S L N T H N Q Q F D Q Y \* \* Y I  
 V K R L F I P I I K N F I R I N N I Y I

14101 TTTTFTAATCCGGGATAAAAATTATCTCGAAATGAATTATGACAGTAAAAACGTCTGTGG 14160  
 L F N P G I K L L A K S L V T M K A S V  
 Y F I L G \* K \* Y L K V \* Y Q \* K Q L C  
 F F \* A R N K I S S \* K I S D N K C V G

14161 AATCAACTTCATCCAAATCAACCACAAAATTGAAATCTATTGGTTCTAAACATACCAGTT 14220  
 K T S T P K T P T K V K S L W S K Y P \*  
 R L Q L L N L Q H K L K L Y G L N T H D  
 \* N F Y T \* N T N \* S \* I V L I Q I T L

14221 ACCATACTAAAACCACTAAAATATGTTTGTGGGGTCCCAAACACACCGTCAACGTCTA 14280  
 H Y S K P S K I C V A G P N P T A T A S  
 I T H N Q H N \* V F L G L T Q H P L Q L  
 P I I K T I K Y L C G W P K T H C N C I

14281 AGAATGATAAGAATATACTACGGATACAACCTGATACACAGTACATAATCTAACACTTAAT 14340  
 E \* \* E \* I I G I N V I H \* T N S Q S N  
 N K S N K Y S A \* T S \* T D H I L N H I  
 R V I R I H H R H Q S H T M Y \* I T F \*

14341 AAACAATTACTATCAATATCTGTTAAGCTAGAACATGTCATACTAAAATGACTAATGTTC 14400  
 N T L S L \* L C N S R T C Y S K V S \* L  
 I Q \* H Y N Y V I R D Q V T H N \* Q N C  
 K N I I T I S L E I K Y L I I K S I V L

14401 AATCTCAACAAATTATTCATAAAATTCATAACCCCATACTTCATAGTAGGATTATGACAC 14460  
 N S N N L L Y K L Y Q P I F Y \* G L V T  
 T L T T \* Y T N \* T N P Y S T D D \* Y Q  
 \* L Q K I L I K L I P T H L I M R I S H

14461 CTAACACTATTACTATCCACATAATAAGTAACACGATTAATAATATATGATAAATCATA 14520  
 S Q S L S L H I I \* Q A L K L I S N L I  
 P N H Y H Y T Y \* E N H \* N \* Y V I \* Y  
 I T I I I P T N N M T S I K I Y \* K T H

14521 CAAAATGGATTATGAACAAAACAGGGGAACAATCTGTTTAAAAACATCTACCACATGGC 14580  
 T K G L V Q K P G R T L C I K T S P T G  
 P K V \* Y K N Q D G Q \* V F K Q L H H V  
 N \* R I S T K T G K N S L N K Y I T Y R

FIG. 3 CONT'D

14581 AAACAACAAAGATAACCAATGGTAATGTTTCTCAATCCACATCAATACTTGAATCTACAA 14640  
 N T T E I P \* W \* L S N P T T I F K S T  
 T Q Q K \* Q N G N C L T L H L \* S S L H  
 K N N R N T V M V F L \* T Y N H V \* I N

14641 CTGTGTGTGGCAATAGCAAACAGAGAATTTCTAAATGAAGAAATACGTCGTCTAGGACGA 14700  
 S V C R \* R K D R L S K S R \* A A S G A  
 Q C V G N D N T E \* L N V E K H L L D Q  
 V C V T I T Q R K F I \* K K I C C I R S

14701 TACGTGCAACGTAGACGATCACGAGACGAACTAAATGCTTGAACAACAAAATCACATCGA 14760  
 I C T A D A L A R S S K R V Q Q K L T A  
 \* A R Q M Q \* H E A Q N V F K N N \* H L  
 H V N C R S T S Q K I \* S S T T K T Y S

14761 CGGTAATGTTCCACATATTTTAAAGTTTGACATTTTGGTCCATTGAAATGGTTCTGAAA 14820  
 A M V L P I F N \* V T F G P L K L W S K  
 Q W \* L H Y L I E F Q L V L Y S \* G L S  
 G N C T T Y F K L S Y F W T V K V L V K

14821 ATGCTCAAACAATTTTCATTTCCGAACAAATTTCTCCCATCATGTCAACTAAACTTTGTA 14880  
 \* S N T L L L P K N L S P L V T S K F C  
 K R T Q \* F Y L S T \* L P Y Y L Q N S V  
 V L K N F T F A Q K F L T T C N I Q F M

14881 AAAAAGAAATGAGTCTACCATTACGACGTTAATGACTAATATTAATAATATTCATATTA 14940  
 K K K V \* S P L A A I V S \* L \* \* L Y L  
 N K R \* E L H Y H Q L \* Q N Y N N Y T Y  
 K E K S L I T I S C N S I I I I I L I I

14941 AATGGATGATACCAACTATAATTCGTCAATAACAAACATAATCTTCAACAAATATTATA 15000  
 K G V I T S I L C N N N T N S T T \* L Y  
 N V \* \* P Q Y \* A T I T Q I L L Q K Y I  
 \* R S H N I N L L \* Q K Y \* F N N I F I

15001 AAACTTAAATACTACCACCAACATATGGTCGTAGTGTCAATAACAATTATTAATACTA 15060  
 K S I \* S P P Q I G A D C T I T L L \* S  
 N Q F K H H H N Y V L M V L \* Q \* Y N H  
 K F N I I T T T Y W C \* L N N N I I I I

15061 TTTTCACGACCAATAGGTAAATTATTTAAACCATTTCCGGTCTGAAATAATACTCCGTAAT 15120  
 L L A P \* G N L L N P L A L S \* \* S A N  
 Y F H Q N D M \* Y I Q Y L W V K N H P M  
 F T S T I W K I F K T F G S K I I L C \*

FIG. 3 CONT'D

15121 AGTAAACTCCTTGTCTTACTTTAAATACGTATATGATTTGCATTACAAGACGGGTGGAAT 15180  
 D N S S C F S I \* A Y V L R L T R G V K  
 I M Q P V S H F K H M Y \* V Y H E A W R  
 \* K L F L I F N I C I S F T I N Q G G \*

15181 TGAGTTTACTTAAATTTTATACGATAGTCACGATTCTTATCTCGAGCGTGACATCGTCCA 15240  
 V \* I F K F Y A I L A L F L A R V T A P  
 L E F S N L I H \* \* H \* S Y L E C Q L L  
 S L H I \* F I S D T S L I S S A S Y C T

15241 CAAAGATAAGAATCATGATACTGTCCGGCTTACAAGGTAGTTTTTACAAACTTCTCATAT 15300  
 T E I R L V I V P R I N W \* F H K F L I  
 H K \* E \* Y \* S L G F T G D F I N S S Y  
 N R N K T S H C A S H E M L F T Q L T Y

15301 CGTCGATGGGCTCCACAAGGACAACAATATCCTTGGTGATTTAAATACCACCAACCCTG 15360  
 A A V R P T G T T I P V V L N \* P P Q S  
 L L \* G L H E Q Q \* L F W \* I K H H N P  
 C S G S T N R N N Y S G S F K I T T P V

15361 CTATACAATGCAGTAGAATATTTCTTACAACCTGTTGGGACAAGAATACCCAACCCTAATA 15420  
 S I N R \* R I F S T S L G T R I P Q S \*  
 R Y T V D D \* L P H Q C G Q E \* P N P N  
 I H \* T M K Y L I N V V R N K H T P I I

15421 GGATTTACACTAGCACGATACGGTTTATAAAACGCATAACAATCATCAAATCAAAACCGG 15480  
 G L H S R A I G F I K R I T L L K T K A  
 D \* I H D H \* A L Y K A Y Q \* Y N L K P  
 R F T I T S H W I N Q T N N T T \* N Q G

15481 GCGTTTGTACTTAAACAACAAGTGTAACACTATCTAAAATAGCGGAACGCTTACTTACA 15540  
 R L C S N Q Q E C P S L N \* R R A F S H  
 G C V H I K N N V H H Y I K D G Q S H I  
 A F M F K T T \* M T I S K I A K R I F T

15541 CGAGTTCAAAACTCACTTTATCAATACACACCGCCAACGATAATACAATTCGGACCACCA 15600  
 A \* T K L S I T I H P P Q \* \* T L G P P  
 H E L K S H F L \* T H R N S N H \* A Q H  
 S L N Q T F Y N H T A T A I I N L R T T

15601 TGATCGTCACCACTACGTTGATGACGAAAACGATTAAGACAAAATTATATACAGTCCGA 15660  
 V L L P S A V V A K A L E T K L I H \* A  
 Y \* C H H H L \* Q K Q \* N Q K \* Y I D P  
 S A T T I C S S S K S I R N K I Y T L S

FIG. 3 CONT'D

15661 CAATGACGATTACAAACAAGAGAATACCGGACATTACCGGTATTCTAACTTCTAAATTC 15720  
T V A L T Q E R I A Q L P W L I S S K L  
Q \* Q \* H K N E \* P R Y H G Y S Q L N L  
N S S I N T R K H G T I A M L N F I \* T

15721 TATGCGTTAAATGTTTTGCGAATATGAGATTACAAATAGCATGTCTAATACAACATA 15780  
I R L K C F R K Y E L T \* R V S \* T S \*  
Y V C N V F V S I S \* H K D Y L N H Q N  
Y A I \* L F A \* V R I N I T C I I N I I

15781 TGTAACAATTACTCATAACTTAAAAATACATTTCGTAATCATACTACTAAAACTCA 15840  
V N T L S Y \* S N K H L C K L I I I K L  
Y M Q \* H T N H I K I Y A N \* Y S S K S  
C K N I L I I F K \* T L M K T H H N Q T

15841 CTACTACCACAACAGACAATATTGAGACTAATACGATCATTCCCAATATATCGATTATAT 15900  
S S P T T Q \* L E S \* A L L P \* I A L I  
H H H H Q R N Y S Q N H \* Y P N Y L \* Y  
I I T N D T I V R I I S T L T I Y S I Y

15901 TCACAAAAGTTGTTCAAAACATGATAGTCTTATTACAGAAAATACAGACTTAGATTTACA 15960  
L T K \* C T K Y \* \* F L T K I D S D L H  
L H K E V L K T S D S Y H R \* T Q I \* I  
T N K L L N Q V I L I I D K H R F R F T

15961 ACCCAACTTTTACTATAATGATTACCAGGAGTACTTAAAACAAGGGTTGTATGATACAAT 16020  
Q T S F S I V L P G \* S N Q E W C V I N  
N P Q F H Y \* \* H D E H I K N G V Y \* T  
P N F I I N S I T R M F K T G L M S H \*

16021 CAATTCTATCTACCACTAATACAATAAATGGTATAGGTCTAGGAAGATCTTAAATCCT 16080  
T L I S P S \* T \* K G Y G S G E L I K P  
L \* S L H H N H K N V M D L D K \* F K L  
N L Y I T I I N I \* W I W I R R S N \* S

16081 CGACCAACAAAACAACACTACTAAATAACTTCTGACTGTCACAAGAAAACATCTCGCGAAA 16140  
A P Q K T S S K N F V S L T R K I S R K  
L Q N N Q Q H N I S S Q C H E K S L A S  
S T T K N I I \* Q L S V T N K Q Y L A K

16141 CATTGAGATCGATATCTACGAATGGGAAATCATGTAGTACTTTTACTTCTTATGGTTTTT 16200  
T L R A I S A \* G K T C \* S F S S Y W F  
Q L D L \* L H K G K L V D H F H L I G F  
Y T \* S Y I S V R \* Y M M F I F F V L F

FIG. 3 CONT'D



16201 CAGAAAGCACATATAAATCTTATATATTTTTTTGACATATTACTAGAACCATGAGTCTAG 16260  
 T K R T Y K S Y I F F S Y L S R P V \* I  
 L R E H I N L I Y L F V T Y H D Q Y E S  
 D K T Y I \* F I Y F F Q I I I K T S L D

16261 AATCTATCAATATCACAATAAAATTCATGAACACTACCAAATTTCAAATGACTTCTTAGT 16320  
 K S L \* L T I K L V Q S P K F N V S S D  
 R L Y N Y H \* K L Y K H H N L T \* Q L I  
 \* I T I T N N \* T S T I T \* L K S F F \*

16321 AAAATGTTCTTATACATAAAATTTTTACGGCACTACGTCTCACATCCACGTACGCAACAA 16380  
 N \* L F I Y K F L A T I C L T P A H T T  
 M K C S Y T N L F H R S A S H L H M R Q  
 K V L I H I \* F T G H H L T Y T C A N N

16381 ACAAGTAGTGTTTGAAGAAACGCAACACCGTCAACATATGCATTCCGAAACAATACAACA 16440  
 Q E D C V E K R Q P L Q I R L G K N H Q  
 K N M V F K K A N H C N Y V Y A K T I N  
 T \* \* L S R Q T T A T T Y T L R Q \* T T

16441 TTTACAACAATACTGGTACAATACCGTTGATTAGTATTTATACAAAACCTCACAGAGTGGA 16500  
 L H Q \* S W T I A V L \* L Y T K L T E G  
 Y I N N H G H \* P L \* D Y I H K S H R V  
 F T T I V M N H C S I M F I N Q T D \* R

16501 ATGCAAACATTACGTGGATTGACACTACACTCACTACAGTGGTTTAATATAAACCCGCCA 16560  
 \* T Q L A G L Q S T L S T V L N Y K P P  
 K R K Y H V \* S H H S H H \* W I I N P R  
 V N T I C R V T I H T I D G F \* I Q A T

16561 TACAGAATGATAACACTTTTTGGTATTTGGGGTAATAAGTAAATTCATCAATACTTACCA 16620  
 I D \* \* Q S F W L G W \* E N L N T I F P  
 Y T K S N H F G Y V G N N M \* T L \* S H  
 H R V I T F V M F G M I \* K L \* N H I T

16621 TACCAGAAACCAACATATTTGTTAGAACGTGCCCAAGTGAATATATCTACTAAAATTA 16680  
 I T K P K Y L C D Q V P E G \* I S S K L  
 Y P R Q N T Y V I K C P N V K Y L H N \*  
 H D K T Q I F L R A R T \* R I Y I I K I

16681 TTCTATCGATCAACATTTACCTGTCTTCACTACTAATACAAGACCGTTTACTCACATAA 16740  
 L I A L Q L H V S T S S \* T R A F S H I  
 Y S L \* N Y I S L L Q H N H E P L H T Y  
 L Y S T T F P C F N I I I N Q C I L T N

FIG. 3 CONT'D

16741 CTTGCAAATTTCAATAAACGACGCTTTTGAGTTTTCCGTTGACTTCTCCGAAAATTTGTT 16800  
 S R K F N N A A S V \* F A V S S A K L C  
 Q V N L T I Q Q L F E F P L Q L P K \* V  
 F T \* L \* K S C F S L L C S F L S K F L

16801 TCGATACGAAGACGATGGTAAGTTCTCTAACAATCACTATCTCTTCAATAAAACACAACC 16860  
 L \* A E A V M \* S I T L S L S T I K H Q  
 F S H K Q \* W E L S Q \* H Y L L \* K T N  
 A I S R S G N L L N N T I S F N N Q T P

16861 CTCTGTCCATTTCAATTTGGTGGTGAATTATTTTAAATACAAAAGTGTCCGATGGTAAAA 16920  
 S V P L T L G G S L L F \* T K V P \* W K  
 P S L Y L \* V V V \* Y F N H K \* L S G N  
 L C T F N F W W K I F I I N E C A V M K

16921 TGATCATGACCATTCTGTCAAAATCCACTCATACAAAAATATTTTCACTTAATTGATTG 16980  
 V L V P L V T K P S Y T K S L L S N V L  
 \* \* Y Q Y S L K L H T H K Q Y F H I L \*  
 S T S T L C N \* T L I N K I F T F \* S V

16981 CCACACATAATGGCGGATGTTGATGAATATTTGAAAGATATCCACTACAAAACAAAAT 17040  
 P T Y \* R A V V V \* L S E I P S T K T K  
 R H T N G R \* L \* K Y V K \* L H H K Q K  
 T H I V A S C S S I F K R Y T I N K N \*

17041 TGTAGTGTAAGACATCGATCAAATTCACGTGGATGTGAACAGGGTGTCTCTTGATACGA 17100  
 V D C E T A L K L A G V S T G C S F \* A  
 L M V N Q L \* N L H V \* V Q G V L S S H  
 C \* M R Y S T \* T C R C K D W L L V I S

17101 TCATATTCTAAAAGATCACAATATCACAAGGTAACCACAAAGTTTTATTACAACGATTA 17160  
 L I L N E L T \* L T G N T N \* F L T A L  
 \* Y L I K \* H K Y H E M P T E F Y H Q \*  
 T Y S K R T N I T N W Q H K L I I N S I

17161 ATAGTCGTGTAACCTTACTTTGCAATAACGTGACAAGTCCAGGGGACCATGCCCTTTC 17220  
 \* \* C M P I F R \* Q V T \* P G G P V P F  
 N D A C Q F S V N N C Q E L D G Q Y P F  
 I L V N S H F T I A S N L T G R T R S L

17221 AGAGTAGAACGATATCCAGATCGACAAAATAATGATGTGTCGTGCACATCAAATATGACGA 17280  
 D \* R A I P R A T \* \* \* V A R T T \* V A  
 T E D Q \* L D L Q K N S C L V H L K Y Q  
 R M K S Y T \* S N I V V C C T Y N I S S

FIG. 3 CONT'D

17281 CGATCAGTACGACGACATCTACGTAACACACTTTTTCGAATATTCAAAAAATTATAATTG 17340  
 A L \* A A T S A N H S F A \* L N K F I L  
 Q \* D H Q Q L H M T H F L K Y T K L Y \*  
 S T M S S Y I C Q T F F S I L K \* I N V

17341 CTAACATGTGCATAATAAGGACGATTTCAAGCACATCTAACAATACTATTCAAATTTTAA 17400  
 S Q V R I I G A L T R T S Q \* S L N L I  
 R N Y V Y \* E Q \* L E H L N N H Y T \* F  
 I T C T N N R S F N T Y I T I I L K F N

17401 TTACTATGGTGAACATTTCATACAAAAATGGTGTATTACGTAATGGTCTCAACCAATGT 17460  
 L S V V Q L Y T K V V I F A N G S N T V  
 \* H Y W K Y T H K \* W L L H M V L T P \*  
 I I G S T L I N K G C Y I C \* W L Q N C

17461 CTATAACAACAACAACACTACTTCAATCATAACGAATGATTAATACTTAACAGACAATATTTA 17520  
 S I T T T S S T L I S V L \* S N D T I F  
 L Y Q Q Q Q H L \* Y A \* \* N H I T Q \* L  
 I N N N N I F N T H K S I I F Q R N Y I

17521 CGAGCATAAATTCGATTTGTAATACATATATAACCTCTAGGACGAGTTAATGGACGTGGT 17580  
 A R I L A L C \* T Y I P S G A \* N G A G  
 H E Y \* L \* V N H I Y Q L D Q E I V Q V  
 S T N F S F M I Y I N S I R S L \* R C W

17581 GCACACGACAACCTCGTTCCCAAGAAATCTTGGATCCGTGAAGTTAAGATAATGATTTTAT 17640  
 R T S N L L P E K S G L C K L E I V L I  
 V H A T S C P N K L V \* A S \* N \* \* \* F  
 T H Q Q A L T R \* F R P V E I R N S F Y

17641 TACACAACAATCCAGGACTATAGAAAACCCCTTTAACAATATCCACAGGATTTCTTTAA 17700  
 I H Q K P G S I K K P F Q \* L H G L S I  
 L T N N L D Q Y R K P F N N Y T D \* L F  
 H T T \* T R I D K Q S I T I P T R F F N

17701 CATCTTTGACAAAGTCGTAACCAAAATACTATTATTGAGTCCGATTTTACTATTATCA 17760  
 T S V T E A N T \* S L L S L A L F S L L  
 Q L F Q K L M P K H Y Y V \* P \* F H Y Y  
 Y F S N \* C Q N I I I F E L S F I I I T

17761 AGTAATACAAAATTCATATAAAATCCCTGTCTGTGTGTACTCTCAAGTTCACGACAT 17820  
 E N H K L T Y K L P C V V C S L E L A T  
 N M I N \* L I N \* P V S L V H S N L H Q  
 \* \* T K F Y I K L S L C C M L T \* T S Y

FIG. 3 CONT'D

17821 TTATAAGTTGCTATATAGATTAATCATTAAAAATTTTCGATTAGGTCAAACCTTATCA 17880  
 F I \* C I Y R I L L N K F A L G T Q F L  
 L Y E V S I D L \* Y I K L L \* D L K S Y  
 I N L L Y I \* N T F K \* F S I W N P I T

17881 CGACAAAAATAATCAGGAATATTATCAGTCTTAATACAACGATTGCGACAAAATCCACAA 17940  
 A T K I L G \* L L \* F \* T A L R T K P T  
 H Q K \* \* D K Y Y D S N H Q \* A H K L H  
 S N K N T R I I T L I I N S L T N \* T N

17941 GTTTGTGTTTGACATCTAAGACGAGTTCCAAGCCTTATACTAATAACAATATATAAGTGT 18000  
 \* V C V T S E A \* P E S Y S \* T I Y E C  
 E F V F Q L N Q E L N P I H N H \* I N V  
 L C L S Y I R S L T R F I I I N Y I \* L

18001 TGTCGCTTTGTCGGGTAAGACAATTACAATTAGCTAAATTACAACGGTATTGATCTCGG 18060  
 V A S V A W E T L T L R N L T A M V L A  
 F L L F L G N Q \* H \* D I \* H Q W L \* L  
 C C F C G M R N I N I S K I N G Y S S G

18061 TTCTTCCCGTAAAAAACACAATACTCATTATACGTTAATAAACTTAGAGAATAAAAATAA 18120  
 L F P M K Q T I L L I C N N S D R L K I  
 W S P C K K H \* S Y Y A I I Q I E \* N \*  
 L L A N K T N H T I H L \* K F R K I K N

18121 TGAGATGGAATCTATTTTAAGTTTTAGTTTGAATGGAGCAAACGTAACGTGTTGATTA 18180  
 V R G K S L I \* F \* V K G R K C Q V V L  
 \* E V K L Y F E F D F K V E N A N C L \*  
 S \* R \* I F N L I L S \* R T Q M A C S I

18181 GAAAAATTTCTAACATCATTTTCAACGAATCCAATAGTAGGTCGCGTACGGGGAGTAAA 18240  
 R K L S Q L L L Q K P \* \* G A C A G E N  
 D K \* L N Y Y F N S L N D D L A H G R M  
 K K F I T T F T A \* T I M W R M G G \* K

18241 AATCGTCAACTACTATTTATATTCCAATTACTTTTAAACCGACATTTAAATTTATAACA 18300  
 K A T S S L Y L T L S F K A T F K F I Q  
 K L L Q H Y I Y P \* H F N P Q L N L Y K  
 \* C N I I F I L N I F I Q S Y I \* I N T

18301 CTTGGACAAAATGTATAAGAGCAAATTATAGAGAATACCCAAAATTTAATCTAAACTGA 18360  
 S G T K V Y E R K I D R I P K L N S K V  
 H V Q K L M N E N L I E \* P N \* I L N S  
 F R N \* C I R T \* Y R K H T K F \* I Q S

FIG. 3 CONT'D

18361 GAACTACCAATAAGATTTAACAAATAATGATTCTACTTCGGTAATTTGCACAATCTCCA 18420  
R S P \* E L N N I V L S S A M L R T L P  
E Q H N N \* I T \* \* \* L H L W \* V H \* L  
K I T I R F Q K N S F I F G N F T N S T

18421 ACCCAACCAAAACTACAACCTCCCGCGAGTACGATGAGCGCTTTTGTAACTTGTGAAA 18480  
Q T P K S T S P A \* A V R S F M P V F K  
N P Q N Q H Q P R E H \* E R F C Q F L S  
P N T K I N L A S M S S A F V N S C V K

18481 GGTGACGTTTATCCAAAAAGTTGACCACACCTAAAACATCAACTTCGATGACCGAATAAA 18540  
G S C I P K E V P T S K T T S A V P K N  
E V A F L N K L Q H P N Q L Q L \* Q S I  
W Q L Y T K \* S T H I K Y N F S S A \* K

18541 CGACTCTCTAACAATATGAAAATTTTTTGACATCGATTTTCGAGGAGGACCACCTTTTT 18600  
A S L S Q \* V K L F V T A L A G G P S F  
Q Q S L N N Y K \* F F Q L \* L E E Q H F  
S L S I T I S K F F S Y S F S R R T F F

18601 AAATTTGTAAATTATGGGGAATACAGTTTTCCAGTTTTCCACCTATAACAATCTTAATCT 18660  
N L C K I G R I D F P \* F H S I T L I L  
I \* V N L V G \* T L L D F T P Y Q \* F \*  
K F M \* Y G K H \* F T L L P I N N S N S

18661 TAACAAGTTTACAATAGACTAATAGAAAATCTGGAAAGACTATCACATCATAAATAATGA 18720  
I T \* I N D S \* R K S R E S L T T N I V  
F Q E F T I Q N D K L G K Q Y H L I \* \*  
N N L H \* R I I K \* V K R I T Y Y K N S

18721 ACCAGACGGTCAAAACTTGAATGAACAAATCCATAAAACGATTTAATCCGTCTCTCGAA 18780  
Q D A L K S S V Q K L Y K A L N P L S S  
K T Q W N Q V \* K N L T N Q \* I L C L A  
P R G T K F K S T \* P I K S F \* A S L K

18781 TTAACATTACACACAAGATTAGCACGATGTACGATGTTAAGATCTTGACCAATAATACCA 18840  
L Q L T H E L R A V H \* L E L V P \* \* P  
\* N Y H T N \* D H \* M S C N \* F Q N N H  
I T I H T R I T S C A V I R S S T I I T

18841 ACAACCGCGGTATCAATATGAACACTAATACACATATTAGGTGAATAACATCTATATGTT 18900  
Q Q R W L \* V Q S \* T Y L G S I T S I C  
N N A G Y N Y K H N H T Y D V \* Q L Y V  
T P A M T I S T I I H I I W K N Y I Y L

FIG. 3 CONT'D

18901 GTCACCCCAATATGTCCAAGAAATTGATCATTAGTGCTATATTAAACATTACATGTATTT 18960  
 C H P \* V P E K V L L \* S I I Q L T C L  
 V T P N Y L N K L \* Y D R Y L K Y H V Y  
 L P T I C T R \* S T I V I Y N T I Y M F

18961 CCACGTGTACAACGCAGTCGACTACGTTAATACTGAGCAACAAATCGTTAGATACTAACA 19020  
 P A C T A D A S A I I V R Q K A I \* S Q  
 L H V H Q T L Q H L \* S E N N L L R H N  
 T C M N R \* S I C N H S T T \* C D I I T

19021 AAAACATTTAGACAATTAACCTTAATCTCATAGGTTATTAAGATTACTCCAGTCATAT 19080  
 K Q L D T L Q F K S Y G I I E L S T L I  
 N K Y I Q \* N S N L T D L L K \* H P \* Y  
 K T F R N I P I \* L I W Y N R I L D T Y

19081 TTATGTAGAACATCCAATAACGTCGCACAGTACGAATTTGACGGTACGATACATTATCT 19140  
 F V D Q L N N C R T M S L A A M S H L L  
 L Y M K Y T I A A H \* A \* L Q W A I Y Y  
 I C R T P \* Q L T D H K F S G H \* T I S

19141 ATGTTGAATACAATACTGTATCCGTTAGGATTTCCAAATCGAACACAGTTTCTAATACTT 19200  
 Y L K H \* S M P L G L P K A Q T L S \* S  
 I C S I N H C L C D \* L N L K H \* L N H  
 V V \* T I V Y A I R F T \* S T D F I I F

19201 AAATTTAAAATACTACGAAAAGGACATCGGTTCCAGACAATTTGTCAATAAAAATACAGATA 19260  
 N L N \* S A K G T A L D T L C N N \* T \*  
 I \* I K H H K E Q L W T Q \* V T I K H R  
 K F K I I S K R Y G L R N F L \* K I D I

19261 CTACACGTATTTCTATTAAAATTTCTACCAAATACATACAAAACCTTAACATTACAACATA 19320  
 S T C L S L K L S P K H I N Q F Q L T S  
 H H A Y L Y N \* L H N I Y T K S N Y H Q  
 I H M F I I K F I T \* T H K P I T I N I

19321 TTTATAGGTAGATTAAGTTAACAAACATCTAAACTGTGAGCTCACAATTTATTTAATTTG 19380  
 L Y G D L E I T Q L N S V R T N F L N F  
 Y I D M \* N L Q K Y I Q C E L T L Y I L  
 F I W R I \* N N T S K V S S H \* I F \* V

19381 GAAGGACCTACATTACCACCATCAAACATACAATTTTGTACGTAAGGTATGATTAGGA 19440  
 R G P H L P P L K Y T L L C A N W V L G  
 G E Q I Y H H Y N T H \* Y V H M G Y \* D  
 K R S T I T T T Q I N I F M C E M S I R

FIG. 3 CONT'D

19441 AAATGATCTTGACAAAAAAGCTTTTAGAATTCGGATACGGAAAAAGATAATAAGTCTATGC 19500  
 K V L V T K S F R L G I G K K \* \* E S V  
 K \* \* F Q K Q F D \* A \* A K K R N N L Y  
 K S S S N K F I K L R H R K E I I \* I R

19501 GGAACACACATGCATCTACCAATCTTAGATTGTGTTCAACTAATGCAAGGAAATCTCTCG 19560  
 G Q T Y T S P K S D L C T S \* T G K L L  
 A K H T R L H N L I \* V L Q N R E K L F  
 R T H V Y I T \* F R F L N I V N R \* S A

19561 CGGTGAACATAGTGTGCCACATTAGATCCACCTCGACAAACAAGTTTCGTACGACTTCTT 19620  
 A V Q I V R H L R P P A T Q E F C A S S  
 R W K Y \* V T Y D L H L Q K N L A H Q L  
 G S T D C P T I \* T S S N T \* L M S F F

19621 ATAACATTGATGGAAGTCAAGATATTATCAATGATGTCGTCGGAATGAAAAACCCAA 19680  
 Y Q L \* R S D \* L I T V V A P K V K Q T  
 I N Y S G Q T K Y Y L \* \* L L S \* K K P  
 I T V V K L R I I Y N S C C A K S K P N

19681 ATATTCTTAAAACTAAAAATATTAAATACCTTGTGAAAATGATGCAATGTCTCAAATCTT 19740  
 \* L F K S K \* L K H F V K V V N C L K S  
 K Y S N Q N K Y N I S C K \* \* T V S N L  
 I L I K I K I I \* P V S K S R \* L T \* F

19741 TTGCATTATATATTGAACCAATTACAACCGTAATACTACCTGCATGTCCACTTAATGGA 19800  
 F T I Y L K T L T P \* \* S P R V P S N G  
 F R L I Y S P \* H Q D N H H V Y L H I V  
 V Y Y I V Q N I N T M I I S T C T F \* R

19801 ACACGATAATACTTACTGTTTCAACAACAATTCTAATTATTACATCTATGACAATAAAAA 19860  
 Q A I I F S L T T T L I L L T S V T I K  
 K H \* \* S H C L Q Q \* S \* Y H L Y Q \* K  
 T S N H I V F N N N L N I I Y I S N N K

19861 TTTTATTATGTAGTAAAGGATGATTATATCGACAACCTTAACAATGTTTTCATCATAG 19920  
 L F L V D N G V L I A T S N N V F R L I  
 \* F Y Y M M E \* \* Y L Q Q I T \* L V Y Y  
 F I I C \* K R S I Y S N F Q K C F T T D

19921 GCCGTGGTGGGACTTGAATCTAAGAATCTTTAAACTGTAACTATAAACAACCTTCGTA 19980  
 R C W G S S L I R L F K F M S I Q Q F C  
 G A G G Q V \* S E \* F N S C Q Y K N S A  
 P V V R F K L N K S I Q V N I N T P L M

FIG. 3 CONT'D

19981 CAGGACACCCTAATACAATTTCTATCAAACAAAACATCAAGGTGAATACCACAAACATTT 20040  
 T R H S \* T L S L K N Q L E V \* P T Q L  
 H G T P N H \* L Y N T K Y N W K H H K Y  
 D Q P I I N F I T Q K T T G S I T N T F

20041 ATGTGTCTAAACTTCAAGTAGCTTTTAAACTTATATGAAAAACTACCAGCACTGTGACCG 20100  
 Y V S K F N M S F K F I S K S P R S V P  
 I C L N S T \* R F N S Y V K Q H D H C Q  
 V C I Q L E D F I Q I Y K K I T T V S A

20101 CGAAATCTTCGAAAATCTTTTCGTTCTTTACCACAAAAATAATCATGACTTTTAAATTC 20160  
 A K S A K L F A L F P T K I L V S F N L  
 R K L L K \* F L L F H H K \* \* Y Q F I L  
 S \* F S K S F C S I T N K N T S F F \* T

20161 TCCAATAGTACTAATTTCCAGGCGTTGCTCGACTAAATTTACCACACTAACACCTATTT 20220  
 L N D I I L P G C R A S K F P T I T S L  
 Y T I L S \* L D A V L Q N L H H S Q P Y  
 P \* \* H N F T R L S S I \* I T H N H I F

20221 CAACCTCTGAGTTTCAACTCAAACCAAGCGATACTCTTTTCTACCACCTGCTACAATAG 20280  
 T P S S L T S N Q N A I L F S P S S T I  
 L Q L V \* L Q T K T R \* S F L H H R H \*  
 N S F E F N L K P E S H S F I T V I N D

20281 AAGTCGGCTTGCTGTCGGATACGAGTTCCGGTAATGACCTCGGGTGTCCATTAGATCCA 20340  
 K L R V S L R H E L W \* Q L G C P L R P  
 R \* G F L C G I S L G N S S G V L Y D L  
 E A S C V A \* A \* A M V P A W L T I \* T

20341 CCATTAACGCGCCCATACAGTAACCATTACTACGAGATTGTGCAAAATGATAGAAATGA 20400  
 P L Q A P L T M P L S A R V R K V I K V  
 H Y N R P Y H \* Q Y H H E L V N \* \* R \*  
 T I A R T I D N T I I S \* C T K S D K S

20401 GTCTCAGCACATAACAGTTCAAACCTTGAGCGAGTCTAAATCTTGCCCTAAAATAACTA 20460  
 \* L R T N D L K S G R E S K S R S K I S  
 E S D H I T L N Q V E S L N L V P N \* Q  
 L T T Y Q \* T K F R A \* I \* F P I K N I

20461 TACCTACTATTAGACAAATAACGATTTATACCAAATCTTCTGATACGTAAACTAGTATAT 20520  
 I S S L R N I A L Y P K S S \* A N S \* I  
 Y P H Y D T \* Q \* I H N L L S H M Q D Y  
 H I I I Q K N S F I T \* F V I C K I M Y

FIG. 3 CONT'D



20521 CAAATACCATCAAATTTGGTATTTCAATATCCTCCAAACGTAACGAATATCCGAATAAA 20580  
 T \* P L K L W L T I P P K C K S I P K N  
 L K H Y N \* G Y L \* L L N A N A \* L S I  
 N I T T K V M F N Y S T Q M Q K Y A \* K

20581 GCATCCTTTTTTTTAGATTAAACAATTAAGTTCTCAAAAATGTCATACTAAGATCATAA 20640  
 R L F F F D L K N I \* S N K C Y S E L I  
 E Y S F F I \* N T L E L T K V T H N \* Y  
 T P F F F R I Q \* N L L K \* L I I R T N

20641 GTAAGTATAAAATAATGACTAGTCTCACACCATCATCATTCTCACAAACATGTCAATAA 20700  
 \* E Y K I V S \* S H P L L L L T Q V T I  
 E N M N \* \* Q D P T H Y Y Y S H K Y L \*  
 M \* I K N S I L L T T T T L T N T C N N

20701 CTAAATAATAATCTACTAAAACAAGATAACAATTCAGTAATTTAAACTCAACACAATCA 20760  
 S K N N S S K T E I T L D N F K L Q T L  
 Q N I I L H N Q K \* Q \* T M L N S N H \*  
 I \* \* \* I I K N R N N L \* \* I Q T T N T

20761 TTTCAACAATTATAATTACAACCTAAAATTCCTAAAAGTTAAATACAACACCACATTACTA 20820  
 L T T L I L T S K L S K \* N I N H H L S  
 Y L Q \* Y \* H Q N \* P N E I \* T T T Y H  
 F N N I N I N I K L I K L K H Q P T I I

20821 TTATTTAATACTGAAAAATAGGATTTTACGTTCCGGTGATTACTAACCTTTGGACCGATA 20880  
 L L I I V K \* G L I C A V L S Q F G P \*  
 Y Y F \* S K K D \* F A L W \* H N S V Q S  
 I F N H S K I R F H L G S I I P F R A I

20881 AGATACGGACAAAACATATTCATAAACTTACAAGGTAATCTCTCAGAGAAATACCTTA 20940  
 E I G T K Y L Y K F T G N S L T E K H F  
 N \* A Q K T Y T N S H E M L S L R K I S  
 R H R N Q I L I Q I N W \* L S D R \* P I

20941 ATACCATTGGATAATTAACGGATGTCGACATACTACTTACAACGATTCATGTGAGTT 21000  
 \* P L G I L K G V P Q I I F T A L Y V \*  
 N H Y V \* \* N A \* L S Y S S H Q \* T C E  
 I T F R N I Q R C A T H H I N S L V S L

21001 AATACAGTCATAAACTTATGATGTTGTAATCGACAAGGACAATTATACGCACAAAATGTA 21060  
 N H \* Y K F V V V N A T G T L I R T K C  
 I I D T N S Y \* L M L Q E Q \* Y A H K V  
 \* T L I Q I S C C \* S N R N I H T N \* M

FIG. 3 CONT'D

21061 AATCCACGTCCTCCAGACTATTTCTTCATCGAGGTCCAAGACGACAAAATTCTGTCCACCAAT 21120  
 K P A P D S L S T A G P E A T K L C H N  
 N L H L T Q Y L L L E L N Q Q K L V T T  
 \* T C P R I F F Y S W T R S N \* S L P \*

21121 GGTAGACCATCATAAGAACATCTATTACTAAATTTGGGTAAACAATCGCTATCAAATCAA 21180  
 G D P L I R T S L S K F G N T L S L K T  
 V M Q Y Y E Q L Y H N L G M Q \* R Y N L  
 W R T T N K Y I I I \* V W K N A I T \* N

21181 TGAATAAAACCTCTAACATACTGAAATGGTAAACTAACAGTAACCCTAAACTATTATAGA 21240  
 V \* K P S Q I V K G N S Q \* Q S K I I D  
 \* K N Q L N Y S K V M Q N D N P N S L I  
 S I K S I T H S \* W K I T M P I Q Y Y R

21241 CTATACATACTAGGAGAATGATTTTTATAACCACTAATATTACACTCATTCTACCCAAA 21300  
 S I Y S G R V L F I P S \* L T L L S P N  
 Q Y T H D E \* \* F Y Q H N Y H S Y P H T  
 I H I I R K S F I N T I I I H T L I P K

21301 AAATGAATGTAAACAGTAAATTAAGCACTATTTAATAGAAACCCACCATCACATCGATAT 21360  
 K V \* M Q \* K I R S L N D K P P L T A I  
 K \* K C K D N L E H Y I I K P H Y H L \*  
 K S V N T M \* N T I F \* R Q T T T Y S Y

21361 TTTTAATGTCTCAAAGAACCTTACGACTAAATATATTTAATTACTCAACAAAACGTAAA 21420  
 F I V S N E Q F A S K Y L N I L Q K A N  
 L F \* L T K K S H Q N I Y I L S N N Q M  
 F N C L K R P I S I \* I F \* H T T K C K

21421 ACCTGTCAAAAAACATGATTACATTACGAAGAAGATCACTCCCAAAAATTATCCATAT 21480  
 Q V T K Q V L T F A E E L S P N K I P I  
 K S L K K Y \* H L H K K \* H L T K L L Y  
 P C N K T S I Y I S R R T F P K \* Y T Y

21481 TTAATGGACCCATTTAGAAGAAAACCTTTATCTACCGTTACAATACGTACGATTGATAAAC 21540  
 F \* R P L D E K S I S P L T I C A L \* K  
 L N G P Y I K K Q F L H C H \* A H \* S N  
 I V Q T F R R K F Y I A I N H M S V I Q

21541 AAAACCTCTTTATCATGTTGTACCTTACCGCCACGAATATCAAATAAACTATACTGATT 21600  
 N Q L F L V V H F P P A \* L K N S I V L  
 T K S F Y Y L M S H R H K Y N I Q Y S \*  
 K P S I T C C P I A T S I T \* K I H S F

FIG. 3 CONT'D

21601 AAAAGAACTTTAACCGACCGTGACGACAACAATTAATTCTGGTCTAGTTAATTTACTA 21660  
 N E K F N A P V A T T L K L G S \* N F S  
 I K K S I P Q C Q Q Q \* N L V L D I L H  
 K R Q F Q S A S S N N I \* S W I L \* I I

21661 AATCAAATAAGAGAATAAAGTTTCTCCATTTAATAATCAAGCGCTATGCGCATTCTCTAA 21720  
 K T \* E R I S L P L N N T R S V R L S I  
 N L K N E \* Q F L Y I I L E R Y A Y L S  
 \* N I R K N F S T F \* \* N A I R T F L N

21721 AAACAACCACTATCAGAACATTTATGAACAATCTAGAGTAATTTAGATTTGATACAATTA 21780  
 K T P S L R T F V Q \* I E N F R F \* T L  
 K Q Q H Y D Q L Y K N S R M L D L S H \*  
 K N T I T K Y I S T L D \* \* I \* V I N I

21781 ATAAAAAATAAAAAATAAAGACAATACCAAAATTTACTTGGAGAATTACAACACAGAGT 21840  
 \* K K I K K N R N H N \* H V E \* H Q T E  
 N N K \* K K I E T I T K I F R K I N H R  
 I K K N K \* K Q \* P K L S G R L T T D \*

21841 AAATTTGGTACTGACCAAAAATAAACCACTATCAGCAAGACTAACATTGGTATAATTATT 21900  
 N L G H S T K I Q H Y D N Q N Y G Y \* Y  
 M \* V M V P K \* K T I T T R I T V M N I  
 K F W S Q N K N P S L R E S Q L W I L L

21901 AAATTTTTAATTTTTTAAACTAATAAACCTATAAGTGGGATCAAACACGTTGTTACCATT 21960  
 N L F \* F N Q N N P Y E G \* N T C C H Y  
 I \* F N F I K I I Q I N V R T Q A V I T  
 K F I L F K S \* K S I \* G L K H L L P L

21961 CTAAAGTAGATCACGGCCACTAAGATAAAAATTTCTCAAAGTAAAGTGAGCTAAAATATT 22020  
 S K M \* H R H N \* K \* S N E N \* E I K Y  
 L N \* R T G T I R N K L T K M E S S K I  
 I E D L A P S E I K L L K \* K V R N \* L

22021 AATGTGACCGCTTCCACTAGTTTAATAAAAAATACTCCACAATTAATAATAGGAATAGT 22080  
 N C Q R L H D F \* K K H P H \* N \* D K D  
 I V S A F T I L N N K I L T N I K I R I  
 \* V P S P S \* I I K \* S P T L K L G \* \*

22081 ATCTAAATTCACAAAAGGATTACCATCATTACTACATACCGAAGAATTGTTCCATTCTAA 22140  
 Y I \* T N E \* H Y Y H H I A E \* C P L I  
 M S K L T K R I T T I I Y P K K V L Y S  
 L N L H K G L P L L S T H S R L L T L N

FIG. 3 CONT'D

22141 AATAGCACGGAATATAAGATTATACCGGAAAAAGCAATAGAATGAAAACACTATAAGG 22200  
 K D H R I N \* Y P R K E N D \* K Q Q Y E  
 K I T G \* I R I H G K K T I K S K N I N  
 \* R A K Y E L I A K K R \* R V K T S I G

22201 AATATTACAAAGAGAAAGATTCAAATTAAGAACATTTTCACTATAAAAATAGTGAATTGTT 22260  
 K Y H K E K \* T \* N K Y F H Y K I V \* C  
 R I I N R K R L K I R T F T I N \* \* K V  
 \* L T E R E L N L E Q L L S I K D S L L

22261 AGGATAAAAAATAATTAATAAGATTCTTCAAATAAAATGAAATAATCCAACAAGAGAAAT 22320  
 D \* K \* \* N N \* P L K N \* K I L N N E K  
 I R N K N I I R L F N I K S \* \* T T R K  
 G I K I L \* E L S T \* K V K N P Q E R \*

22321 AAATCATGGCGAAACGGAAAAATTTAGATTGAAATCAGTCATGATAATATTGTATCTATG 22380  
 N L V A K G K \* I \* S \* D T S N Y C L Y  
 I \* Y R K A K K F R V K T L V I I V Y I  
 K T G S Q R K L D L K L \* Y \* \* L M S V

22381 ACCGAGACAAATACCAAAAAGATTACAACAAATAGGACTAAATCTGACATAAATATAAAG 22440  
 Q S Q K H N K \* H Q K D Q N L S Y K Y K  
 S A R N I T K R I N N I R I \* V T N I N  
 P E T \* P K E L T T \* G S K S Q I \* I E

22441 AGAATTTGGTCCAAGAATATTTCAAAGGTGGTGACGTGGAAAAAATAGGAATGGATGATT 22500  
 E \* V L N K Y L K W W Q V K K I R V \* \*  
 R K F W T R I F N G G S C R K \* G \* R S  
 R L G P E \* L T E V V A G K K D K G V L

22501 TCGAGAGACAAAACATATTTAGATTTGTTAAACATGGACATGTCCAACAACACTAAGATCTAC 22560  
 L E R N Q Y I \* V I Q V Q V P Q Q N \* I  
 F S E T K I F R F L K Y R Y L N N I R S  
 A R Q K S L D L C N T G T C T T S E L H

22561 CTTGTTGCTCGCACGGAGTCTATAAAGAAATAGACAACGTACAGTTAACGGTATAACAAT 22620  
 S C R A H R L Y K K I Q Q M D I A M N N  
 P V V L T G \* I N R \* R N C T L Q W I T  
 F L S R A E S I E K D T A H \* N G Y Q \*

22621 AAAAGCGTTAAGAAGACGATTAATACAACCGTTTCATACTATAAATTGGTGCCACTATCACC 22680  
 N E C N K Q \* N H Q C T H Y \* G R H Y H  
 I K A I R R S I I N A L I I N V V T I T  
 K R L E E A L \* T P L Y S I L W P S L P

FIG. 3 CONT'D

22681 AAAATAAGATAAAATAGACCAGAAAATATATTACAAAGAACATAAAGTATAATACCACA 22740  
 N \* K \* K I Q D K I Y H K K Y K M N H H  
 T K N R N \* R T K \* I I N R T N \* I I T  
 K I E I K D P R K Y L T E Q I E Y \* P T

22741 TAAAAATATACTATTTAAAATGTAGGTAAACCGGGATAATAAGAAAACCATCCACAGGATG 22800  
 I K I H Y N \* M W K A R N N K Q Y T D \*  
 Y K \* I I I K C G N P G I I R K T P T R  
 N K Y S L K V D M Q G \* \* E K P L H G V

22801 TAGAAGATAATAATTTGTAGGTTAAACACAAATACTAAAAACGGATAATAAAATGTTCC 22860  
 M K \* \* \* V D L K H K H N K A \* \* K V L  
 C R R N N F M W N T N I I K Q R N N \* L  
 D E I I L C G I Q T \* S K K G I I K C P

22861 ATAAAAATAACAAATCGAAATGAAAAACAACAAAAGATAATAAAAAACAATATATTGCT 22920  
 Y K I I N L K V K Q Q K E I I K T I Y R  
 T N \* \* T \* S \* K K N N K \* \* K Q \* I V  
 I K N H K A K S K T T K R N N K N Y L S

22921 ATTTAGAGTAATTTAGATTTGTACAATAATTAATAAAAAATAAAACGGATGTTGTAATCGA 22980  
 Y I E N F R F M N N I I K I K G V V N A  
 I F R M L D L C T I L \* K \* K A \* L M L  
 L D \* \* I \* V H \* \* N N K N Q R C C \* S

22981 CAATATCCACTAAAATTAACATGATTAACGATAATTAATAAAATTTGTGGTGTCAAGGA 23040  
 T I P S K L Q V L K A I L S K F V V T G  
 Q \* L H N \* N Y \* N Q \* \* H N L C W L E  
 N Y T I K I T S I K S N I I \* V G C N R

23041 GCGTATTCACCTACACAACCTACAAAGAATACCAAACCCATGTATAATATATGAACATA 23100  
 R M L S Y T T S T E \* P K P V Y \* I S S  
 E C L H T H Q P H K K H N P Y M N Y V Q  
 A Y T L I N H I N R I T Q T C I I Y K I

23101 GCACAAATAAATTTATGATGATATAATAAATGACCAATAAAGGGATTTAGACCACGGTTA 23160  
 R T \* K F V V I N N V P \* K G L D P A L  
 D H K N L Y \* \* I I \* Q N N G \* I Q H W  
 T N I \* I S S Y \* K S T I E R F R T G I

23161 AAATCCCTAGATAGAAATTTCCATGATGTATAAACTCATGAGAAACCATAGTCTTTGGG 23220  
 K L S R D K F P V V Y K L V R Q Y \* F G  
 N \* P D I K L L Y \* M N S Y E K T D S V  
 K P I \* R \* F T S C I Q T S K P I L F G

FIG. 3 CONT'D

23221 AAAAATAGACTAAAATTATTACCATAAAAAAGATCTCAATTCTTATGATTCAACATACAA 23280  
 K K D S K L L P I K E L T L F V L N Y T  
 R K I Q N \* Y H Y K K \* L \* S Y \* T T H  
 K \* R I K I I T N K R S N L I S L Q I N

23281 TTATTTTGAAACATATCACTCAAATCATGATATCAATATCCATCACAAAAATAATTGTG 23340  
 L L V K Y L S N L V I T I P L T K I L L  
 \* Y F K T Y H T \* Y \* L \* L Y H K \* \* C  
 I F S Q I T L K T S Y N Y T T N K N V V

23341 AGAATATGATAACAACAAGTTGGAGTATTACCACAAAACCTCTAATGTGGAACAGTTATG 23400  
 E \* V I T T \* G \* L P T K S I V A Q \* Y  
 S K Y \* Q Q E V E Y H H K P S \* L K D I  
 R I S N N N L R M I T N Q L N C S T L V

23401 TGATACACTCATAGGAGTATGATAAACATTTAGATTTCCATCAAGAGCATTACTTAGA 23460  
 V I H S Y G \* V I Q L D L P L E R L S D  
 C \* T H T D E Y \* K Y I \* L Y N E Y H I  
 S H T L I R M S N T F R F T T R T I F R

23461 ACCGTAAAACATTTAGACTTGGAACACAGACAAGTTCTTTTAAAATGAATATTACAA 23520  
 Q C K S L D S G K H R N L F F K V \* L T  
 K A N Q Y I Q V K T D T \* S F N \* K Y H  
 P M K I F R F R Q T Q E L F I K S I I N

23521 AGATGTCTAACCAACATAAAAAGTAAAATAGTTCTTGCACCGTGAAAAATACGAATAATA 23580  
 E V S Q N Y K \* K \* \* S R P V K \* A \* \*  
 K \* L N T T N E N K D L V H C K K H K N  
 R C I P Q I K M K I L F T A S K I S I I

23581 CGACTAAGACCGTACGGATGATGAAAAATAAATCAAACATAGAACCATGAGAAAATAGA 23640  
 A S E P M G V V K K N L K Y R P V R K D  
 H Q N Q C A \* \* K K I \* N T D Q Y E K I  
 S I R A H R S S K \* K T Q I K T S K \* R

23641 GTAATAATACAAAACGAAACTGAACATTACGATATAGAAGATTATGACTATTACTCTGA 23700  
 \* \* \* T K G K V Q L A I D E L V S L S V  
 E N N H K A K S K Y H \* I K \* Y Q Y H S  
 M I I N Q R Q S T I S Y R R I S I I L S

23701 AATGTTATAACCCAGTGTGGAAACAGATTTGCGGTTATAGAAGAATTTAAACTGTTGGCA 23760  
 K C Y Q T V G K D L R W Y R R L N S L R  
 K V I N P \* V K T \* V G I D E \* I Q C G  
 \* L I P D C R Q R F A L I K K F K V V T

FIG. 3 CONT'D

23761 CCACAATAATGATTACGACAAC TAACAAGATCATCAAAGAAATCGCTCTAAGTTACATTT 23820  
 P T I V L A T S Q E L L K K L S I \* H L  
 H H \* \* \* H Q Q N N \* Y N R \* R S E I Y  
 T N N S I S N I T R T T E K A L N L T F

23821 TGATTAGAAATAATGGATTATGACCACAAATACTGAATAGACCAAATGACAATTCGGA 23880  
 V L D K N G L V P T \* S K D P K V T L G  
 F \* I K I V \* Y Q H K H S I Q N \* Q \* A  
 S F R \* \* R I S T N I V \* R T K S N L R

23881 CAACGTTGACATGTAGCAGCATAAGGACTAAATGGACTAACACTGTAAC TATTACCGAA 23940  
 T A V T C R R I G S K G S Q S M S L H S  
 Q Q L Q V D D Y E Q N V Q N H C Q Y I A  
 N C S Y M T T N R I \* R I T V N I F P K

23941 TTGTTAAAATTACATGGGAGTGGAGAATTAACCCCTTGCATTTTAAAAAAGATTAACGTTG 24000  
 L L K L T G E G R L Q S R L I K E L Q L  
 \* C N \* H V R V E \* N P V Y F K K \* N C  
 V I K I Y G \* R K I P F T F N K R I A V

24001 AAATTAACTCATGAAACGAAGCAAATCAAGTATGACTAAGAAAAAGAACATTATTA AAA 24060  
 K L K L V K S R K T \* V S E K E Q L L K  
 S \* N S Y K A E N L E Y Q N K K K Y Y N  
 K I Q T S Q K T \* N M S I R K R T I I K

24061 CTACTTAGATTCTATATACCATCAACAAAATTCTCATAACAAAATCTATTTAAACGGTAT 24120  
 S S D L I Y P L Q K L L I T K S L N A M  
 Q H I \* S I H Y N N \* S Y Q K L Y I Q W  
 I F R L Y I T T T K L T N N \* I F K G Y

24121 GGGTTGAGGTCTGCTAGACTAAACGTCAACCCGTCAAGACCAAAGACGTTAGAAGATTA 24180  
 G L E L R D S K C N P L E P K R C D E L  
 V W S W V I Q N A T P C N Q N E A I K \*  
 G V G S S R I Q L Q A T R T K Q L R R I

24181 ATATTTTAACTGTGATGAAGATCAAGAACAGTTAACATAATATCAAACGGACGTTAATTA 24240  
 \* L I S V V E L E Q \* N Y \* L K G A I L  
 N Y F Q C \* K \* N K D I T N Y N A Q L \*  
 I F N V S S R T R T L Q I I T Q R C N I

24241 CAATGATAATTATTAATATTAGGAAGAAGAACCTTATCTCCATACCAAATTAATTA AAA 24300  
 T V I L L \* L G E E Q F L L Y P K L L K  
 H \* \* \* Y N Y D K K K S Y F T H N \* Y N  
 N S N I I I I R R R P I S P I T K I I K

FIG. 3 CONT'D

24301 TTAAACTCGAGAGTATCACAAACAATGAGTGCATAACAAAAAGACAATTATTATGAAAA 24360  
 L K L E \* L T T \* E R \* Q K E T L L V K  
 \* N S S E Y H Q K S V N N N K Q \* Y Y K  
 I Q A R M T N N V \* T I T K R N I I S K

24361 ACAGGAACACGATTTGGAAGAAAACGAAGTTCAACGTTCTCAGTATTTGGTGAAGACGA 24420  
 Q G Q A L G E K A E L Q L L \* L G G E A  
 K D K H \* V K K Q K L N C S D Y V V K Q  
 T R T S F R R K S \* T A L T M F W R R S

24421 AGGACAGGATAACCATGATTAATAGCAAGAACACTCTCATGATGACATGAGCTGGTGTGA 24480  
 E Q G I P V L \* R E Q S L V V T S S W V  
 K R D \* Q Y \* N D N K H S Y \* Q V R G C  
 G T R N T S I I T R T L T S S Y E V V S

24481 CTGACCACATCCACAAGAACAATGGACTAGGATATTGACGAATACTGGGATCCAGAACA 24540  
 S Q H L H E Q K G S G I V A \* S G L D Q  
 Q S T Y T N K N V Q D \* L Q K H G \* T K  
 V P T P T R T \* R I R Y S S I V R P R T

24541 AGAGTTTTTTTTTCAGAGACCAACCACAACCCTTGTAACACGTCCCAAGCCACAACACTTT 24600  
 E \* F F D R T P T P S C Q A P N P T S S  
 N E F F T E P Q H Q H V N H L T R H Q H  
 R L F L R Q N T N T F M T C P E T N I F

24601 CTTTTCACACCACATAACCTACCTAGTATATTACAAAGAACAGAAACATCATGACTACGG 24660  
 S F H P T N S P D Y L T E Q R Q L V S A  
 L F T H H I P H I M Y H K K D K Y Y Q H  
 F L T T Y Q I S \* I I N R T K T T S I G

24661 AAAGATCCAACCAGAATACTGTGAACGCAGTCATTGTTGGCAACATTATAAAAAAGATTA 24720  
 K R P Q D \* S V Q T L L L R Q L I K E L  
 R E L N T K H C K R \* Y C G N Y Y K K \*  
 K \* T P R I V S A D T V V T T I N K R I

24721 AAATAAAATTTACCATAGTTATCACCATGGTGAACAAGATTACTAAATAACGTCGGATTA 24780  
 K I K F P I L L P V V Q E L S K N C G L  
 N \* K L H Y \* Y H Y W K N \* H N I A A \*  
 K N \* I T D I T T G S T R I I \* Q L R I

24781 TGACTTCAAAAATGACTACAAAACAACACTAATGCTGGAAATACCATAATGTCCTGTTCCA 24840  
 V S T K V S T Q T S \* S R \* P I V P C P  
 Y Q L K \* Q H K H Q N R G K H Y \* L V L  
 S F N K S I N T N I V V K I T N C S L T

FIG. 3 CONT'D



24841 TAAAAATTTCTTCAAAGACGACAAATAATATTATCAACCGTTTTAGAAAACATACTAAGA 24900  
 I K L S T E A T \* \* L L Q C F R K Y S E  
 Y K \* L L K Q Q K N Y Y N A F D K T H N  
 N K F F N R S N I I I T P L I K Q I I R

24901 TTACCGTTGTAATAACCAAAATTTCTAAAACAATGATTATTTTGTATATTATAAAAGGGA 24960  
 L P L M I P K L S K T V L L V Y L I K G  
 \* H C C \* Q N \* L N Q \* \* Y F M Y Y K G  
 I A V N N T K F I K N S I F C I I N E R

24961 ACAATACGTCCTTCTCAAAGACGACGAAAAGTAGTTTTACGAAGGAGAAACCGAAATGAA 25020  
 Q \* A P L T E A A K \* \* F A E E K A K S  
 K N H L F L K Q Q K E D F H K R K P K V  
 T I C S S N R S S K M L I S G R Q S \* K

25021 ATAGCATTAAATTTTACATCGATACAAAACCTTATTATAAAGAAATGATGAGTCGGTATA 25080  
 \* R L K F H L \* T K F L I E K V V \* G Y  
 K D Y N L I Y S H K S Y Y K K L \* E A M  
 I T I \* F T A I N Q I I N R \* S S L W I

25081 AAATATCAATAGAACCAACGCAAAAATTACGACTATTAAATGACTAATAAGACAAAGA 25140  
 K S L \* R P Q T K L A S L K V S \* E T E  
 N Q Y N D Q N R K \* H Q Y N L Q N N Q K  
 K I T I K T A N K I S I I \* S I I R N R

25141 AGAACACGAGAAGCGTACCCATCACCAAAAACACAACCTAATATTGAGTGAAGAAGAAGG 25200  
 E Q A R R M P L P K Q T S \* L E G E E E  
 K K H E E C P Y H N K H Q N Y S V K K K  
 R T S K A H T T T K T N I I V \* R R R G

25201 AGAAGCGCAGCATTTCATCTTCATAAAGACGAAGAATAGCAAAACAATGAAAACCTGGG 25260  
 E E R R L R L L I E A E \* R K T V K S G  
 R K A D Y V Y F Y K Q K K D N Q \* K Q V  
 R R T T F T S T N R S R I T K N S K F G

25261 AAATTACAGTCAAAAACAATTACTGTCATAACTCAGACACCCACCAGAAATACTCTAGTTT 25320  
 K L T L K T L S L I S D T P P R \* S I L  
 R \* H \* N Q \* H C Y Q T Q P H D K H S \*  
 K I D T K N I V T N L R H T T K I L D F

25321 TAAGGGTGATTGAAATGATATCAACCGTTCTCCTTAAATAAGTTTGATTAAGAGGATTT 25380  
 I G V L K V I T P \* S S N I \* V L E G L  
 F E W \* S \* \* L Q D L P I \* E F \* N E \*  
 N G S V K S Y N T L L F K N L S I R R F

FIG. 3 CONT'D

25381 CAATGATAACTAACAAGAAATAAACAGACAAGATTAATACGTCGAACGGTACTGAATAAC 25440  
 T V I S Q E K N T Q E L \* A A Q W S K N  
 L \* \* Q N N K I Q R N \* N H L K G H S I  
 N S N I T R \* K D T R I I C S A M V \* Q

25441 AGTCTCATACCGTGAAAAACACTATTATAATTATCATAAAATCTACTTCAATTACCAAAT 25500  
 D S Y P V K Q S L I L L I K S S T L P K  
 T L T H C K K H Y Y \* Y Y K L H L \* H N  
 \* L I A S K T I I N I T N \* I F N I T \*

25501 GAACTATGATGAGTTAACGTACATCGACTATGAGAATACGTTCCACAGTGTGAATCGAGG 25560  
 S S V V \* N C T A S V R I C P T V S L E  
 V Q Y \* E I A H L Q Y E \* A L H \* V \* S  
 K I S S L Q M Y S I S K H L T D C K A G

25561 TTAGAATTATGATTAAACGTAAAACTACAACACTATTATAAATTTAGGGATCAACCT 25620  
 L R L V L K C K S T S L I L K L D R T P  
 W D \* Y \* N A N Q H Q Y Y \* N \* I G L Q  
 I K I S I Q M K I N I I N I K F G \* N S

25621 ACAAATCCAGGTGTGACGCCAAGAAGAAGAGCAAGAAAAAACTTCTAAATAACAACTG 25680  
 H K P G C Q P E E E R E K K S S K N N S  
 I N L D V S R N K K E N K K Q L N I T Q  
 T \* T W V A T R R R T R K K F I \* Q K V

25681 TTTCAATTTGAAAGTCTACAACCAAAACAACCTCGAATATTGTTAACATGACCACCATCA 25740  
 L T L S E S T P K T S A \* L L Q V P P L  
 C L \* V K L H Q N Q Q L K Y C N Y Q H Y  
 F N F K \* I N T K N F S I V I T S T T T

25741 CTTAATCTCTAGAAGAACACATGTTAGGAAATTACCATAAATTCAAAACGGAGGATAA 25800  
 S I L S R R Q T C D K L P I L T K G G I  
 H F \* L D E K H V I R \* H Y \* L K A E \*  
 F N S I K K T Y L G K I T N F N Q R R N

25801 AACAGACTTAGAGTTTAAAGACCAATGTGGTGTGCGCGATGACAACGACGATACAAAGGT 25860  
 K D S D \* I E P \* V V A A V T A A I N G  
 K T Q I E F K Q N C W L R \* Q Q Q \* T E  
 Q R F R L N R T V G C G S S N S S H K W

25861 GGTACCAGTCGTCGACCGTATGGTAAAGAGAATTACATGTTATATCTTAATTACCA 25920  
 G H D A A A P M G N E R L T C Y L I L P  
 V M T L L L Q C V M K E \* H V I Y F \* H  
 W P \* C C S A Y W K R K I Y L I S N I T

FIG. 3 CONT'D

25921 AACCCACAATGATACCTACAAGAATTATTTTGTAGTTTTCAACTATCGATGACGAAAATTA 25980  
 K P T V I S T R L L F \* F N I A V A K L  
 N P H \* \* P H E \* Y F D F T S L \* Q K \*  
 Q T N S H I N K I F I L L Q Y S S S K I

25981 TTACGAGAAGAAAGATAAGTCTTACCAAATCACGATGGTTGAGACGTGAACGATTTTAT 26040  
 L A R R E I \* F P K L A V L E A S A L I  
 Y H E E K \* E S H N \* H \* W S Q V Q \* F  
 I S K K R N L I T K T S G V R C K S F Y

26041 GTTTCACAACAATTAAGATTACGAGTTCGTGAATTATCAACAATGTCGTTAATAAATTA 26100  
 C L T T L E L A \* A S L L K N C C N N L  
 V F H Q \* N \* H E L V \* Y N T V A I I \*  
 L T N N I R I S L C K I T Q \* L L \* K I

26101 TTTAAACCACGTTAATCAAGAAGAAATGTTCTTTAAAATAGAGCAGAGCTACGAAATCTC 26160  
 L N P A I L E E K C S I K D R R S A K S  
 Y I Q H L \* N K K V L F K I E D R H K L  
 F K T C N T R R \* L F N \* R T E I S \* L

26161 CGAGTCCAAGTCTAACTATCCGAATAATTACCAGCAAATGACGAAATTTACGAATACAG 26220  
 A \* T \* I S L S I L P R K V A K F A \* T  
 P E P E S Q Y A \* \* H D N L Q K L H K H  
 S L N L N I P K N I T T \* S S \* I S I D

26221 AGAGTTGTCGAATCACTATAAAGAGAACATTTTAAACCACGACGAAATCGATACCTCTTC 26280  
 E \* C S L S I E R T F N P A A K A I S F  
 R E V A \* H Y K E Q L I Q H Q K L \* P S  
 R L L K T I N R K Y F K T S S \* S H L L

26281 CAATTACTCACACAATTTTTCAGTTAGAGGAGCATAATTAAAAACACCATTACCATTAGTA 26340  
 T L S H T L L \* D G R I L K Q P L P L \*  
 P \* H T H \* F D I E E Y \* N K H Y H Y D  
 N I L T N F T L R R T N I K T T I T I M

26341 TAAAACAGTAATCAAGTTTTACGAGGAATACCAAACAACAAATACGTAATAATCAATATTT 26400  
 I K D N T \* F A G \* P K N N I C K L \* L  
 Y K T M L E F H E K H N T T \* A N \* N Y  
 N Q \* \* N L I S R I T Q Q K H M K T I F

26401 GGATAAAGAAAATTTTGACAAAATCATTCAGGACCAACACATATAGTCCACTACATCCA 26460  
 G I E K L V T K T L G P K H I D P S T P  
 V \* K K \* F Q K L L D Q N T Y I L H H L  
 R N R K F S N \* Y T R T Q T Y \* T I Y T

FIG. 3 CONT'D

26461 TAACGTGGATTGTGCCATAAAATAATTTGTATTACTAGTAACCTACAAGTGACCATCA 26520  
 I A G L C P Y K I L C L S \* Q I N V P L  
 Y Q V \* V L T N \* \* V Y H D N S T \* Q Y  
 N C R F L P I K N F M I I M P H E S T T

26521 AGAATGATAATAGGACTTGGTTAAAGTCTATTTTTACAACAAAATACTTATGAACAAGA 26580  
 E \* \* \* G S G I E S L F T T K I F V Q E  
 N K S N D Q V L K L Y F H Q K \* S Y K N  
 R V I I R F W N \* I F I N N K H I S T R

26581 CAATTAATAATGATTCGCGGAGAACAAATAAACTTAGTAAGACATGGTTTTAACAGACTA 26640  
 T L K V L A G R T \* K F \* E T G F N D S  
 Q \* N \* \* L A E Q K N S D N Q V L I T Q  
 N I K S F R R K N I Q I M R Y W F Q R I

26641 AAACCTTAGACTCAATAGAGTAACCAAATTTTTAGTTTGTAGGTAACGCGGATTAAACTGA 26700  
 K S D S N D \* Q N L F \* V D M A G L K V  
 N Q I Q T I E N T \* F D F M W Q A \* N S  
 K F R L \* R M P K F I L C G N R R I Q S

26701 AATTTAGAAGTATGATAATTACGATGAAAAAATCTAAACATAATACTCTACTTAGAATAA 26760  
 K F R \* V I L A V K K S K Y \* S I F R I  
 K L D E Y \* \* H \* K K L N T N H S S D \*  
 \* I K M S N I S S K \* I Q I I L H I K N

26761 GTTCTCAGATAAATCAGAAACTTATTATCAATATAGTTAGAATTTCTATATCCATGTATA 26820  
 \* S D I L D K F L L \* I L R L S I P V Y  
 E L T \* \* T K S Y Y N Y \* D \* L Y L Y M  
 L L R N L R Q I I T I D I K F I Y T C I

26821 CTTTACATACATTTTACCGGAACCATACAACCGATGATTAAAGAAAAAGTAAATATTAT 26880  
 S I Y T F H G Q Y T Q S S I E K E N I I  
 H F T H L I A K T H K A V L K K K M \* L  
 F H I Y F P R P I N P \* \* N R K \* K Y Y

26881 AAGGAACATAACGAGAAAAAATATACAACAACATGACCAACACCAAGACGTACAAAATCA 26940  
 N R T N S K K I H Q Q V P Q P E A H K L  
 I G Q I A R K \* I N N Y Q N H N Q M N \*  
 E K Y Q E K K Y T T T S T T T R C T K T

26941 TTTACAGTATTAACAACACTACTCATACCACCAGTAGTACTAAAACAATAGTTTTGTAGA 27000  
 L H \* L Q Q S S Y P P \* \* S K T I L V D  
 Y I D Y N N H H T H H D D H N Q \* \* F M  
 F T M I T T I L I T T M M I K N D F C R

FIG. 3 CONT'D

27001 GTACTACTAATCTTAGAGAACAGTCTAGAGTAATTTAGATTGAAATAAATACCTGCAAA 27060  
 \* S S \* F R K D S R M L D L S \* K H V N  
 E H H N S D R T L D \* \* I \* V K N I S T  
 M I I L I E Q \* I E N F R F K I \* P R K

27061 CCTCTGGATCGATGTGTGTAAGAGAACAATAATCTCTTAAACCACAATGTTTGGAACTTC 27120  
 P S R A V C M R K N N S F K T N C V K F  
 Q L G L \* V C E R T I L S N P T V F R S  
 S V \* S C V N E Q \* \* L I Q H \* L G Q L

27121 TAAACACAGATTTTCATATTAATGACAGTTGGATAACAACCAATGACATAACATGGAAATT 27180  
 I Q T \* L I I V T L R N N T V T N Y R \*  
 S K H R F Y L \* Q \* G I T P \* Q I T G K  
 N T D L T Y N S D V \* Q Q N S Y Q V K L

27181 TACAAACCACAGCGTTCAAACCGTTTAAACGAAGAGTGAATGTAATGCATCAGTGCTAT 27240  
 I N P T A L K A F K S R V K C \* T T V I  
 F T Q H R L N P L N A E \* K V N R L \* S  
 H K T D C T Q C I Q K E S \* M V Y D R Y

27241 AAAGGGTATCATTATTAATAAACCAACATTGATCAAAATGATGAATACCATTATGACAAA 27300  
 N G M T I I K T N Y S T K S S I T I S N  
 I E W L L L K P T T V L K V V \* P L V T  
 K G Y Y Y N Q H Q L \* N \* \* K H Y Y Q K

27301 GACTCCGACACAGATCTAATCAACTTAGTCGAAGACTTAAATAACAAACCGCACGTCTCC 27360  
 R L S H R S \* N F \* S R F K N N P T C L  
 E S A T D L N T S D A E S N I T Q R A S  
 Q P Q T \* I L Q I L K Q I \* Q K A H L P

27361 GTGAATTATTCATACCAACTAAATAAAAAGTTACTATGACGAACCATGTATCCTGTCTAA 27420  
 C K I L I T S K N K L S V A Q Y M P C I  
 A S L L Y P Q N I K \* H Y Q K T C L V S  
 V \* Y T H N I \* K E I I S S P V Y S L N

27421 AATCAAAATCAAATAAAACAGAATAAAGAAATTAGAAACAACAACGAAAAAATCGTTGA 27480  
 K T K T K N Q R I E K I K T T A K K A V  
 K L K L K I K D \* K K L R Q Q Q K K L L  
 \* N \* N \* K T K N R \* D K N N S K \* C S

27481 TAATTCGAAACATACGTTGAAACACCAAAAACATTAAGAAATAATAAAGTGGAAAGCCGA 27540  
 I L S Q I C S Q P K Q L K K I I E G E A  
 \* \* A K Y A V K H N K Y N R \* \* K V K P  
 N L K T H L K T T K T I E K N N \* R R S

FIG. 3 CONT'D

27541 ATGCAAATATTTTCTCCATACGTCAACATATTCAGAATATCACTTGTTC AATATGGTGGG 27600  
 \* T \* L L P I C N Y L D \* L S C T I G G  
 K R K Y F L Y A T T Y T K Y H V L \* V V  
 V N I F S T H L Q I L R I T F L N Y W G

27601 TGAAGTCTAATAAATTAGATTAGATTGTAACTTATTTAGAAAAGAAGGAGTTAAAT 27660  
 V E S \* K I \* I \* V N H I F R K K R L K  
 W K L N N L R F R F M I F L D K R G \* N  
 S \* I I \* D L D L C \* S Y I K E E E I \*

27661 GAAGACTAGTTCGACAATGTAAGAATTTTCTTACCTTAAAGAGAAACCCACATTATGATG 27720  
 S R I L S N C E \* F F P I E R Q T Y Y \*  
 V E S \* A T V N K F S H F K E K P T I S  
 K Q D L Q \* M R L L I S N R K P H L V V

27721 AAAAAATAATGATAGTATAACGTCAAGCCAATATGCTCGGCATCATACAAACAAATAGAAT 27780  
 K K N S D Y Q L E T I R A T T H K N I K  
 S K I V I M N C N P \* V L R L I N T \* R  
 K \* \* \* \* I A T R N Y S G Y Y T Q K D \*

27781 AGTICTACTAATAAGAAACCGAATACACCGGTAAGTACTGATAGTGGAACTGATATAAATTAA 27840  
 D L H N N K P K H P W Q S D G Q S Y K I  
 I L I I I R Q S I H G N V I V K V I N L  
 \* S S \* E K A \* T A M S \* \* R S \* I \* N

27841 CAAAAATACGAAACTTATTACGAAAAGAACGTAAAAGATATCACAAATGATAATAAAGAT 27900  
 T K I S Q I I S K K C K R Y H K S N N R  
 Q K \* A K F L A K R A N E I T N V I I E  
 N K H K S Y H K E Q M K \* L T \* \* \* K \*

27901 AACAAATACCTAAGAAATAAAACAATTATCATAAGCCGAAAATAATCTTGACCGTCAA 27960  
 N N Y P N K I K N I T N P K K N S S A T  
 I T I H I R \* K T L L I R S K I L V P L  
 Q \* I S E K N Q \* Y Y E A K \* \* F Q C N

27961 CCACCTCAAAATTAGGTCTCTGGTTATTAGAATACACATAACTATACTTTCCGTTCTACA 28020  
 P P T K I W L G I I K H T N I H F A L H  
 Q H L K L G S V L L R I H I S I F P L I  
 T S N \* D L S W Y D \* T Y Q Y S L C S T

28021 AACAAATCCGGTCAATAACTCCTGATAGTGTGTAATTGACGATGACAATAAGCACCAGTAG 28080  
 K N P W N N L V I V C \* S S S N N T T M  
 N T L G T I S S \* \* V N V A V T I R P \*  
 Q \* A L \* Q P S D C M L Q \* Q \* E H D D

FIG. 3 CONT'D

28081 AAATATATGTCCCACAGTTTGAACCGTGACCAATATGAGAAAGTCTAAACGGGCATATAC 28140  
 K I Y L T D F K A S T I S K \* I Q G Y I  
 R \* I C P T L S P V P \* V R E S K G T Y  
 K Y V P H \* V Q C Q N Y E K L N A R I H

28141 AATGACATCGATTCCACGTTTCATGAAACATGGATATTTGCACGGAAAAATCTATTCAATC 28200  
 N S Y S L H L Y K T G I F T G K \* I L \*  
 T V T A L T C T S Q V \* L R A K K S L N  
 \* Q L \* P A L V K Y R Y V H R K L Y T L

28201 TACAATTATCACAAAACGACAAAAACAATTCAGATTTCAACCATTGATAGCAAATGGCA 28260  
 I N I T T K S N K N L R F N T V I T \* R  
 S T L L P K A T K T L D L T P L \* R K G  
 H \* Y H N Q Q K Q \* T \* L Q Y S D N V T

28261 GATCATTTGGATCACCATACCTATGACGGAACAATTTCTCGAATTTAGATTTGATAATCCT 28320  
 R T F R T T H I S G Q \* S S L D L S N P  
 D L L G L P I S V A K N L A \* I \* V I L  
 \* Y V \* H Y P Y Q R T L L K F R F \* \* S

28321 ACAGAATATGAGGGCCAGTAATACGACCTTCATCTTCGAGGAGACCTTTAGCAAGTCCTT 28380  
 H R I S G T M I S S T S A G R S I T \* S  
 I D \* V G P \* \* A P L L L E E P F R E P  
 T K Y E R D N H Q F Y F S R Q F D N L F

28381 AGGAGTTCTTTTGAAGAACCCGACTGGTTAGACTCGCTTTAATGGTTTGGAAATTATCTC 28440  
 D E L F S R P S V L R L S I V L G K I S  
 I R L F V E Q A S W D S R F \* W V K L L  
 G \* S F K K P Q G I Q A F N G F R \* Y L

28441 CGTCITTTTGGGTTGGATTAAAGTGACACAGATGAGTTGGTGTTCCTTTATGATAGGGTG 28500  
 A S F G L R F E S H R S L W L S I S D W  
 P L F V W G L N V T D V \* G C P F V I G  
 C F F G V \* I \* Q T \* E V V L F Y \* G V

28501 TAATAAGGACCAAGAGGCCCTAGTGAGTTAAAGTTTTTCCATCTCTGAAATTTAAAAGTC 28560  
 M I G P E G P D S L K L F T S V K F K \*  
 C \* E Q N E P I V \* N \* F P L S K L N E  
 N N R T R R S \* E I E F L Y L S \* I K L

28561 TACCAGTTCTCAAGGTAACGAAAGCCTCATGGGGGAAGACTTCGTTTTCTATAACCA 28620  
 I T L S N G N S E S Y G R R F C F S I P  
 S P \* P T G M A K P T G G E S A F P Y Q  
 H D L L E W Q K R L V G K Q L L L I N T

FIG. 3 CONT'D

28621 TATCTGTGTCGGCCGCAAGAAAATTTGTGCGACTACCGAGTTGTTTTCGTCAACAATGGCT 28680  
 I S V A P T R K F C S I T L L L L Q \* R  
 Y L C L R R E K L V A S P \* C F C N N G  
 Y V C G A N K \* F L Q H D V F A T T V S

28681 CTACCATAAAGATGATAGAGCCATGGCCGGGTATACGGTTACGTAGGATACCACTTAGGG 28740  
 S P I E V I E T G A W I G I C G I T F G  
 L H Y K \* \* R P V P G Y A L A D \* P S D  
 I T N R S D R Y R G M H W H M R H H I G

28741 AGCTTCCCCAGAAGACCCCAACGATTAGTGGTTCGACTGTGAAGATGAGGGAGGCTACAAA 28800  
 E F P D E P N S I V L S V S R S G G I N  
 R S P T K Q T A L \* W A S V E V G E S T  
 R L P R R P Q \* D G L Q C K \* E R R H K

28801 GCAGTTCCTTAGGATGATGAGTTCTTCGATAGGGATGATCCAAAGCGGACCATGCTAAA 28860  
 R \* P I R S S L F S D R S P K R R T R N  
 E D L S G V V \* S A I G V L N G G P V I  
 T L P D \* \* E L L \* G \* \* T E A Q Y S K

28861 ACGGAGTTCGGATAATACAACCTCCGAGTCCCTCCAGACGAAGATTATCAGCTGGTCCAA 28920  
 Q R L A I I N F A \* S P R S R I T S W T  
 K G \* P \* \* T S P E P L D A E L L R G P  
 A E L S N H Q L S L F T Q K \* Y D V L N

28921 GTGCAAGAGTTAGTGCACCTGGGTTATTAGCAAGTAATTCATCTTCATTAAGATTAATAAT 28980  
 \* T R L \* T S G I I T \* \* T S T I R I K  
 E R E \* D R P G L L R E N L L L L E L K  
 V N E I V H V W Y D N M L Y F Y N \* N \*

28981 CTGTAAGTCTAAGATATCATTTTGGACTATACCGACTACTCTAGCGATTAGAACAAAATC 29040  
 S M \* I R Y Y F R I H S I L D S I K N \*  
 L C E S E I T F G S I A S S I A L R T K  
 V N L N \* L L V Q Y P Q H S R \* D Q K L

29041 GGTTCGAACCATTCTAAGATTGGAGTCGTTTCAGTGATTCGTTTTACGGTTCCTTTAGT 29100  
 G L K T F I R F R L L D S L L I G L F D  
 A L S P L S E L G \* C T V L C F A L S I  
 W A Q Y L N \* V E A L \* \* A F H W P F \*

29101 CCGTATTTTAAAATGTTTTGGAGCGGTTTTCCGCTTGAGGATTATTTGTAACATTACAAG 29160  
 P M F N \* C F R A L L S S R I F M T I N  
 L C L I K V F G R W F R V G L L C Q L T  
 A Y F K L L V E G F A F E \* Y V N Y H E

FIG. 3 CONT'D



29161 TTGTCACAAAACCATTTTCTCTGGAAGAGTTTTAAACCATTACGACTTTACAATTTCC 29220  
 L L T K T F S S R R L I K T I S F H \* L  
 \* C H K P L L P G E \* F K P L A S I N F  
 V T N Q Y F L V K E F N Q Y H Q F T L A

29221 AACCATGATTACTAGGAGTCAAAGGATAAGAACGTCTTAATCGAGGATGTGGTCCACGAA 29280  
 K T S I I R L K R N K C F \* S R C W T S  
 S P V L S G \* N G I R A S N A G V G P A  
 Q Y \* H D E T E \* E Q L I L E \* V L H K

29281 AAAAGAAACCAAGATTTAATCTGAACCAATTTTCTCTAAGGCTCCGACTGAGTGGACAAT 29340  
 K E K T R F \* V Q N F S I G L S V \* R N  
 K K K P E L N S K T L L S E S A S E G T  
 K R Q N \* I L S P \* F L N R P Q S V Q \*

29341 TTCTACAAAAACTTGAAGTAATAAGACCAAGATAATCCAAACTATCATGAAATGGTCCGA 29400  
 F I N K F K M I R T R N P K I T S \* W A  
 L S T K S S \* \* E P E I L N S L V K G P  
 L H K Q V E N N Q N \* \* T Q Y Y K V L S

29401 AACTCTGTTAATACTTTCAAGAACTTCTCTTAAATTTACGAATGCAATTAAGATTAGTCT 29460  
 K L C N H F N K F L I \* I S V N I R I L  
 K S V I I F T R S S F K F A \* T L E L \*  
 Q S L \* S L E Q L S N L H K R \* N \* D S

29461 TGTGACTAAGACTAAGCAACTCAAGATTTGGAGTGCATTTTCTCCACAATTTGTTAATG 29520  
 V S I R I R Q T R F R L T F S T N F L \*  
 F V S E S E N L E L G \* R L L P T L C N  
 C Q N Q N T S N \* V E A Y F L H \* V I V

29521 GTCTTGTCAAACCTGAGAGAATTAATTCACGACCATGAGTCGTGTAAGTTTACTAAAAT 29580  
 W F L K V R K I \* T S T S L V N \* I I K  
 G S C N S E R L K L A P V \* C M E F S K  
 L V T Q S E \* N L H Q Y E A C K L H N \*

29581 GAGGACTCCTAGTATCAAATGAACGATGAGAACTACTAGGAATACATCTTCTGAGACAAC 29640  
 S R L I M T \* K S S K I I R I Y F V R N  
 V G S S \* L K S A V R S S G \* T S S E T  
 E Q P D Y N V Q \* E Q H D K H L L S Q Q

29641 GAATTACTCTTACTTAGGATTAAGCTGTGATCCACCATTGGGGAGCGATAATAAGCCTTA 29700  
 S L S F S D \* N S V L H Y G R A I I R F  
 A \* H S H I R I R C \* T T V G R \* \* E S  
 K I L I F G L E V S P P L G E S N N P I

FIG. 3 CONT'D

29701 TCCTGTGAGAGATAGTCTTACTTAAGAACGACATTATTGTCTATCTCATCCAACAATGTC 29760  
L V S E I L I F E Q Q L L L Y L L N N C  
Y S V R \* \* F S N K S Y Y C I S Y T T V  
P C E R D S H I R A T I V S L T P Q \* L

29761 TGATATATAATTAATCATCTTTAAATATAAATCTGTAAACTAACAACTCATCAATATT 29820  
V I Y \* N T S I K Y K S M Q N N S Y N Y  
S \* I N I L L F K I N L C K I T L T T I  
S Y I L \* Y F N \* I \* V N S Q \* L L \* L

29821 CCAAATCGACATCATATTTGCGGAGGCCCTTCTCGATAGTTAACATCACAATTATATAT 29880  
P K A T T Y V G G P L A I L Q L T \* Y I  
L N L Q L I F A E P F L \* \* N Y H K I Y  
T \* S Y Y L R R R S S S D I T T N L I Y

29881 ATAATCATATACTAACTTTAATTAATATCGGAAAACCTCCTTAATGTTTTTTTTTTTTTTT 29940  
Y \* Y I I S I L \* L R K S S N C F F F F  
I N T Y S Q F \* N Y G K P P I V F F F F  
I L I H N F N I I A K Q L F \* L F F F F

29941 TT 29942  
F  
F

FIG. 3 CONT'D




FIG. 4





FIG. 5A



**FIG. 5B**






FIG. 6



**FIG. 7**



**FIG. 8**



1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGAGATCTCAT 60  
E \* E R I A S V P S I S L R S L V R S H  
N K S E L R P Y R L S A Y D L L S D L I  
I R A N C V R T V Y Q L T I S C Q I S L

61 TAAATCTAAACTTTTTAAACAAGATTCCCTGTTATCCATGCTTGTGAGTGTGGTTAATC 120  
\* I \* T F \* T R F P V I H A C E C G L I  
K S K L F K Q D S L L S M L V S V V \* S  
N L N F L N K I P C Y P C L \* V W F N H

121 ATAATCTTGTATTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTTGGTTGTC 180  
I I L Y F T F H T F H L S A S D V L V V  
\* S C I L L S T L F I S L P V T C W L S  
N L V F Y F P H F S S L C Q \* R V G C P

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAAAACCAGCAAATACGGTCTCGGCTTCAA 240  
L S V P P I G R N D \* N Q Q I R S R L Q  
S A S L P \* V A M I K T S K Y G L G F K  
Q R P S H R S Q \* L K P A N T V S A S S

241 GTGGGCGCCAGAATTTTCGTTGGCTGCTTCCGGATGCAGCGGAGGAGTTGGCTAGTCCTAT 300  
V G A R I S L A A S G C S G G V G \* S Y  
W A P E F R W L L P D A A E E L A S P M  
G R Q N F V G C F R M Q R R S W L V L \*

301 GAAGTCAGATGAGGGTGGGTTATGCCCTCTACTGGTCAAGCGATGGAAAGTGTGGATT 360  
E V R \* G W V M P L Y W S S D G K C W I  
K S D E G G L C P S T G Q A M E S V G F  
S Q M R V G Y A P L L V K R W K V L D L

361 TGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420  
C L \* \* S C E D R L S L H S W T R M A C  
V Y D N H V K I D C R C I L G Q E W H V  
F M I I M \* R \* I V A A F L D K N G M C

421 GCAGTCAAATCTTATCCGTGATATTTTTGTTTCATGAAGATCTACATGTTGTAGAAGTTCT 480  
A V K S Y P \* Y F C S \* R S T C C R S S  
Q S N L I R D I F V H E D L H V V E V L  
S Q I L S V I F L F M K I Y M L \* K F \*

481 AACTAAAACAGCCGTAAAGTCCGGTACGGCAATTTTAATTAATCACCTTTGCATAGCTT 540  
N \* N S R K V R Y G N F N \* I T F A \* L  
T K T A V K S G T A I L I K S P L H S L  
L K Q P \* S P V R Q F \* L N H L C I A W

FIG. 9

541 GGGTGGTTTTCTAAAGGGTATGTTATGGGCTTGTTCCGTTTCATACAAGACTAAACGTTA 600  
G W F S \* R V C Y G L V P F I Q D \* T L  
G G F P K G Y V M G L F R S Y K T K R Y  
V V F L K G M L W A C S V H T R L N V M

601 TGTTGTACATCATCTTTCTATGACTACATCTACTACTAATTTGGTGAAGATTTTTGGG 660  
C C T S S F Y D Y I Y Y \* F W \* R F F G  
V V H H L S M T T S T T N F G E D F L G  
L Y I I F L \* L H L L L I L V K I F W V

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTCCAAAATGGTTTCAATTCTGTAG 720  
L D C T F W F Y A I L C S Q M V S I L \*  
W I V P F G F M P S Y V H K W F Q F C R  
G L Y L L V L C H L M F T N G F N S V G

721 GTTGTATATTGAAGAGAGTGATTTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780  
V V Y \* R E \* F N N F K F \* I \* \* L \* F  
L Y I E E S D L I I S N F K F D D Y D F  
C I L K R V I \* \* F Q I L N L M I M I L

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAATATTACAAAA 840  
\* C R R C L C \* G S C \* A \* R \* I F T K  
S V E D A Y A E V H A E P K G K Y S Q K  
V \* K M L M L R F M L S L K V N I H K K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAACCCGTA CTCTTTGTAGACCAGTA 900  
S L C F T \* T I S W Y \* T R T L C R P V  
A Y A L L R Q Y R G I K P V L F V D Q Y  
L M L Y L D N I V V L N P Y S L \* T S M

901 TGGTTGTGACTATTCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATTCTTT 960  
W L \* L F W \* I S R L S S S L W S L F F  
G C D Y S G K L A D C L Q A Y G H Y S L  
V V T I L V N \* Q I V F K L M V I I L C

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGCGACTTTGATATTGTAGT 1020  
A R Y E T K A V C M A C Q L R L \* Y C S  
Q D M R Q K Q S V W L A N C D F D I V V  
K I \* D K S S L Y G L P I A T L I L \* W

1021 GGCTTGGCATGTAGTTTCGTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080  
G L A C S S \* F T I C Y A P A D Y S Y Y  
A W H V V R D S R F V M R L Q T I A T I  
L G M \* F V I H D L L C A C R L \* L L F

FIG. 9 CONT.

1081 TTGTGGTATTAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGCTGTAGTTAT 1140  
L W Y \* I C C T T Y R R C S R W S C S Y  
C G I K Y V A Q P T E D V V D G A V V I  
V V L N M L H N L Q K M \* \* M E L \* L Y

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTTAAAGCTTCTAGTTTGAT 1200  
T \* T C T F I I C \* C N S F K A S \* F D  
R E P V H L L S A D A I V L K L P S L M  
V N L Y I Y Y L L M Q \* F \* S F L V \* \*

1201 GAAAGTTATGACTCATATGGATGATTTTTCTATTAAATCTATATACAATGTTGATTTGTG 1260  
E S Y D S Y G \* F F Y \* I Y I Q C \* F V  
K V M T H M D D F S I K S I Y N V D L C  
K L \* L I W M I F L L N L Y T M L I C V

1261 TGATTGGGTTTTGTTATGCAGTATGGTTATGTAGATTGTTTTAATGATAATTGTGATTT 1320  
\* L W F C Y A V W L C R L F \* \* \* L \* F  
D C G F V M Q Y G Y V D C F N D N C D F  
I V V L L C S M V M \* I V L M I I V I F

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTCTTGCCATTGTGTTGTACAGT 1380  
L W L G F R \* Y D G W F F L S I V L Y S  
Y G W V S G N M M D G F S C P L C C T V  
M V G F Q V I \* W M V F L V H C V V Q F

1381 TTATGACTCTAGTGAAGTTAAAGCCCAATCATCTGGTGTATTCTGAGAATCCTGTGTT 1440  
L \* L \* \* S \* S P I I W C Y S \* E S C V  
Y D S S E V K A Q S S G V I P E N P V L  
M T L V K L K P N H L V L F L R I L C Y

1441 ATTTACTAATAGTACTGATACTGTTAACCTGATTCTTTTAATTTGTATGGTTATTTCTGT 1500  
I Y \* \* Y \* Y C \* P \* F F \* F V W L F C  
F T N S T D T V N P D S F N L Y G Y S V  
L L I V L I L L T L I L L I C M V I L L

1501 TACACCATTGGTTCTTGTATATATTGGTCACCGCGTCCTGGATTGTGGATTCCTATCAT 1560  
Y T I W F L Y I L V T A S W I V D S Y H  
T P F G S C I Y W S P R P G L W I P I I  
H H L V L V Y I G H R V L D C G F L S L

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTCAGGTGTAGTAGGTTGTAATC 1620  
\* I F S Q V L \* \* F G L F R C S R L \* I  
K S S V K S Y D D L V Y S G V V G C K S  
N L Q S S L M M I W F I Q V \* \* V V N L

FIG. 9 CONT.

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACCTTACTTAGATTATGTTCAATGTAA 1680  
Y C \* R N C S Y Y S C T L L R L C S M \*  
I V K E T A L I T H A L Y L D Y V Q C K  
L L K K L L L L L M H F T \* I M F N V S

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGTGTAAATAATTCTTGGTGTAGGCAACT 1740  
V W \* S \* T K S Y S W C \* \* F L V \* A T  
C G N L E Q N H I L G V N N S W C R Q L  
V V I L N K I I F L V L I I L G V G N C

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTTTAAAAAATATTGACTTGTGTTGTTAAGCG 1800  
V A \* \* R \* L \* Y A F K K Y \* L V C \* A  
L L N R G D Y N M L L K N I D L F V K R  
C L I E V I I I C F \* K I L T C L L S V

1801 TCGTGCTGATTTTGCTTGCAAGTTTGCAGTTTGTGGAGATGGTTTGTACCTTTTTTACT 1860  
S C \* F C L Q V C S L W R W F C T F F T  
R A D F A C K F A V C G D G F V P F L L  
V L I L L A S L Q F V E M V L Y L F Y \*

1861 AGATGGTTTAATCCCGTAGTTATTATCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920  
R W F N S P \* L L S N S E W Y F L Y I F  
D G L I P R S Y Y L I Q S G I F F T S L  
M V \* F P V V I I \* F R V V F S L H L \*

1921 GATGTCTCAATTTTCACAAGAAGTTTCTGATATGTGTTTAAAAATGTGTATTTGTTTAT 1980  
D V S I F T R S F \* Y V F K N V Y F V Y  
M S Q F S Q E V S D M C L K M C I L F M  
C L N F H K K F L I C V \* K C V F C L W

1981 GGACAGAGTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040  
G Q S F S C Y I L Y R A L C \* \* V G Y S  
D R V S V A T F Y I E H Y V N R L V T Q  
T E F Q L L H F I \* S I M L I G W L L N

2041 ATTTAAGTTATTGGTACTACACTTGTTAATAAAAATGGTTAATTGGTTTAAATACCATGTT 2100  
I \* V I G Y Y T C \* \* N G \* L V \* Y H V  
F K L L G T T L V N K M V N W F N T M L  
L S Y W V L H L L I K W L I G L I P C \*

2101 AGATGCTAGTGACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTTGT 2160  
R C \* C T C Y R L A S L P I I E W S F C  
D A S A P A T G W L L Y Q L L N G L F V  
M L V H L L Q A G F F T N Y \* M V F L \*

FIG. 9 CONT.

2161 AGTATCTCAAGCCAACTTTAATTTTGTGGCTTTAATACCTGATTATGCTAAAATTTTAGT 2220  
S I S S Q L \* F C C F N T \* L C \* N F S  
V S Q A N F N F V A L I P D Y A K I L V  
Y L K P T L I L L L \* Y L I M L K F \* L

2221 TAATAAATTTTACACTTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTTAAA 2280  
\* \* I L H F F \* V I I R V C Y S \* C F K  
N K F Y T F F K L L L E C V T V D V L K  
I N F T L F L S Y Y \* S V L Q L M F \* K

2281 AGATATGCCTGTTCTTAAACTATTAATGGTTTGTATTGTATTGTAGGCAATAAGTTTTA 2340  
R Y A C S \* N Y \* W F S L Y C R Q \* V L  
D M P V L K T I N G L V C I V G N K F Y  
I C L F L K L L M V \* F V L \* A I S F I

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTTGTTTTACCATGTAATGCACAGGAACAACA 2400  
\* R \* Y R V N S W F C F T M \* C T G T T  
N V S T G L I P G F V L P C N A Q E Q Q  
T L V Q G \* F L V L F Y H V M H R N N K

2401 AATTTATTTTTTTGAAGGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAGAA 2460  
N L F F \* R R C R I C Y S R R \* C Y \* E  
I Y F F E G V A E S V I V E D D V I E N  
F I F L K A L Q N L L \* \* K M M L L R M

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAAT 2520  
C Q I F F I I L \* V L S T T \* I C R K N  
V K S S L S S Y E Y C Q P P K S V E K I  
S N L L Y H L M S I V N H L N L \* K K F

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAAATTTTTCCCTATTGTCAT 2580  
L Y Y R \* Y V H G \* V W \* \* I F P Y C H  
C I I D N M Y M G K C G D K F F P I V M  
V L \* I I C T W V S V V I N F S L L S \*

2581 GAATGATAAAAAATATTGTCTTTTTAGATCAGGCTTGGCGTTTTCCATGTGCAGGTAGAAA 2640  
E \* \* K Y L S F R S G L A F S M C R \* K  
N D K N I C L L D Q A W R F P C A G R K  
M I K I F V F \* I R L G V F H V Q V E K

2641 AGTTAATTTTAACGAGAAACCTGTTGTTATGGAGATTCCGTCTTTGATGACAGTTAAGGT 2700  
S \* F \* R E T C C Y G D S V F D D S \* G  
V N F N E K P V V M E I P S L M T V K V  
L I L T R N L L L W R F R L \* \* Q L R L

FIG. 9 CONT.

2701 TATGTTTGATTTAGATTCTACTTTTGTGATATTTTAGGTAAAGTTTGTTCAGAATTTGA 2760  
Y V \* F R F Y F \* \* Y F R \* S L F R I \*  
M F D L D S T F D D I L G K V C S E F E  
C L I \* I L L L M I F \* V K F V Q N L K

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTGCTGTTGTTGTGATGCTATAGAGAA 2820  
S R K G C Y C R \* F C R C C L \* C Y R E  
V E K G V T V D D F V A V V C D A I E N  
\* K R V L L \* M I L S L L F V M L \* R M

2821 TGCTTTAAACTCTTGTAAAGATCATCCAGTGGTTGGTTATCAAGTTCGTGCATTTTAA 2880  
C F K L L \* R S S S G W L S S S C I F K  
A L N S C K D H P V V G Y Q V R A F L N  
L \* T L V K I I Q W L V I K F V H F \* I

2881 TAACTTAATGAGAACGTTGTTTATTATTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940  
\* T \* \* E R C L F I \* \* G W \* \* S N G L  
K L N E N V V Y L F D E A G D E A M A S  
N L M R T L F I Y L M R L V M K Q W P L

2941 TCGTATGTATTGTACTTTTGTCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000  
S Y V L Y F C Y \* G C \* R R Y Q \* \* S C  
R M Y C T F A I E D V E D V I S S E A V  
V C I V L L L L R M L K T L S V V K L L

3001 TGAAGATACTATTGATGGTGTGCTTGAAGACACTATTAATGATGATGAAGATGTTGTTAC 3060  
\* R Y Y \* W C R \* R H Y \* \* \* \* R C C Y  
E D T I D G V V E D T I N D D E D V V T  
K I L L M V S L K T L L M M M K M L L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3181 TGGTGATAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240  
W \* \* \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V I M T M K M L L L V T M T M K M L L L

FIG. 9 CONT.

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360  
W \* Q \* R \* R C C Y W \* Q \* R \* R C C Y  
G D N D D E D V V T G D N D D E D V V T  
V T M T M K M L L L V T M T M K M L L L

3361 TGGTGACAATGACGATGAAGAGATTGTTACTGGTGACAATGATGACCAAATTGTTGTTAC 3420  
W \* Q \* R \* R D C Y W \* Q \* \* P N C C Y  
G D N D D E E I V T G D N D D Q I V V T  
V T M T M K R L L L V T M M T K L L L L

3421 TGGTGATGATGTAGATGATATTGAAAGTGTCTATGATTTTGATACTTATAAAGCTCTTTT 3480  
W \* \* C R \* Y \* K C L \* F \* Y L \* S S F  
G D D V D D I E S V Y D F D T Y K A L L  
V M M \* M I L K V S M I L I L I K L F \*

3481 AGTTTTTAATGATGTCTATAATGATGCTTTGTTGTTAGTTATGGTTCTAGTGTGAAAC 3540  
S F \* \* C L \* \* C F V C \* L W F \* C \* N  
V F N D V Y N D A L F V S Y G S S V E T  
F L M M S I M M L C L L V M V L V L K Q

3541 AGAAACATATTTTAAAGTTAATGGTTTATGGTCACCTACTATTACACATACTAACTGTTG 3600  
R N I F \* S \* W F M V T Y Y Y T Y \* L L  
E T Y F K V N G L W S P T I T H T N C W  
K H I L K L M V Y G H L L L H I L T V G

3601 GTTGCCTTCTGTGTTACTTGTAAATGCAGAAATTACCTTTTAAAGTTAAGGATTTAGCTAT 3660  
V A F C V T C N A E I T F \* V \* G F S Y  
L R S V L L V M Q K L P F K F K D L A I  
C V L C Y L \* C R N Y L L S L R I \* L L

3661 TGAAAATATGTGGTTATCTTATAAGGTGGGTATAATCAAAGTTTTGTTGATTATTTACT 3720  
\* K Y V V I L \* G G L \* S K F C \* L F T  
E N M W L S Y K V G Y N Q S F V D Y L L  
K I C G Y L I R W V I I K V L L I I Y \*

3721 GACCACTATTCCTAAAGCTATTGTTTTGCCTCAAGGTGGTTATGTAGCTGACTTTGCTTA 3780  
D H Y S \* S Y C F A S R W L C S \* L C L  
T T I P K A I V L P Q G G Y V A D F A Y  
P L F L K L L F C L K V V M \* L T L L I

FIG. 9 CONT.

3781 TTGGTTTTTAAACCAGTTTGATATTAATGCGTATGCTAATTGGTGTGTTTAAAATGTGG 3840  
L V F K P V \* Y \* C V C \* L V L F K M W  
W F L N Q F D I N A Y A N W C C L K C G  
G F \* T S L I L M R M L I G V V \* N V V

3841 TTTTCTTTTGATTTAAATGGTTTGGATGCTGTGTTTTTTTATGGAGATATTGTGTCTCA 3900  
F F F \* F K W F G C C V F L W R Y C V S  
F S F D L N G L D A V F F Y G D I V S H  
F L L I \* M V W M L C F F M E I L C L M

3901 TGTTTGTAAAGTGTGGACATAATATGACTCTAATAGCAGCGGACTTACCTTGTACATTACA 3960  
C L \* V W T \* Y D S N S S G L T L Y I T  
V C K C G H N M T L I A A D L P C T L H  
F V S V D I I \* L \* \* Q R T Y L V H Y I

3961 TTTTTCATTATTTGATGACAATTTTTGTGCTTTTTGCACCCCTAAAAAATTTTTATTGC 4020  
F F I I \* \* Q F L C F L H P \* K N F Y C  
F S L F D D N F C A F C T P K K I F I A  
F H Y L M T I F V L F A P L K K F L L L

4021 TGCATGTGCTGTGGATGTAACGTTTTGTCACTTCTGTAGCTGTTATAGGTGATGAACAAAT 4080  
C M C C G C K R L S F C S C Y R \* \* T N  
A C A V D V N V C H S V A V I G D E Q I  
H V L W M \* T F V I L \* L L \* V M N K \*

4081 AGATGGTAAGTTTGTACTAAATTTAGTGGTGATAAATTTGATTTTATAGTAGGTTATGG 4140  
R W \* V C Y \* I \* W \* \* I \* F Y S R L W  
D G K F V T K F S G D K F D F I V G Y G  
M V S L L L N L V V I N L I L \* \* V M E

4141 AATGTCATTTAGTATGTCTTCTTTTGTAGTTAGCTCAATTGTATGGTTTGTGTATAACACC 4200  
N V I \* Y V F F \* V S S I V W F V Y N T  
M S F S M S S F E L A Q L Y G L C I T P  
C H L V C L L L S \* L N C M V C V \* H L

4201 TAATGTATGTTTTGTAAAGGTGATATTATAAATGTTGCTAGACTTGTTAAAGCTGATGT 4260  
\* C M F C \* R \* Y Y K C C \* T C \* S \* C  
N V C F V K G D I I N V A R L V K A D V  
M Y V L L K V I L \* M L L D L L K L M L

4261 TATTGTTAACCTGCTAATGGGCATATGCTCCATGGTGGTGGAGTTGCAAAGCTATAGC 4320  
Y C \* P C \* W A Y A P W W W S C K S Y S  
I V N P A N G H M L H G G G V A K A I A  
L L T L L M G I C S M V V E L Q K L \* L

FIG. 9 CONT.



4321 TGTAGCTGCAGGTAAAAAATTTTCTAAAGAACTGCTGCTATGGTTAAATCTAAAGGTGT 4380  
C S C R \* K I F \* R N C C Y G \* I \* R C  
V A A G K K F S K E T A A M V K S K G V  
\* L Q V K N F L K K L L L W L N L K V F

4381 TTGCCAAGTAGGAGATTGTTATGTTTCTACCGGTGGTAAATTATGTAACAATTCTTAA 4440  
L P S R R L L C F Y R W \* I M \* N N S \*  
C Q V G D C Y V S T G G K L C K T I L N  
A K \* E I V M F L P V V N Y V K Q F L I

4441 TATTGTAGGTCCTGATGCTAGACAAGATGGAAGACAATCTTATGTTTTGTTAGCACGTGC 4500  
Y C R S \* C \* T R W K T I L C F V S T C  
I V G P D A R Q D G R Q S Y V L L A R A  
L \* V L M L D K M E D N L M F C \* H V L

4501 TTATAAGCATCTTAATAATTATGATTGTTGTTGTCTACTCTCATATCGGCTGGTATATT 4560  
L \* A S \* \* L \* L L F V Y S H I G W Y I  
Y K H L N N Y D C C L S T L I S A G I F  
I S I L I I M I V V C L L S Y R L V Y L

4561 TAGTGTCCTGCTGATGTGTCATTAACCTTACCTTCTAGGTGTTGTTGATAACAAGTTAT 4620  
\* C S C \* C V I N L P S R C C \* \* T S Y  
S V P A D V S L T Y L L G V V D K Q V I  
V F L L M C H \* L T F \* V L L I N K L S

4621 CCTTGTTAGTAATAATAAAGAAGATTTTGATATTATTCAAAAATGTCAAATTAATTCAGT 4680  
P C \* \* \* \* R R F \* Y Y S K M S N Y F S  
L V S N N K E D F D I I Q K C Q I T S V  
L L V I I K K I L I L F K N V K L L Q L

4681 TGTGGTACTAAAGCATTGGCTGTTAGATTAAGTCTAATGTAGGCCGTGTTATTAATT 4740  
C W Y \* S I G C \* I N C \* C R P C Y \* I  
V G T K A L A V R L T A N V G R V I K F  
L V L K H W L L D \* L L M \* A V L L N L

4741 TGAGACAGATGCATACAACTTTTCTTGAGTGGTGATGATGTTTTGTTTCAAATTCCTC 4800  
\* D R C I Q T F L E W \* \* L F C F K F F  
E T D A Y K L F L S G D D C F V S N S S  
R Q M H T N F S \* V V M I V L F Q I L L

4801 TGTATACAAGAAGTTTTATTGCTTCGTCATGATATACAATTGAATAATGACGTTTCGTGA 4860  
C Y T R S F I A S S \* Y T I E \* \* R S \*  
V I Q E V L L L R H D I Q L N N D V R D  
L Y K K F Y C F V M I Y N \* I M T F V I

FIG. 9 CONT.



5401 TTGTCTTATGTTGCAGCATATTAATCTTAAATTTAATAAATGGCAGTGGCAGGAAGCATG 5460  
L S Y V A A Y \* S \* I \* \* M A V A G S M  
C L M L Q H I N L K F N K W Q W Q E A W  
V L C C S I L I L N L I N G S G R K H G

5461 GTATGAATTTTCGTGCTGGCAGACCACATAGGTTAGTTGCTCTTGTTTTAGCTAAAGGTCA 5520  
V \* I S C W Q T T \* V S C S C F S \* R S  
Y E F R A G R P H R L V A L V L A K G H  
M N F V L A D H I G \* L L L F \* L K V I

5521 TTTTAAATTTGATGAACCATCAGATGCTACTGATTTTATTCGTGTGTTTTGAAACAAGC 5580  
F \* I \* \* T I R C Y \* F Y S C C F E T S  
F K F D E P S D A T D F I R V V L K Q A  
L N L M N H Q M L L I L F V L F \* N K L

5581 TGATTTATCAGGTGCAATTTGTGAATTAGAACTTATTTGTGATTGTGGTATTAACAAGA 5640  
\* F I R C N L \* I R T Y L \* L W Y \* T R  
D L S G A I C E L E L I C D C G I K Q E  
I Y Q V Q F V N \* N L F V I V V L N K K

5641 AAGTCGTGTTGGTGTGATGCTGTTATGCATTTTGGTACATTAGCAAAGACTGATCTTTT 5700  
K S C W C \* C C Y A F W Y I S K D \* S F  
S R V G V D A V M H F G T L A K T D L F  
V V L V L M L L C I L V H \* Q R L I F L

5701 TAATGGTTATAAGATTGGCTGTAATTGTGCAGGTAGAATTGTCCATTGTACTAAATTGAA 5760  
\* W L \* D W L \* L C R \* N C P L Y \* I E  
N G Y K I G C N C A G R I V H C T K L N  
M V I R L A V I V Q V E L S I V L N \* M

5761 TGTACCATTTTTGATTTGTTCTAATACTCCTCTGAGTAAGGATTTACCTGATGATGTTGT 5820  
C T I F D L F \* Y S S E \* G F T \* \* C C  
V P F L I C S N T P L S K D L P D D V V  
Y H F \* F V L I L L \* V R I Y L M M L L

5821 TGCAGCTAACATGTTTATGGGTGTAGGTGTAGGCCATTATACACATTTGAAATGTGGTTC 5880  
C S \* H V Y G C R C R P L Y T F E M W F  
A A N M F M G V G V G H Y T H L K C G S  
Q L T C L W V \* V \* A I I H I \* N V V H

5881 ACCTTACCAACATTATGATGCTTGTAGTGTTAAAAAATATACAGGTGTTAGTGGTTGTTT 5940  
T L P T L \* C L \* C \* K I Y R C \* W L F  
P Y Q H Y D A C S V K K Y T G V S G C L  
L T N I M M L V V L K N I Q V L V V V \*

FIG. 9 CONT.

5941 AACTGACTGCTTGTATCTTAAAAATTTAACCCAGACTTTTACATCTATGTTGACTAATTA 6000  
N \* L L V S \* K F N P D F Y I Y V D \* L  
T D C L Y L K N L T Q T F T S M L T N Y  
L T A C I L K I \* P R L L H L C \* L I I

6001 TTTTTGGATGATGTTGAAATGGTTGCTTATAACCCTGATCTTTCACAATATTATTGTGA 6060  
F F G \* C \* N G C L \* P \* S F T I L L \*  
F L D D V E M V A Y N P D L S Q Y Y C D  
F W M M L K W L L I T L I F H N I I V I

6061 TAATGGTAAGTATTATACAAAACCTATTATAAAGGCTCAGTTTAAACCATTGCTAAAAGT 6120  
\* W \* V L Y K T Y Y K G S V \* T I C \* S  
N G K Y Y T K P I I K A Q F K P F A K V  
M V S I I Q N L L \* R L S L N H L L K L

6121 TGACGGTGTTTATACTAACTTTAAGTTAGTTGGACATGATATTTGTGCTCAATTGAATGA 6180  
\* R C L Y \* L \* V S W T \* Y L C S I E \*  
D G V Y T N F K L V G H D I C A Q L N D  
T V F I L T L S \* L D M I F V L N \* M I

6181 TAAGTTAGGTTTAAATGTAGATTTGCCGTTTGTGAGTACAAAGTAACAGTCTGGCCTGT 6240  
\* V R F \* C R F A V C \* V Q S N S L A C  
K L G F N V D L P F V E Y K V T V W P V  
S \* V L M \* I C R L L S T K \* Q S G L \*

6241 AGCTACTGGTATGTTGTTTGGCATCTGATGATTTATATGTTAAACGTTATTTTAAAGG 6300  
S Y W \* C C F G I \* \* F I C \* T L F \* R  
A T G D V V L A S D D L Y V K R Y F K G  
L L V M L F W H L M I Y M L N V I L K D

6301 ATGTGAAACTTTTGGTAAGCCTGTTATTGGCTTTGTCATGATGAAGCATCATTGAATTC 6360  
M \* N F W \* A C Y L A L S \* \* S I I E F  
C E T F G K P V I W L C H D E A S L N S  
V K L L V S L L F G F V M M K H H \* I L

6361 TCTTACTTATTTTAAATAAACCTAGTTTAAATCTGAAAATAGATATAGTGTTTTGTCTGT 6420  
S Y L F \* \* T \* F \* I \* K \* I \* C F V C  
L T Y F N K P S F K S E N R Y S V L S V  
L L I L I N L V L N L K I D I V F C L L

6421 TGATTCTGTATCTGAGGAGTCACAAGGTAATGTGGTTACTTCTGTTATGGAATCGCAGAT 6480  
\* F C I \* G V T R \* C G Y F C Y G I A D  
D S V S E E S Q G N V V T S V M E S Q I  
I L Y L R S H K V M W L L L L W N R R L

FIG. 9 CONT.

6481 TAGTACTAAAGAGGTTAAGTTAAAGGGTGTAGAAAGACTGTAAAATAGAAGATGCTAT 6540  
\* Y \* R G \* V K G C \* K D C \* N R R C Y  
S T K E V K L K G V R K T V K I E D A I  
V L K R L S \* R V L E R L L K \* K M L L

6541 TATTGTTAATGATGAAAAATAGTTCTATTAAGGTTGTAAAAGTTTATCTTTAGTTGATGT 6600  
Y C \* \* \* K \* F Y \* G C \* K F I F S \* C  
I V N D E N S S I K V V K S L S L V D V  
L L M M K I V L L R L L K V Y L \* L M F

6601 TTGGGATATGATTTTGACAGGTTGTGATTATGTTGTTTGGGTTGCTAATGAATTGTCACG 6660  
L G Y V F D R L \* L C C L G C \* \* I V T  
W D M Y L T G C D Y V V W V A N E L S R  
G I C I \* Q V V I M L F G L L M N C H A

6661 CCTAGTTAAATCACCAACAGTTAGGGAATATATACGATATGGTATTAAACCTATTACTAT 6720  
P S \* I T N S \* G I Y T I W Y \* T Y Y Y  
L V K S P T V R E Y I R Y G I K P I T I  
\* L N H Q Q L G N I Y D M V L N L L L Y

6721 ACCTATAGATTTGTTATGTTAAGAGATGATAATCAAACCTCTTTTAGTTCCTAAAATTTT 6780  
T Y R F V M F K R \* \* S N S F S S \* N F  
P I D L L C L R D D N Q T L L V P K I F  
L \* I C Y V \* E M I I K L F \* F L K F L

6781 TAAAGCAAGAGCTATAGAATTTTATGGTTTTTTGAAGTGGTTGTTTATTTATGTTTTTAG 6840  
\* S K S Y R I L W F F E V V V Y L C F \*  
K A R A I E F Y G F L K W L F I Y V F S  
K Q E L \* N F M V F \* S G C L F M F L V

6841 TTTATTACATTTTACAAATGATAAAACCATTTTTTATACTACAGAAATAGCTTCTAAGTT 6900  
F I T F Y K \* \* N H F L Y Y R N S F \* V  
L L H F T N D K T I F Y T T E I A S K F  
Y Y I L Q M I K P F F I L Q K \* L L S L

6901 TACTTTTAATTTGTTTTGTTTGGCTCTTAAAATGCTTTTCAGACATTTAGATGGAGTAT 6960  
Y F \* F V L F G S \* K C F S D I \* M E Y  
T F N L F C L A L K N A F Q T F R W S I  
L L I C F V W L L K M L F R H L D G V Y

6961 ATTTATAAAAGGTTTTCTTGTGTAGCCACTGTGTTTTGTTTTGGTTTAAATTTTTTGTA 7020  
I Y K R F S C C S H C V F V L V \* F F V  
F I K G F L V V A T V F L F W F N F L Y  
L \* K V F L L \* P L C F C F G L I F C I

FIG. 9 CONT.

7021 TATAAATGTTATTTTTAGTGATTTTTATCTTCCTAATATTAGTGTTCCTATTTTTGT 7080  
Y K C Y F \* \* F L S S \* Y \* C F S Y F C  
I N V I F S D F Y L P N I S V F P I F V  
\* M L F L V I F I F L I L V F F L F L W

7081 GGAAGAATTGTTATGTGGATAAAGGCTACTTTTGGTTGGTTACAATTTGTGATTTTA 7140  
G K N C Y V D K G Y F W F G Y N L \* F L  
G R I V M W I K A T F G L V T I C D F Y  
E E L L C G \* R L L L V W L Q F V I F I

7141 TTCTAAGTTAGGTGTAGGTTTTACAAGTCATTTTTGTAATGGTAGTTTTATATGTGAATT 7200  
F \* V R C R F Y K S F L \* W \* F Y M \* I  
S K L G V G F T S H F C N G S F I C E L  
L S \* V \* V L Q V I F V M V V L Y V N C

7201 GTGTTATTCTGGTTTTGATATGTTGGATACATATGCAGCTATAGATTTTGTTCAGTATGA 7260  
V L F W F \* Y V G Y I C S Y R F C S V \*  
C Y S G F D M L D T Y A A I D F V Q Y E  
V I L V L I C W I H M Q L \* I L F S M K

7261 AGTAGATAGACGTGTTTTATTTGATTATGTTAGTTTAGTCAAATTAATTGTTGAACTCGT 7320  
S R \* T C F I \* L C \* F S Q I N C \* T R  
V D R R V L F D Y V S L V K L I V E L V  
\* I D V F Y L I M L V \* S N \* L L N S L

7321 TATTGGTTATTCATTATATACAGTATGGTTTTATCCATTATTTTGTCTTATTGGTTTACA 7380  
Y W L F I I Y S M V L S I I L S Y W F T  
I G Y S L Y T V W F Y P L F C L I G L Q  
L V I H Y I Q Y G F I H Y F V L L V Y N

7381 ATTATTTACTACATGGTTGCCTGATTTGTTTATGTTAGAACTATGCATTGGTTGATTAG 7440  
I I Y Y M V A \* F V Y V R N Y A L V D \*  
L F T T W L P D L F M L E T M H W L I R  
Y L L H G C L I C L C \* K L C I G \* L D

7441 ATTTATTGTATTTGTAGCTAATATGTTACCTGCTTTTGTCTTGTTCGGTTTTATATAGT 7500  
I Y C I C S \* Y V T C F C L V A V L Y S  
F I V F V A N M L P A F V L L R F Y I V  
L L Y L \* L I C Y L L L S C C G F I \* L

7501 TGTTACTGCTATGTATAAAGTAGTTGGTTTTATTAGGCATATTGTTTATGGTTGTAATAA 7560  
C Y C Y V \* S S W F Y \* A Y C L W L \* \*  
V T A M Y K V V G F I R H I V Y G C N K  
L L L C I K \* L V L L G I L F M V V I K

FIG. 9 CONT.

7561 AGCTGGTTGTTGTTTTGTTATAAACGAAATTGTAGTGTTCGTGTTAAGTGTAGTACTAT 7620  
S W L F V L L \* T K L \* C S C \* V \* Y Y  
A G C L F C Y K R N C S V R V K C S T I  
L V V C F V I N E I V V F V L S V V L L

7621 TGTTGGTGGTGAATTCGTTATTATGATATTACTGCTAATGGTGGTACTGGTTTTTGTGT 7680  
C W W C N S L L \* Y Y C \* W W Y W F L C  
V G G V I R Y Y D I T A N G G T G F C V  
L V V \* F V I M I L L L M V V L V F V L

7681 TAAACATCAATGGAATTGTTTAAATTGCCATTCTTTTAAACCAGGTAACACTTTTATAAC 7740  
\* T S M E L F \* L P F F \* T R \* H F Y N  
K H Q W N C F N C H S F K P G N T F I T  
N I N G I V L I A I L L N Q V T L L \* L

7741 TGTAGAAGCTGCTATAGAACTTTCTAAAGAGCTTAAACGACCTGTAAACCCAACCTGATGC 7800  
C R S C Y R T F \* R A \* T T C K P N \* C  
V E A A I E L S K E L K R P V N P T D A  
\* K L L \* N F L K S L N D L \* T Q L M L

7801 TTCACATTATGTAGTTACTGATATTAAGCAAGTTGGTTGTATGATGCGTTTGTCTATGA 7860  
F T L C S Y \* Y \* A S W L Y D A F V L \*  
S H Y V V T D I K Q V G C M M R L F Y D  
H I M \* L L I L S K L V V \* C V C S M I

7861 TAGAGATGGACAGCGTGTTTACGATGATGTTGATGCTAGTTTATTTGTAGATATTAATAA 7920  
\* R W T A C L R \* C \* C \* F I C R Y \* \*  
R D G Q R V Y D D V D A S L F V D I N N  
E M D S V F T M M L M L V Y L \* I L I I

7921 TCTGTTACATTCTAAAGTCAAAGTTGTTCCCTAATTTGTATGTAGTTGTAGTAGAGAGTGA 7980  
S V T F \* S Q S C S \* F V C S C S R E \*  
L L H S K V K V V P N L Y V V V V E S D  
C Y I L K S K L F L I C M \* L \* \* R V M

7981 TGCTGATAGAGCTAATTTTCTGAATGCTGTTGTGTTTTATGCACAATCATTGTATAGGCC 8040  
C \* \* S \* F S E C C C V L C T I I V \* A  
A D R A N F L N A V V F Y A Q S L Y R P  
L I E L I F \* M L L C F M H N H C I G L

8041 TATATTACTTGTAGACAAAAAGTTAATTACTACAGCTTGTAAATGGTATCTCTGTAACCCA 8100  
Y I T C R Q K V N Y Y S L \* W Y L C N P  
I L L V D K K L I T T A C N G I S V T Q  
Y Y L \* T K S \* L L Q L V M V S L \* P R

FIG. 9 CONT.

8101 GACTATGTTTGATGTTTATGTTGATACTTTTATGTCTCATTGATGTTGATAGAAAGAG 8160  
D Y V \* C L C \* Y F Y V S F \* C \* \* K E  
T M F D V Y V D T F M S H F D V D R K S  
L C L M F M L I L L C L I L M L I E R V

8161 TTTTAATAATTTGTTAACATTGCTCATGCTTCTCTTAGAGAGGGTGTGCAATTAGAAAA 8220  
F \* \* F C \* H C S C F S \* R G C A I R K  
F N N F V N I A H A S L R E G V Q L E K  
L I I L L T L L M L L L E R V C N \* K R

8221 GGTTTTAGATACTTTTGTGGGATGTGTACGTAAATGTTGTTCCATTGATTCAGATGTTGA 8280  
G F R Y F C G M C T \* M L F H \* F R C \*  
V L D T F V G C V R K C C S I D S D V E  
F \* I L L W D V Y V N V V P L I Q M L K

8281 AACAAAGATTTACTAAATCTATGATATCTGCAGTAGCTGCTGGTTTGAATTTACTGA 8340  
N K I Y Y \* I Y D I C S S C W F G I Y \*  
T R F I T K S M I S A V A A G L E F T D  
Q D L L L N L \* Y L Q \* L L V W N L L M

8341 TGAAAATTATAACAATTTGGTACCTACATATTTAAAGAGTGATAATATTGTAGCTGCAGA 8400  
\* K L \* Q F G T Y I F K E \* \* Y C S C R  
E N Y N N L V P T Y L K S D N I V A A D  
K I I T I W Y L H I \* R V I I L \* L Q I

8401 TTTAGGTGTTCTTATACAGAATGGTGCTAAGCATGTACAGGGTAATGTTGCTAAGGCAGC 8460  
F R C S Y T E W C \* A C T G \* C C \* G S  
L G V L I Q N G A K H V Q G N V A K A A  
\* V F L Y R M V L S M Y R V M L L R Q L

8461 TAATATTTCTGTATATGGTTTATTGACACTTTTAATCAACTTACTGCTGATTTACAGCA 8520  
\* Y F L Y M V Y \* H F \* S T Y C \* F T A  
N I S C I W F I D T F N Q L T A D L Q H  
I F L V Y G L L T L L I N L L L I Y S I

8521 TAAATTAATAAAGCATGTGTTAAACTGGCTTGAAGTTAAATGACTTTTAATAAGCA 8580  
\* I K K S M C \* N W L E V K I D F \* \* A  
K L K K A C V K T G L K L K L T F N K Q  
N \* K K H V L K L A \* S \* N \* L L I S K

8581 AGAGGCAAGTGTTCCTATTCTTACAACGCCCTTTTCACTTAAAGGAGGTGTTGTATTGAG 8640  
R G K C S Y S Y N A L F T \* R R C C I E  
E A S V P I L T T P F S L K G G V V L S  
R Q V F L F L Q R P F H L K E V L Y \* V

FIG. 9 CONT.



8641 TAATTTGTTATATATATATTATTTTTATTAGTTTAACTGTTTATATTATTGTGGGCTTT 8700  
\* F V I Y I I F Y \* F N L F Y I I V G F  
N L L Y I L F F I S L I C F I L L W A L  
I C Y I Y Y F L L V \* S V L Y Y C G L Y

8701 ACTGCCTACATATAGTGTTTATAAGTCTGATATTCATTTGCCTGCTTATGCTAGTTTAA 8760  
T A Y I \* C L \* V \* Y S F A C L C \* F \*  
L P T Y S V Y K S D I H L P A Y A S F K  
C L H I V F I S L I F I C L L M L V L K

8761 AGTTATTGATAAAGGTGTTGTTAGAGATATTTTCAGTTAATGATTTATGTTTTGCTAATAA 8820  
S Y \* \* W C C \* R Y F S \* \* F M F C \* \*  
V I D N G V V R D I S V N D L C F A N K  
L L I M V L L E I F Q L M I Y V L L I N

8821 ATTTTTCCAATTTGATCAATGGTATGAGTCCACTTTTGGGTCTTTTTACTATCATAATTC 8880  
I F P I \* S M V \* V H F W V F L L S \* F  
F F Q F D Q W Y E S T F G S F Y Y H N S  
F S N L I N G M S P L L G L F T I I I L

8881 TATGGATTGCCCTATTGTTGTGGCAGTTATGGATGAAGATATTGGTTCTACTATGTTTAA 8940  
Y G L P Y C C G S Y G \* R Y W F Y Y V \*  
M D C P I V V A V M D E D I G S T M F N  
W I A L L L W Q L W M K I L V L L C L M

8941 TGTTCTACTAAAGTTTTGAGACATGGCTTTTCATGTTTTACATTTTCTAACTTATGCATT 9000  
C S Y \* S F E T W L S C F T F S N L C I  
V P T K V L R H G F H V L H F L T Y A F  
F L L K F \* D M A F M F Y I F \* L M H L

9001 TGCTAGTGATAGTGTTCAGTGCTATACACCACATATTCAGATTTCTTATAATGATTTTTTA 9060  
C \* \* \* C S V L Y T T Y S D F L \* \* F L  
A S D S V Q C Y T P H I Q I S Y N D F Y  
L V I V F S A I H H I F R F L I M I F M

9061 TGCTAGTGGTTGTTGTTTTATCATCTTTGTGTACTATGTTTAAAAGAGGTGATGGTACACC 9120  
C \* W L C F I I F V Y Y V \* K R \* W Y T  
A S G C V L S S L C T M F K R G D G T P  
L V V V F Y H L C V L C L K E V M V H H

9121 ACATCCTTATTGTTATTTCAGATGGTGTATGAAGAATGCTTCTTTGTATACATCTTTGGT 9180  
T S L L L F R W C Y E E C F F V Y I F G  
H P Y C Y S D G V M K N A S L Y T S L V  
I L I V I Q M V L \* R M L L C I H L W F

FIG. 9 CONT.

9181 TCCACATACACGTTATAGCCTTGCTAATTCTAATGGTTTTATAAGATTCCTGATGTTAT 9240  
S T Y T L \* P C \* F \* W F Y K I S \* C Y  
P H T R Y S L A N S N G F I R F P D V I  
H I H V I A L L I L M V L \* D F L M L L

9241 TAGTGAAGGTATTGTACGTATTGTAAGAACGCGCTCTATGACTTATTGTAGAGTGGGTGC 9300  
\* \* R Y C T Y C K N A L Y D L L \* S G C  
S E G I V R I V R T R S M T Y C R V G A  
V K V L Y V L \* E R A L \* L I V E W V H

9301 ATGTGAATATGCCGAAGAGGGTATATGTTTTAATTTAATAGTTCCTGGGTTTTGAATAA 9360  
M \* I C R R G Y M F \* F \* \* F L G F E \*  
C E Y A E E G I C F N F N S S W V L N N  
V N M P K R V Y V L I L I V P G F \* I M

9361 TGATTATTATAGAAGTATGCCTGGAACTTTTTGTGGTAGAGATCTTTTTGATTTGTTTTA 9420  
\* L L \* K Y A W N F L W \* R S F \* F V L  
D Y Y R S M P G T F C G R D L F D L F Y  
I I I E V C L E L F V V E I F L I C F I

9421 TCAATTTTTAGTAGTTTTAATTCGTCCTATAGATTTCTTTTCTTACTGCTAGTTCTAT 9480  
S I F \* \* F N S S Y R F L F S Y C \* F Y  
Q F F S S L I R P I D F F S L T A S S I  
N F L V V \* F V L \* I S F L L L L V L F

9481 TTTTGGAGCTATATTGGCTATAGTCGTTGTCTTGGTTTTTTATTATTTAATAAACTTAA 9540  
F W S Y I G Y S R C L G F L L F N K T \*  
F G A I L A I V V V L V F Y Y L I K L K  
L E L Y W L \* S L S W F F I I \* \* N L S

9541 GCGTGCTTTTGGAGATTATACTAGTGTGTAGTTATAAATGTTATTGTTTGGTGTATTAA 9600  
A C F W R L Y \* C C S Y K C Y C L V Y \*  
R A F G D Y T S V V V I N V I V W C I N  
V L L E I I L V L \* L \* M L L F G V L I

9601 TTTTCTTATGCTTTTTGTTTTCAAGTTTATCCTATTTGTGCATGTGTCTATGCTTGTTT 9660  
F S Y A F C F S S L S Y L C M C L C L F  
F L M L F V F Q V Y P I C A C V Y A C F  
F L C F L F F K F I L F V H V S M L V F

9661 TTATTTTTATGTAACATTGTATTTTCTTCTGAAATTAGTGTAAATTATGCATTTGCAATG 9720  
L F L C N I V F S F \* N \* C N Y A F A M  
Y F Y V T L Y F P S E I S V I M H L Q W  
I F M \* H C I F L L K L V \* L C I C N G

FIG. 9 CONT.

9781 TATTGCAAACCATGTTTATGGTTATTTTCATATTGTAGGAAAATTGGTGTAAATGTATG 9840  
Y C K P C F M V I F I L \* E N W C \* C M  
I A N H V L W L F S Y C R K I G V N V C  
L Q T M F Y G Y F H I V G K L V L M Y V

9841 TAATGATAGTACATTTGAAGAAACATCTCTTACTACTTTTATGATTACTAAAGATTCTTA 9900  
\* \* \* Y I \* R N I S Y Y F Y D Y \* R F L  
N D S T F E E T S L T T F M I T K D S Y  
M I V H L K K H L L L L L \* L L K I L I

9901 TTGTAGATTAAGAATTCTGTTTCTGATGTTGCTTACAATAGATATTTGAGTTTGTATAA 9960  
L \* I K E F C F \* C C L Q \* I F E F V \*  
C R L K N S V S D V A Y N R Y L S L Y N  
V D \* R I L F L M L L T I D I \* V C I I

9961 TAAGTATCGTTACTATAGTGGTAAAATGGATACTGCTGCCTATAGAGAAGCGCGTGTTC 10020  
\* V S L L \* W \* N G Y C C L \* R S G V F  
K Y R Y Y S G K M D T A A Y R E A A C S  
S I V T I V V K W I L L P I E K R R V L

10021 TCAGTTAGCTAAAGCTATGGAAACATTTAATCACAATAATGGTAATGATGTCTTATACCA 10080  
S V S \* S Y G N I \* S Q \* W \* \* C L I P  
Q L A K A M E T F N H N N G N D V L Y Q  
S \* L K L W K H L I T I M V M M S Y T N

10081 ACCTCCTACAGCATCTGTTTCTACATCTTTTTTGCAATCAGGTATTGTAAAGATGGTATC 10140  
T S Y S I C F Y I F F A I R Y C K D G I  
P P T A S V S T S F L Q S G I V K M V S  
L L Q H L F L H L F C N Q V L \* R W Y L

10141 TCCTACGTCAAAAATTGAACCTTGATTGTTAGTGTACTTATGGTAGTATGACTTTGAA 10200  
S Y V K N \* T L Y C \* C Y L W \* Y D F E  
P T S K I E P C I V S V T Y G S M T L N  
L R Q K L N L V L L V L L M V V \* L \* M

10201 TGGTTTATGGTTAGATGACAAAGTTTATTGTCCTCGTCATGTTATATGTTTATCCTCTAA 10260  
W F M V R \* Q S L L S S S C Y M F I L \*  
G L W L D D K V Y C P R H V I C L S S N  
V Y G \* M T K F I V L V M L Y V Y P L I

10261 TATGAATGAACCTGATTATTCTGCCTTATTATGTAGAGTTACTCTAGGTGATTTTACTAT 10320  
Y E \* T \* L F C L I M \* S Y S R \* F Y Y  
M N E P D Y S A L L C R V T L G D F T I  
\* M N L I I L P Y Y V E L L \* V I L L \*

FIG. 9 CONT.

9721 GATTGTTATGTATGGTCTATAATGCCTTTTTGGTTTTGTGTCACATATGTAGCTATGGT 9780  
D C Y V W C Y N A F L V L C H I C S Y G  
I V M Y G A I M P F W F C V T Y V A M V  
L L C M V L \* C L F G F V S H M \* L W L

10321 AATGTCTGGCGGATGAGTTTAAACAGTTGTGTCTTACCAGATGCAGGGCTGTCAACTTGT 10380  
N V W A D E F N S C V L P D A G L S T C  
M S G R M S L T V V S Y Q M Q G C Q L V  
C L G G \* V \* Q L C L T R C R A V N L F

10381 TTTGACAGTCTCTTTACAAAATCCTTACACTCCAAAATATACTTTTGGTGTGTGTTAAACC 10440  
F D S L F T K S L H S K I Y F W C C \* T  
L T V S L Q N P Y T P K Y T F G V V K P  
\* Q S L Y K I L T L Q N I L L V L L N L

10441 TGGTGAAACTTTTACTGTTTTAGCTGCGTATAATGGCCGACCACAAGGGGCATTTTCATGT 10500  
W \* N F Y C F S C V \* W P T T R G I S C  
G E T F T V L A A Y N G R P Q G A F H V  
V K L L L F \* L R I M A D H K G H F M L

10501 TACTATGCGTAGTAGTTATACTATTAAGGTTCTTTTTTGTGTGGGTCATGTGGATCTGT 10560  
Y Y A \* \* L Y Y \* R F F F V W V M W I C  
T M R S S Y T I K G S F L C G S C G S V  
L C V V V I L L K V L F C V G H V D L L

10561 TGGTTATGTATTAACAGGTGATAGTGTTAAGTTTGTATATATGCATCAATTAGAGCTCAG 10620  
W L C I N R \* \* C \* V C I Y A S I R A Q  
G Y V L T G D S V K F V Y M H Q L E L S  
V M Y \* Q V I V L S L Y I C I N \* S S V

10621 TACTGGTTGTACACTGGCACTGATTTTTACTGGTAATTTTTTATGGTCCATATAGAGATGC 10680  
Y W L S H W H \* F Y W \* F L W S I \* R C  
T G C H T G T D F T G N F Y G P Y R D A  
L V V T L A L I L L V I F M V H I E M L

10681 TCAAGTTGTACAGTTGCCAGTTAAGGACTACGTCCAAACTGTTAATGTTATTGCTTGGCT 10740  
S S C T V A S \* G L R P N C \* C Y C L A  
Q V V Q L P V K D Y V Q T V N V I A W L  
K L Y S C Q L R T T S K L L M L L L G S

10741 CTATGCAGCTATACTTAATAATGTGCTTGGTTTTGTACAAAATGATGTTTGTCTATTGA 10800  
L C S Y T \* \* L C L V C T K \* C L F Y \*  
Y A A I L N N C A W F V Q N D V C S I E  
M Q L Y L I I V L G L Y K M M F V L L K

FIG. 9 CONT.

10801 AGATTTTAATGTTTGGGCTATGACAAATGGTTTTAGCCAAGTAAAAGCAGATCTTGT TTTT 10860  
R F \* C L G Y D K W F \* P S K S R S C F  
D F N V W A M T N G F S Q V K A D L V L  
I L M F G L \* Q M V L A K \* K Q I L F \*

10861 AGATGCTTTGGCTTCAATGACAGGTGTTTCTATTGAACTTTATTGGCTGCTATTAAGCG 10920  
R C F G F N D R C F Y \* N F I G C Y \* A  
D A L A S M T G V S I E T L L A A I K R  
M L W L Q \* Q V F L L K L Y W L L L S V

10921 TCTATATATGGGATTTCAAGGTCGTCAAATACTAGGAAGTTGTACTTTTGAAGATGAATT 10980  
S I Y G I S R S S N T R K L Y F \* R \* I  
L Y M G F Q G R Q I L G S C T F E D E L  
Y I W D F K V V K Y \* E V V L L K M N W

10981 GGCACCTTCTGACGTTTTATCAACAATGGCTGGTGTAAATTGCAATCTAAAACAAAAG 11040  
G T F \* R L S T I G W C \* I A I \* N K K  
A P S D V Y Q Q L A G V K L Q S K T K R  
H L L T F I N N W L V L N C N L K Q K D

11041 ATTTATTAAGAAACAATTTATTGGATTTTGATATCTACATTTTGT TTTAGTTGTATAAT 11100  
I Y \* R N N L L D F D I Y I F V \* L Y N  
F I K E T I Y W I L I S T F L F S C I I  
L L K K Q F I G F \* Y L H F C L V V \* F

11101 TTCTGCATTTGTAAATGGACTATATTTATGTATATTAATACACATATGATTGGTGT TAC 11160  
F C I C \* M D Y I Y V Y \* Y T Y D W C Y  
S A F V K W T I F M Y I N T H M I G V T  
L H L L N G L Y L C I L I H I \* L V L H

11161 ATTATGTGTACTTTGTTTTGTTAGTTTTATGATGTTACTAGTTAAACATAAGCATT TTTTA 11220  
I M C T L F C \* F Y D V T S \* T \* A F L  
L C V L C F V S F M M L L V K H K H F Y  
Y V Y F V L L V L \* C Y \* L N I S I F I

11221 TTTGACTATGTATATAATTCCTGTACTCTGTACCTTGT TTTTATGTAAATTATTTAGTTGT 11280  
F D Y V Y N S C T L Y L V L C K L F S C  
L T M Y I I P V L C T L F Y V N Y L V V  
\* L C I \* F L Y S V P C F M \* I I \* L S

11281 CTATAAGGAAGGTTTTAGAGGTCTTACTTATGTCTGGCTCTCATAT TTTTGTTCCTGCTGT 11340  
L \* G R F \* R S Y L C L A L I F C S C C  
Y K E G F R G L T Y V W L S Y F V P A V  
I R K V L E V L L M S G S H I L F L L \*

FIG. 9 CONT.

11341 GAATTTTACTTATGTTTATGAAGTATTTTATGGTTGTATTTTATGTGTTTTGCTATTTT 11400  
E F Y L C L \* S I L W L Y F M C F C Y F  
N F T Y V Y E V F Y G C I L C V F A I F  
I L L M F M K Y F M V V F Y V F L L F L

11401 TATAACTATGCATAGTATTAATCATGACATTTTTTCTTTGATGTTTTTGGTTGGTAGAAT 11460  
Y N Y A \* Y \* S \* H F F F D V F G W \* N  
I T M H S I N H D I F S L M F L V G R I  
\* L C I V L I M T F F L \* C F W L V E \*

11461 AGTTACTTTAATTTCTATGTGGTATTTTGGGTCGAATTTAGAAGAGGATGTTTTGTTATT 11520  
S Y F N F Y V V F W V E F R R G C F V I  
V T L I S M W Y F G S N L E E D V L L F  
L L \* F L C G I L G R I \* K R M F C Y L

11521 TATTACAGCCTTTTATAGTACTTATACATGGACCACTATTTTGTTCATTAGCTATAGCAA 11580  
Y Y S L F R Y L Y M D H Y F V I S Y S K  
I T A F L G T Y T W T T I L S L A I A K  
L Q P F \* V L I H G P L F C H \* L \* Q K

11581 AATTGTTGCTAATTGGTTGTCTGTTAATATATTTTATTTTACAGATGTACCTTATATTA 11640  
N C C \* L V V C \* Y I L F Y R C T L Y \*  
I V A N W L S V N I F Y F T D V P Y I K  
L L L I G C L L I Y F I L Q M Y L I L N

11641 ATTGATCTTTTTGAGTTACTTATTTATAGGGTATATTTTATCTTGTATTGGGGATTTTT 11700  
I D S F E L L I Y R V Y F I L L L G I F  
L I L L S Y L F I G Y I L S C Y W G F F  
\* F F \* V T Y L \* G I F Y L V I G D F S

11701 CTCTCTTTTAAACAGTGTTTTTAGAATGCCTATGGGTGTTTATAATTATAAAATTTCTGT 11760  
L S F K Q C F \* N A Y G C L \* L \* N F C  
S L L N S V F R M P M G V Y N Y K I S V  
L F \* T V F L E C L W V F I I I K F L F

11761 TCAAGAATTGCGTTATATGAATGCTAATGGCTTACGTCCACCCGTAATAGTTTTGAGGC 11820  
S R I A L Y E C \* W L T S T P \* \* F \* G  
Q E L R Y M N A N G L R P P R N S F E A  
K N C V I \* M L M A Y V H P V I V L R L

11821 TATTTTGTAAATTTAAACTGCTTGAATAGGTGGCGTGCCAGTTATTGAAGTTTCTCA 11880  
Y F V K F K T A W N R W R A S Y \* S F S  
I L L N L K L L G I G G V P V I E V S Q  
F C \* I \* N C L E \* V A C Q L L K F L K

FIG. 9 CONT.

11881 AATTCAATCAAAATTGACTGATGTGAAATGTGCTAATGTTGTTTGTAAATTGTTTACA 11940  
N S I K I D \* C E M C \* C C F V K L F T  
I Q S K L T D V K C A N V V L L N C L Q  
F N Q N \* L M \* N V L M L F C \* I V Y S

11941 GCATTTGCATGTTGCTTCTAATTCTAGGTTGTGGCAGTATTGTAGTATTTTACATAATGA 12000  
A F A C C F \* F \* V V A V L \* Y F T \* \*  
H L H V A S N S R L W Q Y C S I L H N E  
I C M L L L I L G C G S I V V F Y I M K

12001 AATACTATCTACTTCAGATTTAAGTGTAGCTTTTGATAAGCTTGCTCAATATTGATGT 12060  
N T I Y F R F K C S F \* \* A C S I I D C  
I L S T S D L S V A F D K L A Q L L I V  
Y Y L L Q I \* V \* L L I S L L N Y \* L F

12061 TTTATTGCCAATCCTGCTGCAGTTGATACTAAGTGTCTTGCAAGTATAGATGAAGTTAG 12120  
F I R Q S C C S \* Y \* V S C K Y R \* S \*  
L F A N P A A V D T K C L A S I D E V S  
Y S P I L L Q L I L S V L Q V \* M K L A

12121 CGATGATTATGTTCAAGATAGTACTGTTTTCAGGCTTTGCAAAGTGAGTTGTAAATAT 12180  
R \* L C S R \* Y C F A G F A K \* V C K Y  
D D Y V Q D S T V L Q A L Q S E F V N M  
M I M F K I V L F C R L C K V S L \* I W

12181 GGCTAGTTTTGTTGAATATGAAGTCGCAAAGAAAAATTTGGCTGATGCTAAAAATAGTGG 12240  
G \* F C \* I \* S R K E K F G \* C \* K \* W  
A S F V E Y E V A K K N L A D A K N S G  
L V L L N M K S Q R K I W L M L K I V V

12241 TTCTGTTAATCAACAACAGATAAAACAGTTAGAAAAGGCATGTAATATAGCTAAGTCTGT 12300  
F C \* S T T D K T V R K G M \* Y S \* V C  
S V N Q Q Q I K Q L E K A C N I A K S V  
L L I N N R \* N S \* K R H V I \* L S L C

12301 GTATGAACGCGATAAAGCTGTAGCTCGCAAACGTAACGATGGCAGACCTAGCACTTAC 12360  
V \* T R \* S C S S Q T G T Y G R P S T Y  
Y E R D K A V A R K L E R M A D L A L T  
M N A I K L \* L A N W N V W Q T \* H L L

12361 TAACATGTATAAAGAGGCTCGGATTAATGATAAGAAGAGTAAAGTTGTTCCGCTTTGCA 12420  
\* H V \* R G S D \* \* \* E E \* S C F R F A  
N M Y K E A R I N D K K S K V V S A L Q  
T C I K R L G L M I R R V K L F P L C R

FIG. 9 CONT.

12421 GACAATGCTTTTTAGCATGGTTCGTA AATTGGATAATCAGGCTTTAAATTCTATTCTGGA 12480  
D N A F \* H G S \* I G \* S G F K F Y S G  
T M L F S M V R K L D N Q A L N S I L D  
Q C F L A W F V N W I I R L \* I L F W I

12481 TAATGCTGTTAAAGGTTGTGTACCTTTGAATGCTATTCCAGCGCTGGCTGCTAATACTTT 12540  
\* C C \* R L C T F E C Y S S A G C \* Y F  
N A V K G C V P L N A I P A L A A N T L  
M L L K V V Y L \* M L F Q R W L L I L \*

12541 AACTATAATAATACCAGATAAACAAGTTTTGATAAAGTTGTTGATAATGTTTATGTTGC 12600  
N Y N N T R \* T S F \* \* S C \* \* C L C C  
T I I I P D K Q V F D K V V D N V Y V A  
L \* \* Y Q I N K F L I K L L I M F M L H

12601 ATATGCTGGTAGTGTATGGCATATACAGACTGTTCAAGATGCTGATGGTATTAATAAACA 12660  
I C W \* C M A Y T D C S R C \* W Y \* \* T  
Y A G S V W H I Q T V Q D A D G I N K Q  
M L V V Y G I Y R L F K M L M V L I N S

12661 GTTAAGTATATTAGTGTGATTCTAATTGGCCTCTTGTATTATTGCTAACAGGTATAA 12720  
V N \* Y \* C \* F \* L A S C Y Y C \* Q V \*  
L T D I S V D S N W P L V I I A N R Y N  
\* L I L V L I L I G L L L L L L L T G I M

12721 TGAAGTTGCTAATGCTGTTATGCAGAATAATGAGTTGATGCCTCATAAATTAATAAACA 12780  
\* S C \* C C Y A E \* \* V D A S \* I K N T  
E V A N A V M Q N N E L M P H K L K I Q  
K L L M L L C R I M S \* C L I N \* K Y K

12781 AGTTGTTAATAGTGTCTGATATGAATTGTAACATTCCTACTCAATGTTATTATAATAA 12840  
S C \* \* W F \* Y E L \* H S Y S M L L \* \*  
V V N S G S D M N C N I P T Q C Y Y N N  
L L I V V L I \* I V T F L L N V I I I M

12841 TGGTAGTAGTGGTAGAATAGTTTATGCTGTCTTAGTGATGTTGATGGTCTTAAGTATAAC 12900  
W \* \* W \* N S L C C S \* \* C \* W S \* V Y  
G S S G R I V Y A V L S D V D G L K Y T  
V V V V E \* F M L F L V M L M V L S I L

12901 TAAGATAATAAAGATGATGGAAATTGTGTTGTTTTAGAGCTTGATCCTCCTTGAAATT 12960  
\* D N K R \* W K L C C F R A \* S S L \* I  
K I I K D D G N C V V L E L D P P C K F  
R \* \* K M M E I V L F \* S L I L L V N F

FIG. 9 CONT.



12961 TTCTATACAAGATGTTAAGGGACTTAAAATTAAGTATCTTTATTTTATTAAGGATGTAA 13020  
F Y T R C \* G T \* N \* V S L F Y \* R M \*  
S I Q D V K G L K I K Y L Y F I K G C N  
L Y K M L R D L K L S I F I L L K D V T

13021 CACTTTAGCTAGAGGGTGGGTGTTGGTACTTTATCTTCAACAATTAGATTGCAGGCTGG 13080  
H F S \* R V G C W Y F I F N N \* I A G W  
T L A R G W V V G T L S S T I R L Q A G  
L \* L E G G L L V L Y L Q Q L D C R L V

13081 TGTTGCTACTGAGTATGCAGCTAATTCCTTCTATACTTTCATTATGTGCATTTTCTGTAGA 13140  
C C Y \* V C S \* F F Y T F I M C I F C R  
V A T E Y A A N S S I L S L C A F S V D  
L L L S M Q L I L L Y F H Y V H F L \* I

13141 TCCTAAGAAAACCTATTTAGATTATATACAACAAGGTGGTGTACCTATAATTAATTGTGT 13200  
S \* E N L F R L Y T T R W C T Y N \* L C  
P K K T Y L D Y I Q Q G G V P I I N C V  
L R K L I \* I I Y N K V V Y L \* L I V L

13201 TAAAATGCTCTGTGATCATGCTGGTACTGGTATGGCTATTACTATTAAACCTGAGGCTAC 13260  
\* N A L \* S C W Y W Y G Y Y Y \* T \* G Y  
K M L C D H A G T G M A I T I K P E A T  
K C S V I M L V L V W L L L L N L R L L

13261 TATTAATCAAGATTCTTATGGTGGTGCCTCAGTTTGTATTTACTGCCGTGCACGTGTAGA 13320  
Y \* S R F L W W C L S L Y L L P C T C R  
I N Q D S Y G G A S V C I Y C R A R V E  
L I K I L M V V P Q F V F T A V H V \* S

13321 GCATCCAGATGTAGATGGTTTGTGTAATACGTGGTAAATTTGTACAAGTCCCTTTGGG 13380  
A S R C R W F V \* I T W \* I C T S P F G  
H P D V D G L C K L R G K F V Q V P L G  
I Q M \* M V C V N Y V V N L Y K S L W V

13381 TATAAAGATCCTATTCTCTATGTGTTAACACATGATGTTTGTCAAGTTTGTGGATTTTG 13440  
Y K R S Y S L C V N T \* C L S S L W I L  
I K D P I L Y V L T H D V C Q V C G F W  
\* K I L F S M C \* H M M F V K F V D F G

13441 GAGAGATGGCAGTTGTTCCCTGTGTAGGTTGAGGTGTCGCTGTTCAATCTAAAGATTTAAA 13500  
E R W Q L F L C R F R C R C S I \* R F K  
R D G S C S C V G S G V A V Q S K D L N  
E M A V V P V \* V Q V S L F N L K I \* I

FIG. 9 CONT.

13501 TTTTAAACGGGTTCCGGGTTACTAGTGTGAATGCCCGTCTAGTACCCTGTGCTAGTGGT 13560  
F F K R V R G T S V N A R L V P C A S G  
F L N G F G V L V \* M P V \* Y P V L V V  
F \* T G S G Y \* C E C P S S T L C \* W F

13561 TTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACTAATAGAGCTGGTATA 13620  
L S T D V Q L R A F D I C N T N R A G I  
Y L L M F N \* G H L I F V I L I E L V \*  
I Y \* C S I K G I \* Y L \* Y \* \* S W Y R

13621 GGTATATTATAAAGTGAATTGTTGCCGTTTCAGCGTATAGATGACGACGGTAATAAA 13680  
G L Y Y K V N C C R F Q R I D D D G N K  
V Y I I K \* I V A V F S V \* M T T V I N  
F I L \* S E L L P F S A Y R \* R R \* \* I

13681 TTGGATAAGTCTTTGTTGTTAAAAGAAGTCTAGAGTTTATAATAAAGAGAAAAGT 13740  
L D K F F V V K R T N L E V Y N K E K T  
W I S S L L L K E L I \* K F I I K R K L  
G \* V L C C \* K N \* S R S L \* \* R E N L

13741 TATTATGAGTTGACTAAAAGTTGTGGTGTGGCTGAACATGATTTCTTTACATTTGAT 13800  
Y Y E L T K S C G V V A E H D F F T F D  
I M S \* L K V V V L W L N M I S L H L I  
L \* V D \* K L W C C G \* T \* F L Y I \* Y

13801 ATTGATGGTAGTCGTGTGCCACATATAGTTCGTAAGAACCTCTCAAAGTATACTATGTTA 13860  
I D G S R V P H I V R K N L S K Y T M L  
L M V V V C H I \* F V R T S Q S I L C \*  
\* W \* S C A T Y S S \* E P L K V Y Y V R

13861 GATCTTTGCTATGCATTGCGCCATTTGATTGTAATGATTGTTTCAGTATTGTGTGAAATT 13920  
D L C Y A L R H F D C N D C S V L C E I  
I F A M H C A I L I V M I V Q Y C V K F  
S L L C I A P F \* L \* \* L F S I V \* N S

13921 CTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAAGATTGGTATGATTTT 13980  
L C E Y A D C K E S Y F S K K D W Y D F  
F V S M L I V K N P T F L R K I G M I L  
L \* V C \* L \* R I L L F \* E R L V \* F C

13981 GTTGAAAATCCTGATATTATTAATATTTATAAAAAATTAGGCCCTATTTTAAATAGAGCT 14040  
V E N P D I I N I Y K K L G P I F N R A  
L K I L I L L I F I K N \* A L F L I E L  
\* K S \* Y Y \* Y L \* K I R P Y F \* \* S F

FIG. 9 CONT.

14041 TTACTTAATACTGTCAGTTTTGCAGATACTTTAGTAAAAGTAGGTTTAGTTGGTGTTTTA 14100  
L L N T V S F A D T L V K V G L V G V L  
Y L I L S V L Q I L \* \* K \* V \* L V F \*  
T \* Y C Q F C R Y F S K S R F S W C F N

14101 ACTTTAGATAATCAAGACTTGTATGGTCAATGGTATGATTTTGGTGATTTTATACAAACA 14160  
T L D N Q D L Y G Q W Y D F G D F I Q T  
L \* I I K T C M V N G M I L V I L Y K Q  
F R \* S R L V W S M V \* F W \* F Y T N S

14161 GCTCCAGGTTTTGGTGTGGCAGTTGCAGATTCTTACTATTCTTATATGATGCCTATGTTG 14220  
A P G F G V A V A D S Y Y S Y M M P M L  
L Q V L V W Q L Q I L T I L I \* C L C \*  
S R F W C G S C R F L L F L Y D A Y V D

14221 ACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGTTATAGACAATTCGAT 14280  
T M C H V L D C E L F V N D S Y R Q F D  
L C V M Y \* I V N Y L L M I V I D N S I  
Y V S C I R L \* I I C \* \* \* L \* T I R S

14281 CTTGTACAGTATGATTTTACTGATTATAAGTTAGAATTGTTTAATAAGTATTTTAAGTAT 14340  
L V Q Y D F T D Y K L E L F N K Y F K Y  
L Y S M I L L I I S \* N C L I S I L S I  
C T V \* F Y \* L \* V R I V \* \* V F \* V L

14341 TGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGATAGGTGATTATTTCAT 14400  
W G M K Y H P N T V D C D N D R C I I H  
G V \* S I I L I L W I V I M I G V L F I  
G Y E V S S \* Y C G L \* \* \* \* V Y Y S L

14401 TGTGCTAATTTTAATATATTATTTAGTATGGTCTTACCTAATACTTGTTTTGGTCTCTT 14460  
C A N F N I L F S M V L P N T C F G P L  
V L I L I Y Y L V W S Y L I L V L V L L  
C \* F \* Y I I \* Y G L T \* Y L F W S S C

14461 GTTAGACAAATTTTGTAGATGGTGTCCGTTTGTGTTTCAATTGGTTACCATTATAAAA 14520  
V R Q I F V D G V P F V V S I G Y H Y K  
L D K F L \* M V F R L L F Q L V T I I K  
\* T N F C R W C S V C C F N W L P L \* R

14521 GAGTTAGGTGTAGTTATGAACTTGGATGTTGATACACACCGCTATCGTTTGTCTCTTAAA 14580  
E L G V V M N L D V D T H R Y R L S L K  
S \* V \* L \* T W M L I H T A I V C L L K  
V R C S Y E L G C \* Y T P L S F V S \* R

FIG. 9 CONT.

14581 GACTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCTGCTAGTGCTCTGCTT 14640  
D L L L Y A A D P A M H V A S A S A L L  
T Y F F M Q Q I L L C M L H L L V L C L  
L T S L C S R S C Y A C C I C \* C S A \*

14641 GATTTACGAACCTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGTATAAAGTTTTCAAAC 14700  
D L R T C C F S V A A I T S G I K F Q T  
I Y E L V V L V \* L P L Q V V \* S F K L  
F T N L L F \* C S C H Y K W Y K V S N C

14701 GTTAAACCAGGTAATTTTAACCAAGATTTTTATGAGTTTGTCAAAAGTAAAGGCTTGT 14760  
V K P G N F N Q D F Y E F V K S K G L F  
L N Q V I L T K I F M S L S K V K A C L  
\* T R \* F \* P R F L \* V C Q K \* R L V \*

14761 AAAGAGGTTAGTACAGTTGATTTGAAACACTTTTTCTTTACTCAAGATGGTAATGCTGCA 14820  
K E G S T V D L K H F F F T Q D G N A A  
K R V V Q L I \* N T F S L L K M V M L Q  
R G \* Y S \* F E T L F L Y S R W \* C C N

14821 ATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTTGATATTAAGCAGTTA 14880  
I T D Y N Y Y K Y N L P T M V D I K Q L  
L L I I I I I S I I Y L L W L I L S S Y  
Y \* L \* L L \* V \* F T Y Y G \* Y \* A V I

14881 TTGTTTGTATTAGAAGTTGTTTATAAGTATTTGAAATTTATGATGGTGGTTGTATACCA 14940  
L F V L E V V Y K Y F E I Y D G G C I P  
C L Y \* K L F I S I L K F M M V V V Y Q  
V C I R S C L \* V F \* N L \* W W L Y T S

14941 GCATCACAAGTTATTGTTAATAATTATGACAAAAGTGCTGGTTATCCATTTAATAAATTT 15000  
A S Q V I V N N Y D K S A G Y P F N K F  
H H K L L L I I M T K V L V I H L I N L  
I T S Y C \* \* L \* Q K C W L S I \* \* I W

15001 GGTAAGCTAGACTTTATTATGAGGCATTATCATTTGAGGAGCAGAATGAAATTTATGCA 15060  
G K A R L Y Y E A L S F E E Q N E I Y A  
V K L D F I M R H Y H L R S R M K F M H  
\* S \* T L L \* G I I I \* G A E \* N L C I

15061 TATACTAAACGTAATGTGTTGCCCACTTTAACTCAAATGAATTTAAAATATGCTATTAGT 15120  
Y T K R N V L P T L T Q M N L K Y A I S  
I L N V M C C P L \* L K \* I \* N M L L V  
Y \* T \* C V A H F N S N E F K I C Y \* C

FIG. 9 CONT.

15121 GCTAAGAATAGAGCTCGTACTGTTGCAGGTGTTCCATTCTTAGTACTATGACAGGTCGA 15180  
A K N R A R T V A G V S I L S T M T G R  
L R I E L V L L Q V F P F L V L \* Q V E  
\* E \* S S Y C C R C F H S \* Y Y D R S N

15181 ATGTTTCATCAAAAATGTTTGAAGAGTATAGCAGCTACTCGTGGTGTTCCTGTTGTTATA 15240  
M F H Q K C L K S I A A T R G V P V V I  
C F I K N V \* R V \* Q L L V V F L L L \*  
V S S K M F E E Y S S Y S W C S C C Y R

15241 GGAACTACTAAATTTTATGGTGGCTGGGATGATATGTTACGCCATCTTATAAAGGATGTT 15300  
G T T K F Y G G W D D M L R H L I K D V  
E L L N F M V A G M I C Y A I L \* R M L  
N Y \* I L W W L G \* Y V T P S Y K G C \*

15301 GACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGTCCATGCCAAATATT 15360  
D N P V L M G W D Y P K C D R A M P N I  
T T L F L W V G I I L N V I V P C Q I F  
Q P C S Y G L G L S \* M \* S C H A K Y F

15361 TTGCGTATTGTTAGTAGTTTAGTTTTGGCTCGTAAACATGAATTTTGTGTTTCACATGGT 15420  
L R I V S S L V L A R K H E F C C S H G  
C V L L V V \* F W L V N M N F V V H M V  
A Y C \* \* F S F G S \* T \* I L L F T W \*

15421 GATAGATTCTATCGCCTTGC GAATGAATGTGCTCAAGTTTGTGAGTAAATAGTTATGTGT 15480  
D R F Y R L A N E C A Q V L S E I V M C  
I D S I A L R M N V L K F \* V K \* L C V  
\* I L S P C E \* M C S S F E \* N S Y V W

15481 GGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGTGCAACCACTGCTTTT 15540  
G G C Y Y V K P G G T S S G D A T T A F  
A V A I M L S L V V L A V V M Q P L L L  
R L L L C \* A W W Y \* Q W \* C N H C F C

15541 GCTAACTCTGTTTTTAATATATGTCAAGCTGTACTGCTAATGTTTGTCTCTTATGGCT 15600  
A N S V F N I C Q A V T A N V C S L M A  
L T L F L I Y V K L L L L M F V L L W L  
\* L C F \* Y M S S C Y C \* C L F S Y G L

15601 TGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAAAAACGCTTATACTCT 15660  
C N G H K I E D L S I R N L Q K R L Y S  
V M A I R L K I \* V Y A I Y K N A Y T L  
\* W P \* D \* R F K Y T Q F T K T L I L \*

FIG. 9 CONT.

15661 AATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAGTATTATGAATTTTAA 15720  
N V Y R T D Y V D Y T F V N E Y Y E F L  
M F I V Q I M L I I H L L M S I M N F Y  
C L S Y R L C \* L Y I C \* \* V L \* I F M

15721 TGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTTGTTTATAACTCTGAT 15780  
C K H F S M M I L S D D G V V C Y N S D  
V S I L V \* \* F \* V M M V L F V I T L I  
\* A F \* Y D D F E \* \* W C C L L \* L \* L

15781 TATGCTAGTAAGGGTTATATAGCCAATATAAGTGTTTTTCAACAAGTTTTGTACTATCAG 15840  
Y A S K G Y I A N I S V F Q Q V L Y Y Q  
M L V R V I \* P I \* V F F N K F C T I R  
C \* \* G L Y S Q Y K C F S T S F V L S E

15841 AATAACGTTTTTATGTCTGAATCTAAATGTTGGGTTGAAAATGATATTACTAATGGTCCT 15900  
N N V F M S E S K C W V E N D I T N G P  
I T F L C L N L N V G L K M I L L M V L  
\* R F Y V \* I \* M L G \* K \* Y Y \* W S S

15901 CATGAATTCTGTTCCACAACATACTATGTTGGTTAAGATAGATGGTGACTATGTTTATCTA 15960  
H E F C S Q H T M L V K I D G D Y V Y L  
M N S V H N I L C W L R \* M V T M F I Y  
\* I L F T T Y Y V G \* D R W \* L C L S T

15961 CCCTATCCAGACCCTTCTAGAATTTTAGGAGCTGGTTGTTTGTGATGATTTATTGAAG 16020  
P Y P D P S R I L G A G C F V D D L L K  
P I Q T L L E F \* E L V V L L M I Y \* R  
L S R P F \* N F R S W L F C \* \* F I E D

16021 ACTGACAGTGTCTTTTTGATAGAGCGCTTTGTAAGTCTAGCTATAGATGCTTACCCTTTA 16080  
T D S V L L I E R F V S L A I D A Y P L  
L T V F F \* \* S A L \* V \* L \* M L T L \*  
\* Q C S F D R A L C K S S Y R C L P F S

16081 GTACACCATGAAAATGAAGAATACCAAAAAGTTTTTCGTGTATATTTAGAATATATAAAA 16140  
V H H E N E E Y Q K V F R V Y L E Y I K  
Y T M K M K N T K K F F V Y I \* N I \* K  
T P \* K \* R I P K S F S C I F R I Y K K

16141 AAACATATAATGATCTTGGTAATCAGATCTTAGATAGTTATAGTGTATTTTAAGTACT 16200  
K L Y N D L G N Q I L D S Y S V I L S T  
N Y I M I L V I R S \* I V I V L F \* V L  
T I \* \* S W \* S D L R \* L \* C Y F K Y L

FIG. 9 CONT.

16201 TGTGATGGTTTAAAGTTCACTGATGAATCATTTTATAAGAATATGTATTTAAAAAGTGCC 16260  
 C D G L K F T D E S F Y K N M Y L K S A  
 V M V \* S S L M N H F I R I C I \* K V P  
 \* W F K V H \* \* I I L \* E Y V F K K C R

16261 GTGATGCAGAGTGTAGGTGCATGTGTTGTTTGTTCATCACAGACGTCTTTGCGTTGTGGC 16320  
 V M Q S V G A C V V C S S Q T S L R C G  
 \* C R V \* V H V L F V H H R R L C V V A  
 D A E C R C M C C L F I T D V F A L W Q

16321 AGTTGTATACGGAAGCCTTTGTTGTGTTGTAATGTTGCTATGATCATGTTATGGCAACC 16380  
 S C I R K P L L C C K C C Y D H V M A T  
 V V Y G S L C C V V N V A M I M L W Q P  
 L Y T E A F V V L \* M L L \* S C Y G N Q

16381 AATCATAAATATGTTTTGAGTGTTCACCTTATGTGTGTAATGCACCTAACTGTGATGTG 16440  
 N H K Y V L S V S P Y V C N A P N C D V  
 I I N M F \* V F H L M C V M H L T V M \*  
 S \* I C F E C F T L C V \* C T \* L \* C E

16441 AGTGATGCACCAAATTATATTTGGGTGGTATGTCTTATTATTGTGAAAACCATAAACCT 16500  
 S D V T K L Y L G G M S Y Y C E N H K P  
 V M S P N Y I W V V C L I I V K T I N L  
 \* C H Q I I F G W Y V L L L \* K P \* T S

16501 CATTATTCATTTAAGTTAGTTATGAATGGTATGGTCTTTGGTTTGTATAACAATCTTGT 16560  
 H Y S F K L V M N G M V F G L Y K Q S C  
 I I H L S \* L \* M V W S L V C I N N L V  
 L F I \* V S Y E W Y G L W F V \* T I L Y

16561 ACAGTTACCTTATATAGATGATTTTAAATAAGATAGCTAGTTGTAATGGACAGAAGTT 16620  
 T G S P Y I D D F N K I A S C K W T E V  
 Q V H L I \* M I L I R \* L V V N G Q K L  
 R F T L Y R \* F \* \* D S \* L \* M D R S \*

16621 GATGATTATGTTCTGGCAAATGAGTGTATTGAACGTTTAAAGTTATTTGCTGCAGAAACT 16680  
 D D Y V L A N E C I E R L K L F A A E T  
 M I M F W Q M S V L N V \* S Y L L Q K L  
 \* L C S G K \* V Y \* T F K V I C C R N S

16681 CAAAAGGCAACTGAAGAAGCTTTTAAACAAAGCTATGCTTCTGCTACTATTCAAGAGATT 16740  
 Q K A T E E A F K Q S Y A S A T I Q E I  
 K R Q L K K L L N K A M L L L L F K R L  
 K G N \* R S F \* T K L C F C Y Y S R D C

FIG. 9 CONT.

16741 GTTAGTGATAGAGAAATTATTTTGTGTTGGGAGACAGGTAAAGTTAAACCACCACTTAAT 16800  
V S D R E I I L C W E T G K V K P P L N  
L V I E K L F C V G R Q V K L N H H L I  
\* \* \* R N Y F V L G D R \* S \* T T T \* \*

16801 AAAAATTATGTTTTCACCTGGCTATCATTTTACTAGTACTGGTAAGACAGTTTATAGGTGAG 16860  
K N Y V F T G Y H F T S T G K T V L G E  
K I M F S L A I I L L V L V R Q F \* V S  
K L C F H W L S F Y \* Y W \* D S F R \* V

16861 TATGTTTTTGATAAAAAGTGAATTAACATAATGGTGTATTATATCGCGCTACAACACTACTTAC 16920  
Y V F D K S E L T N G V Y Y R A T T T Y  
M F L I K V N \* L M V F I I A L Q L L T  
C F \* \* K \* I N \* W C L L S R Y N Y L Q

16921 AAACCTTCTATAGGTGATGTTTTGTCTTAACATCACATTCTGTAGCTAATCTAAGTGCA 16980  
K L S I G D V F V L T S H S V A N L S A  
N F L \* V M F L S \* H H I L \* L I \* V H  
T F Y R \* C F C L N I T F C S \* S K C T

16981 CCTACACTTGTCCACAAGAGAACTATGCTAGTATAAGATTTTCTAGTGTTTATAGCGTT 17040  
P T L V P Q E N Y A S I R F S S V Y S V  
L H L F H K R T M L V \* D F L V F I A F  
Y T C S T R E L C \* Y K I F \* C L \* R S

17041 CCTTTGCTGTTTCAAACATAATGTTGCTAACTATCAGCACATTGGAATGAAACGTTATTGC 17100  
P L L F Q T N V A N Y Q H I G M K R Y C  
L C C F K L M L L T I S T L E \* N V I A  
F A V S N \* C C \* L S A H W N E T L L H

17101 ACTGTGCAAGGTCTCTGCTACGGGCAAGTCTCACCTTGCTATAGGTTTAGCTGTTTAT 17160  
T V Q G P P G T G K S H L A I G L A V Y  
L C K V L L V R A S L T L L \* V \* L F I  
C A R S S W Y G Q V S P C Y R F S C L L

17161 TACTATACAGCACGTGTAGTTTATACTGCTAGTCACTGCTGCTAGATGCATTGTGT 17220  
Y Y T A R V V Y T A A S H A A V D A L C  
T I Q H V \* F I L L L V M L L \* M H C V  
L Y S T C S L Y C C \* S C C C R C I V \*

17221 GAAAAAGCTTATAAGTTTTTAAATATTAATGACTGTACACGCATTATACCTGCTAAAGTT 17280  
E K A Y K F L N I N D C T R I I P A K V  
K K L I S F \* I L M T V H A L Y L L K F  
K S L \* V F K Y \* \* L Y T H Y T C \* S S

FIG. 9 CONT.



17281 CGTGTAGATTGTTATGATAAGTTTAAAATTAATGATACTACTTGTAAAGTATGTTTTTACT 17340  
R V D C Y D K F K I N D T T C K Y V F T  
V \* I V M I S L K L M I L L V S M F L L  
C R L L \* \* V \* N \* \* Y Y L \* V C F Y Y

17341 ACAATAAATGCATTACCAGAGTTAGTCACAGATATTGTTGTTGTTGATGAAGTTAGTATG 17400  
T I N A L P E L V T D I V V V D E V S M  
Q \* M H Y Q S \* S Q I L L L L M K L V C  
N K C I T R V S H R Y C C C \* \* S \* Y A

17401 CTTACTAATTATGAATTGCTCTGTATAAATGCTCGTGTAAAGCTAAACATTATGTATAT 17460  
L T N Y E L S V I N A R V K A K H Y V Y  
L L I M N C L L \* M L V L K L N I M Y I  
Y \* L \* I V C Y K C S C \* S \* T L C I Y

17461 ATTGGAGATCCTGCTCAGTTACCTGCACCACGTGTGCTATTGAGTAAGGGTTCTTTAGAA 17520  
I G D P A Q L P A P R V L L S K G S L E  
L E I L L S Y L H H V C Y \* V R V L \* N  
W R S C S V T C T T C A I E \* G F F R T

17521 CCTAGGCATTTTAATTCTATTACTAAAATAATGTGCTGTTTAGGTCCTGATATTTTTTTG 17580  
P R H F N S I T K I M C C L G P D I F L  
L G I L I L L L K \* C A V \* V L I F F W  
\* A F \* F Y Y \* N N V L F R S \* Y F F G

17581 GGAAATTGTTATAGATGTCCTAAAGAAATGTAGAAACTGTTTCAGCATTGGTTTATGAT 17640  
G N C Y R C P K E I V E T V S A L V Y D  
E I V I D V L K K L \* K L F Q H W F M I  
K L L \* M S \* R N C R N C F S I G L \* \*

17641 AATAAACTTAAGGCTAAGAATGATAATAGTTCATTATGCTTTAAAGTATATTTTAAGGGA 17700  
N K L K A K N D N S S L C F K V Y F K G  
I N L R L R M I I V H Y A L K Y I L R D  
\* T \* G \* E \* \* \* F I M L \* S I F \* G T

17701 CAGACAACACATGAGAGTTCAAGTGCTGTAATATTCAACAAATATATTTAATTAGTAAA 17760  
Q T T H E S S S A V N I Q Q I Y L I S K  
R Q H M R V Q V L \* I F N K Y I \* L V N  
D N T \* E F K C C K Y S T N I F N \* \* I

17761 TTTTGAAGCTAATCCAGTTTGAATAGTGCTGTTTTTATTAGTCCTTATAATAGTCAG 17820  
F L K A N P V W N S A V F I S P Y N S Q  
F \* K L I Q F G I V L F L L V L I I V R  
F E S \* S S L E \* C C F Y \* S L \* \* S E

FIG. 9 CONT.

17821 AACTATGTTGCTAAGCGTATTTTAGGTGTTCAAACACAAACTGTTGATTCTGCTCAAGGT 17880  
N Y V A K R I L G V Q T Q T V D S A Q G  
T M L L S V F \* V F K H K L L I L L K V  
L C C \* A Y F R C S N T N C \* F C S R F

17881 TCTGAATATGATTATGTTATATATTCACAAACAGCAGAAACAGCTCATTCTATTAATGTT 17940  
S E Y D Y V I Y S Q T A E T A H S I N V  
L N M I M L Y I H K Q Q K Q L I L L M L  
\* I \* L C Y I F T N S R N S S F Y \* C \*

17941 AATCGATTTAATGTTGCCATAACTAGAGCCAAGAAGGTATTTTCTGTGTTATGAGTAAT 18000  
N R F N V A I T R A K K G I F C V M S N  
I D L M L P \* L E P R R V F S V L \* V I  
S I \* C C H N \* S Q E G Y F L C Y E \* Y

18001 ATGCAATTATTTGAATCTCTTAATTTTATTACTTTACCTTTAGATAAAAATTCAGAATCAA 18060  
M Q L F E S L N F I T L P L D K I Q N Q  
C N Y L N L L I L L L Y L \* I K F R I K  
A I I \* I S \* F Y Y F T F R \* N S E S N

18061 ACTTTATCTCGTTTGCATTGTACTACTAATCTTTTTAAAGATTGTAGTAAAAATTTTTTA 18120  
T L S R L H C T T N L F K D C S K N F L  
L Y L V C I V L L I F L K I V V K I F \*  
F I S F A L Y Y \* S F \* R L \* \* K F F R

18121 GGTTACCACCCAGCTCATGCTCCTTCATTTTTATCAGTTGATGATAAATATAAGGTCAAC 18180  
G Y H P A H A P S F L S V D D K Y K V N  
V T T Q L M L L H F Y Q L M I N I R S T  
L P P S S C S F I F I S \* \* \* I \* G Q R

18181 GAAGATTGGCTGTTTGTTTAAACATTTGTGAACCTGTTTAAACATATTCTCGTTTAATA 18240  
E D L A V C L N I C E P V L T Y S R L I  
K I W L F V \* T F V N L F \* H I L V \* Y  
R F G C L F K H L \* T C F N I F S F N I

18241 TCTCTCATGGGGTTTAAATTGGATTGACTCTTGATGGTTATTCTAAATTTTTTATTACT 18300  
S L M G F K L D L T L D G Y S K F F I T  
L S W G L N W I \* L L M V I L N F L L L  
S H G V \* I G F D S \* W L F \* I F Y Y \*

18301 AAAGACGAAGCTATTAACGTGTTAGAGGTTGGGTTGGTTTTGATGTAGAAGGAGCCCAT 18360  
K D E A I K R V R G W V G F D V E G A H  
K T K L L N V L E V G L V L M \* K E P M  
R R S Y \* T C \* R L G W F \* C R R S P C

FIG. 9 CONT.

18361 GCTACGCGTGACAACATTGGAACAAACTTTCCATTGCAAATAGGTTTTTCAACTGGTGTT 18420  
A T R D N I G T N F P L Q I G F S T G V  
L R V T T L E Q T F H C K \* V F Q L V L  
Y A \* Q H W N K L S I A N R F F N W C \*

18421 GATTTTGTAGTTGAAGCTACTGGCTTATTTGCTGAGAGAGATTGTTATATATTTAAAAGA 18480  
D F V V E A T G L F A E R D C Y I F K R  
I L \* L K L L A Y L L R E I V I Y L K E  
F C S \* S Y W L I C \* E R L L Y I \* K N

18481 ACTGTTGCTAAAGCTCCTCCTGGTGATAACTTTAAACATTTAATACCCCTTATGTCGAAA 18540  
T V A K A P P G D N F K H L I P L M S K  
L L L K L L L V I T L N I \* Y P L C R K  
C C \* S S S W \* \* L \* T F N T P Y V E R

18541 GGTCAAAAGTGGGATGTTGTTAGAATCAGAATTGTTCAAATGTTGTCTGATTATCTTTTG 18600  
G Q K W D V V R I R I V Q M L S D Y L L  
V K S G M L L E S E L F K C C L I I F W  
S K V G C C \* N Q N C S N V V \* L S F G

18601 GATCTTCTGATAGTGTAGTATTTATTACTTGGTCTGCCAGTTTGAACCTACGTGTTTA 18660  
D L S D S V V F I T W S A S F E L T C L  
I F L I V \* Y L L L G L P V L N L R V \*  
S F \* \* C S I Y Y L V C Q F \* T Y V F K

18661 AGGTATTTTGCTAAATTAGGTAGAGAGCTCAATTGTGATGTGTGCCTAATCGTGCAACA 18720  
R Y F A K L G R E L N C D V C P N R A T  
G I L L N \* V E S S I V M C V L I V Q H  
V F C \* I R \* R A Q L \* C V S \* S C N M

18721 TGCTATAATTCTAGAACTGGTTATTACGGTTGTTGGCGCCATAGTTATACTTGTGATTAT 18780  
C Y N S R T G Y Y G C W R H S Y T C D Y  
A I I L E L V I T V V G A I V I L V I M  
L \* F \* N W L L R L L A P \* L Y L \* L C

18781 GTGTATAACCCGCTTATTGTAGATATACAACAGTGGGGTTACACAGGTTCTTTAACTAGT 18840  
V Y N P L I V D I Q Q W G Y T G S L T S  
C I T R L L \* I Y N S G V T Q V L \* L V  
V \* P A Y C R Y T T V G L H R F F N \* \*

18841 AATCATGATATAATTTGTAATGTACATAAAGGTGCACATGTTGCATCATCTGATGCAATT 18900  
N H D I I C N V H K G A H V A S S D A I  
I M I \* F V M Y I K V H M L H H L M Q L  
S \* Y N L \* C T \* R C T C C I I \* C N Y

FIG. 9 CONT.

18901 ATGACTCGGTGTTTAGCAATCTATGATTGTTTTGTAAATCTGTAAATTGGAATTTAGAG 18960  
M T R C L A I Y D C F C K S V N W N L E  
\* L G V \* Q S M I V F V N L L I G I \* S  
D S V F S N L \* L F L \* I C \* L E F R V

18961 TATCCAATAATTTCCAATGAGGTTAGTATAAATACATCTTGTAGGTTATTGCAGCGTGTT 19020  
Y P I I S N E V S I N T S C R L L Q R V  
I Q \* F P M R L V \* I H L V G Y C S V L  
S N N F Q \* G \* Y K Y I L \* V I A A C Y

19021 ATGCTTAAAGCTGCCATGCTATGTAATAGATAACAATTTATGTTATGACATTGGCAATCCT 19080  
M L K A A M L C N R Y N L C Y D I G N P  
C L K L P C Y V I D T I Y V M T L A I L  
A \* S C H A M \* \* I Q F M L \* H W Q S \*

19081 AAAGGTATTGCTTGTGTCAAAGATTATGAATTTAAATCTATGATGCTTCTCCTGTTGTC 19140  
K G I A C V K D Y E F K F Y D A S P V V  
K V L L V S K I M N L N S M M L L L L S  
R Y C L C Q R L \* I \* I L \* C F S C C Q

19141 AAGTCTGTTAAACAGTTGTTTTATGTTTATGATGTTTATAAAGATAATTTTAAAGGATGGT 19200  
K S V K Q L F Y V Y D V H K D N F K D G  
S L L N S C F M F M M F I K I I L R M V  
V C \* T V V L C L \* C S \* R \* F \* G W F

19201 TTATGTATGTTTTGGAATTGTAATGTTGATAAATATCCATCTAATTC AATTGTTTTGTAGA 19260  
L C M F W N C N V D K Y P S N S I V C R  
Y V C F G I V M L I N I H L I Q L F V D  
M Y V L E L \* C \* \* I S I \* F N C L \* I

19261 TTTGATACTCGGGTATTAATAAATAAATTAACCTCCCTGGATGTAATGGTGGTAGTTTGTAT 19320  
F D T R V L N K L N L P G C N G G S L Y  
L I L G Y \* I N \* T S L D V M V V V C M  
\* Y S G I K \* I K P P W M \* W W \* F V C

19321 GTTAATAAACATGCATTTTACTACTAATCCTTTTACCAGAACGGTCTTTGAAAATCTTAAA 19380  
V N K H A F H T N P F T R T V F E N L K  
L I N M H F I L I L L P E R S L K I L N  
\* \* T C I S Y \* S F Y Q N G L \* K S \* T

19381 CCTATGCCATTTTTTTACTATTTCAGATACTCCTTGTGTGTATGTAGATGGTTTGGAAATCC 19440  
P M P F F Y Y S D T P C V Y V D G L E S  
L C H F F T I Q I L L V C M \* M V W N P  
Y A I F L L F R Y S L C V C R W F G I Q

FIG. 9 CONT.

19441 AAACAAGTTGATTATGTGCCTTTAAGAAGCGCTACTTGTATCACACGATGTAATTTAGGT 19500  
K Q V D Y V P L R S A T C I T R C N L G  
N K L I M C L \* E A L L V S H D V I \* V  
T S \* L C A F K K R Y L Y H T M \* F R W

19501 GGTGCTGTTTGTCTAAGCATGCTGAAGATTATTGTAATATCTTGAGTCTTATAATGTA 19560  
G A V C S K H A E D Y C K Y L E S Y N V  
V L F V L S M L K I I V N I L S L I M \*  
C C L F \* A C \* R L L \* I S \* V L \* C S

19561 GCTACTACAGCAGGCTTTACTTTTTGGGTTTATAAGACTTTTGATTTTTATAATTTATGG 19620  
A T T A G F T F W V Y K T F D F Y N L W  
L L Q Q A L L F G F I R L L I F I I Y G  
Y Y S R L Y F L G L \* D F \* F L \* F M E

19621 AATACTTTCCTATGTTGCAGAGCTTAGAAAATGTAATATATAATTTGGTTAATGCTGGT 19680  
N T F T M L Q S L E N V I Y N L V N A G  
I L S L C C R A \* K M \* Y I I W L M L V  
Y F H Y V A E L R K C N I \* F G \* C W S

19681 CATTATGATGGACGTATAGGTGAATTGCCTTGTGCTATTATGAATGACAAAGTTGTTGTT 19740  
H Y D G R I G E L P C A I M N D K V V V  
I M M D V \* V N C L V L L \* M T K L L L  
L \* W T Y R \* I A L C Y Y E \* Q S C C \*

19741 AAGATTAATAATGTAGATACTGTTATTTTTAAAAATAATACATCACTTCCTACTAATATA 19800  
K I N N V D T V I F K N N T S L P T N I  
R L I M \* I L L F L K I I H H F L L I \*  
D \* \* C R Y C Y F \* K \* Y I T S Y \* Y S

19801 GCTGTTGAATTATTTACAAAACGTAGTATTCGCCATCACCTGAACCTAAGATTCTTAGA 19860  
A V E L F T K R S I R H H P E L K I L R  
L L N Y L Q N V V F A I T L N L R F L E  
C \* I I Y K T \* Y S P S P \* T \* D S \* K

19861 AATTGGAATATTGATATTTGTTGGAAGCATGTCCTTTGGGATTATGTTAAAGATAGTTTG 19920  
N L N I D I C W K H V L W D Y V K D S L  
I \* I L I F V G S M S F G I M L K I V C  
F E Y \* Y L L E A C P L G L C \* R \* F V

19921 TTTTGTAGTTCTACCTATGGTGTCTGCAAATACACAGATTTAAATTTTATTGAAAATTG 19980  
F C S S T Y G V C K Y T D L N F I E N L  
F V V L P M V S A N T Q I \* I L L K I \*  
L \* F Y L W C L Q I H R F K F Y \* K F E

FIG. 9 CONT.

19981 AATGTACTTTTTGATGGTCGTGACAATGGTGCTTTAGAAGCTTTTAGAAAAGCAAGAAAT 20040  
N V L F D G R D N G A L E A F R K A R N  
M Y F L M V V T M V L \* K L L E K Q E M  
C T F \* W S \* Q W C F R S F \* K S K K W

20041 GGTGTTTTTATTAGTACTGGAAAATTAAGTAGTTTGTCTATGATTAAGGTCCGCAACGA 20100  
G V F I S T G K L S S L S M I K G P Q R  
V F L L V L E N \* V V C L \* L K V R N E  
C F Y \* Y W K I K \* F V Y D \* R S A T S

20101 GCTGATTTAAATGGCGTAATTGTGGATAAAGTTGGAGAACTCAATGTTGAGTTTTGGTTTT 20160  
A D L N G V I V D K V G E L N V E F W F  
L I \* M A \* L W I K L E N S M L S F G L  
\* F K W R N C G \* S W R T Q C \* V L V C

20161 GCTATGAGAAAAGATGGTGACGATGTTATCTTCAGCCGTGCAGACAGCCTAAGCCCAAGC 20220  
A M R K D G D D V I F S R A D S L S P S  
L \* E K M V T M L S S A V Q T A \* A Q A  
Y E K R W \* R C Y L Q P C R Q P K P K P

20221 CATTACTGGAGCCACAAAGGTAATCTAGGTGGTAATTGTGCAGGTAATGCCAGCGGTAAT 20280  
H Y W S P Q G N L G G N C A G N A S G N  
I T G A H K V I \* V V I V Q V M P A V M  
L L E P T R \* S R W \* L C R \* C Q R \* \*

20281 GATGCTCTAGCGGTTTTACTATCTTTACTCAGAGTCGTGTATTGTCAACCTTTGAACCT 20340  
D A L A R F T I F T Q S R V L S T F E P  
M L \* R V L L S L L R V V Y C Q P L N L  
C S S A F Y Y L Y S E S C I V N L \* T S

20341 CGCTCAGATTTAGAACGGGATTTTATTGATATGGAGGATAGTCTGTTTTATAGCCAAATAT 20400  
R S D L E R D F I D M E D S L F I A K Y  
A Q I \* N G I L L I W R I V C L \* P N M  
L R F R T G F Y \* Y G G \* S V Y S Q I W

20401 GGTTTAGAAGATTATGCATTTGATCATATAGTTTATGGTAGTTTAAATTATAAAGTTATA 20460  
G L E D Y A F D H I V Y G S F N Y K V I  
V \* K I M H L I I \* F M V V L I I K L \*  
F R R L C I \* S Y S L W \* F \* L \* S Y R

20461 GGAGGTTTGCACCTTGCTTATAGGTTTATTTTCGTAGACTAAAAAATCTAATTTGGTAATT 20520  
G G L H L L I G L F R R L K K S N L V I  
E V C T C L \* V Y F V D \* K N L I W \* F  
R F A L A Y R F I S \* T K K I \* F G N S

FIG. 9 CONT.

20521 CAAGAGTTTTGTCAGTATGATTCTAGTATTTCATTCATATTTTCATTACTGATCAAGAGTGT 20580  
Q E F L Q Y D S S I H S Y F I T D Q E C  
K S F C S M I L V F I H I S L L I K S V  
R V F A V \* F \* Y S F I F H Y \* S R V W

20581 GGTAGTAGTAAGAGTGTGGTACAGTTATTGATTATTATTAGATGACTTTGTTGTTATT 20640  
G S S K S V C T V I D L L L D D F V V I  
V V V R V F V Q L L I Y Y \* M T L L L L  
\* \* \* E C L Y S Y \* F I I R \* L C C Y C

20641 GTTAAGTCATTAATAATTTGAATTGTGTAGTAAAGTTGTTAATATTAATGTTGACTTTAAG 20700  
V K S L N L N C V S K V V N I N V D F K  
L S H \* I \* I V L V K L L I L M L T L R  
\* V I K F E L C \* \* S C \* Y \* C \* L \* G

20701 GACTTTCATTTATGTTGTGGTGTAAATGATAATAAAATTATGACTTTTTATCCTAAAATG 20760  
D F Q F M L W C N D N K I M T F Y P K M  
T F N L C C G V M I I K L \* L F I L K C  
L S I Y V V V \* \* \* \* N Y D F L S \* N A

20761 CAAGCTACTAGTACTGGAAACCTGGTTATTCTATGCCTGTTTTATATAAGTATTTGAAT 20820  
Q A T S D W K P G Y S M P V L Y K Y L N  
K L L V T G N L V I L C L F Y I S I \* M  
S Y \* \* L E T W L F Y A C F I \* V F E C

20821 GTTCCATTAGAGAGAGTTTTCTTTATGGAATTATGGTAAAGCTATTAATTTACCAACAGGT 20880  
V P L E R V S L W N Y G K A I N L P T G  
F H \* R E F L Y G I M V K L L I Y Q Q V  
S I R E S F F M E L W \* S Y \* F T N R L

20881 TGTATGATGAATGTTGCTAAGTATACTCAATTATGTCAGTATTTAAATACTACAACATTA 20940  
C M M N V A K Y T Q L C Q Y L N T T T L  
V \* \* M L L S I L N Y V S I \* I L Q H \*  
Y D E C C \* V Y S I M S V F K Y Y N I S

20941 GCTGTTCTGTTAATATGCGTGTCTTACACTTAGGTGCAGGATCTGATAAAGAAGTAGCC 21000  
A V P V N M R V L H L G A G S D K E V A  
L F L L I C V S Y T \* V Q D L I K K \* P  
C S C \* Y A C L T L R C R I \* \* R S S P

21001 CCTGGTCTGCTGTTTTAAGACAGTGGTTACCATCTGGTAGTATTCTTGTAGATAATGAT 21060  
P G S A V L R Q W L P S G S I L V D N D  
L V L L F \* D S G Y H L V V F L \* I M I  
W F C C F K T V V T I W \* Y S C R \* \* F

FIG. 9 CONT.

21061 TTAAATCCTTTTGTAGTGATAGTTTAGTCACTTATTTTGGAGATTGTATGACTTTACCA 21120  
L N P F V S D S L V T Y F G D C M T L P  
\* I L L L V I V \* S L I L E I V \* L Y H  
K S F C \* \* \* F S H L F W R L Y D F T I

21121 TTTGATTGTCATTGGGATCTGATAATATCTGATATGTATGATCCTCTTACTAAGAATATT 21180  
F D C H W D L I I S D M Y D P L T K N I  
L I V I G I \* \* Y L I C M I L L L R I L  
\* L S L G S D N I \* Y V \* S S Y \* E Y W

21181 GGTGATTATAATGTGAGTAAGGATGGTTTCTTTACTTATATTGTTATTTAATTCGTGAT 21240  
G D Y N V S K D G F F T Y I C Y L I R D  
V I I M \* V R M V S L L I F V I \* F V I  
\* L \* C E \* G W F L Y L Y L L F N S \* \*

21241 AAATTATCTTTGGGTGGTAGTGTGCTATAAAAATTACAGAATTTTCTTGAATGCTGAC 21300  
K L S L G G S V A I K I T E F S W N A D  
N Y L W V V V L L \* K L Q N F L G M L T  
I I F G W \* C C Y K N Y R I F L E C \* L

21301 TTATATAAATTAATGAGTTATTTTGCATTCTGGACAGTTTTTTGTTACTAATGTAAATGCT 21360  
L Y K L M S Y F A F W T V F C T N V N A  
Y I N \* \* V I L H S G Q F F V L M \* M L  
I \* I N E L F C I L D S F L Y \* C K C F

21361 TCTTCTAGTGAAGGGTTTTTAATAGGTATAAATTTTGGGTAAGTCCTGCTTTGAAATA 21420  
S S S E G F L I G I N Y L G K S C F E I  
L L V K G F \* \* V \* I I W V S P A L K \*  
F \* \* R V F N R Y K L F G \* V L L \* N R

21421 GATGGCAATGTTATGCATGCCAACTATTTGTTTTGGAGAAATAGTACAACATGGAATGGT 21480  
D G N V M H A N Y L F W R N S T T W N G  
M A M L C M P T I C F G E I V Q H G M V  
W Q C Y A C Q L F V L E K \* Y N M E W W

21481 GGTGCTTATAGTTTATTTGATATGTCTAAATTTTCTTTGAAATTGGCTGGCACTGCTGTA 21540  
G A Y S L F D M S K F S L K L A G T A V  
V L I V Y L I C L N F L \* N W L A L L \*  
C L \* F I \* Y V \* I F F E I G W H C C S

21541 GTAAATTTAAGACCAGATCAATTAATGATTTAGTTTATTCTTATTGAAAGAGGTAAG 21600  
V N L R P D Q L N D L V Y S L I E R G K  
\* I \* D Q I N \* M I \* F I L L L K E V S  
K F K T R S I K \* F S L F S Y \* K R \* V

FIG. 9 CONT.



21601 TTATTAGTGC GTGATACGCGTAAAGAAATTTTGTGGTGATAGTCTTGTAACACTTGT 21660  
L L V R D T R K E I F V G D S L V N T C  
Y \* C V I R V K K F L L V I V L \* T L V  
I S A \* Y A \* R N F C W \* \* S C K H L L

21661 TAGATCTTTCAGTTTGTAAATATTAATACTAAACTATGTTAATTATATTTTATTTTATA 21720  
\* I F Q F V N I K S K L C \* L Y F Y F L  
R S F S L L I L N L N Y V N Y I F I F \*  
D L S V C \* Y \* I \* T M L I I F L F F N

21721 ATTTTGTATTGGTTTAAATGAACCTTTGAATGTTGTGTCTCATTAAACCATGACTGGT 21780  
I F V M V L M N L \* M L C L I \* T M T G  
F L L W F \* \* T F E C C V S F K P \* L V  
F C Y G F N E P L N V V S H L N H D W F

21781 TTTTATTTGGTGATAGTCGTTCTGATTGTAACCATATTAATAATTTAAAAATTAATAAATT 21840  
F Y L V I V V L I V T I L I I \* K L K I  
F I W \* \* S F \* L \* P Y \* \* F K N \* K L  
L F G D S R S D C N H I N N L K I K N Y

21841 ATGGTTATTTGGATATTCACCCTAGTTTGTGTAATAATGGTAAAATTTTCATCTAGTGCTG 21900  
M V I W I F T L V C V I M V K F H L V L  
W L F G Y S P \* F V \* \* W \* N F I \* C W  
G Y L D I H P S L C N N G K I S S S A G

21901 GTGATTCTATTTTAAAGAGTTATCATTTTACCCGGTTTATAATTACACTGGCGAGGGTG 21960  
V I L F L R V I I L P G F I I T L A R V  
\* F Y F \* E L S F Y P V L \* L H W R G \*  
D S I F K S Y H F T R F Y N Y T G E G D

21961 ATCAAATTATTTTATGAGGGTGTAAATTTCAATCCTCATCATAGGTTAAGTGCTTCT 22020  
I K L F F M R V L I S I L I I G L S A S  
S N Y F L \* G C \* F Q S S S \* V \* V L L  
Q I I F Y E G V N F N P H H R F K C F F

22021 TTAATGGTAGTAATGATGTATGGATTTTAAACAAGGTGAGGTTTATCGTGCTTTATATT 22080  
L M V V M M Y G F L T R \* G F I V L Y I  
\* W \* \* \* C M D F \* Q G E V L S C F I F  
N G S N D V W I F N K V R F Y R A L Y S

22081 CTAATATGGCTCTTTTTCGCTATCTTACCTTTGTTGATATTCTTTACAATTTTCTTTTT 22140  
L I W L F F A I L P L L I F F T I F L F  
\* Y G S F S L S Y L C \* Y S L Q F F F F  
N M A L F R Y L T F V D I L Y N F S F S

FIG. 9 CONT.

22141 CTATTAAGGCTAATATTTGTAATAGTAATATTTTATCACTTAATAATCCTATTTTTATTA 22200  
L L R L I F V I V I F Y H L I I L F L L  
Y \* G \* Y L \* \* \* Y F I T \* \* S Y F Y \*  
I K A N I C N S N I L S L N N P I F I S

22201 GTAATAATTATTCTAAGGACGTTTATTTCACTTTATCAGGGTGTCTTTGTATTAGTAC 22260  
V L I I L R T F I S L Y Q G V L C I \* Y  
Y \* L F \* G R L F H F I R V F F V F S T  
T N Y S K D V Y F T L S G C S L Y L V P

22261 CTCTTTGTCTTTTTAAATCTAATTTTAGTCAGTACTATTATAATATGGATACTGGCTTTG 22320  
L F V F L N L I L V S T I I I W I L A L  
S L S F \* I \* F \* S V L L \* Y G Y W L C  
L C L F K S N F S Q Y Y Y N M D T G F A

22321 CTTATGGTTATTCTAATTTTGTCTTCTGATTTAGATTGTACATATATTTCTCTTAAAC 22380  
L M V I L I L F L L I \* I V H I F L L N  
L W L F \* F C F F \* F R L Y I Y F S \* T  
Y G Y S N F V S S D L D C T Y I S L K P

22381 CTGGTTCTATAAAATTTTTCTACTGGTTTTGTTTTATCCATACCTACTAAAGCTCTTT 22440  
L V L I K F F L L V L F Y P Y L L K L F  
W F L \* N F F Y W F C F I H T Y \* S S L  
G S Y K I F S T G F V L S I P T K A L C

22441 GCTTTAATAAATCTAAACAATTTGTACCCGTCAGGTTGTGATTCTAGGTGAACAATC 22500  
A L I N L N N L Y P C R L L I L G G T I  
L \* \* I \* T I C T R A G C \* F \* V E Q S  
F N K S K Q F V P V Q V V D S R W N N L

22501 TTCGTGCATCGGATACTTCATTATCCGATGCATGTCAGTTGCCTTATTGTTATTTTCGCA 22560  
F V H R I L H Y P M H V S C L I V I F A  
S C I G Y F I I R C M S V A L L L F S Q  
R A S D T S L S D A C Q L P Y C Y F R N

22561 ATTCTTCTGGTAATTATGTTGGCAAATATGATATTAATCATGGTGATAATGGTTTTACTT 22620  
I L L V I M L A N M I L I M V I M V L L  
F F W \* L C W Q I \* Y \* S W \* \* W F Y F  
S S G N Y V G K Y D I N H G D N G F T S

22621 CTATTCTATCTGGTCTTTTATATAATGTCTCTTGTATTCTTATTATGGCTCCTTTTTGT 22680  
L F Y L V F Y I M S L V F L I M A P F C  
Y S I W S F I \* C L L Y F L L W L L F V  
I L S G L L Y N V S C I S Y Y G S F L Y

FIG. 9 CONT.

22681 ATGACAATTTTACATCAATTTGGCCTCGTTTTTCTTTTGGTAATTGCCTACATCTGCTT 22740  
M T I L H Q F G L V F L L V I V L H L L  
\* Q F Y I N L A S F F F W \* L S Y I C L  
D N F T S I W P R F S F G N C P T S A Y

22741 ATATTAATAATTAATTGTTTCTATGATCCTTTGCCTATTATTTTACAAGGTATTTATTAT 22800  
I L N \* I V S M I L C L L F Y K V F Y Y  
Y \* I K L F L \* S F A Y Y F T R Y F I I  
I K L N C F Y D P L P I I L Q G I L L F

22801 TTTTAGCTTTATTGTTTATTGTGTTTTACTTTTTCTAGTTTACCATGGCTAATATTAAA 22860  
F \* L Y C L L C F Y F F \* F T M A N I K  
F S F I V Y C V F T F S S L P W L I L N  
L A L L F I V F L L F L V Y H G \* Y \* I

22861 TCTAACATGTTTTTAATTATTTTTATTTTGCCTACAACACTAGCTGTTATAGGTGATTT 22920  
S K H V F N Y F Y F A Y N T S C Y R \* F  
L N M F L I I F I L P T T L A V I G D F  
\* T C F \* L F L F C L Q H \* L L \* V I L

22921 TAATTGTAATACTCTTTTATTAATGATTATAATAAAAACCATTCCGCGTATAAGCGAGGA 22980  
\* L Y \* L F Y \* \* L \* \* N H S A Y K R G  
N C T N S F I N D Y N K T I P R I S E D  
I V L T L L L M I I I K P F R V \* A R M

22981 TGTTGTTGATGTATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTTTATTAAAA 23040  
C C \* C I S W F G H I L C S \* P C L F K  
V V D V S L G L G T Y Y V L N R V Y L N  
L L M Y L L V W A H I M F L T V F I \* I

23041 TACTACCTGTTATTTACAGGTTATTTTCTAAATCTGGTGCTAATTTTAGAGACTTGGC 23100  
Y Y L V I Y R L F S \* I W C \* F \* R L G  
T T L L F T G Y F P K S G A N F R D L A  
L P C Y L Q V I F L N L V L I L E T W L

23101 TTTAAAGGGTTCTAAATATTTGAGTACTCTCTGGTATAAACACCTTTTCTGTCAGATTT 23160  
F K G F \* I F E Y S L V \* T T F S V R F  
L K G S K Y L S T L W Y K P P F L S D F  
\* R V L N I \* V L S G I N H L F C Q I L

23161 TAATAATGGTATTTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAATACTTTGTA 23220  
\* \* W Y F F \* G \* E Y \* V I C \* \* Y F V  
N N G I F S K V K N T K L Y V N N T L Y  
I M V F F L R L R I L S Y M L I I L C I

FIG. 9 CONT.

23221 TAGTGAATTTAGTACTATAGTTATAGGTAGTGTFTTTTGTTAATACTTCTTATACTATTGT 23280  
\* \* I \* Y Y S Y R \* C F C \* Y F L Y Y C  
S E F S T I V I G S V F V N T S Y T I V  
V N L V L \* L \* V V F L L I L L I L L L

23281 TGTTC AACCTCACAATGGTATTTTGGAGATTACAGCTTGT CAGTATACTATGTGTGAATA 23340  
C S T S Q W Y F G D Y S L S V Y Y V \* I  
V Q P H N G I L E I T A C Q Y T M C E Y  
F N L T M V F W R L Q L V S I L C V N I

23341 TCCTCACACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCACATTGATT C 23400  
S S H C L \* V \* G \* Y S \* \* I L A H \* F  
P H T V C K S K G S I R N E S W H I D S  
L T L F V S L R V V F V M N L G T L I L

23401 TTCGGAACCTTTATGCTTGTTTAAGAAAATTTTACTTATAATGTTTCTGCAGATTGGCT 23460  
F G T F M L V \* E K F Y L \* C F C R L A  
S E P L C L F K K N F T Y N V S A D W L  
R N L Y A C L R K I L L I M F L Q I G C

23461 GTATTTTCATTTTTATCAAGAACGTGGTGTFTTTTATGCATATTATGCAGATGTAGGTAT 23520  
V F S F L S R T W C F L C I L C R C R Y  
Y F H F Y Q E R G V F Y A Y Y A D V G M  
I F I F I K N V V F F M H I M Q M \* V C

23521 GCCTACCACTTTCTTATTTAGTTTATATTTAGGTACTATTTTATCTCATTATTATGTTAT 23580  
A Y H F L I \* F I F R Y Y F I S L L C Y  
P T T F L F S L Y L G T I L S H Y Y V M  
L P L S Y L V Y I \* V L F Y L I I M L C

23581 GCCTTTGACTTGTAAAGGCTATATCTTCAAATACTGACAATGAAACTTTAGAATATTGGGT 23640  
A F D L \* G Y I F K Y \* Q \* N F R I L G  
P L T C K A I S S N T D N E T L E Y W V  
L \* L V R L Y L Q I L T M K L \* N I G L

23641 TACACCGCTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTATTACTAA 23700  
Y T A I \* T S V S S \* F \* \* A R C Y Y \*  
T P L S R R Q Y L L N F D E H G V I T N  
H R Y L D V S I F L I L M S T V L L L M

23701 TGCCGTTGATTGTTCAAGTAGTTTCTTAGTGAGATTCAATGTAAAACCTCAATCTTTTGC 23760  
C R \* L F K \* F S \* \* D S M \* N S I F C  
A V D C S S S F L S E I Q C K T Q S F A  
P L I V Q V V F L V R F N V K L N L L H

FIG. 9 CONT.

23761 ACCTAATACTGGTGTATTATGATTGTCTGGTTTTACTGTAAAGCCTGTTGCAACTGTTA 23820  
T \* Y W C L \* F V W F Y C K A C C N C L  
P N T G V Y D L S G F T V K P V A T V Y  
L I L V F M I C L V L L \* S L L Q L F I

23821 TCGTCGGATTCCCTAATTTACCTGATTGTGACATTGACAACCTGGCTTAATAATGTTAGTGT 23880  
S S D S \* F T \* L \* H \* Q L A \* \* C \* C  
R R I P N L P D C D I D N W L N N V S V  
V G F L I Y L I V T L T T G L I M L V Y

23881 ACCTTCACCTCTTAATTGGGAACGTAGAAATTTTTCTAATTGTAACCTCAATTTAAGCAC 23940  
T F T S \* L G T \* N F F \* L \* L Q F K H  
P S P L N W E R R I F S N C N F N L S T  
L H L L I G N V E F F L I V T S I \* A L

23941 TTTACTCGTCTAGTTCATGTTGATTCTTTTTCTTGTAAATAATCTTGATAAATCTAAAAT 24000  
F T S S S S C \* F F F L \* \* S \* \* I \* N  
L L R L V H V D S F S C N N L D K S K I  
Y F V \* F M L I L F L V I I L I N L K F

24001 TTTTGGTAGTTGCTTTAATAGTATTACTGTTGACAAGTTTGCTATACCTAATCGCAGACG 24060  
F W \* L L \* \* Y Y C \* Q V C Y T \* S Q T  
F G S C F N S I T V D K F A I P N R R R  
L V V A L I V L L L T S L L Y L I A D E

24061 AGATGATTGCAATTGGGCAGTTCTGGCTTTTTGCAATCATCTAATTACAAAATAGATAT 24120  
R \* F A I G Q F W L F A I I \* L Q N R Y  
D D L Q L G S S G F L Q S S N Y K I D I  
M I C N W A V L A F C N H L I T K \* I F

24121 TTCTTCTAGTTCTGTCAATTGTATTATAGTTTACCTTTAGTTAATGTTACTATTAATAA 24180  
F F \* F L S I V L \* F T F S \* C Y Y \* \*  
S S S S C Q L Y Y S L P L V N V T I N N  
L L V L V N C I I V Y L \* L M L L L I T

24181 CTTAATCCATCTTCTTGAATAGGAGGTATGGTTTTGGTAGTTTTAATGTGTCTTCTTA 24240  
L \* S I F L E \* E V W F W \* F \* C V F L  
F N P S S W N R R Y G F G S F N V S S Y  
L I H L L G I G G M V L V V L M C L L M

24241 TGACGTTGTTTATTCTGATCATTGTTTTCTGTAAACAGCGACTTTTGCCCTTGTGCAGA 24300  
\* R C L F \* S L F F C \* Q R L L P L C R  
D V V Y S D H C F S V N S D F C P C A D  
T L F I L I I V F L L T A T F A L V Q I

FIG. 9 CONT.

24301 TCCGTCTGTTGTTAATTCTTGTGTTAAATCTAAGCCTCTTTCTGCCATTGTCCTGCTGG 24360  
S V C C \* F L C \* I \* A S F C H L S C W  
P S V V N S C V K S K P L S A I C P A G  
R L L L I L V L N L S L F L P F V L L V

24361 TACTAAATATCGTCATTGCGACTTGGATACTACTCTTTATGTTAATAACTGGTGAGATG 24420  
Y \* I S S L R L G Y Y S L C \* \* L V \* M  
T K Y R H C D L D T T L Y V N N W C R C  
L N I V I A T W I L L F M L I T G V D V

24421 TTCTTGCTACCTGACCCCATTTCTACTTATTCTCCTAACACATGTCCTCAAAGAAGGT 24480  
F L S T \* P H F Y L F S \* H M S S K E G  
S C L P D P I S T Y S P N T C P Q K K V  
L V Y L T P F L L I L L T H V L K R R S

24481 CGTTGTTGGTATAGGTGAACATTGTCCAGGTCTTGGTATTAATGAGGAAAAATGTGGTAC 24540  
R C W Y R \* T L S R S W Y \* \* G K M W Y  
V V G I G E H C P G L G I N E E K C G T  
L L V \* V N I V Q V L V L M R K N V V H

24541 ACAATTAATCATAGTTCCTGTTCTTGTAGTCCTGATGCCTTTTTGGGTTGGTCTTTTGA 24600  
T I K S \* F L F L \* S \* C L F G L V F \*  
Q L N H S S C S C S P D A F L G W S F D  
N \* I I V P V L V V L M P F W V G L L I

24601 TAGTTGTATTAGTAATAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGAATTAA 24660  
\* L Y \* \* \* S L Q Y F F \* F Y F \* W N \*  
S C I S N N R C N I F S N F I F N G I N  
V V L V I I V A I F F L I L F L M E L I

24661 TAGTGGCACCCTTGTCTAATGATTTGTTATATTCTAACACTGAAGTTTCTACTGGTGT 24720  
\* W H H L F \* \* F V I F \* H \* S F Y W C  
S G T T C S N D L L Y S N T E V S T G V  
V A P L V L M I C Y I L T L K F L L V F

24721 TTGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTTAAAGAAGTTTCTGC 24780  
L C \* L \* S L W H H R P R Y F \* R S F C  
C V N Y D L Y G I T G Q G I F K E V S A  
V L I M I F M A S Q A K V F L K K F L R

24781 GGCTTATTATAATAATTGGCAGAATCTTTTGTATGATTCTAATGGTAATATTATTGGTTT 24840  
G L L \* \* L A E S F V \* F \* W \* Y Y W F  
A Y Y N N W Q N L L Y D S N G N I I G F  
L I I I I G R I F C M I L M V I L L V L

FIG. 9 CONT.

24841 TAAAGATTTTTGACTAATAAACTTACACTATACTTCCTTGTTATTCTGGTAGAGTGTC 24900  
\* R F F D \* \* N L H Y T S L L F W \* S V  
K D F L T N K T Y T I L P C Y S G R V S  
K I F \* L I K L T L Y F L V I L V E C L

24901 TGCTGCATTTTATCAAATCTTCTTACCAGCTTTGCTTTATCGTAATTTAAAGTGTAG 24960  
C C I L S K F F F T S F A L S \* F K V \*  
A A F Y Q N S S S P A L L Y R N L K C S  
L H F I K I L L H Q L C F I V I \* S V V

24961 TTATGTTTTGAATAATATTTCTTTTATCTCACAACCATTTTATTTTGATAGTTATCTTGG 25020  
L C F E \* Y F F Y L T T I L F \* \* L S W  
Y V L N N I S F I S Q P F Y F D S Y L G  
M F \* I I F L L S H N H F I L I V I L V

25021 TTGTGTTTTGAATGCTGTTAATTTAACTAGCTATTCTGTATCCTCTTGTGATTTGCGTAT 25080  
L C F E C C \* F N \* L F C I L L \* F A Y  
C V L N A V N L T S Y S V S S C D L R M  
V F \* M L L I \* L A I L Y P L V I C V W

25081 GGGTAGTGGGTTTTGTATTGATTATGCTTTACCCTCTTCTCGGCGTAAGCGTAGAGGTAT 25140  
G \* W V L Y \* L C F T L F S A \* A \* R Y  
G S G F C I D Y A L P S S R R K R R G I  
V V G F V L I M L Y P L L G V S V E V F

25141 TTCTTCTCCTTATCGCTTTGTAACCTTTGAACCCTTTAATGTTAGTTTTGTTAACGATAG 25200  
F F S L S L C N F \* T L \* C \* F C \* R \*  
S S P Y R F V T F E P F N V S F V N D S  
L L L I A L \* L L N P L M L V L L T I V

25201 TGTGAAACTGTTGGTGGTTTTATTTGAGATTCAGATTCCTACTAACTTTACCATAGCTGG 25260  
C \* N C W W F I \* D S D S Y \* L Y H S W  
V E T V G G L F E I Q I P T N F T I A G  
L K L L V V Y L R F R F L L T L P \* L V

25261 TCATGAAGAATTTATTCAGACTAGTCTCCTAAAGTTACTATTGATTGTTTCAGCTTTTGT 25320  
S \* R I Y S D \* F S \* S Y Y \* L F S F C  
H E E F I Q T S S P K V T I D C S A F V  
M K N L F R L V L L K L L L I V Q L L F

25321 TTGCTCTAATTATGCTGCTTGTATGATTATTGTCGGAATATGGCACTTTTTGCGATAA 25380  
L L \* L C C L S \* F I V G I W H F L R \*  
C S N Y A A C H D L L S E Y G T F C D N  
A L I M L L V M I Y C R N M A L F A I I

FIG. 9 CONT.

25381 TATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTGCAGGTTGC 25440  
Y \* \* Y F K \* S Q \* F T \* Y Y S V A G C  
I N S I L N E V N D L L D I T Q L Q V A  
L I V F \* M K S M I Y L I L L S C R L L

25441 TAATGCTTTAATGCAAGGTGTTACACTTAGTTCTAATCTTAATACTAATCTACACTCTGA 25500  
\* C F N A R C Y T \* F \* S \* Y \* S T L \*  
N A L M Q G V T L S S N L N T N L H S D  
M L \* C K V L H L V L I L I L I Y T L M

25501 TGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTTACAATGTGGTTCTTC 25560  
C \* \* Y R F \* I S S R L F R F T M W F F  
V D N I D F K S L L G C L G S Q C G S S  
L I I \* I L N L F \* V V \* V H N V V L R

25561 GTCTAGATCTTTGTTAGAGGATTTATTATCAACAAGGTCAAACCTTCAGATGTAGGTTT 25620  
V \* I F V R G F I I Q Q G Q T F R C R F  
S R S L L E D L L F N K V K L S D V G F  
L D L C \* R I Y Y S T R S N F Q M \* V L

25621 TGTTGAAGCTTATAATAATTGCACTGGTGGTAGTGAAATTAGAGATCTTCTCTGTGTGCA 25680  
C \* S L \* \* L H W W \* \* N \* R S S L C A  
V E A Y N N C T G G S E I R D L L C V Q  
L K L I I I A L V V V K L E I F S V C N

25681 ATCTTTAATGGTATTAAGTATTACCTCCCATTTTATCTGAGACTCAAATTTCTGGCTA 25740  
I F \* W Y \* S I T S H F I \* D S N F W L  
S F N G I K V L P P I L S E T Q I S G Y  
L L M V L K Y Y L P F Y L R L K F L A I

25741 TACTACAGCTGCTACTGTGGCGGCTATGTTCCGCCATGGTCTGCTGCTGCTGGTGTACC 25800  
Y Y S C Y C G G Y V S A M V C C C W C T  
T T A A T V A A M F P P W S A A A G V P  
L Q L L L W R L C F R H G L L L L V Y H

25801 ATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGATGTTCTTAA 25860  
I F S \* C T I \* N \* W F G C Y Y G C S \*  
F S L N V Q Y R I N G L G V T M D V L N  
F L L M Y N I E L M V W V L L W M F L I

25861 TAAGAATCAAAGTTAATAGCTAATGCTTTTAAATAAGCTCTTCTTCTATCCAGAATGG 25920  
\* E S K V N S \* C F \* \* S S S F Y P E W  
K N Q K L I A N A F N K A L L S I Q N G  
R I K S \* \* L M L L I K L F F L S R M V

FIG. 9 CONT.



25921 TTTTACTGCTACTAACTCTGCTCTTGCTAAAATTCAAAGTGTGTTAATGCTAATGCTCA 25980  
F Y C Y \* L C S C \* N S K C R \* C \* C S  
F T A T N S A L A K I Q S V V N A N A Q  
L L L L T L L L L K F K V S L M L M L K

25981 AGCACTTAATAGTTTGTACAACAATTATTTAATAAATTTGGTGCTATTAGTTCTTCTTT 26040  
S T \* \* F V T T I I \* \* I W C Y \* F F F  
A L N S L L Q Q L F N K F G A I S S S L  
H L I V C Y N N Y L I N L V L L V L L Y

26041 ACAAGAAATTTGTCTCGCCTTGATAATTTAGAAGCTCAGGTTTCAGATTGATAGGCTCAT 26100  
T R N F V S P \* \* F R S S G S D \* \* A H  
Q E I L S R L D N L E A Q V Q I D R L I  
K K F C L A L I I \* K L R F R L I G S L

26101 TAATGGTCGTTTACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGATATTACACT 26160  
\* W S F D C F K C L C F S T A \* \* Y Y T  
N G R L T A L N A Y V S Q Q L S D I T L  
M V V \* L L \* M L M F L N S L V I L H L

26161 TATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAAAGTCAATC 26220  
Y \* G W S F S C Y \* E G \* \* V C \* K S I  
I K A G A S R A I E K V N E C V K S Q S  
L R L E L L V L L R R L M S V L K V N P

26221 CCCTCGTATAAATTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAAATGCTCC 26280  
P S Y K F L W Q W \* P H F I I G S K C S  
P R I N F C G N G N H I L S L V Q N A P  
L V \* I F V A M V T T F Y H W F K M L L

26281 TTATGGTTTGCTTTTCATTCAATTTAGTTATAAACCTACTTCTTTTAAAAGTGTCTTAGT 26340  
L W F A F H S F \* L \* T Y F F \* N C L S  
Y G L L F I H F S Y K P T S F K T V L V  
M V C F S F I L V I N L L L L K L S \* \*

26341 AAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGTTATTTTAT 26400  
K S R F M F I R \* \* R Y C T \* A R L F Y  
S P G L C L S G D R G I A P K Q G Y F I  
V Q V Y V Y P V I E V L H L S K V I L L

26401 TAAACAAAATGATTCCCTGGATGTTTACTGGTAGTTTCTTATTATTACCCAGAACCAATTTTC 26460  
\* T K \* F L D V Y W \* F L L L P R T N F  
K Q N D S W M F T G S S Y Y Y P E P I S  
N K M I P G C L L V V P I I T Q N Q F Q

FIG. 9 CONT.

26461 AGATAAAAATGTTGTTTTTCATGAATAGTTGCTCTGTTAATTTTACTAAAGCTCCATTTAT 26520  
R \* K C C F H E \* L L C \* F Y \* S S I Y  
D K N V V F M N S C S V N F T K A P F I  
I K M L F S \* I V A L L I L L K L H L F

26521 TTATCTTAATAATTCTATACCAAATTTGTCTGATTTTGAAGCCGAGTTTTCTCTTTGGTT 26580  
L S \* \* F Y T K F V \* F \* S R V F S L V  
Y L N N S I P N L S D F E A E F S L W F  
I L I I L Y Q I C L I L K P S F L F G L

26581 TAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTTCTCATATTAATGCTACTTT 26640  
\* K S Y F Y S T \* F N L \* F S Y \* C Y F  
K N H T S I A P N L T F N S H I N A T F  
K I I L L \* H L I \* P L I L I L M L L F

26641 TTTAGACTGTATTATGAAATGAATGTTATTTCAGGAATCTATTAAATCTTTGAACAGTAG 26700  
F R S V L \* N E C Y S G I Y \* I F E Q \*  
L D L Y Y E M N V I Q E S I K S L N S S  
\* I C I M K \* M L F R N L L N L \* T V V

26701 TTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGGCCTGGTACAT 26760  
F Y \* S \* R N R Y L \* N V C \* M A L V H  
F I N L K E I G T Y E M Y V K W P W Y I  
L L I L K K \* V L M K C M L N G L G T F

26761 TTGGTTGTTAATGTTCATTTTATTTATAATTTTTCTTATGATACTTTTCTTTATATGCTG 26820  
L V V N C H F I Y N F S Y D T F L Y M L  
W L L I V I L F I I F L M I L F F I C C  
G C \* L S F Y L \* F F L \* Y F S L Y A A

26821 CTGTA CTGGTTGGTTCAGCATGTTTTAGTAAATGTCATAATTGTTGTGATGAGTATGG 26880  
L Y W L W F S M F \* \* M S \* L L \* \* V W  
C T G C G S A C F S K C H N C C D E Y G  
V L V V V Q H V L V N V I I V V M S M G

26881 GGGTCACAATGATTTTGTATTAAAGCATCTCATGATGATTAGATTTTAAATCTAAACTT 26940  
G S Q \* F C Y \* S I S \* \* L D F K S K L  
G H N D F V I K A S H D D \* I L N L N F  
V T M I L L L K H L M M I R F \* I \* T L

26941 TATATATGGAAGTTTGGAGGCCTAGCTATAAATATTTCTTATTACTAGAGAATTTGGTG 27000  
Y I W K F G G L A I N I L L L L E N L V  
I Y G S L E A \* L \* I F S Y Y \* R I W C  
Y M E V W R P S Y K Y S L I T R E F G V

FIG. 9 CONT.

27001 TCACAGATCTTGAGGATTTGTGTTTTAAATATAATTATTGCCAACCTTGTGTTGGTTATT 27060  
S Q I L R I C V L N I I I A N L V L V I  
H R S \* G F V F \* I \* L L P T L C W L L  
T D L E D L C F K Y N Y C Q P C V G Y C

27061 GTATTGTACCTTTAAACGTTTGGTGTCTGTAAGTTTGGTAAATTTGCTTCTTATTTTGTTT 27120  
V L Y L \* T F G V V S L V N L L L I L F  
Y C T F K R L V S \* V W \* I C F L F C F  
I V P L N V W C R K F G K F A S Y F V L

27121 TACGTAGTCATGACACCTCTCATAAGAATAATTTTGGTGTATAACTAGTTTACTAGTT 27180  
Y V V M T P L I R I I L V L \* L V L L V  
T \* S \* H L S \* E \* F W C Y N \* F Y \* L  
R S H D T S H K N N F G V I T S F T S Y

27181 ATGGTAACACTGTTTCTGAGGCTGTTTCTAAATTAGTTGAATCAGCATCTGATTTTATCG 27240  
M V T L F L R L F L N \* L N Q H L I L S  
W \* H C F \* G C F \* I S \* I S I \* F Y R  
G N T V S E A V S K L V E S A S D F I A

27241 CTTGGCGAGCTGAAGCACTTAATAAGTATGGTTGATGATTTTTCTACTGATACTGCTTGG 27300  
L G E L K H L I S M V D V F F T D T A W  
L A S \* S T \* \* V W L M Y F S L I L L G  
W R A E A L N K Y G \* C I F H \* Y C L V

27301 TATGTAGGTCAGATTTTCTTTTTAGTTTTATCTTGTGTCATTTTCTTAATTTTTGTGTT 27360  
Y V G Q I F F L V L S C V I F L I F V V  
M \* V R F S F \* F Y L V S F S \* F L L L  
C R S D F L F S F I L C H F L N F C C C

27361 GCACTTTTAGCAACTATTAACTTTGTATTCAAATTTGIGGTTTTTGTAATATTTTTATT 27420  
A L L A T I K L C I Q I C G F C N I F I  
H F \* Q L L N F V F K F V V F V I F L L  
T F S N Y \* T L Y S N L W F L \* Y F Y Y

27421 ATTTACCTTCTGCCTATGTTTATAATAGAGGTAGACAGTTGTATAAGTCTTATAGTGAA 27480  
I S P S A Y V Y N R G R Q L Y K S Y S E  
F H L L P M F I I E V D S C I S L I V N  
F T F C L C L \* \* R \* T V V \* V L \* \* T

27481 CATGTCATACCTTCTACTTTAGATGATTTAATTTAAATCTAAACATCATGAATGAATCAA 27540  
H V I P S T L D D L I \* I \* T S \* M N Q  
M S Y L L L \* M I \* F K S K H H E \* I N  
C H T F Y F R \* F N L N L N I M N E S I

FIG. 9 CONT.

27541 TTTTCCTCATTGGAATTCTGATCAAGCTATTACATTCTTAAAAGAATGGAATTTCTCTT 27600  
F F L I G I L I K L L H S \* K N G I S L  
F S S L E F \* S S Y Y I L K R M E F L F  
F P H W N S D Q A I T F L K E W N F S L

27601 TGGGTGTAATATTACTTCTCATTACTATCATACTGCAGTTTGGTTATACGAGTCGTAGTA 27660  
W V \* Y Y F S L L S Y C S L V I R V V V  
G C N I T S H Y Y H T A V W L Y E S \* Y  
G V I L L L I T I I L Q F G Y T S R S M

27661 TGTTTGTATTATCTTATTAAGATGATTATTCTTTGGCTTATGTGGCCATTGACCATTATCT 27720  
C L F I L L R \* L F F G L C G H \* P L S  
V C L S Y \* D D Y S L A Y V A I D H Y L  
F V Y L I K M I I L W L M W P L T I I L

27721 TGA CTATATTTAATGCTTTTATGCTTTGAATAATATCTTTCTTGGGCTTTCTATACTGT 27780  
\* L Y L I A F M L \* I I S F L G F L Y C  
D Y I \* L L L C F E \* Y L S W A F Y T V  
T I F N C F Y A L N N I F L G L S I L F

27781 TTACTATTATTTCTATTGTTATATGGATTTTATATTTTGTCAACAGTATTCGGCTTTTTTA 27840  
L L L F L L L Y G F Y I L S T V F G F L  
Y Y Y F Y C Y M D F I F C Q Q Y S A F Y  
T I I S I V I W I L Y F V N S I R L F I

27841 TCAGAACTGGCAGTTGGTGGAGTTTAAACCCAGAGACTAATAATCTTATGTGTATTGATA 27900  
S E L A V G G V L T Q R L I I L C V L I  
Q N W Q L V E F \* P R D \* \* S Y V Y \* Y  
R T G S W W S F N P E T N N L M C I D M

27901 TGAAAGTAAGATGTATGTTAGGCCAGTTATTGAGGACTATCATACTAATACGGCTACTG 27960  
\* K V R C M L G Q L L R T I I H \* R L L  
E R \* D V C \* A S Y \* G L S Y I N G Y C  
K G K M Y V R P V I E D Y H T L T A T V

27961 TTATCCGTGGTCATCTTTATATACAGGGTGTAAACTTGGCACTGGTTACACGCTTGCCG 28020  
L S V V I F I Y R V L N L A L V T R L P  
Y P W S S L Y T G C \* T W H W L H A C R  
I R G H L Y I Q G V K L G T G Y T L A D

28021 ATTTGCCTGTTTATGTTACTGTAGCTAAGGTGCAAGTCTCTGTACTTATAAACGTGCCT 28080  
I C L F M L L \* L R C K S S V L I N V P  
F A C L C Y C S \* G A S P L Y L \* T C L  
L P V Y V T V A K V Q V L C T Y K R A F

FIG. 9 CONT.

28081 TTTTAGATAAGTTAGATGTTAATAGTGGTTTTGCTGTTTTGTTAAGTCTAAAGTTGGTA 28140  
F \* I S \* M L I V V L L F L L S L K L V  
F R \* V R C \* \* W F C C F C \* V \* S W \*  
L D K L D V N S G F A V F V K S K V G N

28141 ACTATCGTTTACCTTCTAGTAAATCTAGTGGTATGGATACTGCCTTGTTGAGAGCTTAAA 28200  
T I V Y L L V N L V V W I L P C \* E L K  
L S F T F \* \* I \* W Y G Y C L V E S L N  
Y R L P S S K S S G M D T A L L R A \* I

28201 TCTAAACTATTAGGATGTCTTATACTCCCGGTCATCATGCTGGAAGTAGAAGCTCCTCTG 28260  
S K L L G C L I L P V I M L E V E A P L  
L N Y \* D V L Y S R S S C W K \* K L L W  
\* T I R M S Y T P G H H A G S R S S S G

28261 GAAATCGTTCAGGAATCCTCAAGAAACTTCTGGGTTGACCAATCTGAGCGAAGCCATC 28320  
E I V Q E S S R K L L G L T N L S E A I  
K S F R N P Q E N F L G \* P I \* A K P S  
N R S G I L K K T S W V D Q S E R S H Q

28321 AAACCTATAATAGAGGCAGAAAACCCCAACCCAAATTCACTGTGTCTACTCAACCACAAG 28380  
K P I I E A E N P N P N S L C L L N H K  
N L \* \* R Q K T P T Q I H C V Y S T T R  
T Y N R G R K P Q P K F T V S T Q P Q G

28381 GAAACCCATCCACATTATTCCTGGTCTCTGGGATTACCCAATTTCAAAAAGGTAGAG 28440  
E T L S H I I P G S L G L P N F K K V E  
K P Y P T L F L V L W D Y P I S K R \* R  
N P I P H Y S W F S G I T Q F Q K G R D

28441 ACTTTAAATTTCCAGATGGTCAAGGAGTACCCATTGCTTACGGGATACCCCTTCTGAAG 28500  
T L N F Q M V K E Y P L L T G Y P L L K  
L \* I S R W S R S T H C L R D T P F \* S  
F K F P D G Q G V P I A Y G I P P S E A

28501 CAAAAGGATATTGGTATAAACACAACCGCGTCTTTTAAACAGCTGATGGTCAACAAA 28560  
Q K D I G I N T T G V L L K Q L M V N K  
K R I L V \* T Q P A F F \* N S \* W S T K  
K G Y W Y K H N R R S F K T A D G Q Q K

28561 AGCAGTTGTTACCAAGATGGTATTTCTACTATCTCGGTACCGGTCCATATGCCAGTTCAT 28620  
S S C Y Q D G I S T I S V P V H M P V H  
A V V T K M V F L L S R Y R S I C Q F I  
Q L L P R W Y F Y Y L G T G P Y A S S S

FIG. 9 CONT.

28621 CCTATGGTGATGCCACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGACACTTCTA 28680  
P M V M P T K V S S G S L V T K L T L L  
L W \* C P R R Y L L G R \* S P S \* H F Y  
Y G D A H E G I F W V A S H Q A D T S I

28681 TTCCCTCCGATGTTTCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTT 28740  
F P P M F R Q G I L L F K K L S L L G F  
S L R C F G K G S Y Y S R S Y P Y \* V F  
P S D V S A R D P T I Q E A I P T R F S

28741 CGCCTGGTACGATTTTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGTCTGCTTCTA 28800  
R L V R F C L K A I M L K A Q E G L L L  
A W Y D F A S R L L C \* R L R K V C F \*  
P G T I L P Q G Y Y V E G S G R S A S N

28801 ATAGCCGGCCAGGTTACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAA 28860  
I A G Q V H V L N H V D P I I V H \* V E  
\* P A R F T F S I T W T Q \* S F I K \* K  
S R P G S R S Q S R G P N N R S L S R S

28861 GTAATTCTAATTTTAGACATTCTGATTCTATAGTGAACCTGATATGGCTGATGAGATTG 28920  
V I L I L D I L I L \* \* N L I W L M R L  
\* F \* F \* T F \* F Y S E T \* Y G \* \* D C  
N S N F R H S D S I V K P D M A D E I A

28921 CTAGTCTGTCTTGGCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTTACCAAGCAAA 28980  
L V L S W P S L V K I L N L S K L P S K  
\* S C L G Q A W \* R F \* T S A S Y Q A K  
S L V L A K L G K D S K P Q Q V T K Q N

28981 ATGCTAAGGAAATTAGGCATAAAATTTTAATGAAACCTCGCCAAAAGCGAACTCCTAATA 29040  
M L R K L G I K F \* . \* N L A K S E L L I  
C \* G N \* A \* N F N E T S P K A N S \* \*  
A K E I R H K I L M K P R Q K R T P N K

29041 AATTTTGAATGTTCAACAGTGTGTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATT 29100  
N F V M F N S V L V K E D R S K T L V I  
I L \* C S T V F W \* K R T A P K L W \* F  
F C N V Q Q C F G K R G P L Q N F G N S

29101 CTGAAATGTTAAAGCTTGGTACTAATGATCCTCAATTCCTATTCTTGCTGAATTAGCCC 29160  
L K C \* S L V L M I L N F L F L L N \* P  
\* N V K A W Y \* \* S S I S Y S C \* I S P  
E M L K L G T N D P Q F P I L A E L A P

FIG. 9 CONT.

29161 CTACACCAGGTGCTTTTTCTTTGGCTCTAAATTAGAGTTGTTTAAAAGAGACTCTGATG 29220  
 L H Q V L F S L A L N \* S C L K E T L M  
 Y T R C F F L W L \* I R V V \* K R L \* C  
 T P G A F F F G S K L E L F K R D S D A

29221 CTGATTCACCTTCTAAAGACACTTTTGAACCTTCGTTATTCTGGTTCTATTAGGTTTGATa 29280  
 L I H L L K T L L N F V I L V L L G L I  
 \* F T F \* R H F \* T S L F W F Y \* V \* \*  
 D S P S K D T F E L R Y S G S I R F D S

29281 GTACTTTACCTGGTTTTGAGACAATTATGAAAGTTCTTAAAGAGAATTTAGATGCTTATG 29340  
 V L Y L V L R Q L \* K F L K R I \* M L M  
 Y F T W F \* D N Y E S S \* R E F R C L C  
 T L P G F E T I M K V L K E N L D A Y V

29341 TTAATTCCTAATCAGAACACTGTTTCTGGTTCGCTGAGTCCTAAACCTCAGCGTAAAAGAG 29400  
 L I L I R T L F L V R \* V L N L S V K E  
 \* F \* S E H C F W F A E S \* T S A \* K R  
 N S N Q N T V S G S L S P K P Q R K R G

29401 GTGTTAAACAATCACCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACA 29460  
 V L N N H L N R L T L L I \* V L I L S T  
 C \* T I T \* I V \* L S \* F K C \* Y S A H  
 V K Q S P E S F D S L N L S A D T Q H I

29461 TTTCAAATGATTTTACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATG 29520  
 F Q M I L L L R I I V Y L L L L M I L M  
 F K \* F Y S \* G S \* F T C Y S \* \* S L C  
 S N D F T P E D H S L L A T L D D P Y V

29521 TAGAAGACTCTGTGCTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTC 29580  
 \* K T L L L N E N E S \* F D T R W \* P L  
 R R L C C L M R M N P N S T L G G N P S  
 E D S V A \* \* E \* I L I R H \* V V T P R

29581 GCTATTAGTCGGAATAGGACACTCTCTATCAGAATGAATTCCTGCTGTACACAGATAG 29640  
 A I S R N R T L S I R M N S C C Y N R \*  
 L L V G I G H S L S E \* I L A V T T D R  
 Y \* S E \* D T L Y Q N E F L L L Q Q I E

29641 AGTAGGTTGTTGCAGACTATATATTAATTAGTAGAACTTTATATTTAAATATTTGATTG 29700  
 S R L L Q T I Y \* L V E T L Y L N I \* L  
 V G C C R L Y I N \* \* K L Y I \* I F D C  
 \* V V A D Y I L I S R N F I F K Y L I V

FIG. 9 CONT.

29701 TTAGAGTAGTTATAAGGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTAGCAATTAT 29760  
L E \* L \* G L A V V \* T P P G R A S N Y  
\* S S Y K V \* L \* Y K R L R E E L A I I  
R V V I R F S C S I N A S G K S \* Q L \*

29761 AGTATTTAATATATATATATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTA 29820  
S I \* Y I Y \* Y M I E I N Y S L L E E L  
V F N I Y I S I \* L K L I I A F W R N Y  
Y L I Y I L V Y D \* N \* L \* P F G G I T

29821 CAAAAAAAAAAAAAAAAA 29836  
Q K K K K X  
K K K K K  
K K K K

FIG. 9 CONT.





Fig. 11. Multiple alignment of the replicase genes of CoV-HKUI from patients 1, 2, 4, 5, 6, 7, 8, 9 and 10.

```

Patient 7      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 9      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 10     TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 6      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 4      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 8      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 2      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 5      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 1      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
*****

Patient 7      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 9      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 10     CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 6      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 4      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 8      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 2      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 5      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 1      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACC 120
*****

Patient 7      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 9      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 10     AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 6      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 4      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 8      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 2      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 5      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 1      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
*****

Patient 7      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 9      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 10     GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 6      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 4      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 8      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 2      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 5      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
Patient 1      GACGACGGTAATAAATTGGATAAGTTCCTTTGTTGTCAAAGAAGTAAATTTAGAAGTTTAT 240
*****

Patient 7      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 9      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 10     AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 6      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 4      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 8      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 2      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 5      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
Patient 1      AATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGTTGGTGTGTTGGCTGAACATGAT 300
*****

Patient 7      TTCTTTATATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 9      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 10     TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 6      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 4      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 8      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 2      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 5      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
Patient 1      TTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCTTTCA 360
*****

Patient 7      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 9      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 10     AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 6      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 4      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 8      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 2      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420
Patient 5      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGATCGTAATGATTGTTCA 420

```

FIG. 11

Patient 1 AAGTATACTATGTTAGATCTTTGCTATGCATTGCGCCATTTGATTGTAATGATTGTTCA 420  
 \*\*\*\*\*

Patient 7 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 9 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 10 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 6 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 4 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 8 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 2 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 5 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 Patient 1 GTATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAGAATCCTACTTTTCTAAGAAA 480  
 \*\*\*\*\*

Patient 7 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 9 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 10 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 6 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 4 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 8 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 2 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 5 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 Patient 1 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540  
 \*\*\*\*\*

Patient 7 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 9 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 10 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 6 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 4 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 8 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 2 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 5 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 Patient 1 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACCTTAGTTGAAGTAGGT 600  
 \*\*\*\*\*

Patient 7 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 9 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 10 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 6 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 4 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 8 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 2 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 5 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 Patient 1 TTAGTTGGTGTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660  
 \*\*\*\*\*

Patient 7 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 9 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 10 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 6 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 4 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 8 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 2 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 5 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 Patient 1 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720  
 \*\*\*\*\*

Patient 7 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 9 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 10 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 6 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 4 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 8 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 2 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 5 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 Patient 1 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTAATTTGTTAATGATAGT 780  
 \*\*\*\*\*

Patient 7 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840  
 Patient 9 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840  
 Patient 10 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840  
 Patient 6 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840  
 Patient 4 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840  
 Patient 8 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840  
 Patient 2 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTAAT 840

FIG. 11 CONT.

Patient 5 TATAGACAAATTCGATCTTGTACAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840  
Patient 1 TATAGACAAATTCGATCTTGTACAGTATGATTTTACTGATTATAAGTTAGAATTTGTTTAAAT 840  
\*\*\*\*\*

Patient 7 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 9 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 10 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 6 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 4 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 8 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 2 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 5 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
Patient 1 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900  
\*\*\*\*\*

Patient 7 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 9 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 10 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 6 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 4 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 8 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 2 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 5 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
Patient 1 AGGTGATTTATTCATTGTGCTAATTTTAAATATACTATTTAGTATGGTTTTACCTAATACT 960  
\*\*\*\*\*

Patient 7 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 9 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 10 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 6 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 4 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 8 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 2 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 5 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
Patient 1 TGTTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGTGTACCCTTTGTTGTTTCTATT 1020  
\*\*\*\*\*

Patient 7 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 9 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 10 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 6 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 4 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 8 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 2 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 5 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACACCGTTAT 1080  
Patient 1 GGTTACCATTATAAAGAGTTAGGTGTAGTTATGAACCTGGATGTTGATACACACCGCTAT 1080  
\*\*\*\*\*

Patient 7 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 9 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 10 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 6 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 4 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 8 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
Patient 2 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCACGTTGCATCT 1140  
Patient 5 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCACGTTGCATCT 1140  
Patient 1 CGTTTGTCTCTTAAAGACTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140  
\*\* \*\*\*\*\*

Patient 7 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 9 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 10 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 6 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 4 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 8 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 2 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 5 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
Patient 1 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200  
\*\*\*\*\*

Patient 7 ATAAAATTTCAAACGTAAAACCGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 9 ATAAAATTTCAAACGTAAAACCGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 10 ATAAAATTTCAAACGTAAAACCGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 6 ATAAAATTTCAAACGTAAAACCGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 4 ATAAAATTTCAAACGTAAAACCGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
Patient 8 ATAAAATTTCAAACGTAAAACCGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260

FIG. 11 CONT.

Patient 2 ATAAAATTTCAAACGTAAAACAGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
 Patient 5 ATAAAATTTCAAACGTAAAACAGGTAACCTTTAACCAAGACTTTTACGAGTTTGTAAA 1260  
 Patient 1 ATAAAGTTTCAAACGTAAAACAGGTAATTTAACCAAGACTTTTATGAGTTTGTCAA 1260  
 \*\*\*\*\*

Patient 7 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 9 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 10 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 6 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 4 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 8 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 2 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 5 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320  
 Patient 1 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACACTTTTTCTTTACTCAA 1320  
 \*\*\*\*\*

Patient 7 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 9 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 10 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 6 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 4 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 8 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 2 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 5 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 Patient 1 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380  
 \*\*\*\*\*

Patient 7 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 9 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 10 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 6 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 4 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 8 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 2 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 5 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTTGAAATTTATGAT 1440  
 Patient 1 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAGTATTTTGAAATTTATGAT 1440  
 \*\*\*\*\*

Patient 7 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 9 GGTGGTTGTATACCAGCATCACAAGTCATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 10 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 6 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 4 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 8 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 2 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 5 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 Patient 1 GGTGGTTGTATACCAGCATCACAAGTTATTGTTAATAAATTATGATAAAAGTGCTGGTTAT 1500  
 \*\*\*\*\*

Patient 7 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 9 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 10 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 6 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 4 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 8 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 2 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 5 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTGGAAGAACAG 1560  
 Patient 1 CCATTTAATAAAATTTGGTAAAGCTAGACTTTATTATGAGGCATTATCATTGAGGAGCAG 1560  
 \*\*\*\*\*

Patient 7 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 9 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 10 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 6 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 4 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 8 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 2 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 5 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 Patient 1 AATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTAACCAAATGAATTTA 1620  
 \*\*\*\*\*

Patient 7 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 9 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 10 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 6 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 4 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680

FIG. 11 CONT.

Patient 8 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 2 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 5 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680  
 Patient 1 AAATATGCTATTAGTGCTAAGAATAGAGCTCGTACTGTTCAGGTGTTCCATTCTTAGT 1680  
 \*\*\*\*\*

Patient 7 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 9 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 10 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 6 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 4 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 8 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 2 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 5 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740  
 Patient 1 ACTATGACAGGTCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACTCGTGT 1740  
 \*\*\*\*\*

Patient 7 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 9 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 10 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 6 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 4 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 8 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 2 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 5 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 Patient 1 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800  
 \*\*\*\*\*

Patient 7 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 9 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 10 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 6 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 4 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 8 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 2 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 5 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 Patient 1 CTTATAAAGGATGTTGACAACCCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860  
 \*\*\*\*\*

Patient 7 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 9 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 10 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 6 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 4 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 8 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 2 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 5 GCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACATGAATTT 1920  
 Patient 1 GCCATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCTCGTAAACATGAATTT 1920  
 \*\* \*\*\*\*\*

Patient 7 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 9 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 10 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 6 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 4 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 8 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 2 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 5 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 Patient 1 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGT 1980  
 \*\*\*\*\*

Patient 7 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 9 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 10 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 6 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 4 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 8 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 2 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 5 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 Patient 1 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040  
 \*\*\*\*\*

Patient 7 GCAACTACTGCTTTTGCTAATTCGTTTTTAATATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 9 GCAACTACTGCTTTTGCTAATTCGTTTTTAATATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 10 GCAACTACTGCTTTTGCTAATTCGTTTTTAATATATATGTCAGGCTGTTACTGCTAACGTT 2100  
 Patient 6 GCAACTACTGCTTTTGCTAATTCGTTTTTAATATATATGTCAGGCTGTTACTGCTAACGTT 2100

FIG. 11 CONT.

Patient 4 GCAACTACTGCTTTTGCTAATCTGTTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 8 GCAACTACTGCTTTTGCTAATCTGTTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 2 GCAACTACTGCTTTTGCTAATCTGTTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 5 GCAACTACTGCTTTTGCTAATCTGTTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
Patient 1 GCAACCCTGCTTTTGCTAATCTGTTTTTAATATATGTCAGGCTGTTACTGCTAACGTT 2100  
\*\*\*\*\*

Patient 7 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 9 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 10 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 6 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 4 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 8 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 2 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 5 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
Patient 1 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160  
\*\*\*\*\*

Patient 7 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 9 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 10 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 6 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 4 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 8 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 2 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 5 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
Patient 1 AAACGCTTACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220  
\*\*\*\*\*

Patient 7 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 9 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 10 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 6 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 4 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 8 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 2 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 5 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
Patient 1 TATTATGAATTTTATGTAAGCATTATAGTATGATGATTTGAGTGATGATGGTGTGTC 2280  
\*\*\*\*\*

Patient 7 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 9 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 10 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 6 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 4 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 8 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 2 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 5 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
Patient 1 TGTTATAACTCTGATTATGCTAGTAAGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340  
\*\*\*\*\*

Patient 7 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 9 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 10 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 6 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 4 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 8 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 2 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 5 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
Patient 1 GTTTTGTACTATCAGAATAAATGTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400  
\*\*\*\*\*

Patient 7 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 9 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 10 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 6 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 4 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 8 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 2 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 5 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
Patient 1 ATTAATAAGGTCCTCATGAATTTGTTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460  
\*\*\*\*\*

Patient 7 GATTATGTTTATTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTGTGTTTGT 2520  
Patient 9 GATTATGTTTATTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTGTGTTTGT 2520  
Patient 10 GATTATGTTTATTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTGTGTTTGT 2520

FIG. 11 CONT.

Patient 6 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTGT 2520  
 Patient 4 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTGT 2520  
 Patient 8 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTGT 2520  
 Patient 2 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTTAGGAGCTGGTTGTTTGT 2520  
 Patient 5 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTTAGGAGCTGGTTGTTTGT 2520  
 Patient 1 GACTATGTTTATCTACCTATCCAGACCTTCTAGAATTTTAGGAGCTGGTTGTTTGT 2520  
 \*\* \*\*\*\*\* \*\*

Patient 7 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 9 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 10 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 6 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 4 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 8 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 2 GATGATTTATTGAAGACTGCAGTATTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 5 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 Patient 1 GATGATTTATTGAAGACTGCAGTGTTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATA 2580  
 \*\*\*\*\* \*\*

Patient 7 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 9 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 10 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 6 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 4 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 8 GATGCTTACCCTTTAGTATATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 2 GATGCTTACCCTTTAGTACATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 5 GATGCTTACCCTTTAGTACATCATGAAAAATGAAGAATACCAAAAAGTCTTTCGTGTATAT 2640  
 Patient 1 GATGCTTACCCTTTAGTACACCATGAAAAATGAAGAATACCAAAAAGTTTTTCGTGTATAT 2640  
 \*\*\*\*\* \*

Patient 7 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 9 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 10 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 6 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 4 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 8 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 2 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 5 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTACTCAGATCTTAGATAGTTATAGT 2700  
 Patient 1 TTAGAATATATAAAAAAAGCTGATAATGATCTTGGTAAATCAGATCTTAGATAGTTATAGT 2700  
 \*\*\*\*\*

Patient 7 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 9 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 10 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 6 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 4 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 8 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 2 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 5 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760  
 Patient 1 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGATGAATCATTTTATAAGAATATG 2760  
 \*\*\*\*\*

Patient 7 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 9 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 10 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 6 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 4 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 8 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 2 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 5 TATTTAAAAAGTGCCGTGATGCAG 2784  
 Patient 1 TATTTAAAAAGTGCCGTGATGCAG 2784  
 \*\*\*\*\*

FIG. 11 CONT.






FIG. 12

Fig. 13. Multiple alignment of the spike genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```

Patient 6      ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 9      ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 10     ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 5      ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 4      ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 7      ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 2      ATGTTATTAATTATTTTATTTTGCCTACAACATTAGCTGTTATAGGTGATTTAATTGT 60
Patient 1      ATGTTTAAATTATTTTATTTTGCCTACAACACTAGCTGTTATAGGTGATTTAATTGT 60
Patient 8      ATGTTTAAATTATTTTATTTTGCCTACAACACTAGCTGTTATAGGTGATTTAATTGT 60
*****

Patient 6      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 9      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 10     ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 5      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 4      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 7      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 2      ACTAATTTTGCTATTAATGATTTAAACACCACAGTTCCTCGCATAAGTGAGTATGTTGTG 120
Patient 1      ACTAACTCTTTTATTAATGATTAATAAAACCATTCCGCGTATAAGCGAGGATGTTGTT 120
Patient 8      ACTAACTCTTTTATTAATGATTAATAAAACCATTCCGCGTATAAGCGAGGATGTTGTT 120
***** * * ***** ** * ** ***** ** ***** ** *****

Patient 6      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 9      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 10     GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 5      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 4      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 7      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 2      GATGTTTCTTATGGTTTGGGTACATATTATATACTTGATCGTGTTTATTTAAATACTACT 180
Patient 1      GATGTATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTTTATTTAAATACTACC 180
Patient 8      GATGTATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTTTATTTAAATACTACC 180
***** *** ***** * *** * *****

Patient 6      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 9      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 10     ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 5      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 4      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 7      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 2      ATATTATTTACTGGTTATTTCCCTAAATCTGGTGCCAATTTTAGGGATCTATCTTTAAAA 240
Patient 1      TTGTTATTTACAGGTTATTTCCCTAAATCTGGTGCTAATTTTAGAGACTTGGCTTTAAAG 240
Patient 8      TTGTTATTTACAGGTTATTTCCCTAAATCTGGTGCTAATTTTAGAGACTTGGCTTTAAAG 240
* ***** ***** ***** * *** * *****

Patient 6      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 9      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 10     GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 5      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 4      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 7      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 2      GGTACTACATATTTGAGTACTCTTTGGTATCAGAAAACCCTTTTATCTGATTTAATAAT 300
Patient 1      GGTCTAAATATTTGAGTACTCTCTGGTATAAACCCCTTTTCTGTCAGATTTAATAAT 300
Patient 8      GGTCTATATATTTGAGTACTCTCTGGTATAAACCCCTTTTCTGTCAGATTTAATAAT 300
*** ** ***** ***** * *** ** * *****

Patient 6      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 9      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 10     GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 5      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 4      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 7      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 2      GGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTTAATAAAAACCTTTGTATAGTGAG 360
Patient 1      GGTATTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAAATACTTTGTATAGTGAA 360
Patient 8      GGTATTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAAATACTTTGTATAGTGAA 360
*****

Patient 6      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 9      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 10     TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 5      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 4      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 7      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 2      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 1      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420
Patient 1      TTTAGTACTATAGTTATAGGTAGTGTTTTATTAACAACCTTATACTATTGTTGTTCAA 420

```

FIG. 13

Patient 8 TTTAGTACTATAGTTATAGGTAGTGTTTTTGTTAATACTTCTTATACTATTGTTGTTCAA 420  
\*\*\*\*\* \* \*\*\*\*\*

Patient 6 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 9 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 10 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 5 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 4 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 7 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 2 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 1 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
Patient 8 CCTCATAATGGTGTTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480  
\*\*\*\*\* \* \*\*\*\*\*

Patient 6 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 9 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 10 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 5 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 4 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 7 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 2 ACTATTTGTAATCTAAAGGTAGTTCTCGTAATGAATCTTGGCATTTTGATAAATCTGAA 540  
Patient 1 ACTGTTTGAAGTCTAAGGGTAGTATTCTCGTAATGAATCTTGGCATTGATTCTTCGGAA 540  
Patient 8 ACTGTTTGAAGTCTAAGGGTAGTATTCTCGTAATGAATCTTGGCATTGATTCTTCGGAA 540  
\*\*\* \* \*\*\*\*\* \* \*\*\*\*\*

Patient 6 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 9 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 10 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 5 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 4 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 7 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 2 CCTTTGTGCTGTTC AAGAAAAATTTACTTATAATGTTTCTACAGATTGGTTGTATTTT 600  
Patient 1 CCTTTATGCTGTTC AAGAAAAATTTACTTATAATGTTTCTGACAGATTGGCTGTATTTT 600  
Patient 8 CCTTTATGCTGTTC AAGAAAAATTTACTTATAATGTTTCTGACAGATTGGCTGTATTTT 600  
\*\*\*\*\* \* \*\*\*\*\*

Patient 6 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 9 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 10 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 5 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 4 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 7 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 2 CATTTTTATCAAGAACGTGGCACTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660  
Patient 1 CATTTTTATCAAGAACGTGGTGTTTTTATGCTATATTATGAGATGATAGGATGCCTACC 660  
Patient 8 CATTTTTATCAAGAACGTGGTGTTTTTATGCTATATTATGAGATGATAGGATGCCTACC 660  
\*\*\*\*\* \* \*\*\*\*\*

Patient 6 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 9 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 10 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 5 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 4 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 7 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 2 ACTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 1 ACTTTCTATTTAGTTTATATTAGGTAATTTTATCTCATTATTATGTTTGCCTTTG 720  
Patient 8 ACTTTCTATTTAGTTTATATTAGGTAATTTTATCTCATTATTATGTTTGCCTTTG 720  
\*\*\*\*\* \* \*\*\*\*\*

Patient 6 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 9 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 10 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 5 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 4 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 7 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 2 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780  
Patient 1 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCG 780  
Patient 8 ACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCG 780  
\*\*\*\*\* \* \*\*\*\*\*

Patient 6 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 9 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 10 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 5 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 4 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 7 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840  
Patient 2 TTGCTAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840

FIG. 13 CONT.

Patient 1 CTATCTAGACGTGATCTTCTTAATTTTGGATGAGCACGGTGTATTACTAATGCCGTT 840  
 Patient 8 CTATCTAGACGTGATCTTCTTAATTTTGGATGAGCACGGTGTATTACTAATGCCGTT 840  
 \* \*\*\*\* \*

Patient 6 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 9 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 10 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 5 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 4 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 7 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 2 GATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAAAACTAAATCTTTATTACCTAAT 900  
 Patient 1 GATTGTTCAAGTAGTTTCTTTAGTAGAGATTCAATGTAAAACTCAATCTTTTGCACCTAAT 900  
 Patient 8 GATTGTTCAAGTAGTTTCTTTAGTAGAGATTCAATGTAAAACTCAATCTTTTGCACCTAAT 900  
 \*

Patient 6 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 9 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 10 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 5 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 4 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 7 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 2 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 1 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 Patient 8 ACTGGTGGTTTATGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960  
 \*

Patient 6 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 9 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 10 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 5 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 4 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 7 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 2 ATTCTGATTTACCTGATTGTGACATTGATAAATGGCTTAACAATTTTAATGTACCCTCA 1020  
 Patient 1 ATTCTAATTTACCTGATTGTGACATTGACAACCTGGCTTAATAATGTTAGTGTACCCTCA 1020  
 Patient 8 ATTCTAATTTACCTGATTGTGACATTGACAACCTGGCTTAATAATGTTAGTGTACCCTCA 1020  
 \*

Patient 6 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 9 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 10 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 5 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 4 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 7 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 2 CCTCTAATTTGGGAACGTAAAATTTTTCTAATGCAACTTTAATTGAGTACTTTGCCT 1080  
 Patient 1 CCTCTAATTTGGGAACGTAGAATTTTTCTAATGTAACCTCAATTAAGCACTTTACTT 1080  
 Patient 8 CCTCTAATTTGGGAACGTAGAATTTTTCTAATGTAACCTCAATTAAGCACTTTACTT 1080  
 \*

Patient 6 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 9 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 10 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 5 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 4 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 7 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 2 CGTTTGTTCATACCTGATCTTTTTCTTGTAAATAATTTIGATGAATCTAAGATATATGGT 1140  
 Patient 1 CGTCTAGTTCATGTTGATCTTTTTCTTGTAAATAATCTGATAAATCTAAAATTTTGGT 1140  
 Patient 8 CGTCTAGTTCATGTTGATCTTTTTCTTGTAAATAATCTGATAAATCTAAAATTTTGGT 1140  
 \*

Patient 6 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 9 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 10 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 5 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 4 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 7 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCTATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 2 AGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATACCCAACCTCCAGACGATCTGAT 1200  
 Patient 1 AGTTGTTTTAATAGTATTACTGTGACAAGTTTGTACTTAACCTTAATGCAGACGAGATGAT 1200  
 Patient 8 AGTTGTTTTAATAGTATTACTGTGACAAGTTTGTACTTAACCTTAATGCAGACGAGATGAT 1200  
 \*

Patient 6 TTGCAGTTGGCAGTTCCTGTTTTCTGCAATCTTCTAATTATAAAATGACACTACTTCT 1260  
 Patient 9 TTGCAGTTGGCAGTTCCTGTTTTCTGCAATCTTCTAATTATAAAATGACACTACTTCT 1260  
 Patient 10 TTGCAGTTGGCAGTTCCTGTTTTCTGCAATCTTCTAATTATAAAATGACACTACTTCT 1260  
 Patient 5 TTGCAGTTGGCAGTTCCTGTTTTCTGCAATCTTCTAATTATAAAATGACACTACTTCT 1260  
 Patient 4 TTGCAGTTGGCAGTTCCTGTTTTCTGCAATCTTCTAATTATAAAATGACACTACTTCT 1260  
 Patient 7 TTGCAGTTGGCAGTTCCTGTTTTCTGCAATCTTCTAATTATAAAATGACACTACTTCT 1260

FIG. 13 CONT.

Patient 2 TTGCAGTTGGGCAGTTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260  
 Patient 1 TTGCAATTGGGCAGTTCTGGCTTTTTGCAATCATCTAATTACAAAATAGATATTTCTTCT 1260  
 Patient 8 TTGCAATTGGGCAGTTCTGGCTTTTTGCAATCATCTAATTACAAAATAGATATTTCTTCT 1260  
 \*\*\*\*\*

Patient 6 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 9 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 10 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 5 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 4 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 7 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 2 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 1 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 Patient 8 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320  
 \*\*\*\*\*

Patient 6 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 9 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 10 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 5 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 4 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 7 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 2 CCTTCTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380  
 Patient 1 CCATCTCTTGG AATAGAAGGTATGGTTTTGGTAGTTTTAATGTGCTCTTATGACGTT 1380  
 Patient 8 CCATCTCTTGG AATAGAAGGTATGGTTTTGGTAGTTTTAATGTGCTCTTATGACGTT 1380  
 \*\*\*\*\*

Patient 6 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 9 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 10 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 5 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 4 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 7 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 2 GTTTACTCACG TTATTGTTTTCTGTTAATAAATACTTTTTGTCCTTGTGCTAAACCTTCT 1440  
 Patient 1 GTTTATTCTGAT CATTGTTTTCTGTTAACAAGCGACTTTTTGCCCTTGTGCTAAACCTTCT 1440  
 Patient 8 GTTTATTCTGAT CATTGTTTTCTGTTAACAAGCGACTTTTTGCCCTTGTGCTAAACCTTCT 1440  
 \*\*\*\*\*

Patient 6 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 9 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 10 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 5 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 4 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 7 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 2 TTTGCTTCAAG TTGCAAGAGTCATAAACACCTTCTGCTTCTGCTCCTATTGGTACTAAT 1500  
 Patient 1 GTTGTAAATTC TTGTTAAATCTAAGCCTCTTCTGCCATTTGTCCTGCTGGTACTAAA 1500  
 Patient 8 GTTGTAAATTC TTGTTAAATCTAAGCCTCTTCTGCCATTTGTCCTGCTGGTACTAAA 1500  
 \*\*\*\*\*

Patient 6 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGATGGGTAGGTGTTCTTGT 1560  
 Patient 9 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGACTGGGTAGGTGTTCTTGT 1560  
 Patient 10 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGACTGGGTAGGTGTTCTTGT 1560  
 Patient 5 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGACTGGGTAGGTGTTCTTGT 1560  
 Patient 4 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGACTGGGTAGGTGTTCTTGT 1560  
 Patient 7 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGACTGGGTAGGTGTTCTTGT 1560  
 Patient 2 TATCGTCTTGT GAGAGTACTACTGTA CTGACCACACTGACTGGGTAGGTGTTCTTGT 1560  
 Patient 1 TATCGTCATGCG ACTTGGATACTACTCTTTATGTTAAATAACTGGGTAGATGTTCTTGT 1560  
 Patient 8 TATCGTCATGCG ACTTGGATACTACTCTTTATGTTAAATAACTGGGTAGATGTTCTTGT 1560  
 \*\*\*\*\*

Patient 6 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 9 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 10 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 5 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 4 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 7 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 2 TTACCTGATCCT ATA AACTGCTTATGACCC TAGGCTTGTCTCAAAAAAGTCTCTGGTT 1620  
 Patient 1 CTACCTGACCCCA TTTCTACTTATTCTCCTAACACATGTCCTCAAAAGAGGTCGTTGTT 1620  
 Patient 8 CTACCTGACCCCA TTTCTACTTATTCTCCTAACACATGTCCTCAAAAGAGGTCGTTGTT 1620  
 \*\*\*\*\*

Patient 6 GGTGTTGGTGA ACATTTGTCAGGGTTCCGGTGTGATGAAGAAAAGTGGGTGATTGGAT 1680  
 Patient 9 GGTGTTGGTGA ACATTTGTCAGGGTTCCGGTGTGATGAAGAAAAGTGGGTGATTGGAT 1680  
 Patient 10 GGTGTTGGTGA ACATTTGTCAGGGTTCCGGTGTGATGAAGAAAAGTGGGTGATTGGAT 1680  
 Patient 5 GGTGTTGGTGA ACATTTGTCAGGGTTCCGGTGTGATGAAGAAAAGTGGGTGATTGGAT 1680  
 Patient 4 GGTGTTGGTGA ACATTTGTCAGGGTTCCGGTGTGATGAAGAAAAGTGGGTGATTGGAT 1680

FIG. 13 CONT.

Patient 7 GGTGTTGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
 Patient 2 GGTGTTGGTGAACATTGTGCAGGGTTCGGTGTGATGAAGAAAAGTGTGGTGTATTGGAT 1680  
 Patient 1 GGTATAGGTGAACATTGTCCAGGTCTTGGTATTAAATGAGGAAAATGTGGTACAC----- 1675  
 Patient 8 GGTATAGGTGAACATTGTCCAGGTCTTGGTATTAAATGAGGAAAATGTGGTACAC----- 1675  
 \* \* \* \* \*

Patient 6 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 9 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 10 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 5 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 4 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 7 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 2 GGATCATATAATGTTTCTTGCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740  
 Patient 1 -AATTAATCATAGTTCCTGTTCTTGAGTCTGATGCCTTTTGGGTTGGTCTTTTGGAT 1734  
 Patient 8 -AATTAATCATAGTTCCTGTTCTTGAGTCTGATGCCTTTTGGGTTGGTCTTTTGGAT 1734  
 \* \* \* \* \*

Patient 6 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 9 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 10 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 5 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 4 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 7 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 2 ACTTGGTCAGTAACAACCGTTGTAATATTTTTCTAATTTTATTTTAAATGGTATCAAT 1800  
 Patient 1 AGTTGATTTAGTAATAAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGAAATTAAT 1794  
 Patient 8 AGTTGATTTAGTAATAAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGAAATTAAT 1794  
 \* \* \* \* \*

Patient 6 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 9 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 10 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 5 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 4 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 7 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 2 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTTACTGATGTT 1860  
 Patient 1 AGTGGCACCACCTGTTCTAATGATTTGTTATATTCTAACACTGAAGTTTTCTACTGGTGT 1854  
 Patient 8 AGTGGCACCACCTGTTCTAATGATTTGTTATATTCTAACACTGAAGTTTTCTACTGGTGT 1854  
 \* \* \* \* \*

Patient 6 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 9 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 10 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 5 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 4 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 7 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 2 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTTAAAGAAGTTTCTGCT 1920  
 Patient 1 TGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTTAAAGAAGTTTCTGCG 1914  
 Patient 8 TGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTTAAAGAAGTTTCTGCG 1914  
 \* \* \* \* \*

Patient 6 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 9 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 10 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 5 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 4 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 7 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 2 GTTTATTATAATAGTTGGCAAAATCTTTTGTATGATTCTAATGGCAACATTATTGGTTTT 1980  
 Patient 1 GCTTATTATAATAATTGGCAGAATCTTTTGTATGATTCTAATGGTAATATTATTGGTTTT 1974  
 Patient 8 GCTTATTATAATAATTGGCAGAATCTTTTGTATGATTCTAATGGTAATATTATTGGTTTT 1974  
 \* \* \* \* \*

Patient 6 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 9 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 10 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 5 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 4 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 7 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 2 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040  
 Patient 1 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034  
 Patient 8 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034  
 \* \* \* \* \*

Patient 6 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
 Patient 9 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
 Patient 10 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100  
 Patient 5 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100

FIG. 13 CONT.

Patient 4 GCTGCTTTTCATCAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAAAGTGTAGC 2100  
 Patient 7 GCTGCTTTTCATCAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAAAGTGTAGC 2100  
 Patient 2 GCTGCTTTTCATCAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAAAGTGTAGC 2100  
 Patient 1 GCTGCATTTTATCAAATTCCTTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094  
 Patient 8 GCTGCATTTTATCAAATTCCTTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094  
 \*\*\*\*\* \*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TATGTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 9 TATGTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 10 TATGTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 5 TATGTTTGAATAATATTTCTTTAACTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 4 TATGTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 7 TATGTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 2 TATGTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157  
 Patient 1 TATGTTTGAATAATATTTCTTTATCTCACAACCATTTTATTTTGATAGTTATCTTGGT 2154  
 Patient 8 TATGTTTGAATAATATTTCTTTATCTCACAACCATTTTATTTTGATAGTTATCTTGGT 2154  
 \*\*\*\*\* \*\*\*\*\* \* \* \* \* \* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 9 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 10 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 5 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 4 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 7 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 2 TGCGTTTTAATGCTGATAAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2217  
 Patient 1 TGTGTTTGAATGCTGTTAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2214  
 Patient 8 TGTGTTTGAATGCTGTTAATTAAGTATTCTGTTTCTTCTGTGCTCTTCGCGATG 2214  
 \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \* \* \* \* \* \*\*\*\*\* \* \* \* \* \*

Patient 6 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 9 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 10 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 5 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 4 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 7 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 2 GGTAGTGGTTTTGTGTTGATTATAACTCACCTTCTTCTTCTCTTCGCGTAAACGT 2277  
 Patient 1 GGTAGTGGTTTTGTGTTGATTATGCTTACCTCTTCT- - - - - CGGCGTAAGCGT 2265  
 Patient 8 GGTAGTGGTTTTGTGTTGATTATGCTTACCTCTTCT- - - - - CGGCGTAAGCGT 2265  
 \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \* \* \* \* \* \*\*\*\*\* \*\* \*\*\*\*\* \*\*

Patient 6 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 9 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 10 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 5 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 4 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 7 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 2 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAATGTCAGTTTGT 2337  
 Patient 1 AGAGGTATTTCTTCTCCTTATCGCTTTGTAACCTTTTGAACCCCTTAATGTTAGTTTGT 2325  
 Patient 8 AGAGGTATTTCTTCTCCTTATCGCTTTGTAACCTTTTGAACCCCTTAATGTTAGTTTGT 2325  
 \*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 9 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 10 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 5 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 4 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 7 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 2 AATGACAGTATTGAGTCTGTTGGTGGTCTTTATGAGATCAAATTCGCCACTAACTTTACT 2397  
 Patient 1 AACGATAGTGTGAAACTGTTGGTGGTCTTTATGAGATTCAGATTCCTACTAACTTTACC 2385  
 Patient 8 AACGATAGTGTGAAACTGTTGGTGGTCTTTATGAGATTCAGATTCCTACTAACTTTACC 2385  
 \*\* \* \* \* \* \* \*\*\*\*\* \* \* \* \* \* \*\*\*\*\* \* \* \* \* \*

Patient 6 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 9 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 10 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 5 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 4 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 7 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 2 ATAGTTGGTCAAGAGGAATTTATCAAACCTAATTCCTCAAAGTTACTATTGATTGTTCT 2457  
 Patient 1 ATAGCTGGTCAAGAGGAATTTATCAGACTAGTTCTCCTCAAAGTTACTATTGATTGTTCA 2445  
 Patient 8 ATAGCTGGTCAAGAGGAATTTATCAGACTAGTTCTCCTCAAAGTTACTATTGATTGTTCA 2445  
 \*\*\*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 TTATTTGTCTGTTCTAATATGACAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
 Patient 9 TTATTTGTCTGTTCTAATATGACAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
 Patient 10 TTATTTGTCTGTTCTAATATGACAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517

FIG. 13 CONT.

Patient 5 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
 Patient 4 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
 Patient 7 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
 Patient 2 TTATTTGCTGTTCTAATTATGCAGCTTGCCATGACTTATTGTCAGAGTATGGCACTTTT 2517  
 Patient 1 GCTTTTGTGCTCTAATTATGCTGCTTGTTCATGATTTATTGTCGGAATATGGCACTTTT 2505  
 Patient 8 GCTTTTGTGCTCTAATTATGCTGCTTGTTCATGATTTATTGTCGGAATATGGCACTTTT 2505  
 \*\*\*\*\*

Patient 6 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 9 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 10 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 5 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 4 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 7 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 2 TGTGATAATATTAATAGTATTTTAGATGAAGTTAATGGTTTACTTGATACTACTCAATTG 2577  
 Patient 1 TGCGATAATATTAATAGTATTTTAAATGAAGTCAATGATTACTTGATATTACTCAGTTG 2565  
 Patient 8 TGCGATAATATTAATAGTATTTTAAATGAAGTCAATGATTACTTGATATTACTCAGTTG 2565  
 \*\*

Patient 6 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 9 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 10 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 5 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 4 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 7 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 2 CATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCCAATCTTAATACTAATTTG 2637  
 Patient 1 CAGGTTGCTAATGCTTTAATGCAAGGTGTTACACTTAGTCTAATCTTAATACTAATCTA 2625  
 Patient 8 CAGGTTGCTAATGCTTTAATGCAAGGTGTTACACTTAGTCTAATCTTAATACTAATCTA 2625  
 \*\*

Patient 6 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 9 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 10 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 5 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 4 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 7 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 2 CATTTTGATGTTGATAATATTAATTTTAAATCCCTAGTTGGATGTTTAGTCCCACTGC 2697  
 Patient 1 CACTCTGATGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTTACAATGT 2685  
 Patient 8 CACTCTGATGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTTACAATGT 2685  
 \*\*

Patient 6 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 9 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 10 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 5 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 4 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 7 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 2 GGTCTCTCTCTCGTTCCTTTTGAAGATTTATTGTTTGACAAAGTTAAACTTTTCAGAT 2757  
 Patient 1 GGTCTCTCTCTAGATCTTTGTTAGAGGATTTATTATTCAACAAGGTCAAACTTTCAGAT 2745  
 Patient 8 GGTCTCTCTCTAGATCTTTGTTAGAGGATTTATTATTCAACAAGGTCAAACTTTCAGAT 2745  
 \*\*\*\*\*

Patient 6 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 9 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 10 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 5 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 4 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 7 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 2 GTTGGTTTTGTTGAAGCTTATAACAATTGTAAGTGGTGGTAGTAAATTAGAGATCTTCTT 2817  
 Patient 1 GTAGGTTTTGTTGAAGCTTATAAATATGCACTGGTGGTAGTAAATTAGAGATCTTCTC 2805  
 Patient 8 GTAGGTTTTGTTGAAGCTTATAAATATGCACTGGTGGTAGTAAATTAGAGATCTTCTC 2805  
 \*\*

Patient 6 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 9 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 10 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 5 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 4 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 7 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 2 TGTGTACAATCCTTTAATGGTATTAAGTTTTCCTCCTATTTTGTCTGAATCTCAAAT 2877  
 Patient 1 TGTGTGCAATCTTTAATGGTATTAAGTATTACCTCCCATTTTATCTGAGACTCAAAT 2865  
 Patient 8 TGTGTGCAATCTTTAATGGTATTAAGTATTACCTCCCATTTTATCTGAGACTCAAAT 2865  
 \*\*\*\*\*

Patient 6 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937  
 Patient 9 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCACCATGGTCAGCAGCAGCT 2937

FIG. 13 CONT.



Patient 10 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 5 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 4 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 7 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 2 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937  
Patient 1 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTCCGCCATGGTCGTGCTGCT 2925  
Patient 8 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTCCGCCATGGTCGTGCTGCT 2925  
\*\*\*\*\* \*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\*\*\*\* \*\*\*\*\* \*\* \*\* \*\*

Patient 6 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 9 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 10 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 5 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 4 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 7 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 2 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997  
Patient 1 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2985  
Patient 8 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2985  
\*\* \*\*\*\*\* \*\*\*\*\*

Patient 6 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 9 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 10 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 5 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 4 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 7 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 2 GTTCTTAATAAAAAATCAAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057  
Patient 1 GTTCTTAATAAAGATCAAAAAGTTAATAGCTAATGCTTTAATAAAGCTCTTCTTTCTATC 3045  
Patient 8 GTTCTTAATAAAGATCAAAAAGTTAATAGCTAATGCTTTAATAAAGCTCTTCTTTCTATC 3045  
\*\*\*\*\* \*\*\*\*\*

Patient 6 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 9 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 10 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 5 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 4 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 7 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 2 CAGAATGGTTTTAGTGCTACCAACTCTGCACCTTGCTAAAAATACAAAGTGTGTTAATTCT 3117  
Patient 1 CAGAATGGTTTTACTGCTACTAACTCTGCTCTTGCTAAAAATCAAAAGTGTGTTAATTCT 3105  
Patient 8 CAGAATGGTTTTACTGCTACTAACTCTGCTCTTGCTAAAAATCAAAAGTGTGTTAATTCT 3105  
\*\*\*\*\* \*\*\*\*\*

Patient 6 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 9 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 10 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 5 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 4 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 7 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 2 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3177  
Patient 1 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3165  
Patient 8 AATGCTCAAGCACCTTAATAGTTTGTACAGCAATTAATTAATAAATTTGGTGCAATTAGT 3165  
\*\*\*\*\* \*\*\*\*\*

Patient 6 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 9 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 10 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 5 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 4 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 7 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 2 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTCAGATTGAT 3237  
Patient 1 TCTTCTTTACAAGAAATTTTGTCTCGCCTTGATAAATTTAGAAGCTCAGGTTCAGATTGAT 3225  
Patient 8 TCTTCTTTACAAGAAATTTTGTCTCGCCTTGATAAATTTAGAAGCTCAGGTTCAGATTGAT 3225  
\*\*\*\*\* \*\*\*\*\*

Patient 6 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 9 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 10 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 5 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 4 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 7 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 2 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGCTCTCAACAGCTTAGTGAT 3297  
Patient 1 AGGCTCATTAAATGGTCGTTTGAATGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGAT 3285  
Patient 8 AGGCTCATTAAATGGTCGTTTGAATGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGAT 3285  
\*\*\*\*\* \*\*\*\*\*

Patient 6 ATTTCTCTTGTAATAAATTTGGTGCTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357

FIG. 13 CONT.

Patient 9 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357  
Patient 10 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357  
Patient 5 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357  
Patient 4 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357  
Patient 7 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357  
Patient 2 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357  
Patient 1 ATTACACTTATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAA 3345  
Patient 8 ATTACACTTATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAA 3345  
\*\*\*\*\*

Patient 6 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 9 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 10 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 5 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 4 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 7 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 2 AGTCAATCTCCTCGTATTAATTTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCFAA 3417  
Patient 1 AGTCAATCCCCTCGTATAAAATTTTTGTGGCAATGGTAACCACTTTTATCATTGGTTCFAA 3405  
Patient 8 AGTCAATCCCCTCGTATAAAATTTTTGTGGCAATGGTAACCACTTTTATCATTGGTTCFAA 3405  
\*\*\*\*\*

Patient 6 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 9 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 10 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 5 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 4 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 7 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 2 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTATTTCTTTTAAAACT 3477  
Patient 1 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTACTTCTTTTAAAACT 3465  
Patient 8 AATGCTCCTTATGGTTTGTGTTTATGCATTTTGTGTTATAAACTACTTCTTTTAAAACT 3465  
\*\*\*\*\*

Patient 6 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 9 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 10 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 5 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 4 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 7 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 2 GTTTTAGTAAGTCTGGTTTGTGTTATATCAGGTGATGTAGGTATTGCACCTAAACAAGGG 3537  
Patient 1 GTCTTAGTAAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGT 3525  
Patient 8 GTCTTAGTAAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGT 3525  
\*\* \*\*\*\*\*

Patient 6 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 9 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 10 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 5 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 4 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 7 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 2 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597  
Patient 1 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3585  
Patient 8 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3585  
\*\*\*\*\*

Patient 6 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 9 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 10 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 5 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 4 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 7 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 2 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657  
Patient 1 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCT 3645  
Patient 8 CCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCT 3645  
\*\*\*\*\*

Patient 6 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 9 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 10 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 5 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 4 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 7 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 2 CCTCTGTTTATTTGAATCATTCTGTACCAAAATTTGCTGATTTTGAATCTGAGTTATCT 3717  
Patient 1 CCATTTATTTATCTTAATAATTTCTATACCAAAATTTGCTGATTTTGAAGCCGAGTTTCT 3705  
Patient 8 CCATTTATTTATCTTAATAATTTCTATACCAAAATTTGCTGATTTTGAAGCCGAGTTATCT 3705  
\*\* \* \*\*\*\*\*

FIG. 13 CONT.

Patient 6 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 9 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 10 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 5 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 4 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 7 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 2 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACTTTAAATCTTCATACTATT 3777  
 Patient 1 CTTGGTTTAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTTCTCATA---TT 3762  
 Patient 8 CTTGGTTTAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTTCTCATA---TT 3762  
 \* \*\*\*\*\* \*\* \*\* \*\* \*\*

Patient 6 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 9 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 10 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 5 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 4 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 7 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 2 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837  
 Patient 1 AATGCTACTTTTTAGATTTGTATTATGAAATGAATGTTATTCAAGAGTCTATTAAGTCT 3822  
 Patient 8 AATGCTACTTTTTAGATTTGTATTATGAAATGAATGTTATTCAAGAGTCTATTAAGTCT 3822  
 \*\*\*\*\* \*\* \*\* \*\*

Patient 6 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 9 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 10 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 5 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 4 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 7 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 2 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATAATGG 3897  
 Patient 1 TTGAACAGTAGTTTATTAACTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGG 3882  
 Patient 8 TTGAACAGTAGTTTATTAACTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGG 3882  
 \*\*\*\*\* \*\* \*\* \*\*

Patient 6 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 9 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 10 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 5 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 4 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 7 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 2 CCTGGTATGTTGGCTACTAATTTCTTTTTTCATTTATAATATTCCTTGTATTGCTCTTT 3957  
 Patient 1 CCTGGTACATTTGGTTGTTAATTTGTCATTTTATTATAATTTTTCTTATGATACTTTTC 3942  
 Patient 8 CCTGGTACATTTGGTTGTTAATTTGTCATTTTATTATAATTTTTCTTATGATACTTTTC 3942  
 \*\*\*\*\* \*\* \*\* \*\*

Patient 6 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 9 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 10 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 5 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 4 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 7 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 2 TTTATATGTTGTTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4017  
 Patient 1 TTTATATGCTGCTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4002  
 Patient 8 TTTATATGCTGCTGACTGGTTGTTGTTCTGTCATGTTTATAGTAAATGTCATAATGTTGTT 4002  
 \*\*\*\*\* \*\* \*\* \*\*

Patient 6 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 9 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 10 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 5 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 4 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 7 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 2 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071  
 Patient 1 GATGAGTATGGGGTCAATGATTTTGTATTAAGCATCTCATGATGATTAG 4056  
 Patient 8 GATGAGTATGGGGTCAATGATTTTGTATTAAGCATCTCATGATGATTAG 4056  
 \*\*\*\*\* \*\* \*\* \*\*

FIG. 13 CONT.

Fig. 14. Multiple alignment of the nucleocapsid genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```

Patient 4      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 6      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 7      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 9      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 10     ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 2      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 5      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 1      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
Patient 8      ATGTCCTATACTCCCGGTCAATTATGCTGGAAGTAGAAGCTCCTCTGGAATCGTTCAGGA 60
*****

Patient 4      ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 6      ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 7      ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 9      ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 10     ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 2      ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGA 120
Patient 5      ATCCTCAAGAAAACCTTCTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGA 120
Patient 1      ATCCTCAAGAAAACCTTCTGGGTTGACCAATCTGAGCGAAGCCATCAAACCTATAATAGA 120
Patient 8      ATCCTCAAGAAAACCTTCTGGGTTGACCAATCTGAGCGAAGCCATCAAACCTATAATAGA 120
*****

Patient 4      GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 6      GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 7      GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 9      GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 10     GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 2      GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 5      GGCAGAAAACCCCAACCTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 1      GGCAGAAAACCCCAACCCAAATTCACCTGTGTCTACTCAACCACAAGGAAACCCCTATCCCA 180
Patient 8      GGCAGAAAACCCCAACCCAAATTCACCTGTGTCTACTCAACCACAAGGAAACCCCTATCCCA 180
*****

Patient 4      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 6      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 7      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 9      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 10     CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 2      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 5      CATTATTCCTGGTTCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 1      CATTATTCCTGGTTCTCCGGGATTACCCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 8      CATTATTCCTGGTTCTCCGGGATTACCCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
*****

Patient 4      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 6      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 7      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 9      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 10     GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 2      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 5      GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 1      GATGGTCAAGGAGTACCCATTTGCTTTCGGGATACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 8      GATGGTCAAGGAGTACCCATTTGCTTTCGGGATACCCCTTCTGAAGCAAAGGATATTGG 300
*****

Patient 4      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 6      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 7      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 9      TATAGACACACCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 10     TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 2      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 5      TATAGACACAGCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 1      TATAAACACACCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCA 360
Patient 8      TATAAACACACCCGGCGTCTTTTAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCA 360
*****

Patient 4      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 6      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 7      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 9      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 10     AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 2      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 5      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 1      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 1      AGATGGTATTTCTACTATCTCGGTACCGGCCCATATGCCAATGCATCCTATGGTGAATCC 420

```

FIG. 14

Patient 8 AGATGGTATTTCTACTACTCGGTACCGGTCCATATGCCAGTTCATCCTATGGTGATGCC 420  
 \*\*\*\*\* \* \*\*\*\*\* \*\*

Patient 4 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 6 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 7 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 9 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 10 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 2 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 5 CTCGAAGGGGCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 1 CACGAAGGTATCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 Patient 8 CACGAAGGTATCTTCTGGGTGCTAATCACCAGCTGACACTTCTACTCCCTCCGATGTT 480  
 \* \*\*\*\*\* \* \*\*\*\*\* \*\*

Patient 4 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 6 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 7 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 9 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 10 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 2 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 5 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 1 TCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 Patient 8 TCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540  
 \*\*\* \*\*\*\*\* \*\*

Patient 4 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 6 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 7 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 9 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 10 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 2 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 5 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 1 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 Patient 8 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGCTGCTTCTAATAGTCGACCAGGT 600  
 \*\*\*\*\* \*\*

Patient 4 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 6 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 7 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 9 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 10 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 2 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 5 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 1 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 Patient 8 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660  
 \*\*\*\*\* \*\*

Patient 4 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 6 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 7 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 9 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 10 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 5 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 1 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 Patient 8 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720  
 \*\*\*\*\* \*\*

Patient 4 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780  
 Patient 6 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780  
 Patient 7 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780  
 Patient 9 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780  
 Patient 10 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780  
 Patient 2 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATC 780  
 Patient 5 GCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATC 780  
 Patient 1 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780  
 Patient 8 GCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATC 780  
 \*\*\*\*\* \*\*

Patient 4 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 6 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 7 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 9 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 10 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 2 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840  
 Patient 5 AGGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840

FIG. 14 CONT.

Patient 1 AGGCATAAAATTTAATGAAACCTCGCCAAAAGCGAACTCCTAATAAATTTGTAATGTT 840  
 Patient 8 AGGCATAAAATTTAATGAAACCTCGCCAAAAGCGAACTCCTAATAAATTTGTAATGTT 840  
 \*\*\*\*\*

Patient 4 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 6 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 7 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 9 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 10 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 2 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 5 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900  
 Patient 1 CAACAGTGTTTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATTTCTGAAATGTTAAAG 900  
 Patient 8 CAACAGTGTTTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATTTCTGAAATGTTAAAG 900  
 \*\*\*\*\*

Patient 4 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 6 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 7 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 9 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 10 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 2 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 5 CTTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCT 960  
 Patient 1 CTTGGTACTAATGATCCTCAATTTCTATTCTTGTGAAATTAGCCCTACACCAGGTGCT 960  
 Patient 8 CTTGGTACTAATGATCCTCAATTTCTATTCTTGTGAAATTAGCTCCTACACCAGGTGCT 960  
 \*\*\*\*\*

Patient 4 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 6 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 7 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 9 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 10 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 2 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 5 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020  
 Patient 1 TTTTCTTTGGCTCTAAATTAGAGTTGTTAAAAGAGACTCTGATGCTGATTACCTTCT 1020  
 Patient 8 TTTTCTTTGGCTCTAAATTAGAGTTGTTAAAAGAGACTCTGATGCTGATTACCTTCT 1020  
 \*\*\*\*\*

Patient 4 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 6 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 7 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 9 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 10 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 2 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 5 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080  
 Patient 1 AAAGACACTTTTGAACCTCGTTATTCTGGTCTATTAGGTTTGATAGTACTTTACCCTGGT 1080  
 Patient 8 AAAGACACTTTTGAACCTCGTTATTCTGGTCTATTAGGTTTGATAGTACTTTACCCTGGT 1080  
 \*\*\*\*\*

Patient 4 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTTCTAATCAG 1140  
 Patient 6 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTTCTAATCAG 1140  
 Patient 7 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTTCTAATCAG 1140  
 Patient 9 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTTCTAATCAG 1140  
 Patient 10 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATTTCTAATCAG 1140  
 Patient 2 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATTTCTAATCAG 1140  
 Patient 5 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATTTCTAATCAG 1140  
 Patient 1 TTTGAGACAATTATGAAAGTTCTTAAAGAGAATTTAGATGCTTATGTTAATTTCTAATCAG 1140  
 Patient 8 TTTGAGACAATTATGAAAGTTCTTAAAGAGAATTTAGATGCTTATGTTAATTTCTAATCAG 1140  
 \*\*\*\*\*

Patient 4 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 6 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 7 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 9 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 10 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 2 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 5 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200  
 Patient 1 AACACTGTTTCGTTTCGCTGAGTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200  
 Patient 8 AACACTGTTTCGTTTCGCTGAGTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200  
 \*\*\*\*\*

Patient 4 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 6 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 7 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 9 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 10 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGGTACTCAGCACATTTCAAATGATTTT 1260  
 Patient 2 CCAGAACAGTTTGACTCTCTTAATTTAAGTGTGGTACTCAGCACATTTCAAATGATTTT 1260

FIG. 14 CONT.

```
Patient 5      CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 1      CCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACATTTCAAATGATTTT 1260
Patient 8      CCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACATTTCAAATGATTTT 1260
                ** *** *****
Patient 4      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 6      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 7      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 9      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 10     ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 2      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 5      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 1      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 8      ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
                ***** ** *****

Patient 4      GCTTAA 1326
Patient 6      GCTTAA 1326
Patient 7      GCTTAA 1326
Patient 9      GCTTAA 1326
Patient 10     GCTTAA 1326
Patient 2      GCTTAA 1326
Patient 5      GCTTAA 1326
Patient 1      GCTTAA 1326
Patient 8      GCTTAA 1326
                *****
```


FIG. 14 CONT.





	LPW1926	LPW1927	
HCoV-HKU1 (Patient 1)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 2)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 4)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 5)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 6)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 7)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 8)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 9)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-HKU1 (Patient 10)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-OC43 (NC_005147)	TAAAGATGTTGACAATCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
SARS-CoV (NC_004718)	CACTGATGTTGAAAGTCCACACTTATGGG/.../TTACCTGCGTAATCATTTCCTATGATGAT		2270
HCoV-229E (NC_002645)	GGCCGATGTTGATGATCCTAATTTGATGGG/.../TTATTGCAAAAGCATTTTCCTATGATGAT		2255
HCoV-NL63 (NC_005831)	TGATGATGTTGAAACCCCTGTTCTTATGGG/.../TTATCTTGCAAATCATTTCCTATGATGAT		2255

FIG. 16



0.02

**FIG. 17**

## NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF

[0001] This is a continuation-in-part application of U.S. patent application Ser. No. 10/895,064 filed Jul. 21, 2004, which is incorporated by reference in its entirety.

### SEQUENCE LISTING

[0002] The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on Mar. 21, 2005, are labeled "CRF", "Copy 1" and "Copy 2", respectively, and each contains only one identical 2.84 MB file (V0690044.APP).

### 1. INTRODUCTION

[0003] The present invention relates to a novel virus causing respiratory tract infection in humans ["coronavirus-HKU1 (CoV-HKU1)"]. Phylogenetic analysis has revealed that the CoV-HKU1 is a new group 2 coronavirus, which has, at least, two (2) genotypes, A and B. The present invention relates to nucleotide sequences comprising the complete genomic sequences of the CoV-HKU1. The invention further relates to nucleotide sequences comprising a portion of the genomic sequences of the CoV-HKU1. The invention also relates to the deduced amino acid sequences of the complete genomes of the CoV-HKU1. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods, such as for immunogens. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequence. Furthermore, the invention relates to vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus as well as protein extracts and subunits of said virus.

### 2. BACKGROUND OF THE INVENTION

[0004] Since no microbiological cause has been identified in a significant proportion of patients with respiratory tract infections (Macfarlane, J. T. et al., 1993, Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community, *Lancet* 341:511-514; Ruiz, M., S. et al., 1990, Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity, *Am. J. Respir. Crit. Care Med.* 160:397-405), research has been conducted to identify possible novel agent(s). Of the three novel agents identified in the recent three years, including human metapneumovirus (Van den Hoogen, et al., 2001, A newly discovered human pneumovirus isolated from young children with respiratory tract disease, *Nat. Med.* 7:719-724), Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV) (Peiris, J. S. et al., 2003, Coronavirus as a possible cause of severe acute respiratory syndrome, *Lancet* 361:1319-1325) and human coronavirus NL63 (HCoV-NL63) (Fouchier, R. A. et al., 2004, A previously undescribed coronavirus associated with respiratory disease in humans, *Proc. Natl. Acad. Sci. USA.* 101:6212-6216; van der Hoek, et al., 2004, Identification of a new human coronavirus, *Nat. Med.* 10:368-373), two were coronaviruses. Coronaviruses possess the largest genome of about 30

kb among all RNA viruses. As a result of the unique mechanism of viral replication, coronaviruses have a high frequency of recombination.

[0005] Based on genotypic and serological characterization, coronaviruses were divided into three distinct groups, with human coronavirus 229E (HCoV-229E) being a group 1 coronavirus and HCoV-OC43 a group 2 coronavirus (Lai, M. M. et al., 1997, The molecular biology of coronaviruses, *Adv. Virus Res.* 48:1-100). They account for 5-30% of human respiratory tract infections. In late 2002 and 2003, the epidemic caused by SARS-CoV affected over 8000 people with 750 deaths (for example, Peiris, J. S. et al., 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, *Lancet* 361:1767-1772). We have also reported the isolation of SARS-CoV-like viruses from Himalayan palm civets, which suggested that animals could be the reservoir for the ancestor of SARS-CoV (Guan, Y. et al., 2003, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China, *Science* 302:276-278). On the basis of genome analysis, SARS-CoV belongs to a fourth group of coronavirus, or alternatively, a distant relative of group 2 coronaviruses (Eickmann, M. et al., 2003, Phylogeny of the SARS coronavirus, *Science* 302:1504-1505; Marra, M. A. et al., 2003, The Genome sequence of the SARS-associated coronavirus, *Science* 300:1399-1404; Rota, P. A. et al., 2003, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, *Science* 300:1394-1399; Snijder, E. J. et al., 2003, Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, *J. Mol. Biol.* 331:991-1004; Yeh, S. H. et al., 2004, Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution, *Proc. Natl. Acad. Sci. USA.* 101:2542-2547). Recently, a novel group 1 human coronavirus associated with respiratory tract infections, HCoV-NL63, has been discovered, and its genome sequenced (37).

[0006] In January, 2004, a 71-year-old Chinese man was admitted to hospital because of fever and chills for two days associated with sore throat, rhinorrhoea, productive cough with purulent sputum, headache and nausea. He had history of pulmonary tuberculosis more than 40 years ago complicated by cicatrization of right upper lobe and bronchiectasis with chronic *Pseudomonas aeruginosa* colonization of airways. He was a chronic smoker and also had chronic obstructive airway disease, hyperlipidemia, and asymptomatic abdominal aortic aneurysm. He had just returned from Shenzhen of China three days before admission. During his three-day trip to Shenzhen, he had no history of contact with or consumption of wild animals. On admission, his oral temperature was 37.6° C. Physical examination showed tracheal deviation to the right and inspiratory crackles over the anterior left lower zone. His haemoglobin level was 14.7 g/dL, total white cell count 12.1×10<sup>9</sup>/L, with neutrophil 9.7×10<sup>9</sup>/L, lymphocyte 1.6×10<sup>9</sup>/L and monocyte 0.5×10<sup>9</sup>/L, and plate count 303×10<sup>9</sup>/L. His liver and renal function tests were within normal limits. Chest radiograph showed right upper lobe collapse and new patchy infiltrates over the left lower zone. Blood culture was performed. Empirical oral amoxicillin/clavulanate and azithromycin were commenced. Nasopharyngeal aspirates for direct antigen detection for respiratory viruses, RT-PCR for influenza A virus, human

metapneumovirus and SARS-CoV, and viral cultures were negative. Sputum for bacterial culture only recovered *P. aeruginosa*. Sputum for mycobacterial culture was negative. Blood culture was negative. Paired sera for antibodies against *Mycoplasma*, *Chlamydia*, *Legionella*, and SARS-CoV did not show any rise in antibody titres. His fever subsided two days after admission. His cough improved and he was discharged after five days of hospitalization. Amoxicillin/clavulanate and azithromycin were continued for a total of seven days. The present inventors were the group involved in the investigation of this patient. All tests for identifying commonly recognized viruses and bacteria were negative in these patients. The etiologic agent responsible for this disease was not known until the complete genome of CoV-HKU1 from this patient by the present inventors as disclosed herein. Further studies disclosed herein have revealed that CoV-HKU1 is a human coronavirus and there are, at least, two (2) genotypes, A and B, within CoV-HKU1. The invention is useful in both clinical and scientific research applications.

### 3. SUMMARY OF INVENTION

[0007] The present invention is based upon the inventor's complete genome sequencing of a novel virus ("CoV-HKU1") causing pneumonia in humans. The virus was first discovered from a patient suffering from pneumonia in Hong Kong. The virus is a single-stranded RNA virus of positive polarity which belongs to the order, Nidovirales, of the family, Coronaviridae. Further studies based on prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period, have revealed that there are, at least, two (2) genotypes for CoV-HKU1. Accordingly, the invention relates to CoV-HKU1 that phylogenetically relates to known members of Coronaviridae and specifically belongs to group 2 coronavirus. In a specific embodiment, the invention provides complete genomic sequences of two (2) genotypes of CoV-HKU1. In a preferred embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides nucleic acids isolated from the virus. The virus preferably comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, in its genome. In a specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:3 or 2919, a

complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or 2919, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. Furthermore, in another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof. In preferred embodiments, such nucleic acid molecules encode amino acid sequences that have biological activities exhibited by the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleic

otide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or proteins include those having the amino acid sequences of SEQ ID NO:2, 34-2918 shown in **FIGS. 2 and 3**, and SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in **FIG. 9**. The invention further provides proteins or polypeptides that are isolated from the CoV-HKU1, including viral proteins isolated from cells infected with the virus but not present in comparable uninfected cells. The polypeptides or the proteins of the present invention preferably have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by the nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934. In another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of

SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. Furthermore, in another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. In other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof.

**[0008]** In one aspect, the invention relates to the use of CoV-HKU1 for diagnostic methods. In a specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-HKU1, or any proteins or polypeptides thereof. In another specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-HKU1-infected cells. In yet another specific embodiment, the invention provides a method of screening for an antibody that immunospecifically binds and neutralizes CoV-HKU1. Such an antibody is useful for a passive immunization or immunotherapy of a subject infected with CoV-HKU1.

**[0009]** The invention further relates to the use of the sequence information of the isolated virus for diagnostic methods. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or at least a portion of the nucleotide sequence thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for hybridization to CoV-HKU1 nucleic acid, including, but not limited to, as PCR primers, Reverse Transcriptase primers, probes for Southern or Northern analysis or other nucleic acid hybridization analysis for the detection of CoV-HKU1 nucleic acids, e.g., consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof.

**[0010]** The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958,

2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptide having the amino acid sequence of SEQ ID NO:2 or any one of SEQ ID NOS:34-2918 shown in **FIGS. 2 and 3**, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in **FIG. 9**, or encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and/or any CoV-HKU1 epitope, having one or more biological activities of a polypeptide of the invention. The invention further provides antibodies that specifically bind cells or tissues that are infected by CoV-HKU1. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab)<sub>2</sub> fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

**[0011]** In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, and so forth. The increased or decreased activity or expression of the CoV-HKU1 in a sample relative to a control sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detecting agents are the antibodies or nucleic acid molecules of the present invention. Antibodies of the invention may also be used to detect and/or treat other coronaviruses, such as Severe Acute Respiratory Syndrome ("SARS") viruses.

**[0012]** In another embodiment, the invention provides vaccine preparations, comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or protein subunits of the virus. In a specific embodiment, the present invention provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific invention, the vaccine preparations of the present invention comprise a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides isolated from or produced from nucleic acid of CoV-HKU1. In a specific embodiment, the vaccine preparations comprise a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID NO:2 or any one of SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing or preventing respiratory tract infections

caused by CoV-HKU1 by administering to a subject in need thereof the anti-viral agents of the present invention, alone or in combination with various anti-viral agents as well as adjuvants, and/or other pharmaceutically acceptable excipients.

**[0013]** In another aspect, the present invention provides methods for preventing or inhibiting, under a physiological condition, binding to a host cell, or infection of a host cell, or replication in a host cell, of CoV-HKU1 or a virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, by administering to the host cell the anti-viral agents of the present invention, alone or in combination with other anti-viral agents. In a specific embodiment, the anti-viral agent of the invention includes the immunogenic preparations of the invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and/or neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the present invention or a nucleic acid molecule of the invention. In a specific embodiment, the host cell is a mammalian cell, including a cell of human, primates, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats. Preferably a host cell is a primate cell, and most preferably a human cell. Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The invention also provides kits containing a pharmaceutical composition of the present invention.

### 3.1 Definitions

**[0014]** The term "an antibody or an antibody fragment that immunospecifically binds a polypeptide of the invention" as used herein refers to an antibody or a fragment thereof that immunospecifically binds to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, and does not non-specifically bind to other polypeptides. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention may cross-react with other antigens. Preferably, an antibody or a fragment thereof that immunospecifically binds to a polypeptide of the invention does not cross-react with other antigens. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention, can be identified by, for example, immunoassays or other techniques known to those skilled in the art.

**[0015]** An "isolated" or "purified" peptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of a polypeptide/protein in which the polypeptide/protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a polypeptide/protein that is substantially free of cellular material includes preparations of the polypeptide/protein

having less than about 30%, 20%, 10%, 5%, 2.5%, or 1%, (by dry weight) of contaminating protein. When the polypeptide/protein is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When polypeptide/protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide/protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than polypeptide/protein fragment of interest. In a preferred embodiment of the present invention, polypeptides/proteins are isolated or purified.

[0016] An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment of the invention, nucleic acid molecules encoding polypeptides/proteins of the invention are isolated or purified. The term "isolated" nucleic acid molecule does not include a nucleic acid that is a member of a library that has not been purified away from other library clones containing other nucleic acid molecules.

[0017] The term "portion" or "fragment" as used herein refers to a fragment of a nucleic acid molecule containing at least about 10, 15, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, or more contiguous nucleic acids in length of the relevant nucleic acid molecule and having at least one functional feature of the nucleic acid molecule (or the encoded protein has one functional feature of the protein encoded by the nucleic acid molecule); or a fragment of a protein or a polypeptide containing at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,100, 4,200, 4,300, 4,350, 4,360, 4,370, 4,380 amino acid residues in length of the relevant protein or polypeptide and having at least one functional feature of the protein or polypeptide.

[0018] The term "having a biological activity of the protein" or "having biological activities of the polypeptides of the invention" refers to the characteristics of the polypeptides or proteins having a common biological activity similar or identical structural domain and/or having sufficient amino acid identity to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the polypeptide having any one of the amino acid sequences of SEQ ID NOS:2, 34-2918, 2921,

2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236, or a complement thereof. Such common biological activities of the polypeptides of the invention include antigenicity and immunogenicity.

[0019] The term "under stringent condition" refers to hybridization and washing conditions under which nucleotide sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to each other remain hybridized to each other. Such hybridization conditions are described in, for example but not limited to, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.; Basic Methods in Molecular Biology, Elsevier Science Publishing Co., Inc., N.Y. (1986), pp. 75-78, and 84-87; and Molecular Cloning, Cold Spring Harbor Laboratory, N.Y. (1982), pp. 387-389, and are well known to those skilled in the art. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6× sodium chloride/sodium citrate (SSC), 0.5% SDS at about 68° C. followed by one or more washes (e.g., about 5 to 30 min each) in 2×SSC, 0.5% SDS at room temperature. Another preferred, non-limiting example of stringent hybridization conditions is hybridization in 6×SSC at about 45° C. followed by one or more washes (e.g., about 5 to 30 min each) in 0.2×SSC, 0.1% SDS at about 45-65° C.

[0020] The term "variant" as used herein refers either to a naturally occurring genetic mutant of CoV-HKU1 or a recombinantly prepared variation of CoV-HKU1 each of which contain one or more mutations in its genome compared to CoV-HKU1. The term "variant" may also refer either to a naturally occurring variation of a given peptide or a recombinantly prepared variation of a given peptide or protein in which one or more amino acid residues have been modified by amino acid substitution, addition, or deletion.

#### 4. BRIEF DESCRIPTION OF FIGURES

[0021] FIG. 1 shows a partial DNA sequence (SEQ ID NO:1) and its deduced amino acid sequence (SEQ ID NO:2) obtained from CoV-HKU1 that has 91% amino acid identity to the RNA-dependent RNA polymerase protein of known *Coronaviruses*.

[0022] FIG. 2 shows the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:34-456; the second-frame translation and amino acid sequences: SEQ ID NOS:457-723; and the third-frame translation and amino acid sequences: SEQ ID NOS:724-1318.

[0023] FIG. 3 shows the complement (SEQ ID NO:1319) of the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 in 3'→5' orientation and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:1319-1907; the second-frame translation and amino acid sequences: SEQ ID NO:1908-2453; and the third-frame translation and amino acid sequences: SEQ ID NOS:2454-2918.

**[0024] FIG. 4** shows genome organization of CoV-HKU1. Overall organization of the 29926-nucleotide CoV-HKU1 genomic RNA. Predicted ORFs 1a and 1b, encoding the nonstructural polyproteins (p28, p65 and nsp1-13) and those encoding the hemagglutinin-esterase, spike, envelope, membrane and nucleocapsid structural proteins are indicated. Arrows indicate putative cleavage sites (with the corresponding nucleotide positions) of the replicase polyprotein encoded by ORF 1a and ORF 1b. ATR, PL1<sup>PRO</sup> and PL2<sup>PRO</sup> represent the acidic tandem repeat and the two papain-like proteases, respectively, in nsp1.

**[0025] FIG. 5A** shows the phylogenetic analysis of the chymotrypsin like protease (3CL<sup>PRO</sup>), RNA-dependent RNA polymerase (Pol), helicase, and hemagglutinin-esterase (HE); and **FIG. 5B** shows that of the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1. The trees were constructed by the neighbor joining method using the Jukes-Cantor correction and bootstrap values were calculated from 1000 trees. A total of 303, 928, 595, 418, 1356, 75, 225 and 406 amino acid positions in 3CL<sup>PRO</sup>, Pol, helicase, HE, S, E, M, and N, respectively, were included in the analysis. The scale bar indicates the estimated number of substitutions per 10 amino acids. HCoV-229E: human coronavirus 229E; PEDV: porcine epidemic diarrhea virus; PTGV: porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63: human coronavirus NL63; HCoV-OC43: human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; SDAV: rat sialodacryoadnitis coronavirus; ECoV: equine coronavirus NC99; PHEV: porcine hemagglutinating encephalomyelitis virus; IBV: infectious bronchitis virus; SARS-CoV: SARS coronavirus.

**[0026] FIG. 6** shows the spike protein of CoV-HKU1 (residues 7-336 of SEQ ID NO: 420) and those of other group 2 coronaviruses (SEQ ID NOS 21-26, respectively, in order of appearance). The spike protein (1356 amino acids) of CoV-HKU1 is depicted by the horizontal bar [SS=N terminal signal sequence (amino acid residues 1 to 13), HR1=heptad repeat 1 (amino acid residues 982 to 1083), HR2=heptad repeat 2 (amino acid residues 1250 to 1297), TM=transmembrane domain (amino acid residues 1301 to 1323)], (the seven sequences below the horizontal bar disclose residues 752-766 of SEQ ID NO: 420 and SEQ ID NOS 28-33, respectively, in order of appearance). Alignment of the N-terminal region important for receptor binding (amino acid residues 1 to 330) and the region upstream to the cleavage site between S1 and S2 of CoV-HKU1 and other group 2 coronaviruses was generated with ClustalX 1.83. Residues that match the CoV-HKU1 exactly are boxed. The three conserved regions (sites I, II, and III) for receptor binding in MHV are shaded. The positions of the four conserved amino acids important for receptor binding in MHV are indicated with arrows. (GenBank accession nos. MHV: P11224; BCoV: NP 150077; HCoV-OC43: NP 937950; SDAV: AAF97738; PHEV: AAL80031; ECoV: AAQ67205).

**[0027] FIG. 7** shows the sequential quantitative RT-PCR (closed squares; copies/ml) for CoV-HKU1 in nasopharyngeal aspirates; and serum IgG antibody titers against N protein of CoV-HKU1 (closed triangles).

**[0028] FIG. 8** shows the Western blot analysis of purified recombinant CoV-HKU1 N protein antigen. Prominent

immunoreactive protein bands of about 53 kDa (i.e., purified recombinant CoV-HKU1 N protein) were detected by the Western blot using the patient's sera obtained during the second and fourth weeks of the illness (lanes 2 and 3). Only very faint bands were observed with the serum samples obtained from the patient during the first week of the illness (lane 1) and two healthy blood donors (lane 4 and 5), respectively.

**[0029] FIG. 9** shows the entire genomic DNA sequence (SEQ ID NO:2919) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (\*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS: 2970-3474; the second-frame translation and amino acid sequences: SEQ ID NOS: 3475-3721; and the third-frame translation and amino acid sequences: SEQ ID NOS: 3722-4236.

**[0030] FIG. 10** shows arrangements of proteins in replicase polyprotein in CoV-HKU1 compared with those in HCoV-OC43, BCoV, and MHV. Alignment of the AC domains of HCoV-OC43 (SEQ ID NO: 4239), BCoV (SEQ ID NO: 4238), and MHV (SEQ ID NO: 4237) and the AC domains and ATR (underlined) of CoV-HKU1 in the two patients (SEQ ID NOS 4240 and 4241) was generated with ClustalX 1.83. AC domain=acidic domain, ATR=acidic tandem repeat. (GenBank accession no. MHV: NC\_001846; BCoV: NC\_003045; HCoV-OC43: AY585229).

**[0031] FIG. 11** shows the multiple alignments of the replicase genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2920 which encodes SEQ ID NO: 2921), 2 (SEQ ID NO: 2922 which encodes SEQ ID NO: 2923), 4 (SEQ ID NO: 2924 which encodes SEQ ID NO: 2925), 5 (SEQ ID NO: 4242 which encodes SEQ ID NO: 4243), 6 (SEQ ID NO: 2926 which encodes SEQ ID NO: 2927), 7 (SEQ ID NO: 2928 which encodes SEQ ID NO: 2929), 8 (SEQ ID NO: 2930 which encodes SEQ ID NO: 2931), 9 (SEQ ID NO: 2932 which encodes SEQ ID NO: 2933) and 10 (SEQ ID NO: 2934 which encodes SEQ ID NO: 2935).

**[0032] FIG. 12** shows the chest radiographs of the two patients who died of community acquired pneumonia associated with CoV-HKU1. The chest radiograph of the first patient (**FIG. 12A**; patient no. 2 in Table 5) showed patchy airspace shadows in both lungs with predominant involvement of the lower zones. The chest radiograph of the second patient (**FIG. 12B**; patient no. 10 in Table 5), with Luque instrumentation in situ, showed extensive airspace shadows in both lungs with the middle zones more severely involved.

**[0033] FIG. 13** shows the multiple alignments of the spike genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2936 which encodes SEQ ID NO: 2937), 2 (SEQ ID NO: 2938 which encodes SEQ ID NO: 2939), 4 (SEQ ID NO: 2940 which encodes SEQ ID NO: 2941), 5 (SEQ ID NO: 4244 which encodes SEQ ID NO: 4245), 6 (SEQ ID NO: 2942 which encodes SEQ ID NO: 2943), 7 (SEQ ID NO: 2944 which encodes SEQ ID NO: 2945), 8 (SEQ ID NO: 2946 which encodes SEQ ID NO: 2947), 9 (SEQ ID NO: 2948 which encodes SEQ ID NO: 2949) and 10 (SEQ ID NO: 2950 which encodes SEQ ID NO: 2951).

**[0034] FIG. 14** shows the multiple alignments of the nucleocapsid genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2952 which encodes SEQ ID NO: 2953), 2 (SEQ ID



NO: 2954 which encodes SEQ ID NO: 2955), 4 (SEQ ID NO: 2956 which encodes SEQ ID NO: 2957), 5 (SEQ ID NO: 4246 which encodes SEQ ID NO: 4247), 6 (SEQ ID NO: 2958 which encodes SEQ ID NO: 2959), 7 (SEQ ID NO: 2960 which encodes SEQ ID NO: 2961), 8 (SEQ ID NO: 2962 which encodes SEQ ID NO: 2963), 9 (SEQ ID NO: 2964 which encodes SEQ ID NO: 2965) and 10 (SEQ ID NO: 2966 which encodes SEQ ID NO: 2967).

[0035] FIG. 15 shows phylogenetic trees and non-synonymous mutations and corresponding amino acid changes of complete pol, S and N gene sequences of HCoV-HKU1 from nine patients with community acquired pneumonia. The trees were inferred from pol (FIG. 15A), S (FIG. 15B) and N (FIG. 15C) gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The trees were rooted using pol, S and N gene sequences of HCoV-OC43, respectively. 2784 nucleotide positions in each pol gene, 4071 nucleotide positions in each S gene, and 1326 nucleotide positions in each N gene, were included in the analysis. The scale bar indicates the estimated number of substitutions per 100 (FIG. 15A) and 50 (FIGS. 15B and 15C) bases, respectively, using Jukes-Cantor correction. The shaded nucleotides are those that differ from the majority at the corresponding locations. Due to the large number of non-synonymous mutations in the S gene, only the NH<sub>2</sub> terminal 45, out of the total of 306, non-synonymous mutations are shown.

[0036] FIG. 16 shows the multiple alignments of nucleotides 1806-1835 and 2229-2258 of the pol genes in the nine HCoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV. Marked differences between the 3' ends of the two primers for RT-PCR (LPW1926; SEQ ID NO: 4248 and LPW1927; SEQ ID NO: 4249) and the corresponding bases in HCoV-OC43 (SEQ ID NOS 4250 and 4251), HCoV-229E (SEQ ID NOS 4254 and 4255), HCoV-NL63 (SEQ ID NOS 4256 and 4257) and SARS-CoV (SEQ ID NOS 4252 and 4253) are observed, indicating the high specificity of the two primers for HCoV-HKU1. The positions of LPW1926 (SEQ ID NO: 4248) and LPW1927 (SEQ ID NO: 4249) are boxed. The bases in HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV that were different from those in the sequence of the primers, were shaded.

[0037] FIG. 17 show a phylogenetic tree of pol gene sequences of the 10 HCoV-HKU1 from patients with community acquired pneumonia. The tree was inferred from pol gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The tree was rooted using pol gene sequence of HCoV:229E and 393 nucleotide positions (primer sequences excluded) in each pol gene were included in the analysis. The scale bar indicates the estimated number of substitutions per 50 bases using Jukes-Cantor correction. HCoV-HKU1: human coronavirus HKU1; HCoV-229E: human coronavirus 229E; HCoV-OC43: human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; PHEV: porcine hemagglutinating encephalomyelitis virus.

##### 5. DETAILED DESCRIPTION OF THE INVENTION

[0038] The present invention relates to the CoV-HKU1 that phylogenetically relates to known *Coronaviruses*. In a specific embodiment, CoV-HKU1 comprises a nucleotide

sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a specific embodiment, the present invention provides isolated nucleic acid molecules of the CoV-HKU1, comprising, or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof or a portion thereof. In another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or specific genes of known member of Coronaviridae, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement

thereof. The polypeptides or the proteins of the present invention preferably have one or more biological activities of the proteins encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the native viral proteins containing the amino acid sequences encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof.

**[0039]** The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides the entire nucleotide sequence of CoV-HKU1 (SEQ ID NO:3 or 2919), or fragments, or complement thereof. Furthermore, the present invention relates to a nucleic acid molecule that hybridizes any portion of the genome of the CoV-HKU1 (SEQ ID NO:3 or 2919) under the stringent conditions. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, or a portion thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for use as hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof. The invention further encompasses chimeric or recombinant viruses or viral proteins encoded by said nucleotide sequences.

**[0040]** The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or any CoV-HKU1 epitope as well as the polypeptides having the amino acid sequences of any one of SEQ ID NO:2, SEQ ID NOS:34-2918 shown in **FIGS. 2 and 3**, SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in **FIG. 9**. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab)<sub>2</sub> fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

**[0041]** In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, sputum, nasopharyngeal aspirates, and so forth. The presence of the CoV-HKU1 in a sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence,

activity or expression of the CoV-HKU1. In a specific embodiment, the detection agents are the antibodies of the present invention. In another embodiment, the detection agent is a nucleic acid of the present invention.

**[0042]** In another embodiment, the invention provides vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or subunits of the virus.

**[0043]** The present invention further provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific embodiment, the vaccine preparations of the present invention comprise one or more nucleic acid molecules comprising or consisting of the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing, or preventing respiratory tract infections by administering to a subject in need thereof the anti-viral agents of the present invention, alone or in combination with other antivirals [e.g., amantadine, rimantadine, gancyclovir, acyclovir, ribavirin, penciclovir, oseltamivir, foscarnet, zidovudine (AZT), didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, delavirdine, indinavir, ritonavir, vidarabine, nelfinavir, saquinavir, renlaza, tamiflu, pleconaril, interferons, etc.], steroids and corticosteroids such as prednisone, cortisone, fluticasone and glucocorticoid, antibiotics, analgesics, bronchodilators, or other treatments for respiratory and/or viral infections. In one aspect, the anti-viral agent of the present invention prevents or inhibits the binding of the virus or viral proteins to a host cell under a physiological condition, thereby preventing or inhibiting the infection of the host cell by the virus. In another aspect, the anti-viral agent of the invention prevents or inhibits replication of the viral nucleic acid molecules in the host cell under a physiological condition by interacting with the viral nucleic acid molecules or its transcription mechanisms. In a specific embodiment, the anti-viral agent of the invention includes the vaccine or immunogenic preparations of the invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and may neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the invention or a nucleic acid molecule of the invention. In addition, the present invention provides a method of preventing or inhibiting replication in a host cell of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or inhibiting the activities of the polypeptides encoded by the nucleotide

sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof, including the polypeptides having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, by administering to said host cell the anti-viral agent of the invention. In a specific embodiment the host cell is a mammalian cell, such as a cell of humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, arivan species and rodents. Preferably, the cell is a primate cell and most preferably a human cell.

[0044] Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The present invention also provides kits comprising pharmaceutical compositions of the present invention.

#### 5.1 Recombinant and Chimeric CoV-HKU1

[0045] The present invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genome of CoV-HKU 1 or natural variants thereof. In a specific embodiment, a recombinant virus is one derived from the CoV-HKU1. In a specific embodiment, the virus has a nucleotide sequence of SEQ ID NO:3 or 2919. In another specific embodiment, a recombinant virus is one derived from a natural variant of CoV-HKU1. A natural variant of CoV-HKU1 has a sequence that is different from the genomic sequence (SEQ ID NO:3 or 2919) of CoV-HKU1, due to one or more naturally occurred mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a phenotypic change. In accordance with the present invention, a viral vector which is derived from the genome of the CoV-HKU, is one that contains a nucleic acid sequence that encodes at least a part of one ORF of the CoV-HKU1. In a specific embodiment, the ORF comprises or consists of a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In a specific embodiment, there are more than one ORF within the nucleotide sequence of SEQ ID NO:3 or 2919, or a fragment thereof. In another embodiment, the polypeptides encoded by the ORF comprises or consists of amino acid sequences of SEQ ID NO:34-2918 shown in **FIGS. 2 and 8**, or SEQ ID NO:2, SEQ ID NO:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or a fragment thereof. In accordance with the present invention these viral vectors may or may not include nucleic acids that are non-native to the viral genome.

[0046] In another specific embodiment, a chimeric virus of the invention is a recombinant CoV-HKU1 which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

[0047] According to the present invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric virus may be encoded by nucleotide sequences derived from different strains or variants of CoV-HKU1. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides derived from different strains or variants of CoV-HKU1.

[0048] A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., *J. Virol.* 72, 2955-2961; Durbin et al., 2000, *J. Virol.* 74, 6821-6831; Skiadopoulos et al., 1998, *J. Virol.* 72, 1762-1768 (1998); Teng et al., 2000, *J. Virol.* 74, 9317-9321). For example, it can be envisaged that a virus vector derived from the CoV-HKU1 expressing one or more proteins of variants of CoV-HKU1, or vice versa, will protect a subject vaccinated with such vector against infections by both the native CoV-HKU1 and the variant. Attenuated and replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses.

[0049] In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains or variants of CoV-HKU1.

[0050] In certain embodiments, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been inserted or added to the vector.

[0051] The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection.

[0052] In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by the CoV-HKU1 and natural variants thereof. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses.

[0053] The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial

antigens, tumor antigens, allergen antigens, and auto antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with CoV-HKU1 and variants thereof.

**[0054]** In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and autoantigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing CoV-HKU1 genes to contain foreign sequences in their respective external domains. Where the heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

**[0055]** Thus, the present invention relates to the use of viral vectors and recombinant or chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The present invention also encompasses recombinant viruses comprising a viral vector derived from the CoV-HKU1 or variants thereof which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer sequences of the virus.

**[0056]** The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of CoV-HKU1 are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the CoV-HKU1 genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

**[0057]** In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial CoV-HKU1 proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

**[0058]** The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

#### 5.2 Formulation of Vaccines and Antivirals

**[0059]** In a preferred embodiment, the invention provides a proteinaceous molecule or CoV-HKU1 specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic

fragments derivable from the virus according to the invention, including envelop protein (E protein), integral membrane protein (M protein), spike protein (S protein), nucleocapsid protein (N protein), hemagglutinin esterase (HE protein), and RNA-dependent RNA polymerase. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as subunit vaccines. Particularly useful are polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-2918 in **FIGS. 2 and 3**, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 in **FIG. 9**, or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments of the CoV-HKU1 genome; of course preferred are those that are within the preferred bounds and metes of ORFs, in particular, for eliciting CoV-HKU1 specific antibody or T cell responses, whether in vivo (e.g. for protective or therapeutic purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

**[0060]** The invention provides vaccine formulations for the prevention and treatment of infections with CoV-HKU1. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the CoV-HKU1.

**[0061]** In another aspect, the present invention also provides DNA vaccine formulations comprising a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another specific embodiment, the DNA vaccine formulations of the present invention comprises a nucleic acid or fragment thereof encoding the antibodies which immunospecifically binds CoV-HKU1. In DNA vaccine formulations, a vaccine DNA comprises a viral vector, such as that derived from the CoV-HKU1, bacterial plasmid, or other expression vector, bearing an insert comprising a nucleic acid molecule of the present invention operably linked to one or more control elements, thereby allowing expression of the vaccinating proteins encoded by said nucleic acid molecule in a vaccinated subject. Such vectors can be prepared by recombinant DNA technology as recombinant or chimeric viral vectors carrying a nucleic acid molecule of the present invention.

**[0062]** Various heterologous vectors are described for DNA vaccinations against viral infections. For example, the vectors described in the following references may be used to express CoV-HKU1 sequences instead of the sequences of the viruses or other pathogens described; in particular, vectors described for hepatitis B virus (Michel, M. L. et al., 1995, DAN-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans, *Proc. Natl. Aca. Sci.*

USA 92:5307-5311; Davis, H. L. et al., 1993, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody, *Human Molec. Genetics* 2:1847-1851), HIV virus (Wang, B. et al., 1993, Gene inoculation generates immune responses against human immunodeficiency virus type 1, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; Lu, S. et al., 1996, Simian immunodeficiency virus DNA vaccine trial in macaques, *J. Virol.* 70:3978-3991; Letvin, N. L. et al., 1997, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, *Proc Natl Acad Sci USA* 94(17):9378-83), and influenza viruses (Robinson, H L et al., 1993, Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA, *Vaccine* 11:957-960; Ulmer, J. B. et al., Heterologous protection against influenza by injection of DNA encoding a viral protein, *Science* 259:1745-1749), as well as bacterial infections, such as tuberculosis (Tascon, R. E. et al., 1996, Vaccination against tuberculosis by DNA injection, *Nature Med.* 2:888-892; Huygen, K. et al., 1996, Immunogenicity and protective efficacy of a tuberculosis DNA vaccine, *Nature Med.*, 2:893-898), and parasitic infection, such as malaria (Sedegah, M., 1994, Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein, *Proc. Natl. Acad. Sci. USA* 91:9866-9870; Doolan, D. L. et al., 1996, Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ T cell-interferon  $\delta$ , and nitric oxide-dependent immunity, *J. Exper. Med.*, 1183:1739-1746).

[0063] Many methods may be used to introduce the vaccine formulations described above. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes. Alternatively, it may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the pathogen for which the vaccine is designed. The DNA vaccines of the present invention may be administered in saline solutions by injections into muscle or skin using a syringe and needle (Wolff J. A. et al., 1990, Direct gene transfer into mouse muscle in vivo, *Science* 247:1465-1468; Raz, E., 1994, Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses, *Proc. Natl. Acad. Sci. USA* 91:9519-9523). Another way to administer DNA vaccines is called "gene gun" method, whereby microscopic gold beads coated with the DNA molecules of interest is fired into the cells (Tang, D. et al., 1992, Genetic immunization is a simple method for eliciting an immune response, *Nature* 356:152-154). For general reviews of the methods for DNA vaccines, see Robinson, H. L., 1999, DNA vaccines: basic mechanism and immune responses (Review), *Int. J. Mol. Med.* 4(5):549-555; Barber, B., 1997, Introduction: Emerging vaccine strategies, *Seminars in Immunology* 9(5):269-270; and Robinson, H. L. et al., 1997, DNA vaccines, *Seminars in Immunology* 9(5):271-283.

### 5.3 Adjuvants and Carrier Molecules

[0064] CoV-HKU1-associated antigens are administered with one or more adjuvants. In one embodiment, the CoV-HKU1-associated antigen is administered together with a mineral salt adjuvant or mineral salt gel adjuvant. Such mineral salt and mineral salt gel adjuvants include, but are not limited to, aluminum hydroxide (ALHYDROGEL,

REHYDRAGEL), aluminum phosphate gel, aluminum hydroxyphosphate (ADJU-PHOS), and calcium phosphate.

[0065] In another embodiment, CoV-HKU1-associated antigen is administered with an immunostimulatory adjuvant. Such class of adjuvants, include, but are not limited to, cytokines (e.g., interleukin-2, interleukin-7, interleukin-12, granulocyte-macrophage colony stimulating factor (GM-CSF), interferon- $\gamma$ -interleukin-1 $\beta$  (IL-1 $\beta$ ), and IL-1 $\beta$  peptide or Selavo Peptide), cytokine-containing liposomes, triterpenoid glycosides or saponins (e.g., QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), Muramyl Dipeptide (MDP) derivatives, such as N-acetylmuramyl-L-threonyl-D-isoglutamine (Threonyl-MDP, sold under the trademark TERMURTIDE), GMDP, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxy phosphoryloxy)-ethylamine, muramyl tripeptide phosphatidylethanolamine (MTP-PE), unmethylated CpG dinucleotides and oligonucleotides, such as bacterial DNA and fragments thereof, LPS, monophosphoryl Lipid A (3D-MLA sold under the trademark MPL), and polyphosphazenes.

[0066] In another embodiment, the adjuvant used is a particular adjuvant, including, but not limited to, emulsions, e.g., Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalene oil-in-water adjuvant formulations, such as SAF and MF59, e.g., prepared with block-copolymers, such as L-121 (polyoxypropylene/polyoxyethylene) sold under the trademark PLURONIC L-121, Liposomes, Virosomes, cochleates, and immune stimulating complex, which is sold under the trademark ISCOM.

[0067] In another embodiment, a microparticulate adjuvant is used. Microparticulate adjuvants include, but are not limited to biodegradable and biocompatible polyesters, homo- and copolymers of lactic acid (PLA) and glycolic acid (PGA), poly(lactide-co-glycolides) (PLGA) microparticles, polymers that self-associate into particulates (poloxamer particles), soluble polymers (polyphosphazenes), and virus-like particles (VLPs) such as recombinant protein particulates, e.g., hepatitis B surface antigen (HbsAg).

[0068] Yet another class of adjuvants that may be used include mucosal adjuvants, including but not limited to heat-labile enterotoxin from *Escherichia coli* (LT), cholera holotoxin (CT) and cholera Toxin B Subunit (CTB) from *Vibrio cholerae*, mutant toxins (e.g., LTK63 and LTR72), microparticles, and polymerized liposomes.

[0069] In other embodiments, any of the above classes of adjuvants may be used in combination with each other or with other adjuvants. For example, non-limiting examples of combination adjuvant preparations that can be used to administer the CoV-HKU1-associated antigens of the invention include liposomes containing immunostimulatory protein, cytokines, or T-cell and/or B-cell peptides, or microbes with or without entrapped IL-2 or microparticles containing enterotoxin. Other adjuvants known in the art are also included within the scope of the invention (see *Vaccine Design: The Subunit and Adjuvant Approach*, Chap. 7, Michael F. Powell and Mark J. Newman (eds.), Plenum Press, New York, 1995, which is incorporated herein in its entirety).

[0070] The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed

against an immunogenic polypeptide containing a CoV-HKU1 polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

[0071] The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid additional salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

[0072] The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

[0073] Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

[0074] The patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats.

#### 5.4 Preparation of Antibodies

[0075] Antibodies which specifically recognize a polypeptide of the invention, such as, but not limited to, polypeptides comprising the sequence of SEQ ID NO:2 or any of SEQ ID NOS: 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or CoV-HKU1 epitope, or antigen-binding fragments thereof, can be used for detecting, screening, and isolating the polypeptide of the invention or fragments thereof, or similar sequences that might encode similar enzymes from the other organisms. For example, in one specific embodiment, an antibody which immunospecifically binds CoV-HKU1 epitope, or a fragment thereof, can be used for various in vitro detection assays, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, Western blot, etc., for the detection of a polypeptide of the invention or, preferably, CoV-HKU1, in samples, for example, a biological material, including cells, cell culture media (e.g., bacterial cell culture media, mammalian cell culture media, insect cell culture media, yeast cell culture media, etc.), blood, plasma, serum, tissues, sputum, nasopharyngeal aspirates, etc.

[0076] Antibodies specific for a polypeptide of the invention or any epitope of CoV-HKU1 may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest, for example, the CoV-HKU1 epitopes or polypeptides encoded by a nucleotide sequence of SEQ ID NO:1 or 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930,

2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides shown in FIG. 2 (SEQ ID NOS:34-1318), FIG. 3 (SEQ ID NOS:1319-2918), as well as SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, can be produced by various procedures well known in the art. For example, an antigen can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc., to induce the production of antisera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful adjuvants for humans such as BCG (*Bacille Calmette-Guerin*) and *Corynebacterium parvum*. Such adjuvants are also well known in the art (see Section 5.4, supra).

[0077] Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, pp. 563-681 (Elsevier, N.Y., 1981) (both of which are incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

[0078] Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by inoculating mice intraperitoneally with positive hybridoma clones.

[0079] Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the complete light chain, and the variable region, the CH1 region and the hinge region of the heavy chain.

[0080] The antibodies of the invention or fragments thereof can be also produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

[0081] The nucleotide sequence encoding an antibody may be obtained from any information available to those skilled in the art (i.e., from Genbank, the literature, or by routine cloning and sequence analysis). If a clone containing a nucleic acid encoding a particular antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

[0082] Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., supra; and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence by, for example, introducing amino acid substitutions, deletions, and/or insertions into the epitope-binding domain regions of the antibodies or any portion of antibodies which may enhance or reduce biological activities of the antibodies.

[0083] Recombinant expression of an antibody requires construction of an expression vector containing a nucleotide sequence that encodes the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art as discussed in the previous sections. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The nucleotide sequence encoding the heavy-chain variable region, light-chain variable region, both the heavy-chain and light-chain variable regions, an epitope-binding fragment of the heavy- and/or light-chain variable region, or one or more complementarity determining regions (CDRs) of an antibody may be cloned into such a vector for expression. Thus-prepared expression vector can be then introduced into appropriate host cells for the expression of the antibody.

Accordingly, the invention includes host cells containing a polynucleotide encoding an antibody specific for the polypeptides of the invention or fragments thereof.

[0084] The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature*, 322:52, 1986; and Kohler, *Proc. Natl. Acad. Sci. USA*, 77:2 197, 1980). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

[0085] In another embodiment, antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods*, 182:41-50, 1995; Ames et al., *J. Immunol. Methods*, 184:177-186, 1995; Kettleborough et al., *Eur. J. Immunol.*, 24:952-958, 1994; Persic et al., *Gene*, 187:9-18, 1997; Burton et al., *Advances in Immunology*, 57:191-280, 1994; PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

[0086] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques*, 12(6):864-869, 1992; and Sawai et al., *AJRI*, 34:26-34, 1995; and Better et al., *Science*, 240:1041-1043, 1988 (each of which is incorporated by reference in its entirety). Examples of techniques which can be used to

produce single-chain Fvs and antibodies include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology*, 203:46-88, 1991; Shu et al., *PNAS*, 90:7995-7999, 1993; and Skerra et al., *Science*, 240:1038-1040, 1988.

**[0087]** Once an antibody molecule of the invention has been produced by any methods described above, it may then be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A or Protein G purification, and sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for the purification of proteins. Further, the antibodies of the present invention or fragments thereof may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

**[0088]** For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science*, 229:1202, 1985; Oi et al., *BioTechniques*, 4:214 1986; Gillies et al., *J. Immunol. Methods*, 125:191-202, 1989; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties. Humanized antibodies are antibody molecules from non-human species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., *Nature*, 332:323, 1988, which are incorporated herein by reference in their entireties. Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular Immunology*, 28(4/5):489-498, 1991; Studnicka et al., *Protein Engineering*, 7(6):805-814, 1994; Roguska et al., *Proc Natl. Acad. Sci. USA*, 91:969-973, 1994), and chain shuffling (U.S. Pat. No. 5,565,332), all of which are hereby incorporated by reference in their entireties.

**[0089]** Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO

98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

**[0090]** Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.*, 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entireties. In addition, companies such as Abgenix, Inc. (Fremont, Calif.), Medarex (NJ) and Genpharm (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

**[0091]** Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology*, 12:899-903, 1988).

**[0092]** Antibodies fused or conjugated to heterologous polypeptides may be used in in vitro immunoassays and in purification methods (e.g., affinity chromatography) well known in the art. See e.g., PCT publication Number WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.*, 39:91-99, 1994; U.S. Pat. No. 5,474,981; Gillies et al., *PNAS*, 89:1428-1432, 1992; and Fell et al., *J. Immunol.*, 146:2446-2452, 1991, which are incorporated herein by reference in their entireties.

**[0093]** Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the polypeptides of the invention or fragments, derivatives, analogs, or variants thereof, or similar molecules having the similar enzymatic activities as the polypeptide of the invention. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

#### 5.5 Pharmaceutical Compositions and Kits

**[0094]** The present invention encompasses pharmaceutical compositions comprising anti-viral agents of the present invention. In a specific embodiment, the anti-viral agent is an antibody which immunospecifically binds CoV-HKU1 or variants thereof, or any proteins derived therefrom. In another specific embodiment, the anti-viral agent is a polypeptide or nucleic acid molecule of the invention. The pharmaceutical compositions have utility as an anti-viral prophylactic agent and may be administered to a subject where the subject has been exposed or is expected to be exposed to a virus.

**[0095]** Various delivery systems are known and can be used to administer the pharmaceutical composition of the



invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432). Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In a preferred embodiment, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

[0096] In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, by means of nasal spray, or by means of an implant, said implant being of a porous, non porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) infected tissues.

[0097] In another embodiment, the pharmaceutical composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, *Science* 249:1527-1533; Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

[0098] In yet another embodiment, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald et al., 1980, *Surgery* 88:507; and Saudek et al., 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., 1985, *Science* 228:190; During et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, i.e., the lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

[0099] Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

[0100] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of recombinant or chimeric CoV-HKU1, and a pharmaceutically acceptable carrier. In a specific embodiment, the term

"pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. The formulation should suit the mode of administration.

[0101] In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0102] The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2 ethylamino ethanol, histidine, procaine, etc.

[0103] The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of

the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose response curves derived from *in vitro* or animal model test systems.

**[0104]** Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

**[0105]** The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a preferred embodiment, the kit contains an anti-viral agent of the invention, e.g., an antibody specific for the polypeptides encoded by a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966 or any CoV-HKU1 epitope, or a polypeptide or protein of the present invention, including those shown in **FIG. 2** (SEQ ID NOS:34-1318), **FIG. 3** (SEQ ID NOS:1319-2918), **FIG. 9** (SEQ ID NOS:2970-4236) and SEQ ID NO:2, or a nucleic acid molecule of the invention, alone or in combination with adjuvants, antivirals, antibiotics, analgesic, bronchodilators, or other pharmaceutically acceptable excipients.

**[0106]** The present invention further encompasses kits comprising a container containing a pharmaceutical composition of the present invention and instructions for use.

#### 5.6 Detection Assays

**[0107]** The present invention provides a method for detecting an antibody, which immunospecifically binds to the CoV-HKU1, in a biological sample, for example blood, serum, plasma, saliva, urine, etc., from a patient suffering from respiratory tract infection. In a specific embodiment, the method comprising contacting the sample with the polypeptides or protein encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-1318 shown in **FIG. 2**, SEQ ID NOS:1319-2918 shown in **FIG. 3**, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937,

2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 shown in **FIG. 9**, directly immobilized on a substrate and detecting the virus-bound antibody directly or indirectly by a labeled heterologous anti-isotype antibody. In another specific embodiment, the sample is contacted with a host cell comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and expressing the polypeptides encoded thereby, and the bound antibody can be detected by immunofluorescent assay.

**[0108]** An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of detecting an epitope or nucleic acid (e.g., mRNA, genomic RNA) of CoV-HKU1 such that the presence of CoV-HKU1 is detected in the sample. A preferred agent for detecting CoV-HKU1 mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof, or a complement thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1,000 or more contiguous nucleotides in length and sufficient to specifically hybridize under stringent conditions to a CoV-HKU1 mRNA or genomic RNA.

**[0109]** In another preferred specific embodiment, the presence of CoV-HKU1 is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the genome of CoV-HKU1 or a genomic nucleic acid sequence of SEQ ID NO:3 or 2919, or based on a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a non-limiting specific embodiment, preferred primers to be used in a RT-PCR method are: 5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5), or 5'-AAAGGATGTTGAC-AACCCTGTT-3' (LPW1926; SEQ ID NO: 2968) and 5'-ATCATCATAC-TAAAATGCT-TACA-3' (LPW1927; SEQ ID NO: 2969), in the presence of 3 mM MgCl<sub>2</sub> and the thermal cycles are, for example, but not limited to, 94° C. for 8 min followed by 40 cycles of 94° C. for 1 min, 50° C. for 1 min, 72° C. for 1 min. In more preferred specific embodiment, the present invention provides a real-time quantitative PCR assay to detect the presence of CoV-HKU1 in a biological sample by subjecting the cDNA obtained by reverse transcription of the extracted total RNA from the sample to PCR reactions using

the specific primers, such as those having nucleotide sequences of SEQ ID NOS:4, 5, 2968 and 2969, and a fluorescence dye, such as SYBR® Green I, which fluoresces when bound non-specifically to double-stranded DNA. The fluorescence signals from these reactions are captured at the end of extension steps as PCR product is generated over a range of the thermal cycles, thereby allowing the quantitative determination of the viral load in the sample based on an amplification plot.

[0110] A preferred agent for detecting CoV-HKU1 is an antibody that specifically binds a polypeptide of the invention or any CoV-HKU1 epitope, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used.

[0111] The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The detection method of the invention can be used to detect mRNA, protein (or any epitope), or genomic RNA in a sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include northern hybridizations, in situ hybridizations, RT-PCR, and RNase protection. In vitro techniques for detection of an epitope of CoV-HKU1 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic RNA include northern hybridizations, RT-PCR, and RNase protection. Furthermore, in vivo techniques for detection of CoV-HKU1 include introducing into a subject organism a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in the subject organism can be detected by standard imaging techniques, including autoradiography.

[0112] In a specific embodiment, the methods further involve obtaining a control sample from a control subject, contacting the control sample with a compound or agent capable of detecting CoV-HKU1, e.g., a polypeptide of the invention or mRNA or genomic RNA encoding a polypeptide of the invention, such that the presence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide is detected in the sample, and comparing the absence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide in the control sample with the presence of CoV-HKU1, or the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

[0113] The invention also encompasses kits for detecting the presence of CoV-HKU1 or a polypeptide or nucleic acid

of the invention in a test sample. The kit, for example, can comprise a labeled compound or agent capable of detecting CoV-HKU1 or the polypeptide or a nucleic acid molecule encoding the polypeptide in a test sample and, in certain embodiments, a means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for use.

[0114] For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention or CoV-HKU1 epitope; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

[0115] For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or to a sequence within the CoV-HKU1 genome or (2) a pair of primers useful for amplifying a nucleic acid molecule containing a CoV-HKU1 sequence. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for use.

## 6. EXAMPLES

[0116] The following examples illustrate the identification of the novel CoV-HKU1. These examples should not be construed as limiting.

### METHODS AND RESULTS

[0117] As a general reference, Wiedbrauk D L & Johnston S L G. (Manual of Clinical Virology, Raven Press, New York, 1993) was used.

#### 6.1 Example 1

##### 6.1.1 Clinical Subject

[0118] The patient is an in-patient of the United Christian Hospital in Hong Kong. Nasopharyngeal aspirates were collected from the patient weekly from the first till the fifth week of the illness, stool and urine in the first and second week of the illness, and sera in the first, second, and fourth weeks of the illness.

##### 6.1.2 Antibody Detection

[0119] To produce a fusion plasmid for protein purification, primers, 5'-TTTTCCTTTT GCGGCCGCTTAAG-CAACAGAGTCTTCTA-3' (SEQ ID NO:6) and 5'-CG-GAATC GATGTCCTATACTCCCGGT-3'(SEQ ID NO:7) were used to amplify the gene encoding the N protein of the CoV-HKU1 by RT-PCR. The sequence coding for amino acid residues 1 to 441 of the N protein was amplified and cloned into the EcoRI and NotI sites of expression vector

pET-28b(+) (Novagen, Madison, Wis., USA) in frame and downstream of the series of six histidine residues. The (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein was expressed in *E. coli* and purified using the Ni<sup>2+</sup>-loaded HiTrap Chelating System (Amersham Pharmacia, USA) according to the manufacturer's instructions.

[0120] Western blot analysis was performed as follows: Two-hundred ng of purified (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein of CoV-HKU1 were loaded into each well of a sodium dodecyl sulfate (SDS)—10% polyacrylamide gel and subsequently electroblotted onto a nitrocellulose membrane (Bio-Rad, Hercules, Calif., USA). The blot was cut into strips and the strips were incubated separately with 1:2000 dilution of serum samples obtained during the first, second, and fourth weeks of the patient's illness. Serum samples of two healthy blood donors were used as controls. Antigen-antibody interaction was detected with an ECL fluorescence system (Amersham Life Science, Buckinghamshire, UK).

[0121] Several prominent immunoreactive bands were visible for serum samples collected during the second and fourth weeks of the patient's illness (FIG. 8, lanes 2 and 3). The sizes of the largest bands were about 53 kDa, consistent with the expected size of 52.8 kDa for the full-length (His)<sub>6</sub>-tagged (SEQ ID NO:27) N protein, whereas the other bands were consistent with the degradation products of the (His)<sub>6</sub>-tagged (SEQ ID NO:27) N protein. Only very faint bands were observed for serum samples obtained from the patient during the first week of the illness (FIG. 8, lane 1) and two healthy blood donors (FIG. 8, lanes 4 and 5).

[0122] ELISA was performed using the recombinant N protein of CoV-HKU1 prepared as described above. Each well of a Nunc immunoplate (Roskilde, Denmark) was coated with 20 ng of purified (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein for 12 h and then blocked in phosphate-buffered saline with 2% bovine serum albumin. The serum samples obtained from the patient during the first, second, and fourth weeks of the illness were serially diluted and were added to the wells of the (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein-coated plates in a total volume of 100  $\mu$ l per well and incubated at 37° C. for 2 h. After washing with washing buffer five times, 100  $\mu$ l per well of 1:4000 diluted horse radish peroxidase-conjugated goat anti-human IgG antibody (Zymed Laboratories Inc., South San Francisco, Calif., USA) were added to the wells and incubated at 37° C. for 1 h. After washing with washing buffer five times, 100  $\mu$ l of diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at room temperature for 15 min. One hundred microliters of 0.3 M H<sub>2</sub>SO<sub>4</sub> were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

[0123] Box titration was carried out with different dilutions of (His)<sub>6</sub>-tagged (SEQ ID NO:27) recombinant N protein coating antigen and serum obtained from the fourth week of the patient's illness. The results identified 20 ng and 80 ng of purified (His)<sub>6</sub>-tagged recombinant N protein per ELISA well as the ideal amount for plate coating and 1:1000 and 1:20 as the most optimal serum dilution for IgG and IgM detection, respectively.

[0124] To establish the baseline for the tests, serum samples (diluted at 1:1000 and 1:20 for IgG and IgM,

respectively) from 100 healthy blood donors were tested in the CoV-HKU1 antibody ELISA. For the 100 sera from healthy blood donors, the mean ELISA OD<sub>450</sub> values for IgG and IgM detection were 0.178 and 0.224, with standard deviations of 0.070 and 0.117. Absorbance values of 0.387 and 0.576 were selected as the cutoff values (that equal the sum of the mean value from the healthy control and three times the standard deviation) for IgG and IgM, respectively. Using these cutoff values, the titers for IgG of the patient's serum samples obtained during the first, second, and fourth weeks of the illness were <1:1000, 1:2000, and 1:8000, respectively (FIG. 7), and those for IgM were 1:20, 1:40, and 1:80, respectively (data not shown).

### 6.1.3 RT-PCR and Real Time Quantitative PCR

#### RT-PCR Assay

[0125] An RT-PCR was developed to detect the CoV-HKU1 sequence from NPA samples. Total RNA from clinical samples was reverse transcribed using random hexamers and cDNA was amplified using primers 5'-GGTTGGGAC-TATCCTAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCAT-CATCAGATAGAATCATCATA-3' (SEQ ID NO:5), which were constructed based on the RNA-dependent RNA polymerase-encoding sequence (SEQ ID NO:1) of the CoV-HKU1 in the presence of 2.5 mM MgCl<sub>2</sub> (94° C. for 8 min followed by 40 cycles of 94° C. for 1 min, 50° C. for 1 min, 72° C. for 1 min).

[0126] The summary of a typical RT-PCR protocol is as follows:

#### [0127] 1. RNA Extraction

[0128] RNA from 140  $\mu$ l of NPA samples was extracted by QIAquick® viral RNA extraction kit and was eluted in 50  $\mu$ l of elution buffer.

#### [0129] 2. Reverse Transcription

RNA	11.5 $\mu$ l
0.1 M DTT	2 $\mu$ l
5 × buffer	4 $\mu$ l
10 mM dNTP	1 $\mu$ l
Superscript II, 200 U/ $\mu$ l (Invitrogen)	1 $\mu$ l
Random hexamers, 0.3 $\mu$ g/ $\mu$ l	0.5 $\mu$ l
Reaction condition	42° C., 50 min 94° C., 3 min 4° C.

#### [0130] 3. PCR

[0131] cDNA generated by random primers was amplified in a 50  $\mu$ l reaction as follows:

cDNA	2 $\mu$ l
10 mM dNTP	0.5 $\mu$ l
10 × buffer	5 $\mu$ l
25 mM MgCl <sub>2</sub>	5 $\mu$ l
25 $\mu$ M Forward primer	0.5 $\mu$ l
25 $\mu$ M Reverse primer	0.5 $\mu$ l
AmpliTaQ Gold® polymerase, 5 U/ $\mu$ l (Applied Biosystems)	0.25 $\mu$ l
Water	36.25 $\mu$ l

[0132] Thermal-cycle condition: 95° C., 10 min, followed by 40 cycles of 95° C., 1 min; 50° C. 1 min; 72° C., 1 min.

[0133] 4. Primer Sequences

[0134] Primers were designed based on the RNA-dependent RNA polymerase encoding sequence (SEQ ID NO:1) of the CoV-HKU1.

Forward primer:  
5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO: 4)

Reverse primer: and  
5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO: 5)

Product size:  
440 bps

[0135] Real-Time Quantitative PCR Assay

[0136] Total RNA from 140 µl of nasopharyngeal aspirate (NPA) was extracted by QIAamp® virus RNA mini kit (Qiagen) as instructed by the manufacturer. Ten µl of eluted RNA samples were reverse transcribed by 200 U of Super-script® II reverse transcriptase (Invitrogen) in a 20 µl reaction mixture containing 0.15 µg of random hexamers, 10 mmol/L DTT, and 0.5 mmol/L dNTP, as instructed. Complementary DNA was then amplified in a SYBR® Green I fluorescence reaction (Roche, Ind.) mixtures. Briefly, 20 µl reaction mixtures containing 2 µl of cDNA, 3.5 mmol/L MgCl<sub>2</sub>, 0.25 µmol/L of forward primer [5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO:4)] and 0.25 µmol/L reverse primer [5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5)] were thermal-cycled by a LightCycler® (Roche) with the PCR program, [95° C., 10 min followed by

50 cycles of 95° C., 10 min; 57° C., 5 sec; 72° C. 9 sec]. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were captured at the end of extension step in each cycle. To determine the specificity of the assay, PCR products (440 base pairs) were subjected to a melting curve analysis at the end of the assay (65° C. to 95° C., 0.1° C. per second) (data not shown).

[0137] The amount of CoV-HKU1 RNA in the nasopharyngeal aspirates was followed weekly. Quantitative RT-PCR showed that the amounts of CoV-HKU1 RNA were 8.5×10<sup>5</sup> and 9.6×10<sup>6</sup> copies per ml in two nasopharyngeal aspirates collected in the first week of the illness, 1.5×10<sup>5</sup> copies per ml of NPA, respectively, at two time points collected in the second week of the illness, but CoV-HKU1 RNA was undetectable in the NPA collected in the third, fourth and fifth weeks of the illness (FIG. 7). CoV-HKU1 RNA was also undetectable in the urine and stool of the patient collected in the first and second weeks of the illness.

DISCUSSION

[0138] The genome of CoV-HKU1 is a 29926-nucleotide long, polyadenylated RNA. The G+C content is 32%, which is the lowest among all known coronaviruses with genome sequences available, with a GC skew of 0.19. Table 1 shows comparison of genomic features of CoV-HKU1 and other coronaviruses and amino acid identities between the predicted chymotrypsin-like protease (3CL<sup>pro</sup>), RNA dependent RNA polymerase (Pol), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses

TABLE 1

Coronaviruses <sup>a</sup>	Genome features		Pairwise amino acid identity (%)							
	Size (bases)	G + C content	3CL <sup>pro</sup>	Pol	Hel	HE	S	E	M	N
Group 1										
HCoV-229E	27317	0.38	45	54	55	—	31	26	35	28
PEDV	28033	0.42	44	56	55	—	30	34	37	37
PTGV	28586	0.38	45	57	57	—	32	34	37	27
CCoV	—	—	—	—	—	—	31	32	36	27
HCoV-NL63	27553	0.34	43	54	54	—	30	28	32	28
Group 2										
CoV-HKU1	29926	0.32	—	—	—	—	—	—	—	—
HCoV-OC43	30738	0.37	82	87	88	57	60	54	76	58
MHV	31357	0.42	85	90	89	50	61	57	84	68
BCoV	31028	0.37	84	88	88	56	61	55	76	57
SDAV	—	—	—	—	—	50	61	60	77	62
ECoV	—	—	—	—	—	53	61	56	78	59
PHEV	—	—	—	—	—	54	61	54	77	57
Group 3										
IBV	27608	0.38	41	60	57	—	32	28	38	27
SARS-CoV	29751	0.41	48	65	63	—	33	27	34	31

<sup>a</sup>HCoV-229E, human coronavirus 229E; PEDV, porcine epidemic diarrhea virus; PTGV, porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63, human coronavirus NL63; HCoV-OC43, human coronavirus OC43; MHV, murine hepatitis virus; BCoV, bovine coronavirus; SDAV, rat sialodacryoadenitis coronavirus; ECoV, equine coronavirus NC99; PHEV, porcine hemagglutinating encephalomyelitis virus; IBV, infectious bronchitis virus; SARS-CoV, SARS coronavirus

[0139] The genome organization is the same as other coronaviruses, with the characteristic gene order 5'-replicase, S, E, M, N-3'. Both 5' and 3' ends contain short untranslated regions. The 5' end of the genome consists of a putative 5' leader sequence. A putative transcription regulatory sequences (TRS) motif, 5'-CUAAAC-3', was found at the 3' end of the leader sequence and precedes each translated ORF except ORF4 and ORF6 which encodes the putative E protein. Table 2 shows the putative transcription regulatory sequences in the genome of CoV-HKU1.

TABLE 2

Number of base up-stream of AUG ORF	TRS sequence	SEQ ID NO.
-140 Leader	UUAAAUCUAAACUUUUUAA AUG (127)	8
-7 Hemagglutinin esterase	UUAAAUCUAAACU AUG	9
-6 Spike	UUAAAUCUAAAC AUG	10
-13 ORF 5	UUAAAUCUAAACUUUUUUU AUG	11
-9 Membrane	CUAAAUCUAAACAUU AUG	12
-13 Nucleocapsid	UUAAAUCUAAACUAUUUAGG AUG	13
-35 ORF 9	UUAAAUCUAAACUAUUUAGGAUGUCUUU ACUCCCGUCAU AUG	14

[0140] As in SDAV (Sialodacryoadenitis virus) and MHV (mouse hepatitis virus), ORF6 may share the same TRS with ORF 5, suggesting that the translation of the E protein is cap-independent, possibly via an internal ribosomal entry site. The 3' untranslated region contains a predicted pseudoknot structure 59-119 bp downstream of N gene. This pseudoknot structure is highly conserved among coronaviruses and plays a role in coronavirus RNA replication.

[0141] The coding potential of the CoV-HKU1 genome is shown in FIG. 4 and Table 3 and the phylogenetic analyses of the chymotrypsin-like protease (3CL<sup>PRO</sup>), replicase, helicase, haemagglutinin-esterase (HE), S, E, M and N, are shown in FIGS. 5A and 5B.

TABLE 3

ORFs	Start-end (base)	No. of bases	No. of amino acids	Frame	Candidate TRS
ORF 1a	206-13600	13395	4465	+2	—
ORF 1b	13600-21753	8154	2717	+1	—
HE (ORF 2)	21773-22933	1161	386	+2	Strong
S (ORF 3)	22942-27012	4071	1356	+1	Strong
ORF 4	26960-27070	111	36	+2	None
ORF 5	27051-27380	330	109	+3	Strong
E (ORF 6)	27373-27621	249	82	+1	None
M (ORF 7)	27633-28304	672	223	+3	Strong
N (ORF 8)	28320-29645	1326	441	+3	Strong
ORF 9	28342-28959	618	205	+1	Strong

[0142] The replicase 1a ORF (bases 206-13600) and replicase 1b ORF (bases 13600-21753) occupy 21.5 kb of the CoV-HKU1 genome. Similar to other coronaviruses, a frame shift interrupts the protein-coding regions and separates the 1a and 1b ORFs. This ORF encodes a number of putative proteins, including papain-like protease (PLP) with two copies of the PLP domain, PLP1<sup>PRO</sup> and PLP2<sup>PRO</sup>, 3CL<sup>PRO</sup>, replicase, helicase, and other proteins of unknown functions. These proteins are produced by proteolytic cleavages of a large polyprotein (FIG. 4). The sequence of the resulting putative proteins is the same as that in the MHV genome. This polyprotein is synthesized by a -1 ribosomal frameshift at a conserved site (UUUAAAAC) upstream of a pseudoknot structure at the junction of ORF 1 a and ORF 1b. This ribosomal frameshift would result in a polyprotein of 7182 amino acids, which has 75-77% amino acid identities with the polyprotein in other Group 2 coronaviruses and 43-47% amino acid identities with the polyprotein in other non-Group 2 coronaviruses. The replicase gene of CoV-HKU1, which encodes 928 amino acids, has 87-89% amino acid identities with the replicase of other Group 2 coronaviruses and 54-65% amino acid identities with the replicase of other non-Group 2 coronaviruses (Table 4 and FIG. 5A). Table 4 shows amino acid identities between the predicted chymotrypsin-like protease (3CL<sup>PRO</sup>), replicase (Rep), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses.

TABLE 4

Group	Virus	Pairwise amino acid identity (%)							
		3CL <sup>PRO</sup>	Rep	Hel	HE	S	E	M	N
1	HCoV-229E	45	54	55	—	31	26	35	28
	PEDV	44	56	55	—	30	34	37	37
	PTGV	45	57	57	—	32	34	37	27
	CCoV	—	—	—	—	31	32	36	27
	HCoV-NL63	43	54	54	—	30	28	32	28
2	HCoV-OC43	82	87	88	57	60	54	76	58
	MHV	85	89	87	50	58	55	78	60
	BCoV	84	88	88	56	61	55	76	57
	SDAV	—	—	—	50	61	60	77	62
	ECoV	—	—	—	53	61	56	78	59
3	PHEV	—	—	—	54	61	54	77	57
	IBV	41	60	57	—	32	28	38	27
	SARS-CoV	48	65	63	—	33	27	34	31

HCoV-229E = human coronavirus 229E;  
 PEDV = porcine epidemic diarrhea virus;  
 PTGV = porcine transmissible gastroenteritis virus;  
 CCoV = canine enteric coronavirus;  
 HCoV-NL63 = human coronavirus NL63;  
 HCoV-OC43 = human coronavirus OC43;  
 MHV = murine hepatitis virus;  
 BCoV = bovine coronavirus;  
 SDAV = rat sialodacryoadenitis coronavirus;  
 ECoV = equine coronavirus NC99;  
 PHEV = porcine hemagglutinating encephalomyelitis virus;  
 IBV = infectious bronchitis virus;  
 SARS-CoV = SARS coronavirus

[0143] The catalytic histidine and cysteine amino acid residues, conserved among the 3CL<sup>PRO</sup> in all coronaviruses, are present in the predicted 3CL<sup>PRO</sup> of CoV-HKU1 (amino acids His<sup>3375</sup> and Cys<sup>3479</sup> of ORF 1a). In the N-terminal of the putative PLP (amino acid residues 945 to 1104 of ORF 1a), there are 14 tandem copies of a 30-base repeat, which

encode NDDDEDVVTGD (SEQ ID NO:15), followed by two 30-base regions that encode NNDEEIVTGD (SEQ ID NO:16) and NDDQIVVTGD (SEQ ID NO:17), located upstream to the first copy of PLP domain, PLP1<sup>PRO</sup>. This repeat is not observed in other coronaviruses.

**[0144]** ORF 2 (bases 21773-22933) encodes the predicted HE glycoprotein with 386 amino acids. The HE protein of CoV-HKU1 has 50-57% amino acid identities with the HE proteins of other Group 2 coronaviruses (Table 4 and **FIG. 5A**). PFAM and InterProScan analyses of the ORF show that amino acid residues 1 to 349 of the predicted protein is a member of the haemagglutinin esterase family (PFAM accession no.: PF03996 and INTERPRO accession no. IPR007142). This family contains membrane glycoproteins that are present on viral surface and are involved with the cell infection process. It contains haemagglutinin chain 1 (HE1) and haemagglutinin chain 2 (HE2), and forms a homotrimer with each monomer being formed by two chains linked by a disulphide bond. Furthermore, PFAM and InterProScan analyses of the ORF show that amino acid residues 122 to 236 of the predicted protein are the haemagglutinin domain of HE-fusion glycoprotein family (PFAM accession no.: PF02710 and INTERPRO accession no. IPR003860). HE is also present in other Group 2 coronaviruses and influenza C virus. SignalP analysis reveals a signal peptide probability of 0.738, with a cleavage site between residues 13 and 14. Although TMPred and TMHMM analyses of the ORF show four and three transmembrane domains, respectively, PHDhtm analysis of the ORF shows only one transmembrane domain at positions 354 to 376. This concurs with only one transmembrane region reported in the C terminal of the HE of BCoV (bovine coronavirus) and puffinosis virus. PrositeScan analysis of the HE protein of CoV-HKU1 reveals eight potential N-linked glycosylation (six NXS and two NXT) sites. These are located at positions 83 (NYT), 110, (NGS), 145 (NVS), 168 (NYS), 193 (NFS), 286 (NSS), 314 (NVS, and 328 (NFT). The putative active site for neuraminidase O-acetyl-esterase activity, FGDS (SEQ ID NO:18), is located at positions 31-34.

**[0145]** ORF 3 (bases 22942-27012) encodes the predicted S glycoprotein (PFAM accession no. PF01601) with 1356 amino acids. The S protein of CoV-HKU1 has 58-61% amino acid identities with the S proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the S proteins of Group 1, Group 3, and SARS-CoV (Table 4 and **FIG. 5B**). InterProScan analysis predicts it as a type I membrane glycoprotein. Important features of the S protein of CoV-HKU1 are depicted in **FIG. 6**. PrositeScan of the S protein of CoV-HKU1 reveals 28 potential N-linked glycosylation (12 NXS and 16 NXT) sites. SignalP analysis reveals a signal peptide probability of 0.909, with a cleavage site between residues 13 and 14. By multiple alignments with the S proteins of other Group 2 coronaviruses, a potential cleavage site located after RRRRR (SEQ ID NO:19), between residues 760 and 761, where S will be cleaved into S1 and S2, is identified. Immediately upstream to RRRRR (SEQ ID NO:19), there is a series of five serine residues that are not present in any other known coronaviruses (**FIG. 6**). Most of the S protein (residues 15 to 1300) is exposed on the outside of the virus, with a transmembrane domain at the C terminus (TMHMM analysis of the ORF shows one transmembrane domain at positions 1301 to 1356), followed by a cytoplasmic tail rich in cysteine residues. Two heptad repeats (HR), located at residues 982

to 1083 (HR1) and 1250 to 1297 (HR2), identified by multiple alignments with other coronaviruses, are present. In MHV, it has been confirmed that the receptor for its S protein binding is CEACAMI, a member of the carcinoembryonic antigen (CEA) family of glycoproteins in the immunoglobulin superfamily. Furthermore, it has been shown, by site-directed mutagenesis, that three conserved regions (sites I, II, and III) and some amino acid residues (Thr<sup>62</sup>, Thr<sup>212</sup>, Tyr<sup>214</sup>, and Tyr<sup>216</sup> in MHV) in the N-terminal of the S protein are particularly important for its receptor-binding activity. By multiple alignments with the N-terminal 330 amino acids of the S protein of MHV and other group 2 coronaviruses, it is observed that these conserved regions and amino acids are present in CoV-HKU1 (**FIG. 6**). This infers that the receptor for CoV-HKU1 could be a member of the CEA family on the surface of the cells in the respiratory tract. On the other hand, for HCoV-OC43, it has been shown in vitro that the receptor for the S protein is a sialic acid. However, the amino acid residues on the S protein of HCoV-OC43 that are important for receptor binding are not well defined.

**[0146]** ORF 4 (bases 26960-27070) encodes a predicted protein with 36 amino acids. This ORF overlaps with the ORF that encodes the S protein. This ORF is not present in other coronaviruses and BlastP analysis of the ORF does not show any hits.

**[0147]** ORF 5 (bases 27051-27380) encodes a predicted protein with 109 amino acids. This ORF overlaps with the ORF that encodes the E protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus non-structural protein NS2 family (PFAM accession no.: PF04753). TMPred and TMHMM analysis do not reveal any transmembrane helix. This predicted protein of CoV-HKU1 has 44-51% amino acid identities with the corresponding proteins of other Group 2 coronaviruses.

**[0148]** ORF 6 (bases 27373-27621) encodes the predicted E protein with 82 amino acids. The E protein of CoV-HKU1 has 54-60% amino acid identities with the E proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the E proteins of Group 1, Group 3, and SARS-CoV (Table 4 and **FIG. 5B**). PFAM and InterProScan analyses of the ORF show that the predicted E protein is a member of the non-structural protein NS3/Small envelope protein E (NS3<sub>envE</sub>) family (PFAM accession no.: PF02723). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.995). TMPred analysis of the ORF shows two transmembrane domains at positions 16 to 34 and 39 to 59, and TMHMM analysis of the ORF shows two transmembrane domains at positions 10 to 32 and 39 to 58, consistent with the anticipated association of the E protein with the viral envelope. Both programs predict that both the N and C termini are located on the surface of the virus.

**[0149]** ORF 7 (bases 27633-28304) encodes the predicted M protein with 223 amino acids. The M protein of CoV-HKU1 has 76-78% amino acid identities with the M proteins of other Group 2 coronavirus, but has fewer than 40% amino acid identities with the M proteins of Group 1, Group 3, and SARS-CoV (Table 4 and **FIG. 5B**). PFAM analysis of the ORF shows that the predicted M protein is a member of the coronavirus matrix glycoprotein (Corona\_M) family (PFAM accession no.: PF01635). SignalP analysis predicts the pres-

ence of a transmembrane anchor (probability 0.926). TMpred analysis of the ORF shows three transmembrane domains at positions 21 to 42, 53 to 74, and 77 to 98. TMHMM analysis of the ORF shows three transmembrane domains at positions 20 to 39, 46 to 68, and 78 to 100. The N terminal 19-20 amino acids are located on the outside and the C terminal 123-125-amino acid hydrophilic domain on the inside of the virus.

**[0150]** ORF 8 (bases 28320-29645) encodes the predicted N protein (PFAM accession no.: PF00937) with 441 amino acids. The N protein of CoV-HKU1 has 57-62% amino acid identities with the N proteins of other Group 2 coronaviruses, but has fewer than 40% amino acid identities with the N proteins of Group 1, Group 3, and SARS-CoV (Table 4 and FIG. 5B).

**[0151]** ORF 9 (bases 28342-28959) encodes a hypothetical protein (N2) of 205 amino acids within the ORF that encodes the predicted N protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus nucleocapsid I protein (Corona\_I) family (PFAM accession no.: PF03187). This hypothetical N2 protein of CoV-HKU1 has 32-39% amino acid identities with the N2 proteins of other Group 2 coronaviruses.

**[0152]** We report the characterization and complete genome sequence of a novel coronavirus detected in the nasopharyngeal aspirates of patients with pneumonia. The clinical significance of the virus in the first patient was evident by the high viral loads in the patient's nasopharyngeal aspirates during the first week of his illness, which coincided with the acute symptoms developed in the patient. The viral load decreased during the second week of the illness and was undetectable in the third week of the illness. In addition, the fall in viral load was accompanied by the recovery from the illness and development of specific antibody response to the recombinant N protein of the virus. Similar to other recently discovered viruses, such as hepatitis C virus, GB virus C, transfusion transmitted virus, and SEN virus, the present virus could not be recovered from cell cultures using the standard cell lines. This could be related to the inherently low recovery rate of coronaviruses. Human coronaviruses are particularly difficult to culture in vitro. Many decades after the recognition of HCoV-229E and HCoV-OC43, there are still only a handful of primary virus isolates available and organ culture is required for primary isolation of HCoV-OC43. In our experience, SARS-CoV can only be recovered from less than 20% of patients with serologically and RT-PCR documented SARS-CoV pneumonia. Therefore, it is not surprising that the new coronavirus CoV-HKU1 has been so far proven difficult to culture in vitro. After the discovery of CoV-HKU1 in the first patient, we conducted a preliminary study on 400 nasopharyngeal aspirates that were collected last year during the SARS epidemic period. Among these 400 nasopharyngeal aspirates, CoV-HKU1 was detected in one specimen, with a viral load comparable to that of the first patient. These results have suggested that CoV-HKU1 is not only incidentally found in one patient, but a previously unrecognized coronavirus associated with pneumonia.

**[0153]** Genomic analysis has revealed that CoV-HKU1 is a Group 2 coronavirus. The genome organization of CoV-HKU1 concurs with those of other coronaviruses, with the characteristic gene order, i.e., 5'-replicase, S, E, M, N-3',

short untranslated regions in both 5' and 3' ends, 5' conserved coronavirus core leader sequence, putative TRS upstream to multiple ORFs, and conserved pseudoknot in the 3' untranslated region. In contrast to coronaviruses of other groups, CoV-HKU1 contains certain features that are characteristics of Group 2 coronaviruses, including the presence of HE, ORF 5, and N2. Phylogenetic analysis of the 3CL<sup>pro</sup>, replicase, helicase, S, E, M, and N proteins showed that these genes of CoV-HKU1 were clustered with the corresponding genes in other Group 2 coronaviruses. However, the proteins of CoV-HKU1 formed distinct branches in the phylogenetic trees, indicating that CoV-HKU1 is a distinct member of the group, and is not very closely related to any other known members of Group 2 coronaviruses (FIGS. 4A and 4B).

**[0154]** In addition to phylogenetic analysis of the putative proteins, CoV-HKU1 exhibits certain features that are distinct from other Group 2 coronaviruses. Compared to other Group 2 coronaviruses, there is a deletion of about 800 bps between the replicase ORF 1b and the HE ORF 2 in CoV-HKU1. In other Group 2 coronaviruses, including MHV, SDAV, HCoV-OC43 and BCoV, an ORF of 798-837 bp (273-278 amino acids) is present between the replicase 1b ORF and the HE ORF 2. This ORF encodes a protein of the coronavirus non-structural protein NS2a family (PFAM accession no.: PF05213). The absence of this ORF in CoV-HKU1 indicates that this is probably a non-essential gene of coronavirus. In addition to the deletion, the N-terminal of the putative PLP in ORF 1a contains 14 tandem copies of a 30-bp repeat that codes for a highly acidic domain. Similar repeats, with different amino acid compositions, have been found in the genomes of human, rat and parasites, but have not been found in other coronaviruses. The function of these repeats is not well understood, although some authors have suggested that the repeats could be important antigens, and their biological role may be related to their special three-dimensional structures. The vitellaria antigenic protein of *Clonorchis sinensis* contains 23 tandem copies of a 30-bp repeat that codes for DGGAQP-PKSG (SEQ ID NO:20). In the case of *Plasmodium falciparum*, it has been shown that the antigenicity of the circumsporozoite protein is due to its repeating epitope structure. It has also been suggested that the tandemly repeated peptide may induce strong humoral immune response in the infected host and thus may also be useful in serological diagnosis. Further experiments should be performed to delineate the antigenic properties, biological role, and possible clinical usefulness of the repeat in the PLP of CoV-HKU1.

**[0155]** The geographical, political, and economic location of Hong Kong makes it a unique place for the study of emerging infectious disease. Hong Kong, as the gateway of southern China, with thousands of people crossing the border on surface and by air every day, has a high potential of importing and exporting infectious diseases to and from China, countries in Southeast Asia and from the rest of the world. In 1997, the first 18 human cases of avian influenza A H5N1 virus infection were reported in Hong Kong. In early 2003, two cases of human infection caused by avian influenza A (H5N1) that was acquired in Fujian, were diagnosed in Hong Kong, which provided an early warning of the impending disease threat for humans and poultry in Southeast Asia that followed in 2004. For the SARS epidemic, although both epidemiological and genomic evidence revealed that the disease had first occurred in southern



China in November 2002, it did not receive as much international attention until the disease was spread to Hong Kong and through Hong Kong to Singapore, Toronto, Vietnam, and the United States of America. As for emerging bacterial infections, 50% of the patients with gastroenteritis associated with the recovery of *Laribacter hongkongensis* had recent history of travel to southern China. In this report, one of the patients also had recent history of travel to Shenzhen of China prior to the development of the respiratory illness. We speculate that he might have contacted the virus in Shenzhen. More intensive surveillance of emerging infectious pathogens in this locality is warranted.

## 6.2 Example 2

**[0156]** We prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period. A 453-bp fragment of the pol gene of CoV-HKU1 was amplified from the extracted RNA by RT-PCR using CoV-HKU1 specific primers. The epidemiological, clinical, laboratory and radiological features of patients with pneumonia associated with CoV-HKU1 were analyzed. Specific antibodies were detected using a recombinant CoV-HKU1 N protein based ELISA. The complete pol, S and N genes of the CoV-HKU1 were amplified and sequenced. RNA extracted from 208 nasopharyngeal swabs and fecal samples from 56 wild and domestic animals in Hong Kong and southern China were subject to RT-PCR of pol gene of CoV-HKU1 using CoV-HKU1 specific primers.

### 6.2.1 Patients and Microbiological Methods

**[0157]** All prospectively collected NPAs from patients with community-acquired pneumonia sent to the clinical microbiology laboratories of four regional hospitals in Hong Kong during a 12-month period [Mar. 22, 2003 (beginning of SARS epidemic in Hong Kong)—Mar. 21, 2004] for detection of SARS-CoV but negative for SARS-CoV RNA by RT-PCR were included in the study. Community-acquired pneumonia is defined as symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which there is no other explanation that develop prior to or within 48 h after presentation to hospital. Once CoV-HKU1 was detected from NPAs, the hospital records, laboratory results and chest radiographs of the corresponding patients were retrieved and examined by two infectious disease physicians. The RNA extracted from the NPAs was subject to RT-PCR for influenza A virus and human metapneumovirus (Peiris J S M et. al., *Lancet* 2003; 361: 1319-25). Available stored serum samples were subject to serological assays for detection of antibodies against *Mycoplasma*, *Chlamydia*, *Legionella* and SARS-CoV by SERODIA-MYCO II (Fujirebio Inc., Tokyo, Japan), *Chlamydia pneumoniae* MIF IgG (Focus technologies, Cypress, Calif., USA), indirect immunofluorescence (MRL, San Diego, Calif., USA) and our recently developed enzyme-linked immunosorbent assay (ELISA), respectively (Woo P C Y et al., *Lancet* 2004; 363:841-5).

**[0158]** To determine the possible risk factors associated with CoV-HKU1 pneumonia, two age- and sex-matched controls per patient with CoV-HKU1 pneumonia were randomly selected from those with community-acquired pneumonia but their NPAs negative for CoV-HKU1. Controls

were within five years older or younger than the corresponding patients with CoV-HKU1 pneumonia, and were admitted within 15 days before or after admission of the corresponding patients with CoV-HKU1 pneumonia. The hospital records, laboratory results and chest radiographs of the controls were retrieved and examined by the two infectious disease physicians.

### 6.2.2 RNA Extraction

**[0159]** Viral RNA was extracted from NPAs using QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions within 10 h upon receipt of specimens. The eluted RNA was used as the template for RT-PCR. All extracted RNA was stored immediately at  $-70^{\circ}$  C. until use.

### 6.2.3 RT-PCR of RNA-Dependent RNA Polymerase Gene of Coronavirus-HKU1 Using Coronavirus-HKU1 Specific Primers and DNA Sequencing

**[0160]** A 453-bp fragment of the RNA dependent RNA polymerase (pol) gene of CoV-HKU1 was amplified by RT-PCR using CoV-HKU1 specific primers, 5'-AAAG-GATGT-TGACAACCCTGTT-3' (LPW1926; SEQ ID NO:2968) and 5'-ATCATCATACTAAAATGC-TTACA-3' (LPW1927; SEQ ID NO:2969) designed by multiple alignment of the nucleotide sequences of the pol genes of the two CoV-HKU1 (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895) and those of the available pol genes of other known human coronaviruses. RT was performed using the SuperScript II kit (Invitrogen, San Diego, Calif., USA) according to manufacturer's instructions. The PCR mixture (50  $\mu$ l) contained cDNA, PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 3 mM MgCl<sub>2</sub> and 0.01% gelatin), 200  $\mu$ M of each dNTPs and 1.0 U Taq polymerase (Boehringer Mannheim, Germany). The mixtures were amplified in 40 cycles of 94 $^{\circ}$  C. for 1 min, 48 $^{\circ}$  C. for 1 min and 72 $^{\circ}$  C. for 1 min, and a final extension at 72 $^{\circ}$  C. for 10 min in an automated thermal cycler (Perkin-Elmer Cetus, Gouda, The Netherlands). Distilled water was used as the negative control. To ensure the high specificity of the CoV-HKU1 specific primers, RNA extracted from 200 NPAs positive for influenza A and B viruses, parainfluenza viruses 1-3, respiratory syncytial virus (RSV), or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV were also subject to RT-PCR using the two CoV-HKU1 specific primers.

**[0161]** Ten microlitres of each amplified product was electrophoresed in 1.5% (w/v) agarose gel, with a molecular size marker ( $\Phi$ X-174 DNA HaeIII digest, Boehringer Mannheim, Germany) in parallel. Electrophoresis in Tris-borate-EDTA buffer was performed at 100 V for 1.5 h. The gel was stained with ethidium bromide (0.5  $\mu$ g/ml) for 15 minutes, rinsed and photographed under ultraviolet light illumination.

**[0162]** The PCR products were gel-purified using the QIAquick gel extraction kit (QIAGEN, Hilden, Germany). Both strands of the PCR products were sequenced twice with an ABI Prism 3700 DNA Analyzer according to manufacturers' instructions (Applied Biosystems, Foster City, Calif., USA), using the two PCR primers. The sequences of the PCR products were compared with the sequences of the pol genes of the two CoV-HKU1 (Woo, P

C. et al., *J. of Virol.*, 2005, p. 884-895) and those of the pol genes of coronaviruses in the GenBank database.

#### 6.2.4 ELISA Using Recombinant Nucleocapsid Protein of CoV-HKU1

**[0163]** The ELISA-based IgG and IgM antibody tests were performed according to our published protocol (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895). Briefly, each well of a Nunc immunoplate (Roskilde, Denmark) was coated with purified (His)<sub>6</sub>-tagged recombinant N protein (20 ng for IgG and 80 ng for IgM) for 1 h and then blocked in phosphate-buffered saline with 5% skim milk. The serum samples obtained from the patients during the acute and convalescent phase of the illness were serially diluted and were added to the wells of the (His)<sub>6</sub>-tagged (SEQ ID NO: 27) recombinant N protein-coated plates in a total volume of 100  $\mu$ l and incubated at 37° C. for 2 h. After washing with washing buffer five times, 100  $\mu$ l of diluted horse radish peroxidase-conjugated goat anti-human IgG (1:4000) and mouse anti-human IgM (1:1000) antibodies (Zymed Laboratories Inc., South San Francisco, Calif., USA) were added to the wells and incubated at 37° C. for 1 h. After washing with washing buffer five times, 100  $\mu$ l diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at room temperature for 15 min. One hundred microlitres of 0.3 M H<sub>2</sub>SO<sub>4</sub> were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

#### 6.2.5 RT-PCR and Sequencing of the Complete RNA-Dependent RNA Polymerase, Spike and Nucleocapsid Genes of Coronavirus-HKU1 and Phylogenetic Analysis

**[0164]** The complete pol, spike (S) and N genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced using the RNA extracted from the NPAs as template. The RNA was converted to cDNA by a combined random-priming and oligo(dT) priming strategy. The cDNA was amplified by degenerate primers designed by multiple alignment of the regions encoding the pol, S and N genes in the genomes of the two CoV-HKU1 (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895) and those of other group 2 coronaviruses and additional primers designed from the results of the first and subsequent rounds of sequencing. Sequences were assembled and manually edited to produce the complete sequences of the pol, S and N genes of CoV-HKU1 from different patients. The nucleotide and the deduced amino acid sequences of the pol, S and N genes were compared to those of the two CoV-HKU1 (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895) and other group 2 coronaviruses. Phylogenetic tree construction was performed using PileUp method with GrowTree (Genetics Computer Group, Inc.).

#### 6.2.6 Animal Surveillance

**[0165]** Two hundred and eight nasopharyngeal swabs and faecal samples from 56 wild and domestic animals [including Chinese ferret-badger (*Melogale moschata*), domestic cat (*Felis catus*), hog-badger (*Arctonyx collaris*), masked palm civet (*Paguma larvata*), racoon dog (*Nyctereutes procyonoides*), Chinese pygmy dormouse (*Typhlomys*

*cinereus*), common pangolin (*Manis pentadactyla*), nutria (*Myocastor coypus*), dog (*Canis familiaris*), rabbit (Leporidae family), snake (Serpentes suborder) and bat (Microchiroptera suborder)] in Hong Kong and southern China (Guan Y, et al., *Science* 2003; 302: 276-8) were subjected to RNA extraction and RT-PCR of pol gene of CoV-HKU1 using the CoV-HKU1 specific primers (LPW1926; SEQ ID NO:2968 and LPW1927; SEQ ID NO:2969) and protocol described above.

#### 6.2.7 Results

##### Clinical and Laboratory Characteristics

**[0166]** During the 12-month period, NPAs from 418 patients [male:female=198:220, age (mean $\pm$ SD)=49 $\pm$ 26] with community-acquired pneumonia, for detection of SARS-CoV but were negative for SARS-CoV RNA by RT-PCR, were identified in the four hospitals. A 453-bp fragment of the pol gene of CoV-HKU1 was amplified and sequenced in 10 (2.5%) patients. Sequence analysis revealed 0-2% nucleotide differences between the sequences of the fragments and the sequence of the pol gene of the CoV-HKU1 from the reported index patient (patient no. 5) described in Example 1 above (**FIG. 11**) (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895). In contrast, using our CoV-HKU1 specific primers, none of the 200 NPAs that were positive for influenza A and B viruses, parainfluenza viruses 1-3, RSV, or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV, was RT-PCR positive.

**[0167]** The epidemiological, clinical and radiological characteristics of the 10 patients, including patient no. 5 (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895), with community-acquired pneumonia associated with CoV-HKU1 are summarized in Table 5. No epidemiological linkage was identified among the 10 cases. All cases occurred in either winter or spring (January-May). The median age was 71.5 (range: 13-96). Seven were males and three were females. Nine were Chinese and one was an Arabian. Eight had underlying diseases, and four had underlying diseases of the respiratory tract. Four had recent travel histories to southern China. Five were smokers. Clinically, the illness was not distinguishable from other community-acquired pneumonia. Fever, productive cough and dyspnoea were common presenting symptoms. Upper respiratory tract symptoms were present in only two patients (patient nos. 1 and 5). One patient (patient no. 7) had loose stool diarrhea. Oxygen saturation on room air upon admission was <95% in two. Airspace shadows were observed in the right lungs of six patients and the left lungs of six patients. The upper, middle and lower zones were affected in two, four and nine patients respectively. All patients, except patient no. 10, had normal platelet counts and normal liver and renal function tests. Bacterial or mycobacterial pathogens were not detected in any of the sputum samples from the patients. Direct antigen detection for influenza A and B viruses, parainfluenza viruses 1-3, RSV, adenovirus (Woo P C Y et al., *J Clin Microbiol* 1997; 35: 1579-81) and RT-PCR for influenza A virus and metapneumovirus, was negative in all NPAs. Antibodies against *M. pneumoniae*, *C. pneumoniae*, *C. psittaci*, *L. pneumophila* and SARS-CoV were negative in all the six patients (patient nos. 1, 4, 5, 6, 8 and 9) whose serum samples were available. All these six patients showed a four-fold change in IgG titer (patient nos. 4, 5 and 6) and/or the presence of IgM (patient nos. 1, 5, 8 and 9) against CoV-HKU1.

TABLE 5

Characteristics	Patient no.				
	1	2	3	4	5
Month/Year	Mar/03	Apr/03	May/03	Jan/04	Jan/04
Sex/Age	F/35	M/66	M/13	M/75	M/71
Ethnic origin	Chinese	Arabian	Chinese	Chinese	Chinese
Underlying diseases	-	Diabetes mellitus, old myocardial infarction, gastric lymphoma	Asthma, situs inversus, dextrocardia	Hypertension	Chronic obstructive airway disease, hyperlipidaemia, abdominal aortic aneurysm
History of travel within two weeks of disease onset	-	-	Shenzhen, China	Guangdong, China	Shenzhen, China
History of smoking	-	-	-	+	+
<u>Clinical features</u>					
Fever	+	-	+	-	+
Chills	-	-	-	-	+
Rigor	-	-	-	-	-
Myalgia	-	-	-	-	-
Headache	-	-	-	-	+
Cough	+	-	+	+	+
Sputum production	-	-	+	+	+
Dyspnoea	-	+	-	+	-
Pleurisy	-	-	-	-	-
Rhinorrhoea	-	-	-	-	+
Sore throat	+	-	-	-	+
Oxygen saturation on room air (%)	99	83	100	99	99
Chest radiograph features	RLZ airspace shadows	Bilateral airspace shadows	LMZ and LLZ airspace shadows	LLZ airspace shadows	LLZ airspace shadows
Outcome	Survived	Died	Survived	Survived	Survived
Duration of hospitalization (no. of days)	2	Died on day 12	3	7	5

Characteristics	Patient no.				
	6	7	8	9	10
Month/Year	Jan/04	Jan/04	Jan/04	Mar/04	Mar/04
Sex/Age	F/96	M/78	M/68	F/83	M/72
Ethnic origin	Chinese	Chinese	Chinese	Chinese	Chinese
Underlying diseases	Hypertension	Chronic obstructive airway disease, diabetes mellitus	-	Chronic obstructive airway disease, parathyroid adenoma, dementia	Prostate carcinoma, cerebrovascular accident, diabetes mellitus
History of travel within two weeks of disease onset	-	-	Guangdong, China	-	-
History of smoking	-	+	-	+	+
<u>Clinical features</u>					
Fever	+	+	+	+	+
Chills	-	-	-	-	-
Rigor	-	-	-	-	-
Myalgia	-	-	-	-	-
Headache	-	-	-	-	-

TABLE 5-continued

Cough	-	+	+	-	+
Sputum production	-	+	+	-	+
Dyspnoea	-	+	+	+	+
Pleurisy	-	-	-	-	-
Rhinorrhoea	-	-	-	-	-
Sore throat	-	-	-	-	-
Oxygen saturation on room air (%)	97	97	95	99	88
Chest radiograph features	RLZ airspace shadows	LLZ airspace shadows	RMZ airspace shadows	RLZ airspace shadows	Bilateral airspace shadows
Outcome	Survived	Survived	Survived	Survived	Died
Duration of hospitalization (no. of days)	7	13	5	6	Died on day 6

+ = present;  
 - = absent;  
 RUZ = right upper zone;  
 LUZ = left upper zone;  
 RMZ = right middle zone;  
 LMZ = left middle zone;  
 RLZ = right lower zone;  
 LLZ = left lower zone

[0168] In comparison with age- and sex-matched controls with non-CoV-HKU1 pneumonia, no epidemiological, clinical, haematological, serum biochemical and radiological risk factors were identified in patients with CoV-HKU1 pneumonia (Table 6).

TABLE 6

Characteristics	Pneumonia*		
	HCoV-HKU1 (n = 10)	Non-HCoV-HKU1 (n = 20)	P value
Underlying diseases	8	12	0.42
History of travel within two weeks of disease onset	4	6	0.69
History of smoking	5	7	0.46
<b>Clinical features</b>			
Fever	8	14	0.68
Cough	7	17	0.37
Sputum production	6	12	1.00
Dyspnoea	6	6	0.12
Rhinorrhoea	1	2	1.00
Sore throat	2	2	0.58
<b>Haematological features</b>			
Haemoglobin (g/dl)	12.4	13.2	0.27
Leukocyte count ( $\times 10^9/l$ )	9.9	9.7	0.95
Neutrophil count ( $\times 10^9/l$ )	7.35	7.4	0.71
Lymphocyte count ( $\times 10^9/l$ )	0.95	1.02	0.48
Monocyte count ( $\times 10^9/l$ )	0.55	0.65	0.35
Platelet count ( $\times 10^9/l$ )	240	292	0.20
<b>Serum biochemical features</b>			
Sodium (mmol/l)	136	137	0.59
Potassium (mmol/l)	3.9	4.0	0.42
Creatinine ( $\mu\text{mol/l}$ )	92	76.5	0.06
Urea (mmol/l)	5.25	4.9	0.62
Albumin (g/l)	37	38	0.59
Globulin (g/l)	36.5	30	0.07
Bilirubin ( $\mu\text{mol/l}$ )	12	10	1.00

TABLE 6-continued

	Pneumonia*		P value
	HCoV-HKU1 (n = 10)	Non-HCoV-HKU1 (n = 20)	
ALT (U/l)	20	17	0.42
Alkaline phosphatase (U/l)	102	91	0.95
Oxygen saturation on room air (%)	96	98	0.86
<b>Radiological features</b>			
Bilateral involvement	2	5	1.00
No. of zones involved	1	1	0.81
Mortality	2	0	0.10

\*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

[0169] Two of the 10 patients died of CoV-HKU1 pneumonia. The first patient (patient no. 2) was a 66-year old man who presented with dyspnoea for one day. He had type 2 diabetes mellitus, old myocardial infarction and gastric lymphoma with total gastrectomy in 2002 and was put on chemotherapy. He had severe lymphopenia ( $0.2 \times 10^9/L$ ) and an oxygen saturation of only 83% on admission. Chest radiograph revealed patchy airspace shadows in both lungs with predominant involvement of the lower zones (FIG. 12A). He died 11 days after admission. The other patient (patient no. 10) was a 72-year old man who presented with fever and productive cough for one week. He had type 2 diabetes mellitus, cerebrovascular accident and prostatic carcinoma with bone metastasis complicated by spinal cord compression with laminectomy and Luque instrumentation performed. He had lymphopenia ( $0.9 \times 10^9/L$ ), thrombocytopenia ( $33 \times 10^9/L$ ), deranged liver and renal function tests and an oxygen saturation of only 88% on admission. Chest radiograph revealed extensive airspace shadows in both lungs, with the middle zones more severely involved (FIG. 12B). He died 5 days after admission.

[0170] The clinical, laboratory and radiological characteristics of patients who survived and those who died with community acquired pneumonia associated with CoV-HKU1 were compared (Table 7). Patients who died had lower hemoglobin concentration (P=0.04), monocyte count (P=0.04), serum albumin (P=0.04) and oxygen saturation on admission (P=0.03) and bilateral involvement (P=0.003) and more number of zones involved (P=0.01) on chest radiograph.

TABLE 7

Characteristics	Outcome*		
	Survived (n = 8)	Died (n = 2)	P value
<u>Characteristics</u>			
Sex (M:F)	5:3	2:0	1.00
Age	73	69	0.60
Underlying diseases	6	2	0.45
History of travel within two weeks of disease onset	4	0	0.24
History of smoking	4	1	1.00
<u>Clinical features</u>			
Fever	7	1	0.26
Cough	6	1	0.51
Sputum production	5	1	0.76
Dyspnoea	4	2	0.22
Rhinorrhoea	1	0	0.62
Sore throat	2	0	0.45
<u>Haematological features</u>			
Haemoglobin (g/dl)	13.4	9	0.04
Leukocyte count ( $\times 10^9/l$ )	9.7	7.85	0.43
Neutrophil count ( $\times 10^9/l$ )	7.4	6.9	0.79
Lymphocyte count ( $\times 10^9/l$ )	1.35	0.55	0.15
Monocyte count ( $\times 10^9/l$ )	0.7	0.3	0.04
Platelet count ( $\times 10^9/l$ )	292	200.5	0.79
<u>Serum biochemical features</u>			
Sodium (mmol/l)	137.5	134	0.11
Potassium (mmol/l)	3.9	4.5	0.06
Creatinine ( $\mu\text{mol/l}$ )	79	76.5	0.69
Urea (mmol/l)	4.6	10.75	0.19
Albumin (g/l)	38.5	26	0.04
Globulin (g/l)	30	30	1.00
Bilirubin ( $\mu\text{mol/l}$ )	10	30.5	0.79
ALT (U/l)	16.5	30.5	0.36
Alkaline phosphatase (U/l)	86	190.5	0.07
Oxygen saturation on room air (%)	99	85.5	0.03
<u>Radiological features</u>			
Bilateral involvement	0	2	0.003
No. of zones involved	1	6	0.01

\*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

RT-PCR and Sequencing of the Complete RNA-Dependent RNA Polymerase, Spike and Nucleocapsid Genes of Coronavirus-HKU1 and Phylogenetic Analysis

[0171] The complete pol (FIG. 11), S (FIG. 13) and N (FIG. 14) genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced. The phylogenetic trees and non-synonymous mutations and the corresponding amino acid changes are shown in FIG. 15. In all three genes, the phylogenetic trees using nucleotides or amino acids for construction showed the same topologies. For the S gene, there were 317 and 306 nucleotide positions with synonymous and non-synonymous mutations respectively (FIG.

15B). For the N gene, there were 42 and 53 nucleotide positions with synonymous and non-synonymous mutations respectively (FIG. 15C). The nucleotide sequences of seven of the nine S or N genes showed similar sequences (genotype A, FIGS. 16B and 16C) and those of the other two also showed similar sequences (genotype B, FIGS. 16B and 16C). For the CoV-HKU1 from patient 1, two peaks (T and C) were consistently observed at nucleotide position 1300 of the N gene, suggesting the presence of quasi-species (FIG. 15C). For the pol gene, there were 95 and 13 nucleotide positions with synonymous and non-synonymous mutations respectively (FIG. 15A). The nucleotide sequences of the pol genes in the seven CoV-HKU1 of genotype A were also clustered together (FIG. 15A). Interestingly, the seven CoV-HKU1 of genotype A were from seven patients with underlying diseases and the two of genotype B were from the two patients without underlying diseases (Table 5). Furthermore, multiple alignments of the nucleotides sequences of the pol genes of the nine CoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV revealed that the primers we used in the present study should be specific for CoV-HKU1 (FIG. 16).

#### Animal Surveillance

[0172] None of the 208 nasopharyngeal swabs and faecal samples from 56 wild and domestic animals in Hong Kong and southern China was positive for CoV-HKU1 RNA.

#### 6.2.8 Discussion

[0173] CoV-HKU1, a novel group 2 coronavirus, is associated with community-acquired pneumonia. Since the SARS epidemic in 2003, we have started to prospectively collect NPAs and store the extracted RNA from patients with community-acquired pneumonia so that when a novel virus is discovered, the epidemiology and hence the clinical, laboratory and radiological features of the disease can be studied timely. In January 2004, we discovered a novel coronavirus, CoV-HKU1, from a patient with community-acquired pneumonia (Woo, P. C. et al., *J. of Virol.*, 2005, p. 884-895). The RNA extracted from prospectively collected NPAs were immediately retrieved and the presence of CoV-HKU1 RNA looked for. Ten of the 418 NPAs were positive for RNA of CoV-HKU1, giving an incidence of 2.5%. The presence of CoV-HKU1 RNA in these specimens was genuine, instead of due to contamination, as amplification and sequencing of multiple genes (pol, S and N) of CoV-HKU1 indicated the presence of CoV-HKU1 with different nucleotide sequences in the NPAs from the different patients. Moreover, the clinical significance of CoV-HKU1 was further confirmed by the presence of specific antibody responses in all six patients whose serum samples were available.

[0174] Similar to HCoV-229E, HCoV-OC43 and HCoV-NL63, CoV-HKU1 is probably a human coronavirus that is endemic in human. Similar to other human coronavirus infections, cases of CoV-HKU1 pneumonia also occurred in winter and spring. Most patients with CoV-HKU1 pneumonia were old (80% older than 65) with major underlying diseases, especially those of the respiratory and cardiovascular systems. In order to study the phylogeny and relationships among the 10 CoV-HKU1, we sequenced the pol, S and N genes of the nine CoV-HKU1 cases which provided adequate amount of RNA. Combined with the data of partial

sequencing of the pol genes of the 10 CoV-HKU1 (FIG. 17), results showed that unlike the epidemiology of SARS-CoV, the 10 CoV-HKU1 were not clonal and the topology of the phylogenetic trees did not follow the pattern of a clonal outbreak (FIG. 15). Interestingly, the phylogenetic tree constructed using the sequences of both the S and N genes showed that CoV-HKU1 of genotype B was associated with the two patients without underlying diseases, but CoV-HKU1 of genotype A was associated with patients with underlying diseases (Table 5; and FIGS. 16B and 16C). Sequencing of more CoV-HKU1 may reveal the presence of genotypes or clades of CoV-HKU1 with differential virulence. To investigate for the possibility of an animal reservoir of CoV-HKU1, we tried to look for the presence of CoV-HKU1 RNA from wild and domestic animals in Hong Kong and southern China by RT-PCR. Our results revealed that none of the specimens showed the presence of CoV-HKU1 RNA. With the results of these clinical epidemiology, molecular epidemiology and eco-epidemiology studies, we conclude that CoV-HKU1 is probably a human coronavirus, and propose to rename CoV-HKU1 as human coronavirus HKU1 (HCoV-HKU1).

[0175] Compared with SARS-CoV pneumonia, HCoV-HKU1 pneumonia is a monophasic disease and most patients had relatively mild symptoms that were localized to the respiratory tract and were only briefly hospitalized. SARS-CoV pneumonia is often described as a biphasic disease, with the first phase due to cell lysis as a result of active viral replication, and the second phase may be due to immunopathological damage (Peiris J S M et al., *Lancet* 2003; 361: 1319-25; Peiris J S M et al., *Lancet* 2003; 361: 1767-72). On the other hand, all 10 patients with HCoV-HKU1 pneumonia showed the pattern of a monophasic disease. Although dyspnoea was present in half of the patients with HCoV-HKU1 pneumonia at initial presentation, as compared to only about 20% of patients with SARS-CoV pneumonia at initial presentation (Peiris J S M et al., *Lancet* 2003; 361: 1319-25), patients with HCoV-HKU1 pneumonia often recovered quickly, but patients with SARS-CoV pneumonia deteriorated after 7-10 days (Peiris J S M et al., *Lancet* 2003; 361:1319-25; Peiris J S M et al., *Lancet* 2003; 361: 1767-72). For the eight patients who recovered, the median duration of hospitalization was only 5.5 days. This rapid recovery of patients with HCoV-HKU1 pneumonia could be related to the rapid control of the virus by the immune system. This is in line with our previous study showing the index patient (patient 5) with HCoV-HKU1 pneumonia had his peak viral load at around day 3 after onset of illness (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895). Moreover, only one of the patients had extrapul-

monary symptoms and all available extrapulmonary specimens (stool, urine and serum) were RT-PCR negative for CoV-HKU1 (unpublished data). On the other hand, for SARS-CoV pneumonia, patients usually had their peak viral loads 7-10 days after the onset of illness (Peiris J S M et al., *Lancet* 2003; 361: 1767-72). Furthermore, the virus can be readily detected in extrapulmonary specimens, in which the viral loads correlated with the manifestations in the corresponding systems (Hung, I F N et al., *Emerg Infect Dis* 2004; 10: 1550-1557). These imply that the virus was not well controlled by the immune system in the initial phase of the illness.

[0176] Despite the relatively mild disease in most patients, HCoV-HKU1 pneumonia is associated with mortality in a minority of patients who had lower haemoglobin concentration, monocyte count, serum albumin and oxygen saturation on admission and more extensive involvement on chest radiograph. As in most cases of pneumonia, more extensive involvement in the lungs will result in poor gaseous exchange and hence hypoxia and eventually fatality. The lower haemoglobin concentration, monocyte count and serum albumin could represent poorer pre-morbid states and narrower margins to fight against infections. Both patients who died had underlying diabetes mellitus, malignancy (gastric lymphoma in one and carcinoma of the prostate in the other) and cardiovascular disease (old myocardial infarct in one and cerebrovascular accident in the other).

## 7. MARKET POTENTIAL

[0177] The two genomic types of CoV-HKU1 are completely sequenced. These sequences allow the development of various diagnostic tests and therapeutic methods as described hereinabove. In addition, the genetic information of CoV-HKU1 is extremely important and valuable for clinical and scientific research applications.

## 8. EQUIVALENTS

[0178] Those skilled in the art will recognize, or be able to ascertain many equivalents to the specific embodiments of the invention described herein using no more than routine experimentation. Such equivalents are intended to be encompassed by the following claims.

[0179] All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification.

[0180] Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

---

## SEQUENCE LISTING

The patent application contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20060034853A1>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

---

What is claimed:

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2919, a complement thereof, or a fragment thereof.

2. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a replicase gene of CoV-HKU1.

3. The nucleic acid molecule of claim 2 comprising the nucleotide sequence of SEQ ID NO:2920, 2922, 2924, 2926, 2928, 2930, 2932 or 2934.

4. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a spike gene of CoV-HKU 1.

5. The nucleic acid molecule of claim 4 comprising the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948 or 2950.

6. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a nucleocapsid gene of CoV-HKU1.

7. The nucleic acid molecule of claim 6 comprising the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964 or 2966.

8. An isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes an amino acid sequence which has a biological activity exhibited by a polypeptide encoded by the nucleic acid molecule of claim 1.

9. A vector comprising the nucleic acid molecule of claim 1.

10. A vector comprising the nucleic acid molecule of claim 2.

11. A vector comprising the nucleic acid molecule of claim 4.

12. A vector comprising the nucleic acid molecule of claim 6.

13. A host cell comprising the vector of claim 9.

14. A host cell comprising the vector of claim 10

15. A host cell comprising the vector of claim 11.

16. A host cell comprising the vector of claim 12.

17. An isolated polypeptide encoded by the nucleic acid molecule of claim 1.

18. An isolated polypeptide encoded by the nucleic acid molecule of claim 2.

19. An isolated polypeptide encoded by the nucleic acid molecule of claim 4.

20. An isolated polypeptide encoded by the nucleic acid molecule of claim 6.

21. A nucleic acid molecule encoding the polypeptide of claim 17.

22. A nucleic acid molecule encoding the polypeptide of claim 18.

23. A nucleic acid molecule encoding the polypeptide of claim 19.

24. A nucleic acid molecule encoding the polypeptide of claim 20.

\* \* \* \* \*